0001558370-22-016733.txt : 20221108 0001558370-22-016733.hdr.sgml : 20221108 20221108070642 ACCESSION NUMBER: 0001558370-22-016733 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221108 DATE AS OF CHANGE: 20221108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Voyager Therapeutics, Inc. CENTRAL INDEX KEY: 0001640266 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37625 FILM NUMBER: 221367182 BUSINESS ADDRESS: STREET 1: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-5340 MAIL ADDRESS: STREET 1: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 10-Q 1 vygr-20220930x10q.htm 10-Q
385203362400000http://www.voyagertherapeutics.com/20220930#DepositsAndOtherNonCurrentAssetshttp://www.voyagertherapeutics.com/20220930#DepositsAndOtherNonCurrentAssetsfalse0001640266--12-312022Q33791839500P1Y0001640266us-gaap:CommonStockMember2021-07-012021-09-300001640266vygr:PfizerMembervygr:SecondMaterialRightMember2022-09-300001640266vygr:PfizerMembervygr:FirstMaterialRightMember2022-09-300001640266vygr:PfizerMembervygr:OptionAndLicenseAgreementMember2022-03-040001640266vygr:NeurocrineBiosciencesIncMembervygr:VyaadcProgramMembervygr:NeurocrineCollaborativeArrangementMember2022-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:FaProgramMembervygr:NeurocrineCollaborativeArrangementMember2022-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:DiscoveryProgramTwoMembervygr:NeurocrineCollaborativeArrangementMember2022-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:DiscoveryProgramOneMembervygr:NeurocrineCollaborativeArrangementMember2022-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:DiscoveryAndFaProgramsMembervygr:NeurocrineCollaborativeArrangementMember2022-09-300001640266vygr:NeurocrineCollaborativeArrangementMember2022-01-012022-09-300001640266vygr:NonProfitAgreementMember2016-01-012016-12-310001640266vygr:NonProfitAgreementMember2016-12-310001640266vygr:NonProfitAgreementMember2017-12-310001640266vygr:PfizerMembervygr:OptionAndLicenseAgreementMember2021-10-010001640266vygr:NovartisPharmaAgMembersrt:MaximumMembervygr:NovartisLicenseAgreementMember2022-03-040001640266vygr:NovartisPharmaAgMembervygr:NovartisLicenseAgreementMember2022-03-040001640266vygr:PfizerMembersrt:MinimumMembervygr:OptionAndLicenseAgreementMember2021-10-010001640266vygr:TouchlightIpLtdMembervygr:TouchlightIpLtdLicenseAgreementMember2022-09-300001640266vygr:TouchlightIpLtdMembervygr:TouchlightIpLtdLicenseAgreementMember2022-07-012022-09-300001640266srt:MaximumMember2022-01-012022-09-300001640266vygr:NeurocrineBiosciencesIncMembersrt:MaximumMembervygr:NeurocrineCollaborativeArrangementMember2019-03-012019-03-310001640266vygr:NeurocrineBiosciencesIncMembervygr:FaProgramMembervygr:NeurocrineCollaborativeArrangementMember2022-01-012022-09-300001640266vygr:FaProgramMembervygr:NeurocrineCollaborativeArrangementMember2022-01-012022-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:FaProgramMembervygr:NeurocrineCollaborativeArrangementMember2019-03-012019-03-310001640266vygr:FaProgramMembervygr:NeurocrineCollaborativeArrangementMember2019-03-012019-03-310001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2022-09-300001640266vygr:PfizerMembervygr:OptionAndLicenseAgreementMember2021-10-012021-10-010001640266vygr:NovartisPharmaAgMembervygr:NovartisLicenseAgreementMembervygr:SalesMilestoneMember2022-03-042022-03-040001640266vygr:PfizerMembervygr:OptionAndLicenseAgreementMembervygr:SalesMilestoneMember2021-10-012021-10-010001640266vygr:PfizerMembervygr:OptionAndLicenseAgreementMembervygr:DevelopmentRegulatoryAndCommercializationMilestoneMember2021-10-012021-10-010001640266vygr:NeurocrineBiosciencesIncMembervygr:FaProgramMembervygr:NeurocrineCollaborativeArrangementMembervygr:DevelopmentAndRegulatoryMilestonesMember2019-03-012019-03-310001640266vygr:NeurocrineBiosciencesIncMembervygr:DiscoveryProgramOneMembervygr:NeurocrineCollaborativeArrangementMembervygr:DevelopmentAndRegulatoryMilestonesMember2019-03-012019-03-310001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMembervygr:CommercialMilestoneMember2019-03-012019-03-310001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2021-10-012021-12-310001640266vygr:NovartisPharmaAgMembervygr:NovartisLicenseAgreementMember2022-03-042022-03-040001640266vygr:PerformanceBasedMilestoneAwardsMember2022-07-310001640266vygr:PerformanceBasedMilestoneAwardsMember2019-12-310001640266us-gaap:CommonStockMember2022-07-012022-09-300001640266us-gaap:CommonStockMember2022-01-012022-03-310001640266us-gaap:CommonStockMember2021-01-012021-03-310001640266vygr:FoundersRestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2014-01-012014-01-310001640266vygr:FoundersRestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2014-01-012014-01-310001640266us-gaap:CommonStockMember2022-04-012022-06-300001640266us-gaap:CommonStockMember2021-04-012021-06-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2019-06-012019-06-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2019-03-012019-03-310001640266us-gaap:RetainedEarningsMember2022-09-300001640266us-gaap:AdditionalPaidInCapitalMember2022-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001640266us-gaap:RetainedEarningsMember2022-06-300001640266us-gaap:AdditionalPaidInCapitalMember2022-06-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000016402662022-06-300001640266us-gaap:RetainedEarningsMember2022-03-310001640266us-gaap:AdditionalPaidInCapitalMember2022-03-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100016402662022-03-310001640266us-gaap:RetainedEarningsMember2021-12-310001640266us-gaap:AdditionalPaidInCapitalMember2021-12-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001640266us-gaap:RetainedEarningsMember2021-09-300001640266us-gaap:AdditionalPaidInCapitalMember2021-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001640266us-gaap:RetainedEarningsMember2021-06-300001640266us-gaap:AdditionalPaidInCapitalMember2021-06-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000016402662021-06-300001640266us-gaap:RetainedEarningsMember2021-03-310001640266us-gaap:AdditionalPaidInCapitalMember2021-03-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100016402662021-03-310001640266us-gaap:RetainedEarningsMember2020-12-310001640266us-gaap:AdditionalPaidInCapitalMember2020-12-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001640266us-gaap:CommonStockMember2022-09-300001640266us-gaap:CommonStockMember2022-06-300001640266us-gaap:CommonStockMember2022-03-310001640266us-gaap:CommonStockMember2021-12-310001640266us-gaap:CommonStockMember2021-09-300001640266us-gaap:CommonStockMember2021-06-300001640266us-gaap:CommonStockMember2021-03-310001640266us-gaap:CommonStockMember2020-12-310001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2019-03-310001640266vygr:NonStatutoryStockOptionsMembervygr:InducementStockOptionAwardsMember2022-07-012022-09-300001640266vygr:NonStatutoryStockOptionsMembervygr:InducementStockOptionAwardsMember2022-01-012022-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2021-12-310001640266vygr:FoundersRestrictedStockMember2014-01-012014-01-310001640266us-gaap:EmployeeStockOptionMembervygr:InducementStockOptionAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-07-012022-09-300001640266us-gaap:EmployeeStockOptionMembervygr:InducementStockOptionAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-01-012022-09-300001640266us-gaap:EmployeeStockOptionMembervygr:InducementStockOptionAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-07-012022-09-300001640266us-gaap:EmployeeStockOptionMembervygr:InducementStockOptionAwardsMember2022-07-012022-09-300001640266vygr:PerformanceBasedMilestoneAwardsMember2022-07-012022-07-310001640266us-gaap:EmployeeStockOptionMembervygr:InducementStockOptionAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-01-012022-09-300001640266us-gaap:EmployeeStockOptionMembervygr:InducementStockOptionAwardsMember2022-01-012022-09-300001640266vygr:PerformanceBasedMilestoneAwardsMember2019-12-012019-12-310001640266srt:MinimumMembervygr:FoundersRestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2014-01-012014-01-310001640266srt:MaximumMembervygr:FoundersRestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2014-01-012014-01-310001640266vygr:PfizerMembervygr:OptionAndLicenseAgreementMember2022-07-012022-09-300001640266vygr:PfizerMembervygr:OptionAndLicenseAgreementMember2022-01-012022-09-300001640266vygr:Sidney75StreetMember2022-09-300001640266vygr:RelatedPartyTransactionBoardAndScientificAdvisoryServicesMembervygr:DrDinahSahMember2022-07-012022-09-300001640266vygr:RelatedPartyTransactionConsultingAndManagementServicesMembervygr:DrAlfredSandrockMember2022-01-012022-09-300001640266vygr:RelatedPartyTransactionBoardAndScientificAdvisoryServicesMembervygr:DrDinahSahMember2022-01-012022-09-300001640266vygr:RelatedPartyTransactionBoardAndScientificAdvisoryServicesMembervygr:DrDinahSahMember2021-07-012021-09-300001640266vygr:RelatedPartyTransactionBoardAndScientificAdvisoryServicesMembervygr:DrDinahSahMember2021-01-012021-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001640266us-gaap:RetainedEarningsMember2022-07-012022-09-300001640266us-gaap:RetainedEarningsMember2022-04-012022-06-300001640266us-gaap:RetainedEarningsMember2022-01-012022-03-310001640266us-gaap:RetainedEarningsMember2021-07-012021-09-300001640266us-gaap:RetainedEarningsMember2021-04-012021-06-300001640266us-gaap:RetainedEarningsMember2021-01-012021-03-310001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-09-300001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-09-300001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001640266vygr:Sidney75StreetMember2021-09-300001640266vygr:Sidney75StreetMember2022-07-012022-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2019-06-300001640266us-gaap:RestrictedStockUnitsRSUMember2022-09-300001640266us-gaap:EmployeeStockOptionMember2022-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2022-07-012022-09-300001640266vygr:NovartisPharmaAgMembervygr:NovartisLicenseAgreementMember2022-01-012022-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2021-07-012021-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2021-01-012021-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeArrangementMember2022-01-012022-09-300001640266vygr:RelatedPartyTransactionCollaborationArrangementMembervygr:NeurocrineBiosciencesIncMember2022-09-3000016402662021-09-3000016402662020-12-310001640266us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001640266us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001640266us-gaap:MoneyMarketFundsMember2022-09-300001640266us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001640266us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001640266us-gaap:MoneyMarketFundsMember2021-12-3100016402662021-01-012021-12-310001640266us-gaap:USTreasurySecuritiesMember2022-09-300001640266us-gaap:USTreasurySecuritiesMember2021-12-310001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001640266us-gaap:FairValueMeasurementsRecurringMember2022-09-300001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001640266us-gaap:FairValueMeasurementsRecurringMember2021-12-310001640266us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001640266us-gaap:RestrictedStockMember2022-07-012022-09-300001640266us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001640266us-gaap:RestrictedStockMember2022-01-012022-09-300001640266us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300001640266us-gaap:RestrictedStockMember2021-07-012021-09-300001640266us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001640266us-gaap:RestrictedStockMember2021-01-012021-09-300001640266us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001640266srt:MaximumMembervygr:PerformanceBasedMilestoneAwardsMember2022-07-012022-09-300001640266us-gaap:StockCompensationPlanMember2022-07-012022-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001640266us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001640266us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001640266us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001640266srt:MaximumMembervygr:PerformanceBasedMilestoneAwardsMember2022-01-012022-09-300001640266us-gaap:StockCompensationPlanMember2022-01-012022-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001640266us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001640266us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001640266us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001640266us-gaap:StockCompensationPlanMember2021-07-012021-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300001640266us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001640266us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001640266us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001640266us-gaap:StockCompensationPlanMember2021-01-012021-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001640266us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001640266us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001640266us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001640266us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-3000016402662022-07-012022-09-300001640266us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000016402662022-04-012022-06-300001640266us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016402662022-01-012022-03-310001640266us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-3000016402662021-07-012021-09-300001640266us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000016402662021-04-012021-06-300001640266us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100016402662021-01-012021-03-3100016402662021-01-012021-09-3000016402662022-09-3000016402662021-12-3100016402662022-11-0400016402662022-01-012022-09-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purevygr:itemvygr:Programvygr:multiplevygr:individual

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission file number: 001-37625

Voyager Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

Delaware

46-3003182

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

64 Sidney Street,
Cambridge, Massachusetts

02139

(Address of principal executive offices)

(Zip Code)

(857) 259-5340

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

VYGR

Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes     No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes       No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes       No  

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of November 4, 2022 was 38,607,346.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “contemplate,” “anticipate,” “goals,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:

our plans to develop and commercialize our product candidates based on adeno-associated virus, or AAV, gene therapy and our proprietary antibodies;
our ability to continue to develop our proprietary gene therapy platform technologies, including our TRACERTM discovery platform, our proprietary antibodies, and our vectorized antibody platform;
our ability to identify and optimize product candidates and proprietary AAV capsids;
our strategic collaboration with and funding from our collaboration partner Neurocrine Biosciences, Inc., or Neurocrine, from our option and license arrangement with Pfizer Inc., or Pfizer, and from our option and license arrangement with Novartis Pharma AG, or Novartis;
our ongoing and planned preclinical development efforts, related timelines and studies;
the timing of and our ability to submit applications and obtain and maintain regulatory approvals for our product candidates, including the ability to file investigational new drug, or IND, applications for our programs;
our estimates regarding expenses, contingent liabilities, future revenues, existing cash resources and capital requirements;
our ability to conduct clinical trials compliant with current good clinical practices and to develop a manufacturing capability compliant with current good manufacturing practices for our product candidates;
our intellectual property position and our ability to obtain, maintain and enforce intellectual property protection for our proprietary assets;
our estimates regarding the size of the potential markets for our product candidates and our ability to serve those markets;
the rate and degree of market acceptance of our product candidates for any indication once approved;
our need for additional funding and our plans and ability to raise additional capital, including through equity offerings, debt financings, collaborations, strategic alliances, and option and license arrangements;
our competitive position and the success of competing products that are or become available for the indications that we are pursuing;
the impact of government laws and regulations including in the United States, the European Union, and other important geographies such as Japan;

2

our ability to enter into future collaborations, strategic alliances, or option and license arrangements;
our ability to control costs and reprioritize our product candidate pipeline successfully in connection with our strategic initiatives; and
the potential impact of the COVID-19 pandemic on our research and development efforts and other business operations.

These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. You should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in “Part II, Item 1A — Risk Factors,” and our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2022, particularly in “Part I, Item 1A — Risk Factors,” that could cause actual future results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

RISK FACTOR SUMMARY

Investment in our securities involves risk and uncertainties that you should be aware of when evaluating our business. The following is a summary of what we believe to be the principal risks facing our business, as more fully described under “Part II, Item 1A—Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations.

We have a history of incurring significant losses and anticipate that we will continue to incur losses for the foreseeable future and may never achieve or maintain consistent profitability. We may not be able to generate sufficient revenue from the commercialization of our product candidates and may never be consistently profitable.
We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.
To date, all of our revenue has been derived from our ongoing collaboration with Neurocrine, from our option and license arrangements with Pfizer Inc., or Pfizer, and Novartis Pharma AG, or Novartis, and from our prior collaborations with Sanofi Genzyme Corporation, AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company. If any ongoing or future collaboration, or option and license agreements were to be terminated, our business financial condition, results of operations and prospects could be harmed.
Our AAV gene therapy and other biological therapy product candidates are based on a proprietary technology and, in several disease areas, unvalidated treatment approaches, which makes it difficult and potentially infeasible to predict the duration and cost of development of, and subsequently obtaining regulatory approval for, our product candidates.
Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. Such requirements may lengthen the regulatory review process, require us

3

to modify current studies or perform additional studies or increase our development costs, which in turn may force us to delay, limit, or terminate certain of our programs.
We are early in our development efforts. Our primary product candidates are in the discovery and preclinical development stages. We may encounter substantial delays or difficulties in commencement, enrollment or completion of our preclinical studies or clinical trials, or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing our current and future product candidates on a timely basis, if at all.
Our product candidates or the process for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.
We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may harm our business and financial condition, and our ability to successfully market or commercialize our product candidates.
Our gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business.
Our gene therapy and vectorized antibody approaches utilize vectors derived from viruses that are selectively engineered, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
If we are unable to obtain and maintain patent protection for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected.
Our future success depends on our ability to retain key members of our management and research and development teams, and to attract, retain and motivate qualified personnel. Our inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and could harm our business, financial condition, results of operations and prospects.
A widespread outbreak of an illness or other health issue could significantly disrupt our operations. The current COVID-19 pandemic and the response to it have had, and we expect they will continue to have, an adverse effect on our business, operations, and future results.

4

VOYAGER THERAPEUTICS, INC.

FORM 10-Q

TABLE OF CONTENTS

Page

PART I. FINANCIAL INFORMATION

ITEM 1.

   

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

6

CONDENSED CONSOLIDATED BALANCE SHEETS

6

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE Income (LOSS)

7

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

9

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

10

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

29

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

47

ITEM 4.

CONTROLS AND PROCEDURES

48

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

48

ITEM 1A.

RISK FACTORS

48

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

117

ITEM 5.

OTHER INFORMATION

117

ITEM 6.

EXHIBITS

118

SIGNATURES

120

5

PART I. FINANCIAL INFORMATION

Voyager Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(amounts in thousands, except share and per share data)

(unaudited)

September 30, 

December 31, 

 

    

2022

    

2021

 

Assets

    

    

Current assets:

Cash and cash equivalents

$

96,860

$

117,433

Marketable securities, current

 

34,778

 

15,106

Accounts receivable

10,000

Related party collaboration receivable

225

732

Prepaid expenses and other current assets

 

5,079

 

3,427

Total current assets

 

146,942

 

136,698

Property and equipment, net

 

18,082

 

21,920

Deposits and other non-current assets

 

1,515

 

1,779

Operating lease, right-of-use asset

 

15,941

 

33,458

Total assets

$

182,480

$

193,855

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

1,337

$

574

Accrued expenses

 

12,529

 

10,950

Other current liabilities

2,746

5,571

Deferred revenue, current

 

56,630

 

33,886

Total current liabilities

 

73,242

50,981

Deferred revenue, non-current

 

7,391

 

8,210

Other non-current liabilities

 

22,024

 

39,609

Total liabilities

 

102,657

98,800

Commitments and contingencies (see note 8)

Stockholders’ equity:

Preferred stock $0.001 par value: 5,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021

Common stock, $0.001 par value: 120,000,000 shares authorized at September 30, 2022 and December 31, 2021; 38,520,336 and 37,918,395 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively

 

38

 

38

Additional paid-in capital

 

450,008

 

442,259

Accumulated other comprehensive loss

 

(337)

 

(138)

Accumulated deficit

 

(369,886)

 

(347,104)

Total stockholders’ equity

 

79,823

 

95,055

Total liabilities and stockholders’ equity

$

182,480

$

193,855

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Voyager Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(amounts in thousands, except share and per share data)

(unaudited)

Three Months Ended

Nine Months Ended

September 30, 

 

September 30, 

 

    

2022

    

2021

 

2022

    

2021

 

Collaboration revenue

$

41,086

    

$

1,482

$

42,457

    

$

9,342

Operating expenses:

Research and development

 

19,337

 

17,914

 

46,213

 

59,767

General and administrative

 

7,307

 

8,714

 

22,518

 

28,895

Total operating expenses

 

26,644

26,628

 

68,731

88,662

Operating income (loss)

14,442

(25,146)

(26,274)

(79,320)

Other income, net:

Interest income

 

545

 

121

 

816

 

253

Other income (expense)

 

2,637

 

(112)

 

2,676

 

2,161

Total other income, net

 

3,182

 

9

 

3,492

 

2,414

Net income (loss)

$

17,624

$

(25,137)

$

(22,782)

$

(76,906)

Other comprehensive income (loss)

Net unrealized (loss) gain on available-for-sale securities

 

27

 

(2)

 

(199)

 

6

Total other comprehensive income (loss)

 

27

 

(2)

 

(199)

 

6

Comprehensive income (loss)

$

17,651

$

(25,139)

$

(22,981)

$

(76,900)

Net income (loss) per share, basic

$

0.46

$

(0.67)

$

(0.59)

$

(2.04)

Net income (loss) per share, diluted

$

0.45

$

(0.67)

$

(0.59)

$

(2.04)

Weighted-average common shares outstanding, basic

38,507,542

37,780,547

38,292,497

37,623,309

Weighted-average common shares outstanding, diluted

39,570,394

37,780,547

38,292,497

37,623,309

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

Voyager Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(amounts in thousands, except share data)

(unaudited)

Accumulated

 

Additional

Other

 

Common Stock

Paid-In

Comprehensive

Accumulated

Stockholders’

 

    

Shares

    

Amount

    

Capital

    

Income (Loss)

    

Deficit

    

Equity

 

Balance at December 31, 2020

37,368,027

$

37

$

430,324

$

(134)

$

(275,907)

$

154,320

Exercises of vested stock options

3,811

1

27

28

Vesting of restricted stock units

184,217

Stock-based compensation expense

3,498

3,498

Unrealized gain on available-for-sale securities, net of tax

11

11

Net loss

(21,649)

(21,649)

Balance at March 31, 2021

37,556,055

$

38

$

433,849

$

(123)

$

(297,556)

$

136,208

Vesting of restricted stock units

114,412

Issuance of common stock under ESPP

101,752

580

580

Stock-based compensation expense

3,871

3,871

Unrealized loss on available-for-sale securities, net of tax

(3)

(3)

Net loss

(30,120)

(30,120)

Balance at June 30, 2021

37,772,219

$

38

$

438,300

$

(126)

$

(327,676)

$

110,536

Vesting of restricted stock units

9,567

Stock-based compensation expense

2,025

2,025

Unrealized loss on available-for-sale securities, net of tax

(2)

(2)

Net loss

(25,137)

(25,137)

Balance at September 30, 2021

37,781,786

$

38

$

440,325

$

(128)

$

(352,813)

$

87,422

Balance at December 31, 2021

37,918,395

$

38

$

442,259

$

(138)

$

(347,104)

$

95,055

Exercises of vested stock options

11,484

12

12

Vesting of restricted stock units

312,090

Stock-based compensation expense

2,268

2,268

Unrealized loss on available-for-sale securities, net of tax

(85)

(85)

Net loss

(21,319)

(21,319)

Balance at March 31, 2022

38,241,969

$

38

$

444,539

$

(223)

$

(368,423)

$

75,931

Exercises of vested stock options

63,012

575

575

Vesting of restricted stock units

32,165

Issuance of common stock under ESPP

102,105

313

313

Stock-based compensation expense

2,460

2,460

Unrealized loss on available-for-sale securities, net of tax

(141)

(141)

Net loss

(19,087)

(19,087)

Balance at June 30, 2022

38,439,251

$

38

$

447,887

$

(364)

$

(387,510)

$

60,051

Exercises of vested stock options

5,341

15

15

Vesting of restricted stock units

75,744

Stock-based compensation expense

2,106

2,106

Unrealized gain on available-for-sale securities, net of tax

27

27

Net income

17,624

17,624

Balance at September 30, 2022

38,520,336

$

38

$

450,008

$

(337)

$

(369,886)

$

79,823

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

Voyager Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(amounts in thousands)

(unaudited)

Nine Months Ended

September 30, 

 

    

2022

    

2021

 

Cash flow from operating activities

    

    

Net loss

$

(22,782)

$

(76,906)

Adjustments to reconcile net loss (income) to net cash used in operating activities:

Stock-based compensation expense

 

6,998

 

9,670

Depreciation

 

5,357

 

3,683

Amortization of premiums and discounts on marketable securities

(23)

324

Other non-cash items

 

(2,468)

 

(2,460)

Changes in operating assets and liabilities:

Accounts receivable

(10,000)

Related party collaboration receivable

507

6,847

Prepaid expenses and other current assets

 

(1,652)

 

1,731

Operating lease, right-of-use asset

 

3,005

 

2,265

Other non-current assets

69

Accounts payable

 

763

 

(42)

Accrued expenses

 

1,536

 

(2,912)

Operating lease liabilities

 

(3,280)

 

(2,348)

Other non-current liabilities

(151)

Deferred revenue

 

21,925

 

(4,641)

Net cash used in operating activities

 

(265)

 

(64,720)

Cash flow from investing activities

Purchases of property and equipment

 

(1,558)

 

(1,262)

Purchases of marketable securities

 

(54,848)

 

Proceeds from sales and maturities of marketable securities

 

35,000

 

72,632

Net cash (used in) provided by investing activities

 

(21,406)

 

71,370

Cash flow from financing activities

Proceeds from the exercise of stock options

 

602

 

28

Proceeds from the purchase of common stock under ESPP

232

357

Net cash provided by financing activities

 

834

 

385

Net (decrease) increase in cash, cash equivalents, and restricted cash

 

(20,837)

 

7,035

Cash, cash equivalents, and restricted cash beginning of period

 

119,212

 

106,219

Cash, cash equivalents, and restricted cash end of period

$

98,375

$

113,254

Supplemental disclosure of cash and non-cash activities

Capital expenditures incurred but not yet paid

$

40

$

22

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

VOYAGER THERAPEUTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of business

Voyager Therapeutics, Inc. (the “Company”) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines, with the goal of either halting or slowing disease progression or reduce symptom severity, therefore providing clinically meaningful impact to patients. The Company’s gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (“AAV”) based gene therapies that it believes have the potential to safely provide durable efficacy. The Company’s team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which the Company believes an AAV gene therapy or other biological therapy will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. The Company then engineers and optimizes an AAV vector or other biological therapy for activity in, efficacy in, or delivery to, the targeted tissue or cells.

The Company is identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. The Company’s team has developed a proprietary AAV capsid discovery platform called TRACERTM (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (“BBB”). The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The Company believes that the capsids it discovers through its TRACER discovery platform (“TRACER Capsids”) have the potential to significantly enhance the efficacy and safety of its single dose gene therapies, which it expects to be delivered with targeted surgical delivery or systemic infusions, as compared with conventional capsids.

In addition to leveraging TRACER capsids in potential licensing arrangements, the Company is advancing its own proprietary pipeline of drug candidates for neurological diseases. The Company's three prioritized pipeline programs include: GBA1 gene therapy for Parkinson’s disease, SOD1 gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease. The Company plans to identify lead development candidates for all three programs between the fourth quarter of 2022 and the first half of 2023, with investigational new drug (IND) filings expected in 2024 and 2025.

In addition to these three lead programs, the Company has a collaboration ongoing with Neurocrine Biosciences, Inc. (“Neurocrine”) to develop a gene therapy for Friedreich's ataxia, which Neurocrine is funding through Phase 1. At that point, the Company has an option to either (1) co-develop and co-commercialize the asset with Neurocrine in the United States under a 60/40 cost and profit-sharing arrangement, 60% to Neurocrine and 40% to the Company, or (2) retain the right to receive milestone payments and royalties based on global sales pursuant to the full global commercial rights granted to Neurocrine.

The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy and other biological therapy programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy and antibody development and manufacturing. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in specific geographies with collaborators, as the Company has demonstrated through its ongoing collaboration with Neurocrine under a collaboration agreement that became effective in January 2019 (the “Neurocrine Collaboration Agreement”), or out-licensing activities including option and license agreements related to the TRACER capsids such as the Company’s October 2021 option and license agreement with Pfizer Inc. (“Pfizer”), pursuant to which Pfizer exercised an option effective as of September 30, 2022, and the Company’s March 2022 option and license agreement with Novartis Pharma AG (“Novartis”). The Company believes there is an ongoing opportunity for option and license transactions related to the TRACER capsids. To maximize the potential of TRACER capsids for the Company’s own

10

programs and option and license transactions, the Company has retained to date, and expects to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with a particular optionee’s or licensee’s transgenes.

The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products.

The Company has a history of incurring annual net operating losses. As of September 30, 2022, the Company had an accumulated deficit of $369.9 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from fees, milestone payments, and cost reimbursements associated with its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”) and AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaboration with Neurocrine, its option and license agreement with Pfizer, and its option and license agreement with Novartis.

As of September 30, 2022, the Company had cash, cash equivalents, and marketable securities of $131.6 million. Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable securities at September 30, 2022, together with amounts expected to be received as reimbursement for development costs under the Neurocrine Collaboration Agreement, and the Pfizer option exercise payment of $10.0 million received in the fourth quarter of 2022 will be sufficient to meet the Company’s planned operating expenses and capital expenditure requirements into 2024.

There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.

2. Summary of significant accounting policies and basis of presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (“SEC”) on March 8, 2022. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Principles of Consolidation

The unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiary as disclosed in Note 2, under the heading “Summary of Significant Accounting Policies - Basis of

11

Presentation”, within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.

Summary of Significant Accounting Policies

There have been no changes in the Company's significant accounting policies as described in Note 2, “Summary of Significant Accounting Policies,” within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

3. Fair value measurements

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 are as follows:

Quoted Prices

Significant

 

in Active

Other

Significant

 

Markets for

Observable

Unobservable

 

Identical Assets

Inputs

Inputs

Assets

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

September 30, 2022

(in thousands)

 

Money market funds included in cash and cash equivalents

    

$

93,043

    

$

93,043

    

$

    

$

Marketable securities - U.S. Treasury notes

 

34,778

 

34,778

 

 

Total

$

127,821

$

127,821

$

$

December 31, 2021

Money market funds included in cash and cash equivalents

    

$

100,305

    

$

100,305

    

$

    

$

Marketable securities - U.S. Treasury notes

15,106

15,106

Total

$

115,411

$

115,411

$

$

The Company measures the fair value of money market funds and U.S. Treasury notes based on quoted prices in active markets for identical securities.

12

4. Cash, cash equivalents, restricted cash, and available-for-sale marketable securities

Cash, cash equivalents, and marketable securities included the following at September 30, 2022 and December 31, 2021:

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

(in thousands)

As of September 30, 2022

    

    

    

    

    

    

    

    

Money market funds included in cash and cash equivalents

$

93,043

$

$

$

93,043

Marketable securities - U.S. Treasury notes

 

34,987

(209)

34,778

Total money market funds and marketable securities

$

128,030

$

$

(209)

$

127,821

As of December 31, 2021

    

    

    

    

    

    

    

    

Money market funds included in cash and cash equivalents

$

100,305

$

$

$

100,305

Marketable securities - U.S. Treasury notes

15,117

(11)

15,106

Total money market funds and marketable securities

$

115,422

$

$

(11)

$

115,411

All of the Company’s marketable securities as of September 30, 2022 have a contractual maturity of one year or less.

The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. In connection with these investments, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the condensed consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the condensed consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.

The Company held $30.0 million and $15.1 million marketable securities that were in an unrealized loss position as of September 30, 2022 and December 31, 2021, respectively, and held $5.0 million marketable securities that were in an unrealized gain position as of September 30, 2022. No marketable securities were in an unrealized gain position as of December 31, 2021. The unrealized losses at September 30, 2022 and December 31, 2021 were attributable to changes in interest rates and the unrealized losses do not represent credit losses. The Company does not intend to sell these securities and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:

As of September 30, 

As of December 31, 

2022

    

2021

(in thousands)

Cash and cash equivalents

$

96,860

$

117,433

Restricted cash included in deposits and other non-current assets

1,515

1,779

Total cash, cash equivalents, and restricted cash

$

98,375

$

119,212

13

5. Accrued expenses

Accrued expenses as of September 30, 2022 and December 31, 2021 consist of the following:

As of September 30, 

As of December 31, 

    

2022

    

2021

 

(in thousands)

Employee compensation costs

$

3,585

$

5,022

Research and development costs

7,768

3,719

Professional services

 

675

 

727

Accrued goods and services

501

1,482

Total

$

12,529

$

10,950

6. Lease obligation

Operating Leases

As of September 30, 2022, the Company has a lease for office and laboratory space at 64 Sidney Street in Cambridge, Massachusetts through November 30, 2026 and a lease for additional laboratory and office space at 75 Hayden Avenue in Lexington, Massachusetts through January 31, 2031.

In September 2021, the Company entered into an agreement with BioNTech US, Inc. (“BioNTech US”) to sublease part of the office and laboratory space leased by the Company at 75 Sidney Street in Cambridge, Massachusetts (the “Sublease Agreement”) at that time. The sublease term was for approximately 3.3 years. The sublease did not relieve the Company of its original obligation under the lease, and therefore the Company did not adjust the operating lease right-of-use asset as a result of the sublease and accounted for the sublease as a separate lease.

On June 22, 2022 the Company entered into a Lease Termination Agreement (the “Lease Termination Agreement”) and terminated the lease for office and laboratory space at 75 Sidney Street (the “75 Sidney Street Lease”), effective immediately. The 75 Sidney Street Lease was previously scheduled to terminate, in accordance with its terms, on November 30, 2026. In connection with the Lease Termination Agreement, the Company also entered into a Sublease Termination Agreement (the “Sublease Termination Agreement”) and terminated the Sublease Agreement with BioNTech US. The Company did not incur any termination penalties in connection with the Lease Termination Agreement or Sublease Termination Agreement. The Company derecognized the related right-of-use asset of approximately $14.5 million and the operating lease liabilities of $17.0 million, accordingly, resulting in a gain of $2.5 million in the three-month period ended June 30, 2022.

The Company’s lease agreements require the Company to maintain a cash deposit or irrevocable letter of credit in the aggregate amount of $1.5 million payable to its landlords as security for the performance of its obligations under the leases. These amounts are recorded as restricted cash and are included in deposits and other non-current assets in the accompanying condensed consolidated balance sheets.

During the three and nine months ended September 30, 2022, the Company incurred lease expenses of $1.0 million and $3.8 million, respectively, for operating leases. During the three and nine months ended September 30, 2021, the Company incurred lease expenses of $1.7 million and $5.4 million, respectively, for operating leases. As of September 30, 2022, the weighted average remaining lease term was 6.3 years and the weighted average incremental borrowing rate used to determine the operating lease liability was 7.4%.

14

The following table summarizes the operating sublease income generated under the Sublease Agreement for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2022

    

2021

2022

    

2021

(in thousands)

Operating sublease income

$

$

204

$

1,380

$

204

7. Other liabilities

As of September 30, 2022 and December 31, 2021, other current and non-current liabilities consisted of the following:

As of September 30, 

As of December 31, 

2022

    

2021

(in thousands)

Other current liabilities

Lease liability

2,746

5,571

Total other current liabilities

$

2,746

$

5,571

Other non-current liabilities

Lease liability

$

21,024

$

38,608

Other

1,000

1,001

Total other non-current liabilities

$

22,024

$

39,609

Strategic Restructuring

On August 6, 2021, the board of directors of the Company approved a strategic restructuring plan to eliminate a portion of its workforce as part of an initiative to reduce expenses and enhance operations. The strategic restructuring plan was approved in connection with its portfolio reevaluation efforts and its strategic shift to invest additional resources in the Company’s TRACER capsid development efforts.

During the year ended December 31, 2021, the Company incurred restructuring costs of approximately $2.6 million, which consists of severance-related costs. Substantially all costs have been paid as of September 30, 2022.

8. Commitments and contingencies

Significant Agreements

Neurocrine Collaboration Agreement

Summary of Agreement

In March 2019, the Company entered into the Neurocrine Collaboration Agreement for the research, development and commercialization of certain of its AAV gene therapy products. Under the Neurocrine Collaboration Agreement, the Company agreed to collaborate on the conduct of four collaboration programs (the “Neurocrine Programs”) which include: (i) VY-AADC (NBIb-1817) for Parkinson’s disease (the “VY-AADC Program”), (ii) VY-FXN01 for Friedreich’s ataxia (the “FA Program”) (collectively, with the VY-AADC Program, the “Legacy Programs”), and (iii) two programs to be determined by the Company and Neurocrine at a later date (the “Discovery Programs”).

In June 2019, in conjunction with the termination of the collaboration agreement with Sanofi Genzyme (the “Sanofi Genzyme Collaboration Agreement”), the Company gained ex-U.S. rights to the FA Program. The Company’s

15

ex-U.S. rights to the FA Program were subsequently transferred to Neurocrine under the terms of the Neurocrine Collaboration Agreement. To facilitate the transfer of the ex-U.S. rights to the FA Program to Neurocrine, the Company and Neurocrine executed an amendment to the Neurocrine Collaboration Agreement (the “June 2019 Modification”), and Neurocrine paid $5.0 million to the Company. There were no other changes in pricing or scope of the obligations required to be performed under the Neurocrine Collaboration Agreement.

In February 2021, Neurocrine notified the Company that it had elected to terminate the Neurocrine Collaboration Agreement solely with regards to the VY-AADC Program, effective August 2, 2021 (the “Neurocrine VY-AADC Program Termination Effective Date”). The Neurocrine Collaboration Agreement remains in full force and effect for each other program thereunder. As a result of the termination, Neurocrine is no longer obligated to reimburse the Company for research and development activities related to the VY-AADC Program.

Under the terms of the Neurocrine Collaboration Agreement, the Company originally agreed to collaborate with Neurocrine on, and to grant, exclusive, royalty-bearing, non-transferable, sublicensable licenses to certain of its intellectual property rights, for all human and veterinary diagnostic, prophylactic, and therapeutic uses, for the research, development, and commercialization of gene therapy products (the “Collaboration Products”) on a worldwide basis under (i) the VY-AADC Program; (ii) the FA Program; and (iii) each Discovery Program. As a result of the termination of the Neurocrine Collaboration Agreement with regards to the VY-AADC Program, in accordance with the terms of the Neurocrine Collaboration Agreement, the licenses granted by the Company to Neurocrine regarding the VY-AADC Program have expired, and the Company has regained worldwide intellectual property rights regarding the VY-AADC Program, in each case as of the VY-AADC Termination Effective Date.

Pursuant to development plans agreed by the parties, which are overseen by a joint steering committee (“JSC”), the Company has operational responsibility, subject to certain exceptions, for the conduct of each Neurocrine Program prior to the occurrence of a specified event for such Neurocrine Program (a “Transition Event”), as described below, and is required to use commercially reasonable efforts to develop the corresponding Collaboration Products. Neurocrine has agreed to be responsible for all costs incurred by the Company in conducting these activities for each Neurocrine Program, in accordance with an agreed budget for each Neurocrine Program. If the Company breaches its development responsibilities or in certain circumstances upon a change in control, Neurocrine has the right but not the obligation to assume the activities under such Neurocrine Program.

Upon the occurrence of a Transition Event for each Neurocrine Program, Neurocrine has agreed to assume responsibility for development, manufacturing and commercialization activities for such Neurocrine Program from the Company and to pay milestones and royalties on future net sales as described further below. As a result of Neurocrine’s termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program, the Transition Event with respect to the VY-AADC Program is no longer applicable. The Transition Events for the remaining programs are (i) with respect to the FA Program, the Company’s receipt of topline data for the initial Phase 1 clinical trial for an FA Program product candidate; and (ii) with respect to each Discovery Program, the preparation by the Company and the approval by Neurocrine of an IND application to be filed with the U.S. Food and Drug Administration (the “FDA”) by Neurocrine for the first development candidate in such Discovery Program. For the FA Program, the Company was granted the option (the “FA Co-Co Option”) to co-develop and co-commercialize the FA Program upon the occurrence of a specified event (a “FA Co-Co Trigger Event”). The Company agreed, upon its exercise of the FA Co-Co Option, to enter into a cost- and profit-sharing arrangement with Neurocrine (the “FA Co-Co Agreement”), and (i) jointly develop and commercialize the Collaboration Products for the FA Program (“FA Collaboration Products”), (ii) share in its costs, profits and losses, and (iii) forfeit certain milestones and royalties on net sales in the United States during the effective period of the FA Co-Co Agreement. The FA Co-Co Trigger Event is the receipt of topline data for the initial Phase 1 clinical trial for an FA Program product candidate.

Under the Neurocrine Collaboration Agreement, subject to exceptions specified therein, the Company and Neurocrine agreed that profits and losses under the Company’s FA Co-Co Option would be allocated 60% to Neurocrine and 40% to the Company for any FA Collaboration Product. The parties agreed that FA Co-Co Agreement would provide the Company the right to terminate for any reason upon prior written notice to Neurocrine and Neurocrine the right to terminate in certain circumstances upon change of control.

16

The Company’s research and development activities under the Neurocrine Collaboration Agreement are conducted pursuant to plans agreed to by the parties, on a program-by-program basis, and overseen by the JSC, as detailed in the Neurocrine Collaboration Agreement.

Under the Neurocrine Collaboration Agreement, the parties committed to agree on a list of up to eight target genes (the “Targets”) from which Neurocrine had the right to nominate Targets for the two Discovery Programs. The Company and Neurocrine completed the nomination process, and the JSC has approved the two Targets for development under the Discovery Programs. The two Targets are currently under development.

The Neurocrine Collaboration Agreement provides for an upfront non-refundable payment of $115.0 million, as well as for aggregate development and regulatory milestone payments from Neurocrine to the Company for Collaboration Products under (i) the VY-AADC Program of up to $170.0 million, which the Company is no longer eligible to receive in light of the partial termination of the Neurocrine Collaboration Agreement; (ii) the FA Program of up to $195.0 million, and (iii) each of the two Discovery Programs of up to $130.0 million per Discovery Program. The Company may be entitled to receive aggregate commercial milestone payments for each Collaboration Product of up to $275.0 million, subject to an aggregate cap on commercial milestone payments across all Neurocrine Programs of $1.1 billion. Furthermore, in connection with the Neurocrine Collaboration Agreement, Neurocrine purchased 4,179,728 shares of the Company’s common stock at a price of $11.9625 per share, for an aggregate purchase price of $50.0 million.

Neurocrine also agreed to pay the Company royalties, based on future net sales of the Collaboration Products. Such royalty percentages, for net sales in and outside the United States, as applicable, range (i) for the VY-AADC Program, from the mid-teens to low thirties and the low-teens to low twenties, respectively; (ii) for the FA Program, from the low-teens to high-teens and high-single digits to mid-teens, respectively; and (iii) for each Discovery Program, from the high-single digits to mid-teens and mid-single digits to low-teens, respectively. On a country-by-country and program-by-program basis, royalty payments would commence on the first commercial sale of a Collaboration Product and terminate on the later of (a) the expiration of the last patent covering the Collaboration Product or its method of use in such country, (b) ten years from the first commercial sale of the Collaboration Product in such country and (c) the expiration of regulatory exclusivity in such country (the “Royalty Term”). Royalty payments may be reduced by up to 50% in specified circumstances, including expiration of patents rights related to a Collaboration Product, approval of biosimilar products in a given country or required payment of licensing fees to third parties related to the development and commercialization of any Collaboration Product. As a result of Neurocrine’s termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program, the Company is no longer entitled to receive royalties related to the VY-AADC Program. Additionally, the licenses granted to Neurocrine shall automatically convert to fully paid-up, non-royalty bearing, perpetual, irrevocable, exclusive licenses on a country-by-country and product-by-product basis upon the expiration of the Royalty Term applicable to such Collaboration Product in such country.

Under the terms of the Neurocrine Collaboration Agreement and subject to specified exceptions therein, each party owns the entire right, title and interest in and to all intellectual property rights made solely by its employees or agents in the course of the collaboration. The parties jointly own all rights, title and interest in and to all intellectual property rights made or invented jointly by employees or agents of both parties.

During the term of the Neurocrine Collaboration Agreement, neither party nor any of its respective affiliates is permitted to directly or indirectly exploit any AAV-based gene therapy products directed to a Target to which a Collaboration Product is directed, subject to specified exceptions, including the parties’ conduct of basic research activities.

Unless earlier terminated, the Neurocrine Collaboration Agreement expires on the later of (i) the expiration of the last to expire royalty term with respect to a Collaboration Product in all countries in the relevant territory or (ii) the expiration or termination of any FA Co-Co Agreement. Neurocrine may terminate the Neurocrine Collaboration Agreement in its entirety or on a program-by-program or country-by-country basis by providing at least (x) 180-day advance notice if such notice is provided prior to the first commercial sale of the Collaboration Product to which the termination applies or (y) one-year advance notice if such notice is provided after the first commercial sale of the Collaboration Product to which the termination applies. The Company may terminate the Neurocrine Collaboration Agreement, subject to specified conditions, if Neurocrine challenges the validity or enforceability of certain of the

17

Company’s intellectual property rights. Subject to a cure period, either party may terminate the Neurocrine Collaboration Agreement in the event of a material breach by the other party in whole or in part, subject to specified conditions.

Upon termination in certain cases, Neurocrine has agreed to grant to the Company licenses to certain Neurocrine intellectual property, subject to a negotiation between the parties to establish royalty rates for use of such intellectual property. In the event of a breach by the Company with respect to a Neurocrine Program, if such termination were to occur after a Transition Event, then (i) with respect to the FA Program, if an FA Co-Co Agreement is in effect, Neurocrine can terminate the FA Co-Co Agreement for such program and the Company would no longer have co-development and co-commercialization rights with respect to the FA Collaboration Products and (ii) subject to any license agreements, Neurocrine would no longer have any obligations with respect to any Collaboration Products resulting from such program.

Termination of VY-AADC Program

As described above, as of the Neurocrine VY-AADC Program Termination Effective Date, the license granted by the Company to Neurocrine thereunder regarding the VY-AADC Program expired, the Company regained worldwide intellectual property rights regarding the VY-AADC Program, and the restrictions on the Company to develop, manufacture or commercialize a gene therapy product directed to the target of the VY-AADC Program terminated, in each case in accordance with the terms of the Neurocrine Collaboration Agreement. As of the Neurocrine VY-AADC Program Termination Effective Date, Neurocrine no longer is obligated to reimburse the Company for research and development activities related to the VY-AADC Program, and the Company is no longer entitled to receive future milestone or royalty payments related to the VY-AADC Program. The Company is supporting Neurocrine, the study sponsor and IND holder, on ongoing matters related to the completion of imaging and clinical assessments requested by the Data Safety and Monitoring Board (the “DSMB”), and the provision of other information requested by the FDA for the RESTORE-1 Phase 2 clinical trial.

Accounting Analysis

At inception, the Neurocrine Collaboration Agreement included the following performance obligations: (i) research and development services for each Legacy Program combined with a development and commercialization license for each such program and (ii) research and development services for each Discovery Program combined with a development and commercialization license for each program. The research services and license on a program-by-program basis are not distinct as Neurocrine cannot benefit from such license on its own or from other resources commonly available in the industry, without the corresponding research services due to the unique and specialized expertise of the Company that is not readily available in the marketplace.

The Company identified $92.4 million of fixed transaction price consisting of the $115.0 million upfront fee and $5.0 million payment from the June 2019 Modification, offset by a discount of $27.6 million related to the $50.0 million equity investment of 4,179,728 shares when measured at fair value on the date of issuance. The Company is also entitled to reimbursement of costs incurred by the Company prior to the Transition Events associated with each Neurocrine Program. These amounts are determinable based on program plans and budgets, and the Company has a contractual right to the payment of cost incurred under the agreed upon program plans. The Company utilized the most likely amount approach and estimated the expected cost reimbursement to be $431.1 million at inception. The Company concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Company considers this estimate at each reporting date and updates the estimate based on information available. During the fourth quarter of 2021, the Company further revised the estimate of the expected reimbursement to approximately $80.0 million based on expectations resulting from decisions made at the JSC meeting in the fourth quarter of 2021, which are expected to result in significantly less research and development services being provided by the Company under the Neurocrine Collaboration Agreement. As of September 30, 2022, the estimate of the expected reimbursement is $79.4 million based on expectations as of such date. Additional consideration to be paid to the Company upon reaching certain milestones are excluded from the transaction price at inception due to the uncertainty of achieving the development and regulatory milestones.

The Company allocated the fixed transaction price to the separate performance obligations based on the relative standalone selling price of each performance obligation or in the case of certain variable consideration to one or more performance obligations. The estimated standalone selling prices for performance obligations, which include a license

18

and research services, were developed using the estimated selling price of the license, using comparable and market data, and an estimate of the overall effort to perform the research services along with a reasonable profit for research services.

The Company concluded that the variable consideration related to the cost reimbursement of each program will be allocated to each respective program as the cost reimbursement relates specifically to the respective program services being performed under the Neurocrine Collaboration Agreement. The reimbursement of research services is considered to be at a market rate and the allocation of the fixed consideration to all of the performance obligations depicts the estimated amounts in which it would expect to receive for these obligations, absent the variable consideration related to the research reimbursement. The total variable consideration allocated to each program related to the expected cost reimbursement was as follows as of September 30, 2022:

Performance Obligation

Amount

(in thousands)

Variable Consideration

VY-AADC Program

$

53,863

FA Program

16,938

Discovery Program 1

5,236

Discovery Program 2

3,372

Total

$

79,409

Based on the relative standalone selling price allocation, the allocation of the transaction price, exclusive of the variable consideration allocated to the individual performance obligations, to the separate performance obligations was as follows:

Performance Obligation

Amount

(in thousands)

Fixed Consideration

VY-AADC Program

$

49,045

FA Program

20,647

Discovery Program 1

14,443

Discovery Program 2

8,247

Total

$

92,382

The Company recognizes the transaction price associated with each performance obligation on a proportional performance basis over the period of service using input-based measurements such as costs incurred to date, to estimate proportion performed, and remeasures its progress towards completion at the end of each reporting period.

The Company determined the partial termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program represented a modification of the arrangement under ASC 606 and that the remaining fixed transaction price at the Neurocrine VY-AADC Program Termination Effective Date of $42.2 million should be re-allocated to the FA Program and Discovery Program 1 and 2 based on their standalone selling prices. Accordingly, the Company recorded a cumulative adjustment to revenue of approximately $0.9 million on the partially satisfied remaining performance obligations, as the remaining services to be performed under each of the performance obligations are not distinct from the services prior to the modification. The Company determined that reasonable changes to the Company’s estimates of standalone selling prices for the FA Program, Discovery Program 1 and Discovery Program 2 performance obligations did not have a material impact on the re-allocation or the amount of revenue recorded pursuant to the cumulative catch-up adjustment.

During the three and nine months ended September 30, 2022, the Company recognized $1.1 million and $2.5 million, respectively, of revenue associated with its collaboration with Neurocrine related to research and development services performed during the period and the corresponding cost reimbursement receivable. During the three and nine months ended September 30, 2021, the Company recognized $1.5 million and $9.3 million of revenue, respectively, associated with its collaboration with Neurocrine related to research and development services performed during the period and the corresponding cost reimbursement receivable.

19

The following table presents changes in the balances of the Company’s related party collaboration receivables and contract liabilities during the nine months ended September 30, 2022:

Balance at

    

Balance at

December 31, 2021

Additions

Deductions

September 30, 2022

(in thousands)

Related party collaboration receivable

$

732

$

583

$

(1,090)

$

225

Contract liabilities:

Deferred revenue

$

12,096

$

-

$

(2,075)

$

10,021

The change in the receivable balance for the nine months ended September 30, 2022 is primarily driven by amounts owed to the Company for research and development services provided, offset by amounts collected from Neurocrine during the period.

Costs incurred relating to the Company’s collaboration programs under the Neurocrine Collaboration Agreement consist of internal and external research and development costs, which primarily include: salaries and benefits, laboratory supplies, preclinical research studies, clinical studies, consulting services, and commercial development. These costs are included in research and development expenses in the Company’s condensed consolidated statements of operations during the three and nine months ended September 30, 2022.

The Company incurred approximately $0.8 million of costs to obtain the Neurocrine Collaboration Agreement which were payable only upon the close of the deal and therefore considered incremental costs of obtaining a contract with a customer and capitalized. The costs are recorded in prepaid expenses and other non-current assets and are being amortized over the period in which the research services will be provided.

Pfizer Option and License Agreement

Summary of Agreement

On October 1, 2021, the Company entered into an option and license agreement with Pfizer (the “Pfizer Agreement”), pursuant to which the Company has granted Pfizer options to receive an exclusive license (the “Pfizer License Options”) to certain TRACER capsids to develop and commercialize certain AAV gene therapy candidates comprised of a capsid and specified Pfizer transgenes (the “Pfizer Transgenes”). Under the terms of the Pfizer Agreement, during an initial research term that ended as of October 1, 2022 (the “Pfizer Research Term”) Pfizer had the right to evaluate the potential use of the capsids in combination with up to two Pfizer Transgenes to help treat respective central nervous system (“CNS”) and cardiovascular diseases.

During the Pfizer Research Term, the Company agreed to provide Pfizer with certain quantities of materials encoding specified existing capsids for Pfizer’s evaluation. Further, during the Pfizer Research Term the Company agreed to disclose to Pfizer, on a rolling basis, the performance characteristics identified during the Pfizer Research Term for all such capsid candidates. Pfizer had the right, in its sole discretion, to select any capsid candidate for evaluation to determine its interest in exercising a Pfizer License Option with respect to such capsid candidate. Pfizer had the right to exercise up to two Pfizer License Options, provided that it could exercise only one Pfizer License Option for each Pfizer Transgene.

Effective as of September 30, 2022, Pfizer exercised its Pfizer License Option with respect to a capsid for the specified Pfizer Transgene for potential treatment of a rare neurological disease. Pfizer did not exercise its option to license a capsid for the potential treatment of a cardiovascular disease. As result, Pfizer’s right to exercise a Pfizer License Option for a cardiovascular disease has terminated in accordance with the terms of the Pfizer Agreement and all rights to capsids for that cardiovascular disease have reverted to the Company. Pfizer’s exercise of a Pfizer License Option extends the Pfizer Research Term to October 1, 2024, during which period the Company may, at its sole discretion and expense, conduct additional research activities to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of the rare neurological disease associated with the exercise of the applicable Pfizer License Option.

20

Pursuant to the exercise of the Pfizer License Option, the Company granted Pfizer an exclusive, worldwide license, with the right to sublicense, under certain of the Company’s intellectual property, the rights to develop and commercialize rare neurological disease products utilizing the capsid candidate and incorporating the corresponding Pfizer Transgene (the “Pfizer Licensed CNS Products”). Until October 1, 2024, while the Company is not obligated to conduct additional research activities to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of rare neurological diseases, it has agreed to continue to disclose to Pfizer, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available. Pfizer may, during the Pfizer Research Term, conduct additional evaluations of such capsid candidates and has the right to substitute any other capsid candidate for the capsid it previously elected to license when it exercised the Pfizer License Option.

Under the Pfizer Agreement, Pfizer is solely responsible for, and has sole decision-making authority with respect to, development and commercialization of the Pfizer Licensed CNS Products. Pfizer is required to use commercially reasonable efforts to develop and obtain regulatory approval for at least one Pfizer Licensed CNS Product for which Pfizer has exercised its Pfizer License Option in (i) the United States and (ii) at least one of the following countries: the United Kingdom, France, Germany, Italy, Spain and Japan (each of which is referred to as a “Pfizer Major Market Country”), subject to certain limitations. Pfizer is also required to use commercially reasonable efforts to commercialize each Pfizer Licensed CNS Product in the United States and at least one Pfizer Major Market Country where Pfizer or its designated affiliates or sublicensees has received regulatory approval for such Pfizer Licensed CNS Product, subject to certain limitations.

Under the terms of the Pfizer Agreement, Pfizer paid the Company an upfront payment of $30.0 million in October 2021. Following the exercise of the Pfizer License Option, Pfizer is obligated to pay the Company a fee of $10.0 million and the Company is also eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $115.0 million for the first corresponding Pfizer Licensed CNS Product to achieve the corresponding milestone. On a Pfizer Licensed CNS Product-by-Pfizer Licensed CNS Product basis, the Company is also eligible to receive (a) specified sales milestone payments of up to an aggregate of $175.0 million per Pfizer Licensed CNS Product and (b) tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Pfizer Licensed CNS Product. The royalties are subject to potential reductions in customary circumstances including patent claim expiration, payments for certain third-party licenses, and biosimilar market penetration, subject to specified limits.

Under the terms of the Pfizer Agreement, each the Company and Pfizer owns the entire right, title, and interest in and to all patents or know-how controlled by such party and existing as of or before the effective date of the Pfizer Agreement, or invented, developed, created, generated or acquired solely by or on behalf of such party after such effective date.

Subject to certain specified exceptions, any patents and know-how that are invented or otherwise developed jointly by or on behalf of the parties during the term of the Pfizer Agreement and in the course of the Company’s and Pfizer’s activities under the Pfizer Agreement will follow inventorship under U.S. patent law. Subject to certain limitations and exceptions, the Company agreed (i) during the Pfizer Research Term, not to conduct any internal program or program on behalf of a third party that is directed to development or commercialization of any capsid candidates, or grant any third party or affiliate any right or license under the Company’s rights in such capsid candidates to exploit any therapeutic product, in combination with any Pfizer Transgene in any indication for therapeutic, diagnostic and prophylactic human and veterinary use; and (ii) after Pfizer’s exercise of a Pfizer License Option, not to grant any third party or affiliate any right or license under the Company’s patents to exploit any licensed capsid in combination with any Pfizer Transgene.

Unless earlier terminated, the Pfizer Agreement expires on the expiration of the last-to-expire royalty term with respect to all Pfizer Licensed CNS Products in all countries. Subject to a cure period, either party may terminate the Pfizer Agreement, in whole or in part, subject to specified conditions, in the event of the other party’s uncured material breach. Pfizer may also terminate the Pfizer Agreement, in whole or in part, subject to specified conditions, for the Company’s insolvency, the occurrence of a violation of global trade control laws, or for the Company’s noncompliance with certain anti-bribery or anti-corruption covenants. Pfizer may also terminate the Pfizer Agreement, in whole or in part, for any or no reason upon ninety days’ written notice to us.

21

Upon certain terminations for cause by Pfizer, the licenses that the Company has granted to Pfizer under the Pfizer Agreement shall become irrevocable and perpetual, and all milestone payments and royalties that would have otherwise been payable by Pfizer under such licenses had the Pfizer Agreement remained in effect would be substantially reduced.

Accounting Analysis

The Company assessed the promised goods and services under the Pfizer Agreement, in accordance with ASC 606, and determined that the Pfizer Agreement contains two performance obligations consisting of two material rights, one for each of the Pfizer License Options. The Company concluded that each Pfizer License Option provides a material right as consideration for each option is less than the amount that the Company would otherwise have expected to receive outside the context of the contract. The promises at inception do not include the underlying goods or services that would be delivered upon exercise of the option, but rather represent the value to the customer of having the right to exercise the Pfizer License Option at the specified exercise fee. Upon the exercise of a Pfizer License Option, until October 1, 2024, while the Company is not obligated to conduct additional research activities upon option exercise to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of central nervous system or cardiovascular diseases, it has agreed to continue to disclose to Pfizer, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available. Pfizer may, conduct additional evaluations of such capsid candidates and has the right to substitute any other capsid candidate for the capsid it previously elected to license when it exercised the Pfizer License Option. The Company determined that this promise to provide Pfizer the ability to evaluate and potentially substitute other capsid candidates for the capsid it previously elected to license when it exercised the Pfizer License Option, if and when available, is an additional performance obligation in the arrangement (“the Pfizer Substitution Right Performance Obligation”).

The Company received a nonrefundable, upfront payment of $30.0 million as consideration under the Pfizer Agreement, which represents the transaction price at inception. Additional consideration to be paid to the Company upon exercise of the Pfizer License Option or upon reaching certain milestones are excluded from the transaction price as they relate to option fees and milestones that could only be achieved subsequent to an option exercise.

The Company allocated the transaction price to the two material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be willing to pay an equal amount for each Pfizer License Option on a standalone basis. The Company reached this conclusion after considering (i) the downstream economics including option fees, milestones and royalties related to each Pfizer License Option being identical and (ii) comparable market data. The Company determined the standalone selling price for the Pfizer Substitution Right Performance Obligation was insignificant to the allocation of the transaction price using the relative standalone selling price model and, accordingly, did not allocate any transaction price to the Pfizer Substitution Right Performance Obligation. This determination was supported by qualitative and quantitative assessments of the standalone selling price that considered the cost of identifying other potential capsid candidates and the likelihood of license substitution. As such, based on the relative standalone selling price for each of the two material rights, the allocation of the transaction price to the separate performance obligations is $15.0 million for each material right.

The amount allocated to each material right was initially recorded as deferred revenue.

During the three and nine months ended September 30, 2022, the Company recognized $40.0 million in collaboration revenue related to the Pfizer Agreement. Of this $40.0 million, $25.0 million is attributable to the exercise of the first material right for the Pfizer License Option for a rare neurological disease and includes the option exercise fee of $10.0 million. The remaining $15.0 million is attributable to the expiration of the second material right associated with the Pfizer License Option for a cardiovascular disease.

22

Novartis Option and License Agreement

Summary of Agreement

On March 4, 2022 (the “Novartis Effective Date”), the Company entered into an option and license agreement with Novartis (the “Novartis Agreement”). Pursuant to the Novartis Agreement, the Company has granted Novartis options (the “Novartis License Options”) to license TRACER capsids (“Novartis Licensed Capsids”) for exclusive use with certain targets to develop and commercialize adeno-associated virus gene therapy candidates comprised of Novartis Licensed Capsids and payloads directed to such targets (the “Novartis Payloads”).

During the period commencing on the Novartis Effective Date and ending on the first anniversary thereof or, in the event Novartis exercises a Novartis License Option, the third anniversary thereof (the “Novartis Research Term”), the Company has granted Novartis a non-exclusive research license to evaluate the Company’s TRACER capsids for potential use, in combination with Novartis Payloads, in programs targeting three specified genes (the “Initial Novartis Targets”). Upon the payment of additional fees, Novartis may also assess the Company’s TRACER capsids for use with two other targets (the “Additional Novartis Targets”), subject to certain conditions including that such target is not part of, or reasonably competitive with, the Company’s current development programs (the Initial Novartis Targets and the Additional Novartis Targets collectively, the “Novartis Targets”). During the Novartis Research Term, the Company may, at its sole discretion and expense, conduct further research activities to identify additional TRACER capsids. If the Company elects to do so, the Company has agreed to disclose performance characteristics of such new TRACER capsids to Novartis on a rolling basis.

During the Novartis Research Term, Novartis may exercise up to three Novartis License Options—or up to five Novartis License Options if Novartis is evaluating the Additional Novartis Targets—in the aggregate, provided that Novartis may only exercise one Novartis License Option for each Novartis Target. Upon the exercise of any Novartis License Option, the Company has agreed to grant Novartis a target-exclusive, worldwide license, with the right to sublicense, under certain of the Company’s intellectual property, the rights to develop and commercialize the applicable Novartis Licensed Capsid as incorporated into products containing the corresponding Novartis Payload (the “Novartis Licensed Products”). Upon the exercise of a Novartis License Option, the Company has agreed to provide certain additional know-how to enable Novartis to exploit the Novartis Licensed Capsid and the corresponding Novartis Payload for use in a Novartis Licensed Product. Novartis may, during the Novartis Research Term but following the exercise of a Novartis License Option, conduct additional evaluation of the Company’s capsid candidates and has the right to substitute any other TRACER capsid for a Novartis Licensed Capsid.

Subject to the Company’s disclosure obligations described above, the Company and Novartis have agreed to conduct their respective research and evaluation activities independently, with communications being managed by two alliance managers comprised of a designee from each of the Company and Novartis.

Under the Novartis Agreement, Novartis is solely responsible for, and has sole decision-making authority with respect to, development and commercialization of the Novartis Licensed Products. In the event Novartis exercises a Novartis License Option, Novartis is required to use commercially reasonable efforts to develop and obtain regulatory approval for at least one Novartis Licensed Product for each Novartis Target for which it has exercised a Novartis License Option in (i) the United States and (ii) at least three of the following countries: the United Kingdom, France, Germany, Italy, Spain and Japan (each of which, a “Novartis Major Market Country”), subject to certain limitations. Novartis is also required to use commercially reasonable efforts to commercialize each Novartis Licensed Product in the United States and at least three Novartis Major Market Countries where Novartis or its designated affiliates or sublicensees has received regulatory approval for such Novartis Licensed Product, subject to certain limitations.

During the Novartis Research Term, the Company has agreed to provide plasmids to Novartis for the production of TRACER capsids for evaluation upon request. The Company has also granted Novartis a non-exclusive license, effective upon an exercise of a Novartis License Option and in addition to its options for target-exclusive licenses under certain of the Company’s intellectual property described above, on a Novartis Licensed Capsid-by-Novartis Licensed Capsid basis, under certain of the Company’s know-how to exploit the applicable Novartis Licensed Capsid as incorporated into Novartis Licensed Products containing the corresponding Novartis Payload.

23

Under the terms of the Novartis Agreement, Novartis paid the Company an upfront payment of $54.0 million. Novartis has also agreed to pay the Company a fee of $18.0 million per Additional Novartis Target it elects to add to the collaboration and, upon each exercise of a Novartis License Option, an option exercise fee of $12.5 million. Following each exercise of a Novartis License Option, the Company is also eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $125.0 million for the first corresponding Novartis Licensed Product to achieve the corresponding milestone. On a Novartis Licensed Product-by-Novartis Licensed Product basis, the Company is also eligible to receive (a) specified sales milestone payments of up to an aggregate of $175.0 million per Novartis Licensed Product and (b) tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Novartis Licensed Product. The royalties are subject to potential reductions in customary circumstances including patent claim expiration, payments for certain third-party licenses, and biosimilar market penetration, subject to specified limits.

Under the terms of the Novartis Agreement, each party owns the entire right, title, and interest in and to all patents or know-how controlled by such party and existing as of or before the Novartis Effective Date, or invented, developed, created, generated or acquired solely by or on behalf of such party after the Novartis Effective Date. Subject to certain specified exceptions, any patents and know-how that are invented or otherwise developed jointly by or on behalf of the parties during the term of the Novartis Agreement and in the course of the parties’ activities under the Novartis Agreement will follow inventorship under U.S. patent law.

Subject to certain limitations and exceptions, the Company has agreed (i) during the Novartis Research Term, not to conduct any internal program or program on behalf of a third party that is directed to the development or commercialization of any Company’s capsids, or grant any third party or affiliate any right or license under the Company’s rights in such capsids, to exploit any therapeutic product containing a capsid in combination with a payload designed to have therapeutic effect on any of the Novartis Targets; and (ii) after Novartis’s exercise of any Novartis License Option, not to grant any third party or affiliate any right or license under the Company’s patents to exploit any Novartis Licensed Capsid for the applicable Novartis Target.

Unless earlier terminated, the Novartis Agreement expires on the earlier to occur of (i) the first anniversary of the Novartis Effective Date , if no Novartis License Option is exercised, and (ii) the expiration of the last-to-expire royalty term with respect to all Novartis Licensed Products in all countries if at least one Novartis License Option is exercised. Subject to a cure period, either party may terminate the Novartis Agreement, in whole or in part, subject to specified conditions, in the event of the other party’s uncured material breach. Novartis may also terminate the Novartis Agreement, in whole or in part, subject to specified conditions, for the Company’s insolvency, the occurrence of a violation of global trade control laws, or for the Company’s non-compliance with certain anti-bribery or anti-corruption covenants. Novartis may terminate the Novartis Agreement, in whole or in part, for any or no reason upon ninety days’ written notice to the Company.

Upon certain terminations for cause by Novartis, the licenses granted by the Company to Novartis under the Novartis Agreement shall become irrevocable and perpetual, and all milestone payments and royalties that would have otherwise been payable by Novartis under such licenses had the Novartis Agreement remained in effect would be substantially reduced.

Accounting Analysis

The Company assessed the promised goods and services under the Novartis Agreement, in accordance with ASC 606, and determined that the Novartis Agreement contains three performance obligations consisting of three material rights, one for each of the Novartis License Options. The Company concluded that each Novartis License Option provides a material right as consideration for each option is less than the amount that the Company would otherwise have expected to receive outside the context of the contract. The promises at inception do not include the underlying goods or services that would be delivered upon exercise of the option, but rather represent the value to the customer of having the right to exercise the Novartis License Option at the specified exercise fee. Upon the exercise of a Novartis License Option, until March 4, 2025, while the Company is not obligated to conduct additional research activities upon any option exercise to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of central nervous system or cardiovascular diseases, it has agreed to continue to disclose to Novartis, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available.

24

Novartis may conduct additional evaluation of such capsid candidates and has the right to substitute any other capsid candidate for the Novartis Licensed Capsid it previously elected to license when it exercised the Novartis License Option. The Company determined that this promise to provide Novartis the ability to evaluate and potentially substitute other capsid candidates for the Novartis Licensed Capsid it previously elected to license when it exercised the Novartis License Option, if and when available, is an additional performance obligation in the arrangement (the “Novartis Substitution Right Performance Obligation”). The Company concluded the options for Additional Novartis Targets are not material rights as the price reflects the standalone selling price of the options. The Company will therefore account for the options for Additional Novartis Targets separately, if exercised.

The Company received a nonrefundable, upfront payment of $54.0 million as consideration under the Novartis Agreement, which represents the transaction price at inception. Additional consideration to be paid to the Company upon exercise of the Novartis License Options or upon reaching certain milestones are excluded from the transaction price as they relate to option fees and milestones that could only be achieved subsequent to an option exercise.

The Company allocated the transaction price to the three material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be willing to pay an equal amount for each Novartis License Option on a standalone basis. The Company reached this conclusion after considering (i) the downstream economics including option fees, milestones and royalties related to each Novartis License Option being identical and (ii) comparable market data. The Company determined the standalone selling price for the Novartis Substitution Right Performance Obligation was insignificant to the allocation of the transaction price using the relative standalone selling price model and did not allocate any transaction price to the Novartis Substitution Right Performance Obligation, accordingly. This determination was supported by qualitative and quantitative assessments of the standalone selling price that considered the cost of identifying other potential capsid candidates and the likelihood of license substitution. As such, based on the relative standalone selling price for each of the three material rights, the allocation of the transaction price to the separate performance obligations is $18.0 million for each material right.

The amount allocated to each material right was recorded as deferred revenue and will be recognized either upon exercise of the Novartis License Option or upon expiration of the Novartis License Option.

During the three and nine months ended September 30, 2022, the Company did not recognize any revenue related to the Novartis Agreement. As of September 30, 2022, the entire transaction price of $54.0 million is recorded as deferred revenue, current in the accompanying consolidated balance sheet.

License Agreement with Touchlight IP Limited

On November 3, 2022, the Company and Touchlight IP Limited (“Touchlight”) entered into a license agreement (the “Touchlight License Agreement”) to authorize historical use by the Company of a certain DNA preparation process (“Subject DNA Preparation Process”), and to authorize the prospective exploitation of TRACER Capsids created with the use of the Subject DNA Preparation Process.

The terms of the Touchlight License Agreement include a one-time, non-refundable technology access fee of $5.0 million, payable to Touchlight during the fourth quarter of 2022. As of September 30, 2022, the Company determined that this technology access fee was a probable liability that could be reasonably estimated in accordance with ASC 450 Contingencies as of such date. The Company recorded the $5.0 million charge during the third quarter of 2022, accordingly.

The terms of the Touchlight License Agreement also include future milestone payments and low single-digit royalties payable to Touchlight if the Company or its program collaborators or licensees choose to utilize in a therapeutic product TRACER Capsids that were created with the historical use of the Subject DNA Preparation Process. Additionally, the Company is obligated to pay low single-digit royalties to Touchlight on future payments the Company receives in connection with licensing of TRACER capsids that were created with the historical use of the Subject DNA Preparation Process, excluding the licensing of or collaboration on any Company therapeutic programs.

25

Other Agreements

During the year ended December 31, 2016, the Company entered into a research and development funding arrangement with a non-profit organization that provides up to $4.0 million in funding to the Company upon the achievement of clinical and development milestones. The agreement provides that the Company repay amounts received under certain circumstances including termination of the agreement, and to pay an amount up to 2.6 times the funding received upon successful development and commercialization of any products developed. During the year ended December 31, 2017, the Company earned a milestone payment of $1.0 million. The Company has evaluated the arrangement and has concluded that it represents a research and development financing arrangement as it is probable that the Company will repay amounts received under the arrangement. As a result, the $1.0 million earned to date is recorded as a non-current liability in the condensed consolidated balance sheet.

Litigation

The Company was not a party to any material legal matters or claims as of September 30, 2022 or December 31, 2021. The Company did not have contingency reserves established for any litigation liabilities as of September 30, 2022 or December 31, 2021.

9. Stock-based compensation

Founder Awards

In January 2014, the Company issued 1,188,233 shares of restricted stock to its founders (each, a “Founder”) at an original issuance price of $0.0425 per share. Of the total restricted shares awarded to the Founders, 835,292 shares generally vest over one to four years, based on each Founder’s continued service to the Company in varying capacities as a Scientific Advisory Board member, consultant, director, officer or employee, as set forth in each grantee’s individual restricted stock purchase agreement.

The remaining 352,941 of the shares issued were subject to vesting upon the achievement of certain performance objectives as well as continued service to the Company, as set forth in the agreements. These performance conditions were tied to certain milestone events specific to the Company’s corporate goals, including but not limited to preclinical and clinical development milestones related to the Company’s product candidates. Stock-based compensation expense associated with these performance-based awards is recognized when the achievement of the performance condition is considered probable, using management’s best estimates. Management concluded that the achievement of the performance milestone associated with the performance-based award for one Founder had been met during 2016.

In December 2019, the Company modified one of the remaining Founder performance awards, repurchasing 58,823 shares of common stock previously issued to this Founder. Additionally, the Company modified the award to vest solely based on time rather than on performance. The Company revalued the award at the modification date and is recognizing expense on a straight-line basis over the three-year vesting period from the modification date.

In July 2022, the Company modified the last remaining Founder performance award, repurchasing 72,647 shares of common stock previously issued to this Founder. Additionally, the Company modified the award to vest solely based on time rather than on performance. The Company revalued the award at the modification date and is recognizing expense on a straight-line basis over the two-year vesting period. Stock-based compensation related to the modification of this award was less than $0.1 million for both the three and nine months ended September 30, 2022.

26

Inducement Awards

During the three and nine months ended September 30, 2022, the Company issued to two executives non-statutory stock options to purchase an aggregate of 276,000 shares of the Company’s common stock outside of the Company’s 2015 Stock Option Plan as an inducement material to such executive’s acceptance of an offer of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option vests over a four-year period, with 25% of the shares underlying the option award vesting on the first anniversary of the effective date of the award and the remaining 75% of the shares underlying the award vesting in 36 equal monthly installments following the first anniversary of the effective date of the award.

Stock-Based Compensation Expense

Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations and comprehensive income (loss) is as follows:

Three Months Ended

Nine Months Ended

September 30, 

 

September 30, 

 

    

2022

    

2021

 

2022

    

2021

 

(in thousands)

 

Research and development

$

588

$

702

$

2,170

$

3,409

General and administrative

 

1,601

 

1,375

 

4,828

 

6,261

Total stock-based compensation expense

$

2,189

$

2,077

$

6,998

$

9,670

Stock-based compensation expense by type of award included within the condensed consolidated statements of operations and comprehensive income (loss) was as follows:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2022

    

2021

2022

    

2021

(in thousands)

Stock options

$

1,357

$

1,372

$

4,452

$

6,375

Restricted stock awards and units

748

651

2,382

3,018

Employee stock purchase plan awards

 

84

 

54

164

277

Total stock-based compensation expense

$

2,189

$

2,077

6,998

9,670

Restricted Stock Units

A summary of the status of and changes in unvested restricted stock unit activity under the Company’s equity award plans for the nine months ended September 30, 2022 was as follows:

    

    

Weighted

Average

Grant Date

Fair Value

    

Units

    

Per Unit

Unvested restricted stock units as of December 31, 2021

 

806,379

$

7.26

Granted

 

770,580

$

3.89

Vested

 

(419,999)

6.71

Forfeited

 

(215,685)

$

4.96

Unvested restricted stock units as of September 30, 2022

 

941,275

$

5.27

Stock-based compensation of restricted stock units is based on the fair value of the Company’s common stock on the date of grant and is recognized over the vesting period. Restricted stock units granted by the Company typically vest in equal amounts, annually over three years. All of the restricted stock units granted in the nine months ended September 30, 2022 vest in equal amounts, annually over three years. The stock-based compensation expense related to

27

restricted stock units and awards was $0.7 million and $2.4 million for the three and nine months ended September 30, 2022, respectively. The stock-based compensation expense related to restricted stock units and awards was $0.7 million and $3.0 million for the three and nine months ended September 30, 2021, respectively.

As of September 30, 2022, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $3.3 million, which is expected to be recognized over the remaining average vesting period of 1.9 years.

Stock Options

The following is a summary of stock option activity for the nine months ended September 30, 2022:

    

    

Weighted

    

Remaining

    

Aggregate

Average

Contractual

Intrinsic

Exercise

Life

Value

    

Shares

    

Price

    

(in years)

    

(in thousands)

Outstanding at December 31, 2021

 

5,013,193

$

12.69

5.6

$

1,165

Granted

 

3,504,675

$

5.14

Exercised

 

(79,837)

$

7.56

Cancelled or forfeited

 

(2,358,960)

$

13.22

Outstanding at September 30, 2022

 

6,079,071

$

8.20

 

8.1

$

5,693

Exercisable at September 30, 2022

 

2,581,363

$

10.85

 

6.4

$

1,838

As of September 30, 2022, the Company had unrecognized stock-based compensation expense related to its unvested stock options of $13.5 million which is expected to be recognized over the remaining weighted-average vesting period of 3.1 years.

10. Net income (loss) per share

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net income (loss) per share because to include them would be anti-dilutive:

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2022

    

2021

2022

    

2021

Unvested restricted common stock awards

 

64,608

156,863

64,608

156,863

Unvested restricted common stock units

523,627

947,265

941,275

947,265

Outstanding stock options

 

5,433,867

5,406,072

6,079,071

5,406,072

Total

 

6,022,102

6,510,200

7,084,954

6,510,200

Basic net income (loss) and diluted weighted-average shares outstanding are as follows for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended September 30, 

Nine Months Ended September 30, 

2022

    

2021

2022

    

2021

(in thousands, except share data)

Numerator:

Net income (loss)

$

17,624

$

(25,137)

$

(22,782)

$

(76,906)

Denominator for basic net income (loss) per share:

Weighted average shares outstanding-basic

38,507,542

37,780,547

38,292,497

37,623,309

Denominator for diluted net income (loss) per share:

Weighted average shares outstanding-basic

38,507,542

37,780,547

38,292,497

37,623,309

Common stock options and restricted stock units

1,062,852

Weighted average shares outstanding-diluted

39,570,394

37,780,547

38,292,497

37,623,309

28

Basic net loss per share for the nine months ended September 30, 2022 and 2021, and for the three months ended September 30, 2021, is the same as diluted net loss per share as shown on the Company’s condensed consolidated statement of operations.

11. Related-party transactions

During the three and nine months ended September 30, 2022, the Company received scientific advisory board and other scientific advisory services from one of its prior executives, Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Sah for services provided during the three and nine months ended September 30, 2022, was $93,600 and $185,925, respectively. The total amount of fees paid to Dr. Sah for services provided during the three and nine months ended September 30, 2021 was $30,000 and $120,000, respectively.

During the nine months ended September 30, 2022, the Company received advisory services related to strategic planning, operations, and management from Alfred Sandrock, M.D., Ph.D., the Company’s current President and Chief Executive Officer and a member of the Company’s Board of Directors, before he commenced service in the capacity of President and Chief Executive Officer in March 2022. The total amount of fees paid to Dr. Sandrock for services provided was $60,000 for the nine months ended September 30, 2022.

Under the Neurocrine Collaboration Agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization activities for certain of the Company’s AAV gene therapy products (Note 8). Amounts due from Neurocrine are reflected as related party collaboration receivables. As of September 30, 2022, the Company had approximately $0.2 million in related party collaboration receivables associated with Neurocrine.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or the SEC, on March 8, 2022.

Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.

The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under “Part II, Item 1A-Risk Factors.”

These forward-looking statements are made under the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are neither promises nor guarantees. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

29

Overview

We are a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; we are leveraging expertise in capsid discovery and neuropharmacology to address these constraints. Our gene therapy platforms enable us to engineer, optimize, manufacture and deliver adeno-associated virus, or AAV, based gene therapies that we believe have the potential to safely provide durable efficacy. Our team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which we believe an AAV gene therapy or other biological therapy will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. We then engineer and optimize an AAV vector or other biological therapy for activity in, efficacy in, or delivery to, the targeted tissue or cells.

We are identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. Our team has developed a proprietary AAV capsid discovery platform called TRACERTM (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier, or BBB. The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. We believe that capsids we discover through our TRACER discovery platform, which we refer to as TRACER capsids, have the potential to significantly enhance the efficacy and safety of our single dose gene therapies, which we expect to be delivered with targeted surgical delivery or systemic infusions, as compared with conventional capsids.

We are also applying the TRACER discovery platform to generate targeted capsid variant libraries for the selection of capsids with tropism and transduction in additional cell and tissue types. We are actively engaged in discussions with multiple parties to make TRACER capsids available to third parties for use in their drug development programs through potential option and license and other arrangements.

In addition to leveraging TRACER capsids in potential licensing arrangements, we are advancing our own proprietary pipeline of drug candidates for neurological diseases. Our three prioritized pipeline programs include: glucocerebrosidase 1, or GBA1, gene therapy for Parkinson’s disease, superoxide dismutase 1, or SOD1, gene therapy for amyotrophic lateral sclerosis, or ALS, and an anti-tau antibody for Alzheimer’s disease. We plan to identify lead development candidates for all three programs between the fourth quarter of 2022 and the first half of 2023, with investigational new drug, or IND, filings expected in 2024 and 2025.

In addition to these three lead programs, we have a collaboration ongoing with Neurocrine Biosciences, Inc., which we refer to as Neurocrine, to develop a gene therapy for Friedreich's ataxia, which Neurocrine is funding through Phase 1. At that point, we have an option to either (1) co-develop and co-commercialize the asset with Neurocrine in the United States under at a 60/40 cost and profit-sharing arrangement, 60% to Neurocrine and 40% to us, or (2) retain the right to receive milestone payments and royalties based on global sales pursuant to the full global commercial rights granted to Neurocrine.

Our business strategy focuses on discovering, developing, manufacturing and commercializing our gene therapy and other biological therapy programs. As part of this strategy, we have developed core competencies specific to AAV gene therapy development and manufacturing. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in specific geographies with collaborators, as we have demonstrated through our ongoing collaboration with Neurocrine or out-licensing activities including option and license agreements related to our TRACER capsids with Pfizer Inc., which we refer to as Pfizer, and with Novartis Pharma, AG, which we refer to as Novartis. We believe there is an ongoing opportunity for option and license transactions related to the TRACER capsids. To maximize the potential of TRACER capsids for both our own programs and option and license transactions, we have retained to date, and expect to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with a particular optionee’s or licensee’s transgenes. Since our inception, our operations have focused on organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, determining which neurological and other diseases to pursue, advancing

30

our product candidates including delivery and manufacturing, and conducting preclinical studies and early-phase clinical trials. We do not have any product candidates approved for sale and have not generated any revenue from product sales, and all of our current product candidates are in the discovery and preclinical development stages.

We have funded our operations primarily through private placements of redeemable convertible preferred stock, public offerings of our common stock, and fees, milestone payments, and cost reimbursements associated with our strategic collaborations, including our prior collaboration with Sanofi Genzyme Corporation, or the Sanofi Genzyme Collaboration, which commenced in February 2015 and was terminated in June 2019, our prior collaboration with AbbVie Biotechnology Ltd. focusing on tau-related disease, or the AbbVie Tau Collaboration, which commenced in February 2018 and was terminated in August 2020, our prior collaboration with AbbVie Ireland Unlimited Company focusing on pathological species of alpha-synuclein, or the AbbVie Alpha-Synuclein Collaboration, which commenced in February 2019 and was terminated in August 2020, our ongoing collaboration with Neurocrine, which commenced in March 2019, our option and license agreement with Pfizer, which commenced in October 2021, and our option and license agreement with Novartis, which commenced in March 2022. We refer to our collaboration agreement with Neurocrine as the Neurocrine Collaboration Agreement. We refer to our option and license agreement with Pfizer as the Pfizer Agreement, and to our option and license agreement with Novartis as the Novartis Agreement.

We remain interested in advancing our other programs and are pursuing additional product candidates in the discovery and preclinical stages of development, including our second-generation program for the treatment of Huntington’s disease, our program for the treatment of spinal muscular atrophy, or SMA, and our program for the treatment of human epidermal growth factor receptor positive, or HER2+, brain metastases. We are evaluating opportunities to do so via collaborative partnership, and will continue to conduct preclinical research for our second-generation program for the treatment of Huntington’s disease and our program for the treatment of HER2+ brain metastases. We expect to continue to conduct early preclinical research for our second-generation program for the treatment of SMA as we seek a collaborative partner for the program.

We continue to partner with Neurocrine on programs for diseases including Friedreich’s ataxia. All of our current product candidates are in the early stages of development. We also continue to evaluate additional diseases that could be treated using AAV gene therapy or our proprietary antibodies and are also actively exploring additional potential treatment methods that can utilize our proprietary TRACER capsids.

Our pipeline of prioritized gene therapy and other biological therapy programs, all of which are in preclinical development, is summarized in the table below:

Graphic

*Early research programs include vHER2 vectorized antibody for brain metastases from metastatic breast cancer and HTT gene therapy for Huntington’s disease.

**After Phase 1, Voyager has an option to co-develop/co-commercialize the FA program in the U.S., with 40% of the cost/profit allocated to Voyager and 60% to Neurocrine, or to grant Neurocrine global commercial rights.

Graphic

31

Overview of Our Pipeline

We have leveraged our TRACER discovery platform and other gene therapy platforms, our expertise with proprietary antibodies, and our vectorized antibody platform to assemble a pipeline of proprietary AAV gene therapies and passive and vectorized antibodies for the treatment of neurological and other diseases with high unmet medical need. Depending on the disease, our current AAV gene therapies will use a gene replacement or gene silencing approach, and our current antibodies will use a passive administration or vectorized delivery approach. Our goal is to address the underlying cause or the predominant manifestations of specific diseases by significantly increasing or decreasing expression of the relevant proteins in targeted tissues.

TRACER Capsid Discovery

Our scientists have developed TRACER, a proprietary AAV capsid discovery platform to facilitate the selection of TRACER capsids for particular therapeutic applications based on BBB-crossing and cell-specific transduction properties in multiple species, including non-human primates, or NHPs. In May 2021, we presented data demonstrating that we have developed a series of TRACER capsids which, following intravenous administration, could achieve up to 1000-fold higher RNA expression in the brain and 100-fold higher expression in the spinal cord of NHPs than AAV9, the current natural AAV serotype with the best ability to cross the BBB. We also identified a TRACER capsid which displayed strong cardiac transduction and significant dorsal root ganglia de-targeting in NHPs, which may avoid toxicities associated with AAV9 delivery. We believe these TRACER capsids may allow for significantly enhanced gene delivery to specific types of cells in the brain at lower doses and, potentially, with fewer safety and tolerability issues than first-generation therapies. These TRACER capsids are now in advanced stages of characterization for deployment in our gene therapy development programs. We are also applying the TRACER discovery platform towards further capsid variant libraries and the selection for tropism and transduction in additional cell and tissue types. We continue to perform screening campaigns with our TRACER discovery platform to identify additional proprietary AAV9- and AAV5-derived TRACER capsids and to refine previously-identified TRACER capsids to target or de-target multiple tissue and cell types.

At the American Society of Gene & Cell Therapy 25th Annual Meeting in May 2022, or the ASGCT 2022 Meeting, we presented new preclinical data on several families of TRACER capsids. We presented preclinical results for an AAV9-derived TRACER capsid, VCAP-102, which demonstrated 50-fold better transduction in mice and 60-fold better transduction in NHPs, compared to conventional AAV9 capsids, following intravenous administration. We believe demonstrating equivalent cross-species functionality is important to increasing a capsid’s potential for translation into humans. The study also demonstrated that VCAP-102 and other TRACER capsids showed preferential tropism for glial cells in mice, which may facilitate addressing CNS indications that would benefit from non-neuronal cell transduction. We also presented preclinical data for an AAV5-derived TRACER capsid with enhanced CNS transduction across species. AAV5 capsids have a reduced prevalence of preexisting neutralizing antibodies, but conventional AAV5 capsids do not have sufficient CNS transduction to be used effectively for gene therapies targeting the CNS. Our AAV5-derived TRACER capsid showed 20-fold higher brain transduction and five-fold higher spinal cord transduction compared to conventional AAV9 in NHPs and improved transduction in multiple CNS regions and cell types in NHPs with partial de-targeting of the dorsal root ganglia.

At the European Society of Gene & Cell Therapy 29th Annual Congress in October 2022, or the ESGCT 2022 Meeting, we presented new preclinical data demonstrating the potential for ultra-low dosing with an AAV9-derived TRACER capsid family. In the relevant dose-response NHP study, a TRACER capsid achieved high levels of BBB penetration and CNS target engagement when administered in the range of 2e12 vector genomes per kilogram, or VG/kg, to 2e13 VG/kg, which is 2% to 20% of the dose used in current approved intravenous gene therapies. Intravenous delivery of doses of 2e12 VG/kg and higher were sufficient to achieve widespread and potentially therapeutically relevant CNS transduction and supra-physiological mRNA expression of a model transgene, and expression in the liver and dorsal root ganglia was confirmed to be at or near background levels at these doses. These data collectively suggest that the relevant TRACER capsid shows strong effect at well-tolerated doses, potentially addressing the narrow therapeutic windows and subsequent toxicity issues that have hampered the gene therapy field.

32

We have identified a highly conserved membrane protein as the primary cell surface attachment receptor used by our VCAP-101/102 TRACER capsid family. We presented preclinical data regarding this discovery at the ESGCT 2022 Meeting. In addition to demonstrating direct binding to the human isoform of this receptor, our experiments have demonstrated that overexpression of the human or murine orthologs of this receptor mediates improved transduction with AAV in cultured cells, supporting a conserved cross-species mechanism of action of transduction of this BBB-penetrant TRACER capsid. Further, the specificity of this AAV-to-receptor interaction is supported by experiments demonstrating that pharmacological manipulation of the receptor functionally impacts cellular transduction by the capsid, and that inhibition of the receptor translocation to the cell surface negates the positive effect on transduction. Expression of this receptor has been confirmed in rodent, NHP, and human endothelial cells and multiple other CNS cell types. Accordingly, we believe that the characterization of this receptor and confirmation that VCAP-101 and VCAP-102 capsids can bind to the human isoform of the receptor increases the probability that the TRACER capsid will cross the BBB in humans. We expect the discovery of this receptor to support the clinical translatability of this TRACER capsid toward human application, and inform our approach to the design of future TRACER capsids for intravenous delivery. We also intend to explore whether this receptor has the potential to enable intravenous delivery to the CNS for other therapeutic modalities such as proteins, antibodies, and oligonucleotides.

We are actively engaged in discussions to make TRACER capsids available to third parties for use in their drug development programs through potential option and license and other arrangements. We believe there is significant opportunity for option and license transactions related to our TRACER capsids. To maximize the potential of our TRACER capsids for both our own programs and option and license transactions, we have retained to date, and expect to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with the optionee’s or licensee’s transgenes.

Pfizer Option and License Agreement

In October 2021, we entered into the Pfizer Agreement, pursuant to which we have granted Pfizer options to receive an exclusive license, or the Pfizer License Options, to certain TRACER capsids to develop and commercialize certain AAV gene therapy candidates comprised of a capsid and specified Pfizer transgenes, which we refer to as the Pfizer Transgenes. Under the terms of the Pfizer Agreement, during an initial research term that ended as of October 1, 2022, or the Pfizer Research Term, Pfizer had the right to evaluate the potential use of the capsids in combination with up to two Pfizer Transgenes to help treat respective CNS and cardiovascular diseases.

During the Pfizer Research Term, we agreed to provide Pfizer with certain quantities of materials encoding specified existing capsids for Pfizer’s evaluation. Further, during the Pfizer Research Term, we agreed to disclose to Pfizer, on a rolling basis, the performance characteristics identified during the Pfizer Research Term for all such capsid candidates. Pfizer had the right, in its sole discretion, to select any capsid candidate for evaluation to determine its interest in exercising a Pfizer License Option with respect to such capsid candidate. Pfizer had the right to exercise up to two Pfizer License Options, provided that it could exercise only one Pfizer License Option for each Pfizer Transgene.

Effective as of September 30, 2022, Pfizer exercised a Pfizer License Option with respect to a capsid for the specified Pfizer Transgene for potential treatment of a rare neurological disease. Pfizer did not exercise its option to license a capsid for the potential treatment of a cardiovascular disease. As result, Pfizer’s right to exercise a Pfizer License Option for a cardiovascular disease has terminated in accordance with the terms of the Pfizer Agreement and all rights to capsids for that cardiovascular disease have reverted to us. Pfizer’s exercise of a Pfizer License Option extends the Pfizer Research Term to October 1, 2024, during which period we may, at our sole discretion and expense, conduct additional research activities to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of the rare neurological disease associated with the exercise of the applicable Pfizer License Option.

Effective September 30, 2022, pursuant to the exercise of the Pfizer License Option for a rare neurological disease, we granted Pfizer an exclusive, worldwide license, with the right to sublicense, under certain of our intellectual property, the rights to develop and commercialize rare neurological disease products utilizing the capsid candidate and incorporating the corresponding Pfizer Transgene, or the Pfizer Licensed CNS Products. Pfizer may, during the Pfizer Research Term, conduct additional evaluations of capsid candidates and has the right to substitute any other capsid candidate for the capsid it previously elected to license when it exercised the Pfizer License Option.

33

Novartis Option and License Agreement

In March 2022, we entered into the Novartis Agreement, pursuant to which we have granted Novartis options, which we refer to as the Novartis License Options, to license novel capsids generated from our TRACER discovery platform, or Novartis Licensed Capsids, for exclusive use with certain targets to develop and commercialize adeno-associated virus gene therapy candidates comprised of Novartis Licensed Capsids and payloads directed to such targets, or the Novartis Payloads.

During the period, which we refer to as the Novartis Research Term, commencing on the Novartis Effective Date and ending on the first anniversary thereof or, in the event Novartis exercises a Novartis License Option, the third anniversary thereof, we have granted Novartis a non-exclusive research license to evaluate our TRACER capsids for potential use, in combination with Novartis Payloads, in programs targeting three specified genes, which we refer to as the Initial Novartis Targets. Upon the payment of additional fees, Novartis may also assess our TRACER capsids for use with two other targets, which we refer to as Additional Novartis Targets, subject to certain conditions including that such target is not part of, or reasonably competitive with, our current development programs. We refer to the Initial Novartis Targets and the Additional Novartis Targets, collectively, as the Novartis Targets. During the Novartis Research Term, we may, at our sole discretion and expense, conduct further research activities to identify additional TRACER capsids. If we elect to do so, we have agreed to disclose performance characteristics of such new TRACER capsids to Novartis on a rolling basis.

During the Novartis Research Term, Novartis may exercise up to three Novartis License Options—or up to five Novartis License Options if Novartis is evaluating the Additional Novartis Targets—in the aggregate, provided that Novartis may only exercise one Novartis License Option for each Novartis Target. Upon the exercise of any Novartis License Option, we have agreed to grant Novartis a target-exclusive, worldwide license, with the right to sublicense, under certain of our intellectual property, the rights to develop and commercialize the applicable Novartis Licensed Capsid as incorporated into products containing the corresponding Novartis Payload, or the Novartis Licensed Products. Upon the exercise of a Novartis License Option, we have agreed to provide certain additional know-how to enable Novartis to exploit the Novartis Licensed Capsid and the corresponding Novartis Payload for use in a Novartis Licensed Product. Novartis may, during the Novartis Research Term but following the exercise of a Novartis License Option, conduct additional evaluation of our capsid candidates and has the right to substitute any other TRACER capsid for a Novartis Licensed Capsid.

Neurocrine Collaboration

In January 2019, we entered into the Neurocrine Collaboration Agreement for the research, development and commercialization of four programs including the VY-AADC Program, a gene therapy for the treatment of Friedreich’s ataxia, or the FA Program, and other undisclosed programs, or the Discovery Programs. The Neurocrine Collaboration Agreement became effective in March 2019. Under the terms of the Neurocrine Collaboration Agreement, we received an upfront payment of $115.0 million and may receive future development and regulatory milestone payments and royalties. In connection with the Neurocrine Collaboration Agreement, Neurocrine also paid us $50.0 million as consideration for an equity purchase of 4,179,728 shares of our common stock. In June 2019, in conjunction with the termination of the collaboration agreement that we entered into with Genzyme Corporation in February 2015, we transferred ex-U.S. rights to the FA Program to Neurocrine pursuant to an amendment to the Neurocrine Collaboration Agreement and received a $5.0 million payment from Neurocrine. Neurocrine is responsible for all costs incurred by us in conducting development activities for programs under the Neurocrine Collaboration Agreement, in accordance with an agreed budget.

The FA Program is currently in preclinical development. We and Neurocrine are evaluating the potential use of our TRACER capsids in the context of the FA Program to allow for enhanced transduction across the disease target tissues. If we and Neurocrine successfully identify a development candidate for this program, we plan to complete IND enabling studies to evaluate its safety and efficacy.

34

We and Neurocrine have nominated targets for the two Discovery Programs, the joint steering committee has approved those targets for development under the Discovery Programs, and the two targets are currently under development.

GBA1 Gene Replacement Program for the Treatment of Parkinson’s Disease

We are developing a gene therapy leveraging a BBB-penetrant, CNS-tropic TRACER capsid to treat diseases linked to GBA1 mutations via a gene replacement approach. Our lead indication for this gene therapy is Parkinson’s disease with GBA1 mutations. Mutations in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase, or GCase, are the most common genetic risk factor for synucleinopathies such as Parkinson’s disease. Parkinson’s disease is among the most common neurodegenerative diseases, impacting about one million patients in the United States and more than 10.0 million patients worldwide. Up to 10% of Parkinson’s disease patients have a GBA1 mutation, and these mutations increase the risk of Parkinson’s disease by approximately 20-fold. GBA1 mutations decrease the expression of GCase, leading to the accumulation of GCase substrates and alpha-synuclein aggregates, which is thought to be toxic to neurons.

We believe that restoring GCase activity may attenuate disease progression and potentially slow neurodegeneration. We anticipate delivering GBA1 via intravenous administration to enable widespread distribution to multiple affected brain regions and to avoid the need for more invasive approaches. We believe that the measurement of the GCase substrates such as glucosylsphingosine as cerebrospinal fluid biomarkers may facilitate efficient clinical demonstration of proof-of-biology. Such substrates of the GCase enzyme are elevated in the cerebrospinal fluid of Parkinson’s disease patients who harbor the GBA1 mutation, and we expect that substrate levels would fall to normal if our gene therapy restores GCase enzyme expression in the brain. This gene therapy may also have potential utility in idiopathic Parkinson’s disease, where there is evidence of loss of GCase activity in the substantia nigra in Parkinson’s disease patients even in the absence of GBA1 mutations as well as evidence of lysosomal dysfunction in general.

At the ASGCT 2022 Meeting, we presented preclinical data demonstrating CNS target engagement and delivery of therapeutically relevant levels of GCase in a GBA loss of function mouse model, as well as sustained expression for three or more months following intravenous administration.

SOD1 Gene Silencing Program for the Treatment of ALS

We are developing a gene therapy leveraging a BBB-penetrant, CNS-tropic TRACER capsid to treat ALS caused by the SOD1 mutation via a gene silencing approach. SOD1 ALS is typically fatal within approximately three years of diagnosis and impacts approximately 800 patients in the United States, 1,000 patients in the European Union, and 500 patients in Japan. SOD1 mutations in ALS patients are thought to cause a toxic gain-of-function that leads to the degeneration of motor neurons along the entire length of the spinal cord, the brainstem, and the upper motor neurons in the cerebral cortex. We believe that a therapeutic delivering a highly potent small interfering RNA, or siRNA, construct via intravenous administration of an AAV gene therapy with a vectorized siRNA may enable broad CNS knockdown of SOD1, potentially slowing the decline of functional ability in ALS patients with the SOD1 mutation. We believe that a Phase 1 clinical trial to demonstrate reduction in SOD1 in cerebrospinal fluid and neurofilament light chain in plasma will provide evidence of target engagement and the attenuation of motor neuron loss, respectively.

At the ASGCT 2022 Meeting, we presented preclinical data demonstrating robust SOD1 knockdown in all levels of the spinal cord and significant improvements in motor performance, body weight, and survival in an SOD1-ALS mouse model following intravenous delivery of a vectorized siRNA using a mouse BBB-penetrant capsid.

Anti-Tau Antibody Program for the Treatment of Alzheimer’s Disease

We are developing proprietary antibodies that selectively target pathological tau to treat tauopathies and our lead indication is Alzheimer’s disease. We have maintained a long-standing focus on developing proprietary and complimentary approaches to disrupt the progression of tau pathology believed to be central to Alzheimer’s disease and other tauopathies. Reduction of toxic tau aggregates may slow disease progression and cognitive decline in these diseases. We are exploring both passive administration and vectorized delivery utilizing our BBB-penetrant TRACER

35

capsids with our anti-tau antibody. Our anti-tau antibodies have differentiated properties including improved targeting of specific regions of tau protein that could offer an improved profile compared to first-generation approaches. We believe that our antibody targeting the C-terminus is highly differentiated from other approaches. Further, we believe that following the clearance of an IND application, clinical assessments utilizing positron emission tomography (PET) imaging of human tau, together with measuring plasma and cerebrospinal fluid biomarkers, have the potential to enable an efficient and accelerated demonstration of human proof-of-biology.

At the Alzheimer’s Association International Conference in August 2022, we presented data for our proprietary anti-tau antibodies, targeting the mid-domain and C-terminus with high affinity and showing favorable biophysical characteristics and strong activity in preclinical studies in mouse models. In the P301S seeding-propagation tauopathy mouse model, our C-terminal targeting anti-tau antibody blocked the seeding/propagation of filamentous tau and demonstrated substantial reduction of induced tau pathology.

Vector Engineering and Optimization

The key components of an AAV vector include: (i) the capsid; (ii) the therapeutic gene, or transgene; and (iii) payload control elements, including the promoter or other DNA sequences that modulate the expression of the transgene. We have advanced or intend to advance our multiple preclinical programs towards selection of lead clinical candidates using AAV vectors that we believe are best suited for each of our programs either through use of our existing capsids, through exercising a non-exclusive worldwide commercial license to capsid sequences covered by third parties, or by engineering or optimizing TRACER capsids. We have also built, or intend to build, capabilities to design, screen, and advance genetic sequences within our AAV vectors, including transgenes and payload control elements, to create optimized therapeutic candidates for each of our preclinical programs.

Accumulated Deficit

We have a history of incurring significant losses. Our net loss was $22.8 million for the nine months ended September 30, 2022. As of September 30, 2022, we had an accumulated deficit of $369.9 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

continue investing in our gene therapy platform to optimize capsid engineering and payload development, manufacturing, dosing, and delivery techniques;
increase our investment in and support for TRACER, our proprietary discovery platform to facilitate the selection of AAV capsids and expand our investment to discover TRACER capsids with broad tropism in CNS and other tissues with cell-specific transduction properties for particular therapeutic applications;
continue to develop our proprietary antibodies and vectorized antibody platform;
enter into option and license agreements regarding our TRACER capsids, such as the Pfizer Agreement and the Novartis Agreement;
conduct preclinical development activities and initiate IND-enabling studies and clinical trials in connection with our tau antibody program, our GBA1 gene therapy program, and our SOD1 ALS gene therapy program;
initiate additional preclinical studies and clinical trials for, and continue research and development of, our other programs;
conduct joint research and development under our strategic collaborations for the research, development, and commercialization of certain of our pipeline programs;

36

continue our process research and development activities, as well as establish our research-grade and commercial manufacturing capabilities;
identify additional diseases for treatment with our AAV gene therapies and develop additional programs or product candidates;
seek marketing and regulatory approvals for any of our product candidates or devices that successfully complete clinical development;
maintain, expand, protect and enforce our intellectual property portfolio;
identify, acquire or in-license other product candidates and technologies;
develop a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval;
expand our operational, financial and management systems and personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;
increase our product liability and clinical trial insurance coverage as we expand our clinical trials and commercialization efforts;
continue to operate as a public company; and
determine the appropriate path forward, if any, for VY-AADC (NBIb-1817) as a treatment for Parkinson’s disease.

Financial Operations Overview

Revenue

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. For the nine months ended September 30, 2022, we recognized $40.0 million of collaboration revenue from the Pfizer Agreement and $2.5 million of collaboration revenue from the Neurocrine Collaboration.

For additional information about our revenue recognition policy related to collaborations and a description of the key terms of the Neurocrine Collaboration Agreement, the Pfizer Agreement, and the Novartis Agreement, refer to Note 8, Commitments and Contingencies, of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

For the foreseeable future, we expect substantially all of our revenue will be generated from the Neurocrine Collaboration Agreement, the Pfizer Agreement, the Novartis Agreement, and any other strategic collaborations and out-licensing arrangements we may enter into. If our development efforts are successful, we may also generate revenue from product sales in the future.

37

Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our program discovery efforts, and the development of our programs, gene therapy platform, proprietary antibodies, and vectorized antibody platform which include:

employee-related expenses including salaries, benefits, and stock-based compensation expense;
costs of funding research performed by third parties that conduct research and development, clinical and preclinical activities, manufacturing and production design on our behalf;
the cost of purchasing laboratory supplies and non-capital equipment used in designing, developing and manufacturing preclinical study materials;
consultant fees;
facility costs including rent, depreciation and maintenance expenses
the cost of securing and protecting intellectual property rights associated with our research and development activities; and
fees for maintaining licenses under our third-party licensing agreements.

Research and development costs are expensed as incurred. Costs for certain activities, such as manufacturing, preclinical studies, and clinical trials, are generally recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and collaborators.

At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product candidates. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty of:

identifying additional product candidates;
completing preclinical studies successfully;
designing, initiating, enrolling and completing clinical trials successfully;
establishing an appropriate safety profile;
establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
receiving marketing approvals from applicable regulatory authorities;
commercializing the product candidates, if and when approved, whether alone or in collaboration with others;
obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;

38

continued acceptable safety profiles of the products following approval; and
recruiting and retaining key research and development personnel.

A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate.

Research and development activities are central to our business model. We are in the early stages of development of our product candidates. Our research and development costs have decreased relative to pre-2021 levels as a result of our strategic restructuring, the reevaluation of our product candidate pipeline, our strategic shift to invest in TRACER capsid development efforts, and our initiation of other cost-saving initiatives. As our development programs progress and as we identify product candidates and initiate preclinical studies and clinical trials, we expect research and development costs to increase.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development, legal and human resource functions. Other significant costs include corporate facility costs not otherwise included in research and development expenses, legal fees related to patent and corporate matters and fees for accounting and consulting services.

Our general and administrative expenses have decreased relative to pre-2021 levels as a result of our strategic restructuring costs. As a result of the strategic restructuring, there are decreases including a reduction in personnel costs and fees paid to outside consultants, as well as other cost-saving initiatives including a reduction in facility-related expenditures. As our development programs progress and we identify product candidates and initiate preclinical studies and clinical trials, we expect general and administrative expenses to increase to support these additional research and development activities.

Other Income, net

Other income, net for the three months ended September 30, 2022 consists primarily of an employee retention tax credit under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, and interest income on our marketable securities.

Critical Accounting Policies and Estimates

We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate. There were no changes to our critical accounting policies during the nine months ended September 30, 2022, as compared to those identified in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. It is important that the discussion of our operating results that follow be read in conjunction with the critical accounting policies disclosed in our Annual Report on Form 10-K, as filed with the SEC on March 8, 2022.

39

Results of Operations

Comparison of the three months ended September 30, 2022 and 2021

The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021, together with the changes in those items in dollars:

Three Months Ended

September 30, 

2022

    

2021

    

Change

(in thousands)

Collaboration revenue

$

41,086

    

$

1,482

    

$

39,604

Operating expenses:

Research and development

 

19,337

 

17,914

 

1,423

General and administrative

 

7,307

 

8,714

 

(1,407)

Total operating expenses

 

26,644

 

26,628

 

16

Other income, net:

Interest income

545

121

424

Other income (expense)

2,637

(112)

2,749

Total other income, net

 

3,182

 

9

 

3,173

Net income (loss)

$

17,624

$

(25,137)

$

42,761

Collaboration Revenue

Collaboration revenue was $41.1 million and $1.5 million for the three months ended September 30, 2022 and 2021, respectively. The increase in collaboration revenue was largely a result of revenue recognized during the three months ended September 30, 2022 in connection with Pfizer’s decision to exercise the first material right for the Pfizer License Option, along with the expiration of the second material right associated with the Pfizer License Option. This is offset by decreased research and development services and cost reimbursement from the Neurocrine Collaboration. During the three months ended September 30, 2021, collaboration revenue was entirely related to research services and cost reimbursement from the Neurocrine Collaboration. As a result of changes in our estimates of research and development services in the fourth quarter of 2021, we expect to record less revenue associated with research and development services for the Neurocrine Collaboration. We expect a significant portion of revenue recognized in future periods to be attributable to the Novartis Agreement. Our collaboration revenues were not materially impacted by the coronavirus disease 2019, or COVID-19, pandemic during the three months ended September 30, 2022. In subsequent periods, the COVID-19 pandemic could affect our collaboration revenues and our operations.

Research and Development Expense

Research and development expense increased by $1.4 million from $17.9 million for the three months ended September 30, 2021, to $19.3 million for the three months ended September 30, 2022. The following table summarizes our research and development expenses for the three months ended September 30, 2022 and 2021, together with the changes in those items in dollars:

Three Months Ended

September 30, 

2022

    

2021

    

Change

(in thousands)

Employee and consultant

$

7,804

$

8,697

$

(893)

External research and development

7,787

    

4,436

3,351

Facilities and other

 

1,846

 

2,547

 

(701)

Professional fees

 

1,900

 

2,234

 

(334)

Total research and development expenses

$

19,337

$

17,914

$

1,423

40

The increase in research and development expense for the three months ended September 30, 2022 was primarily attributable to the following:

approximately $3.4 million for external research and development costs primarily related to the non-refundable technology access fee for our license agreement with Touchlight IP Limited, or Touchlight, partially offset by a reduction in clinical activities to prepare for the first-in-humans trial of VY-HTT01 for our first-generation Huntington’s disease program;
partially offset by approximately $0.9 million for decreased employee and consultant related costs associated with lower headcount in research and development functions as compared to the prior year; and
partially offset by approximately $0.7 million for decreased facility and other costs primarily related to the termination of the lease for office and laboratory space at 75 Sidney Street during the second quarter of 2022.

General and Administrative Expense

General and administrative expense decreased by $1.4 million from $8.7 million for the three months ended September 30, 2021 to $7.3 million for the three months ended September 30, 2022. The decrease in general and administrative expense was primarily attributable to the following:

approximately $0.9 million for decreased compensation costs and stock-based compensation associated with recognition of the severance expensed as a result of the reduction in force during the three months ended September 30, 2021; and
approximately $0.4 million for decreased facility and other costs primarily related to the termination of the lease for office and laboratory space at 75 Sidney Street during the second quarter of 2022.

Other Income, net

Other income, net of approximately $3.2 million was recognized during the three months ended September 30, 2022 as compared to less than $0.1 million during the three months ended September 30, 2021. Other income, net during the three months ended September 30, 2022 primarily related to an employee retention tax credit under the CARES Act and interest income on marketable securities balances, while other income, net during the three months ended September 30, 2021 primarily related to interest income on marketable securities balances.

41

Comparison of the nine months ended September 30, 2022 and 2021

The following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021, together with the changes in those items in dollars:

Nine Months Ended

September 30, 

2022

    

2021

    

Change

(in thousands)

Collaboration revenue

$

42,457

    

$

9,342

    

$

33,115

Operating expenses:

Research and development

 

46,213

 

59,767

 

(13,554)

General and administrative

 

22,518

 

28,895

 

(6,377)

Total operating expenses

 

68,731

 

88,662

 

(19,931)

Other income, net:

Interest income

816

253

563

Other income

2,676

2,161

515

Total other income, net

 

3,492

 

2,414

 

1,078

Net loss

$

(22,782)

$

(76,906)

$

54,124

Collaboration Revenue

Collaboration revenue was $42.5 million and $9.3 million for the nine months ended September 30, 2022 and 2021, respectively. The increase in collaboration revenue was largely a result of revenue recognized during the nine months ended September 30, 2022 in connection with Pfizer’s decision to exercise the first material right for the Pfizer License Option, along with the expiration of the second material right associated with the Pfizer License Option. This is offset by decreased research and development services and cost reimbursement from the Neurocrine Collaboration. During the nine months ended September 30, 2021, collaboration revenue was entirely related to research services and cost reimbursement from the Neurocrine Collaboration. As a result of changes in our estimates of research and development services in the fourth quarter of 2021, we expect to record less revenue associated with research and development services for the Neurocrine Collaboration. We expect a significant portion of revenue recognized in future periods to be attributable to the Novartis Agreement. Our collaboration revenues were not materially impacted by the COVID-19 pandemic during the nine months ended September 30, 2022. In subsequent periods, the COVID-19 pandemic could affect our collaboration revenues and our operations.

Research and Development Expense

Research and development expense decreased by $13.6 million from $59.8 million for the nine months ended September 30, 2021, to $46.2 million for the nine months ended September 30, 2022. The following table summarizes our research and development expenses for the nine months ended September 30, 2022 and 2021, together with the changes in those items in dollars:

Nine Months Ended

September 30, 

2022

    

2021

    

Change

(in thousands)

Employee and consultant

$

21,370

    

$

30,382

$

(9,012)

External research and development

12,382

14,784

(2,402)

Facilities and other

 

6,465

 

7,525

 

(1,060)

Professional fees

 

5,996

 

7,076

 

(1,080)

Total research and development expenses

$

46,213

$

59,767

$

(13,554)

42

The decrease in research and development expense for the nine months ended September 30, 2022 was primarily attributable to the following:

approximately $9.0 million for decreased employee and stock-based compensation associated with lower headcount in research and development functions compared to the prior year;
approximately $2.4 million for decreased external research and development costs primarily related to a reduction in clinical and manufacturing activities to prepare for the first-in-humans trial of the VY-HTT01 for the Huntington’s disease and a reduction in external costs incurred in connection with the Neurocrine Collaboration Agreement, partially offset by the non-refundable technology access fee for our license agreement with Touchlight;
approximately $1.1 million for decreased facility and other costs primarily related to the termination of the lease for office and laboratory space at 75 Sidney Street during the second quarter of 2022; and
approximately $1.1 million for decreased professional fees and related expenses to support the pipeline programs.

General and Administrative Expense

General and administrative expense decreased by $6.4 million from $28.9 million for the nine months ended September 30, 2021 to $22.5 million for the nine months ended September 30, 2022. The decrease in general and administrative expense was primarily attributable to the following:

approximately $4.0 million for decreased compensation costs and stock-based compensation associated with recognition of the severance as a result of the reduction in force during the nine months ended September 30, 2021;
approximately $1.2 million for decreased facility and other costs primarily related to the termination of the lease for office and laboratory space at 75 Sidney Street during the second quarter of 2022; and
approximately $1.2 million for decreased legal costs and intellectual property related expenses.

Other Income, net

Other income, net of approximately $3.5 million was recognized during the nine months ended September 30, 2022, as compared to $2.4 million during the nine months ended September 30, 2021. Other income, net during the nine months ended September 30, 2022 primarily related to an employee retention tax credit under the CARES Act and interest income on marketable securities balances, while other income, net during the nine months ended September 30, 2021 primarily related to interest income on marketable securities balances.

License Agreement with Touchlight

On November 3, 2022, we and Touchlight entered into a license agreement, or the Touchlight License Agreement, to authorize historical use by us of a certain DNA preparation process, or the Subject DNA Preparation Process, and to authorize the prospective exploitation of TRACER Capsids created with the use of the Subject DNA Preparation Process.

The terms of the Touchlight License Agreement include a one-time, non-refundable technology access fee of $5.0 million, payable to Touchlight during the fourth quarter of 2022. As of September 30, 2022, we determined that this technology access fee was a probable liability that could be reasonably estimated in accordance with ASC 450

43

Contingencies as of such date. The Company recorded the $5.0 million charge during the third quarter of 2022, accordingly.

The terms of the Touchlight License Agreement also include future milestone payments and low single-digit royalties payable to Touchlight if we or our program collaborators or licensees choose to utilize in a therapeutic product TRACER Capsids that were created with the historical use of the Subject DNA Preparation Process. Additionally, we are obligated to pay low single-digit royalties to Touchlight on future payments we receive in connection with licensing of TRACER capsids that were created with the historical use of the Subject DNA Preparation Process, excluding the licensing of or collaboration on our therapeutic programs.

COVID-19

The COVID-19 pandemic continues to evolve. We have and will continue to be guided by applicable guidelines and safety measures, including any stay-at-home policies for certain non-essential employees, consultants, contractors, and staff. Certain of our collaboration partners, suppliers and consultants have experienced facility closures or been subject to quarantines, travel restrictions and other governmental restrictions or supply chain disruptions and have appropriately diverted attention and resources to respond to the impacts of COVID-19 on their own operations and personnel. Some have even become involved in research and development efforts related to COVID-19.

We will continue to monitor the issues raised by the global spread of COVID-19 and have put in place and will continue to put in place measures as appropriate and necessary for, or that we believe to be in the best interest of, our business, employees, collaborators, stockholders, and the community.

Liquidity and Capital Resources

Sources of Liquidity

We have funded our operations primarily through private placements of redeemable convertible preferred stock, public offerings of our common stock, strategic collaborations and option and license arrangements, including our ongoing Neurocrine Collaboration, our ongoing option and license arrangements with Pfizer and Novartis under the Pfizer Agreement and the Novartis Agreement, respectively, and our prior Sanofi Genzyme Collaboration, AbbVie Tau Collaboration, and AbbVie Alpha-Synuclein Collaboration.

As of September 30, 2022, we had cash, cash equivalents, and marketable securities of $131.6 million. Based upon our current operating plans, we expect that our existing cash, cash equivalents, and marketable securities at September 30, 2022, together with amounts expected to be received as reimbursement for development costs under the Neurocrine Collaboration Agreement, and the Pfizer option exercise payment of $10.0 million paid to us in the fourth quarter of 2022, will enable us to meet our planned operating expenses and capital expenditure requirements into 2024.

Cash Flows

The following table provides information regarding our cash flows for the nine months ended September 30, 2022 and 2021:

Nine Months Ended

September 30, 

2022

    

2021

    

    

(in thousands)

Net cash (used in) provided by:

    

Operating activities

$

(265)

$

(64,720)

Investing activities

 

(21,406)

 

71,370

Financing activities

 

834

 

385

Net (decrease) increase in cash, cash equivalents, and restricted cash

$

(20,837)

$

7,035

44

Net Cash Used in Operating Activities

Net cash used in operating activities was $0.3 million during the nine months ended September 30, 2022 compared to $64.7 million of net cash used in operating activities during the nine months ended September 30, 2021. The decrease in cash used in operating activities was primarily due to an increase in deferred revenue, as well as a decrease in net loss during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021.

Net Cash (Used in) Provided by Investing Activities

Net cash used in investing activities was $21.4 million during the nine months ended September 30, 2022 compared to $71.4 million of net cash provided by investing activities during the nine months ended September 30, 2021. The net cash used in investing activities for the nine months ended September 30, 2022 was primarily due to $54.8 million for purchases of marketable securities offset by $35.0 million in proceeds from sales and maturities of marketable securities. The net cash provided by investing activities for the nine months ended September 30, 2021 was primarily due to proceeds of $72.6 million from sales and maturities of marketable securities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was $0.8 million and $0.4 million during the nine months ended September 30, 2022 and September 30, 2021, respectively, primarily due to the proceeds from the exercise of stock options.

Funding Requirements

We expect our expenses to decrease during the current year as compared with the prior year as a result of our strategic restructuring, the reevaluation of our product candidate pipeline, our strategic shift to invest in TRACER capsid development efforts, and our initiation of other cost-saving initiatives. We expect our expenses to increase in the longer term, however, as we continue the research and development of, conduct clinical trials of, and seek marketing approval for, our product candidates and as we continue to enter into or conduct activities in connection with our collaboration agreements. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to program sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. Furthermore, we expect to incur increasing costs associated with operating as a public company, meeting financial controls, satisfying regulatory and quality standards, fulfilling healthcare compliance requirements, and maintaining product, clinical trial and directors’ and officers’ liability insurance coverage. We also anticipate the cost of goods and services and the levels of compensation paid to employee will increase due to inflationary conditions existing in the general economy. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital or enter into business development transactions when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

Based upon our current operating plan, we expect that our existing cash, cash equivalents, and marketable securities at September 30, 2022, together with amounts expected to be received as reimbursement for development costs under the Neurocrine Collaboration Agreement and the Pfizer option exercise payment of $10.0 million paid to us in the fourth quarter of 2022, will be sufficient to meet our planned operating expenses and capital expenditure requirements into 2024. Our future capital requirements will depend on many factors, including:

the scope, progress, results, and costs of product discovery, preclinical studies and clinical trials for our product candidates;
the scope, progress, results, costs, prioritization, and number of our research and development programs;
the progress and status of our strategic collaborations and option and license agreements and any similar arrangement we may enter into in the future, including any research and development costs for which we

45

are responsible, our collaborators’ or licensors’ willingness and ability to approve desirable budgets for research and development costs for which they are responsible, the potential exercise by our collaboration partners or licensors of any options to develop or license certain products and product candidates that they might have, our potential receipt of future milestone payments and royalties from our collaboration partners or licensors, and any decisions by our collaborators or licensors to exercise their rights to terminate a collaboration in whole or in part;
the extent to which we are obligated to reimburse, or entitled to reimbursement of, preclinical development and clinical trial costs, or the achievement of milestones or occurrence of other developments that trigger payments such as milestone and royalty payments under any collaboration or license agreements to which we might become a party, such as the Touchlight License Agreement;
the costs, timing and outcome of regulatory review of our product candidates;
our ability to establish and maintain collaboration, distribution, or other marketing arrangements for our product candidates on favorable terms, if at all;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
the extent to which we acquire or in-license other product candidates and technologies, including any intellectual property associated with such candidates or technologies, acquire or invest in other businesses, or out-license our product candidates, capsids or other technologies;
the costs of advancing our manufacturing capabilities and securing manufacturing arrangements for pre-commercial and commercial production;
the level of product sales by us or our collaborators from any product candidates for which we obtain marketing approval in the future;
the costs of operating as a public company, meeting applicable financial, regulatory, and quality control standards, fulfilling healthcare compliance requirements, and maintaining adequate product, clinical trial, and directors’ and officers’ liability insurance coverage; and
the costs of establishing or contracting for sales, manufacturing, marketing, distribution, and other commercialization capabilities if we obtain regulatory approvals to market our product candidates.

Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete. We may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenues, if any, and any commercial milestone payments or royalty payments under our collaboration agreements, will be derived from sales of products that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing and business development transactions to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Until such time, if ever, as we can generate product revenues sufficient to achieve consistent profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and option and license arrangements. We do not have any committed external source of funds other than the amounts we are entitled to receive from our collaboration partners and licensors for reimbursement of certain research and development expenses, potential option exercises, the achievement of specified regulatory and commercial milestones, and royalty payments under our collaboration, and option and license agreements, as applicable. To the extent that we raise additional capital through the sale of equity or equity-linked securities, including convertible debt,

46

our stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders’ rights as holders of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, obtaining additional capital, acquiring or divesting businesses, making capital expenditures or declaring dividends.

If we raise additional funds through collaborations, strategic alliances, or option and license arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Contractual Obligations

We enter into agreements in the normal course of business with clinical research organizations, contract manufacturing organizations, and institutions to license intellectual property. These contracts are generally cancelable at any time by us, upon 30 to 90 days prior written notice.

Our agreements to license intellectual property include potential milestone payments that are dependent upon the development of products using the intellectual property licensed under the agreements and contingent upon the achievement of clinical trial or regulatory approval milestones. We may also be required to pay annual maintenance fees or minimum amounts payable ranging from low-four digits to low five-digits depending upon the terms of the applicable agreement. In certain instances, we are also obligated to pay our licensors royalties based on sales of products, if approved, using the intellectual property licensed under the applicable agreement.

We also have non-cancelable operating lease commitments arising from our leases of office and laboratory space at our facilities in Cambridge and Lexington, Massachusetts.

Other than the termination of our lease for office and laboratory space at 75 Sidney Street, as discussed elsewhere in this Quarterly Report on Form 10-Q, there were no material changes to our contractual obligations and commitments described under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 8, 2022.

Off-Balance Sheet Arrangements

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. We have policies requiring us to invest in high-quality issuers, limit our exposure to any individual issuer, and ensure adequate liquidity. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents, are in the form of money market funds and marketable securities and are invested in U.S. Treasury notes. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.

We are not currently exposed to market risk related to changes in foreign currency exchange rates; however, we may contract with vendors that are located in Asia and Europe in the future and may be subject to fluctuations in foreign currency rates at that time.

47

Inflation generally affects us by increasing our costs of labor, goods, and services. We do not believe that inflation had a material effect on our business, financial condition, or results of operations during the three and nine months ended September 30, 2022.

ITEM 4. CONTROLS AND PROCEDURES

Management’s Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act to mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and other procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of September 30, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.

We continue to review and document our disclosure controls and procedures and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.

Changes in Internal Control over Financial Reporting

During the three months ended September 30, 2022, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements and other matters. While the outcome of any such matters cannot be predicted with certainty, as of September 30, 2022, we were not party to any material pending proceedings. No material governmental proceedings are pending or, to our knowledge, contemplated against us. We are not a party to any material proceedings in which any director, member of senior management or affiliate of ours is either a party adverse to us or our subsidiaries or has a material interest adverse to us or our subsidiaries.

ITEM 1A. RISK FACTORS

The following risk factors and other information in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and related notes thereto, should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see page 1 of this Quarterly Report on Form 10-Q for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.

48

Risks Related to Our Financial Position and Need for Capital

We have a history of incurring significant losses and anticipate that we will continue to incur losses for the foreseeable future and may never achieve or maintain consistent profitability.

We are an early-stage gene therapy company with a limited operating history and have not yet generated revenues from the sales of our product candidates. All of our product candidates are in the early stages of development. Investment in biotechnology companies is highly speculative because it entails substantial upfront capital expenditures and significant risk that any product candidates will fail to be safe and efficacious, obtain regulatory approval or become commercially viable. We have not yet demonstrated the ability to complete any clinical trials of our product candidates, obtain marketing approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization. We continue to incur significant expenses related to research and development, and other operations in order to commercialize our product candidates. We have a history of incurring significant operating losses. We had net losses of $22.8 million and $76.9 million for the nine months ended September 30, 2022 and September 30, 2021, respectively. As of September 30, 2022, we had an accumulated deficit of $369.9 million.

We historically have financed our operations primarily through private placements of our redeemable convertible preferred stock, public offerings of our common stock, and strategic collaborations, including our prior collaborations with Sanofi Genzyme Corporation, or Sanofi Genzyme, and AbbVie, and our ongoing collaboration with Neurocrine Biosciences, Inc., or Neurocrine, our option and license agreement with Pfizer Inc., or Pfizer, which commenced in October 2021, and our option and license agreement with Novartis Pharma, AG, or Novartis, which commended in March 2022. We refer to the Pfizer option and license agreement as the Pfizer Agreement, and to the Novartis option and license agreement as the Novartis Agreement.

To date, we have devoted substantially all of our financial resources to building our gene therapy platform, selecting product programs, conducting research and development, including preclinical development of our product candidates, building our intellectual property portfolio, building our team, and establishing strategic collaborations. We expect that it could be several years before we have a commercialized product, if we ever succeed in doing so. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We also anticipate the cost of goods and services and the levels of compensation paid to employees will increase due to inflationary conditions existing in the general economy. The net losses we incur may fluctuate significantly from quarter to quarter.

Although our expenses have decreased relative to pre-2021 as a result of our strategic restructuring, the reevaluation of our product candidate pipeline, and our strategic shift to invest in TRACER capsid development efforts, we anticipate that our expenses will increase substantially if, and as, we:

continue investing in our gene therapy platform to optimize capsid engineering and payload development, manufacturing, dosing, and delivery techniques;
increase our investment in and support for TRACERTM (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA), our proprietary discovery platform to facilitate the selection of AAV capsids and expand our investment to discover TRACER capsids with broad tropism in central nervous system, or CNS and other tissues with cell-specific transduction properties for particular therapeutic applications;
continue to develop our proprietary antibodies and vectorized antibody platform;
enter into option and license agreements regarding our TRACER capsids, such as the Pfizer Agreement and the Novartis Agreement;
conduct preclinical development activities and initiate investigational new drug, or IND, application-enabling studies and clinical trials in connection with our tau antibody program, our GBA1 gene therapy program, and our SOD1 ALS gene therapy program;

49

initiate additional preclinical studies and clinical trials for, and continue research and development of, our other programs;
conduct joint research and development under our strategic collaborations for the research, development, and commercialization of certain of our pipeline programs;
continue our process research and development activities, as well as establish our research-grade and commercial manufacturing capabilities;
identify additional diseases for treatment with our AAV gene therapies and develop additional programs or product candidates;
seek marketing and regulatory approvals for any of our product candidates or devices that successfully complete clinical development;
maintain, expand, protect and enforce our intellectual property portfolio;
identify, acquire or in-license other product candidates and technologies;
develop a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval;
expand our operational, financial and management systems and personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;
increase our product liability and clinical trial insurance coverage as we expand our clinical trials and commercialization efforts;
continue to operate as a public company; and
determine the appropriate path forward, if any, for VY-AADC (NBIb-1817) as a treatment for Parkinson’s disease.

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve consistent profitability. Our expenses will increase if:

we are required by the U.S. Food and Drug Administration, or FDA, or the European Medicines Agency, or EMA, or other regulatory agencies to redesign or modify trials or studies or to perform trials or studies in addition to those currently expected;
there are any delays in the receipt of regulatory clearance to begin our planned clinical programs; or
there are any delays in enrollment of patients in or completing our clinical trials or the development of our product candidates.

To become and remain profitable, we must develop and commercialize, alone or with our collaborators, product candidates with significant market potential, which will require us to be successful in a range of challenging activities. These activities include completing preclinical studies and clinical trials of our product candidates; obtaining marketing approval for these product candidates; contracting with third parties with expertise in current good manufacturing practice, or cGMP, manufacturing to manufacture our product candidates at clinical and commercial scale; marketing and selling those products that are approved; satisfying any post-marketing requirements and achieving an adequate level

50

of market acceptance of and obtaining and maintaining adequate coverage and reimbursement from third-party payors for such products; and protecting our rights to our intellectual property portfolio. We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause our stockholders to lose all or part of their investment.

We may not be able to generate sufficient revenue from the commercialization of our product candidates and may never be consistently profitable.

Our ability to generate revenue and achieve profitability depends on our ability, alone or with our collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our current and future product candidates. All of our product candidates are in the early stages of development. We do not anticipate generating revenues from product sales for at least the next several years, and we may never succeed in doing so. Our ability to generate future revenues from product sales depends heavily on our and our collaborators and licensors’ success in:

completing preclinical and clinical development of our product candidates or product candidates incorporating our licensed capsids or other technologies and identifying new product candidates;
seeking and obtaining regulatory and marketing approvals for product candidates for which we or they complete clinical trials;
launching and commercializing product candidates for which we or they obtain regulatory and marketing approval by establishing a sales, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner;
obtaining and maintaining adequate coverage and reimbursement by government and third-party payors for our product candidates if and when approved;
maintaining and enhancing a sustainable, scalable, reproducible and transferable manufacturing process for our vectors and product candidates;
establishing and maintaining supply and manufacturing relationships with third parties that have the financial, operating and technical capabilities to provide adequate products and services, in both amount and quality, to support clinical development and the market demand for our or their product candidates, if and when approved;
obtaining an adequate level of market acceptance of our or their product candidates as a viable treatment option;
addressing any competing technological and market developments;
implementing additional internal systems and infrastructure, as needed;
negotiating favorable terms in any collaboration, option, licensing, or other arrangements into which we may enter and performing our obligations in such collaborations;
obtaining, maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;
avoiding and defending against third-party claims of interference or infringement; and

51

attracting, hiring and retaining qualified personnel.

Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, EMA, or other regulatory authorities to redesign or modify preclinical studies or clinical trials or to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.

We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.

Although our expenses have decreased relative to pre-2021 levels as a result of our strategic restructuring, the reevaluation of our product candidate pipeline, and our strategic shift to invest in TRACER capsid development efforts, we expect our expenses to increase over time in connection with our ongoing and planned activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. Since the completion of our IPO on November 16, 2015, we have also incurred costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital or enter into business development transactions when needed or on acceptable terms, we could be forced to delay, reduce or eliminate certain of our research and development programs or any future commercialization efforts.

Our operations have consumed significant amounts of cash since inception. As of September 30, 2022, our cash, cash equivalents, and marketable securities were $131.6 million. Based upon our current operating plan, we expect that our existing cash, cash equivalents, and marketable securities at September 30, 2022, together with amounts expected to be received as reimbursement for development costs under our collaboration and license agreement with Neurocrine, or the Neurocrine Collaboration Agreement, and the Pfizer option exercise payment of $10.0 million in the fourth quarter of 2022, will enable us to meet our planned operating expenses and capital expenditure requirements into 2024.

Our future capital requirements will depend on many factors, including:

the scope, progress, results, and costs of product discovery, preclinical studies and clinical trials for our product candidates;
the scope, progress, results, costs, prioritization, and number of our research and development programs;
the progress and status of our strategic collaborations and option and license agreements and any similar arrangement we may enter into in the future, including any research and development costs for which we are responsible, our collaborators’ or licensors’ willingness and ability to approve desirable budgets for research and development costs for which they are responsible, the potential exercise by our collaboration partners or licensors of any options to develop or license certain products and product candidates that they might have, our potential receipt of future milestone payments and royalties from our collaboration partners or licensors, and any decisions by our collaborators or licensors to exercise their rights to terminate a collaboration in whole or in part;
the extent to which we are obligated to reimburse, or entitled to reimbursement of, preclinical development and clinical trial costs, or the achievement of milestones or occurrence of other developments that trigger payments, such as milestone and royalty payments, under any collaboration or license agreement to which we might become a party, such as our license agreement with Touchlight IP Limited, or Touchlight, which we refer to as the Touchlight License Agreement;

52

the costs, timing and outcome of regulatory review of our product candidates;
our ability to establish and maintain collaboration, distribution, or other marketing arrangements for our product candidates on favorable terms, if at all;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
the extent to which we acquire or in-license other product candidates and technologies, including any intellectual property associated with such candidates or technologies, acquire or invest in other businesses, or out-license our product candidates, capsids or other technologies;
the costs of advancing our manufacturing capabilities and securing manufacturing arrangements for pre-commercial and commercial production;
the level of product sales by us or our collaborators from any product candidates for which we obtain marketing approval in the future;
the costs of operating as a public company, meeting applicable financial, regulatory, and quality control standards, fulfilling healthcare compliance requirements, and maintaining adequate product, clinical trial, and directors’ and officers’ liability insurance coverage; and
the costs of establishing or contracting for sales, manufacturing, marketing, distribution, and other commercialization capabilities if we obtain regulatory approvals to market our product candidates.

Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete. We may never generate the necessary data or results required to maintain the financial support of our collaborators or obtain marketing approval and achieve product sales. In the event we are unable to achieve milestones necessary to demonstrate progress on those programs, a current or future collaboration partner or licensor may be unwilling to fund these programs at the desired levels or at all, which could require us to fund these programs to a greater extent than we have expected, to decline to pursue certain program objectives or to discontinue one or more of the programs. Our ability to develop a product candidate for any of our lead gene therapy or other biological therapy programs may take longer than we anticipate, or may not happen at all, and could require funding at a level higher than we expect. Our product revenues, if any, and any commercial milestone payments or royalty payments under our collaboration or option and license agreements will be derived from sales of products that may not be commercially available for many years, if at all. In addition, our product candidates, if approved, may not achieve commercial success. Accordingly, we will need to continue to rely on additional financing and business development to achieve our business objectives. Adequate additional financing or business development transactions may not be available to us on acceptable terms, or at all.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate product revenues sufficient to achieve consistent profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and option and license arrangements. We do not have any committed external source of funds other than the amounts we are entitled to receive from our collaboration partner Neurocrine for the reimbursement of certain research and development expenses, the achievement of specified regulatory and commercial milestones, and royalty payments under our collaboration agreement and the amounts we are entitled to receive from our licensors Pfizer and Novartis for the achievement of specified development, regulatory, and commercialization milestones and royalty payments under the applicable option and license agreements. To the extent that we raise additional capital through the sale of equity or equity-linked securities, including convertible debt, our stockholders’ ownership interests will be diluted. The amount of stockholder dilution will be affected by the size of each securities offering and the offering price for the securities sold. The offering price will likely reflect the prevailing market price for our securities, with dilution increasing as the

53

prevailing market price for our securities decreases. The terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders’ rights as holders of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, obtaining additional capital, acquiring or divesting businesses, making capital expenditures or declaring dividends. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. Our issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our common stock to decline. Further, our existing stockholders may not agree with the terms of such financings.

If we raise additional funds through collaborations, strategic alliances, or option and license arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. Such collaborations, alliances, or option and license arrangements could therefore cause the market price of common stock to decline.

The early stage of our business may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability.

Our operating history to date has been limited to building our team, business planning, raising capital, establishing our intellectual property portfolio, determining which neurological diseases to pursue, advancing our product candidates including delivery and manufacturing and conducting preclinical studies and early-phase clinical trials. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had an operating history that included the late stage of clinical development, completion of clinical development, or commercialization of one or more product candidates.

In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors such as the regulatory actions that previously occurred in connection with the VY-AADC Program for Parkinson’s disease and the VY-HTT01 Program for Huntington’s disease. These and other events that are part of our operating history, and ongoing activities such as our decision to conduct a reevaluation of our product candidate pipeline and to restructure our workforce, may impact our ability to operate our business and to raise capital. All of our product candidates are in the early stages of development. To achieve our current goals, we will need to transition in the future from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.

We expect our financial condition and operating results to continue to fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond our control. Accordingly, our stockholders should not rely upon the results of any quarterly or annual periods as indications of future operating performance.

Risks Related to the Development and Regulatory Approval of Our Product Candidates

Our AAV gene therapy and other biological therapy product candidates are based on a proprietary technology and, in several disease areas, unvalidated treatment approaches, which makes it difficult and potentially infeasible to predict the duration and cost of development of, and subsequently obtaining regulatory approval for, our product candidates. Only two AAV gene therapy products are approved in the United States. In Europe, only four AAV gene therapy products are approved.

We have concentrated our research and development efforts to date on our gene therapy platform, identifying our initial targeted disease indications, and our initial product candidates. Our future success depends on our successful development of viable AAV gene therapy product candidates. We currently only have one product candidate, VY-AADC (NBIb-1817), which has entered clinical development, and the RESTORE-1 Phase 2 clinical trial in which VY-

54

AADC (NBIb-1817) is being evaluated is on clinical hold. Our collaboration partner Neurocrine is the study sponsor and IND holder for the VY-AADC program, and it terminated its participation in the program, effective August 2, 2021. We determined in 2021 that we would not advance the VY-AADC program unless the program is partnered with another collaborator. The remainder of our product candidates are in preclinical development.

AAV gene therapies are a relatively new technology. We cannot accurately predict when or if any of our product candidates will prove effective or safe in humans or whether these product candidates will receive marketing approval. Additionally, there can be no assurance that we will not experience problems or delays in the preclinical testing or development of our product candidates and that such problems or delays will not cause unanticipated costs, or that any such problems or delays can be solved in a timely or profitable basis, if at all. We also may experience unanticipated problems or delays in expanding our manufacturing capacity.

The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the product candidate. The regulatory approval process for novel product candidates such as gene therapies can be more expensive and take longer than for other, better known or more extensively studied product candidates. Until August 2017, the FDA had never approved an AAV gene therapy product. Since that time, it has approved a limited number of gene therapy products including Luxturna, an AAV gene therapy product by Spark Therapeutics, Inc. (acquired by F. Hoffmann-La Roche Ltd., or Roche, in 2019), or Spark, for patients with an inherited form of vision loss, and Zolgensma, an AAV gene therapy product by Avexis, a Novartis company, for pediatric patients with spinal muscular atrophy. In Europe, a similarly limited number of AAV gene therapy products including Luxturna and Zolgensma, as well as Upstaza by PTC Therapeutics, Inc., or PTC, Roctavian by BioMarin Pharmaceuticals, Inc., and Glybera by uniQure N.V., or uniQure, have been granted marketing authorization; however, uniQure decided not to pursue renewal of such authorization in 2017 and has since withdrawn Glybera from the European market.

It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in either the United States or the European Union or how long it will take to commercialize our product candidates. The few regulatory approvals to date may not be indicative of what the FDA, European Commission, or other regulatory authorities may require for approval or whether different or additional preclinical studies or clinical trials may be required to support regulatory approval in a particular jurisdiction. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects may be harmed.

Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. Such requirements may lengthen the regulatory review process, require us to modify current studies or perform additional studies or increase our development costs, which in turn may force us to delay, limit, or terminate certain of our programs.

The Center for Biologics Evaluation and Research, or CBER, of the FDA regulates biological products for human use. The Office of Tissues and Advanced Therapies, or OTAT, formerly known as the Office of Cellular, Tissue and Gene Therapies, within CBER reviews gene therapy and related products and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.

NIH-funded institutions need to have their institutional biosafety committee, or IBC, as well as their institutional review board, or IRB, review proposed clinical trials to assess the safety of the trial. The PD-1101 Phase 1b clinical trial of VY-AADC (NBIb-1817), the PD-1102 Phase 1 trial exploring the delivery of VY-AADC (NBIb-1817) using a posterior trajectory, and the RESTORE-1 Phase 2 clinical trial were conducted at multiple sites, and therefore are subject to oversight by these authorities. If the protocol for such a trial was amended, it would need to be re-reviewed by the respective institutional IRBs of each institution. Any delay in or failure to obtain institutional IRB approval for any protocol or protocol amendment could delay, interrupt, or limit the conduct of the clinical trial at one or more participating clinical trial sites. For example, in connection with the RESTORE-1 Phase 2 clinical trial, we and our collaboration partner Neurocrine paused screening of new patients, in part to facilitate IRB reviews of certain

55

amendments made to the clinical trial protocol. As the FDA imposed a clinical hold on the RESTORE-1 Phase 2 clinical trial in December 2020, the resumption of any patient screening or dosing in the trial is now subject to the resolution of the clinical hold currently in effect.

Adverse or unforeseen developments in clinical trials of gene therapy products conducted by us or others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. Similarly, EMA and local health authorities of individual countries within the European Union may issue new guidelines concerning the clinical development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. The EMA and agencies at both the federal and state level in the United States have expressed an interest in further regulating new biotechnologies, including gene therapy. In addition, gene therapy products are considered genetically-modified organism, or GMO, products and are regulated as such in each country. Designation of the type of GMO product and subsequent handling and disposal requirements can vary across countries and is variable throughout the European Union. Addressing each specific country requirement and obtaining approval to commence a clinical trial in these countries could result in delays in starting, conducting, or completing a clinical trial. Similar issues could be faced in other regions of the world including the Asia-Pacific region.

These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. For example, we requested feedback from the FDA on, among other matters, the regulatory pathway for VY-AADC (NBIb-1817) and the design of the proposed pivotal program. We had multiple interactions with the FDA throughout 2018 and received certain written feedback requiring additional clarification. In December 2018, we held a Type B meeting with the FDA to discuss the overall development and pivotal program for VY-AADC (NBIb-1817). We received written feedback from the FDA, including FDA guidance received during the Type B meeting that in a disease such as Parkinson’s two adequate and well-controlled clinical trials is suggested.

In connection with our Neurocrine Collaboration Agreement, we agreed to transfer sponsorship of the clinical research program for VY-AADC (NBIb-1817) in Parkinson’s disease, or the VY-AADC Program, to Neurocrine, which required the related IND application to be transferred to Neurocrine. The transition process required additional regulatory filings with and review by the FDA. Based upon feedback received from the FDA, we and Neurocrine amended the RESTORE-1 clinical trial protocol. Following Neurocrine’s termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program, Neurocrine remains the sponsor of the RESTORE-1 Phase 2 clinical trial and the holder of the applicable IND. If sponsorship of the RESTORE-1 Phase 2 clinical trial is transferred back to us at our request, such transition would require additional regulatory filings with and review by the FDA, and would likely lead to additional costs and delays in the enrollment of patients in any potential future clinical trials we or a collaboration partner would pursue in connection with the VY-AADC Program.

In October 2020, the FDA notified us that the IND application for our planned Phase 1 and 2 clinical trial to evaluate VY-HTT01 in patients with Huntington’s disease was placed on clinical hold pending the resolution of certain information requests regarding chemistry, manufacturing, and controls, or CMC, matters. We had previously sought and received FDA feedback on the VY-HTT01 development program in a pre-IND meeting in 2017. Because the FDA only grants one pre-IND meeting per product in a given indication, however, we were unable to have additional formal consultations with the FDA prior to our submission of our IND application in September 2020 concerning changes to the program since our 2017 meeting. Although we resolved the clinical hold, we decided in August 2021 not to commence the VYTAL Phase 1 and 2 clinical trial for VY-HTT01 and to pursue the development of a second-generation program for the treatment of Huntington’s disease using a novel, proprietary AAV capsid to enable enhanced transduction and broad distribution with intravenous administration. These and other regulatory delays may require us to incur additional clinical development costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue from our product candidates.

We plan to continue to seek and incorporate FDA guidance in our ongoing development plans for each of our potential clinical candidates. If we fail to consult or solicit guidance from regulators or are unable to obtain sufficiently

56

frequent or detailed guidance from regulators, we may be required to delay or discontinue development of certain of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of increased or lengthier regulatory approval process and further restrictions on development of our product candidates can be costly and could negatively impact our or our collaborators ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.

Results from preclinical studies and early-stage clinical trials may not be indicative of efficacy in late-stage clinical trials.

All of our product candidates are in early stages of development, and the risk of failure is high. Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. Our product candidates may fail to show the desired safety and efficacy in preclinical testing or clinical development despite demonstrating promising results in earlier preclinical studies or clinical trials. In addition, the outcome of preclinical testing and early clinical trials may not be predictive of the success of later stage clinical trials. Similarly, interim results generated from clinical trials do not necessarily predict final results, and results from one completed clinical trial may not be replicated in a subsequent clinical trial with a similar study design. For example, data from the PD-1101 Phase 1b clinical trial and from the separate PD-1102 Phase 1 clinical trial exploring the delivery of VY-AADC (NBIb-1817) using a posterior trajectory suggest that one-time treatment with VY-AADC (NBIb-1817) could result in sustained improvement in motor function in patients with Parkinson’s disease. These results, however, may not be predictive of the results of the RESTORE-1 Phase 2 clinical trial or any future clinical trials that we or a collaboration partner could choose to conduct on VY-AADC (NBIb-1817). Some of our clinical trials, including the PD-1101 and PD-1102 clinical trials, were conducted with small patient populations and were not blinded or placebo-controlled, making it difficult to predict whether the favorable results that we observed in such trials will be sustained or repeated in larger and more advanced clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.

There is a high failure rate for product candidates proceeding through preclinical studies and clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage clinical trials. If a larger population of patients does not experience positive results, if these results are not reproducible, or if our products show diminishing activity over time, our products may not receive approval from the EMA or the FDA. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may encounter regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of product development. Failure to confirm favorable results from earlier trials by demonstrating the safety and effectiveness of our products in late-stage clinical trials with larger patient populations could harm our business and we may never succeed in commercialization or generating product revenue.

We may in the future conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.

To date, we have only conducted clinical trials in the United States. However, we may in the future choose to conduct one or more of our clinical trials or include sites in current or future clinical trials outside the United States.

Although the FDA may accept data from sites or clinical trials outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well-designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials or trial sites are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials or trial sites also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial or trial site outside the United

57

States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of the applicable product candidates.

Other risks inherent in conducting international clinical trials or using international trial sites include:

foreign regulatory requirements that could restrict or limit our ability to conduct our clinical trials;
the administrative burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment;
the failure of enrolled patients to adhere to clinical protocols or inadequate collection and assessment of clinical data as a result of differences in healthcare services or cultural customs;
foreign exchange fluctuations;
diminished or loss of protection of intellectual property in the relevant jurisdiction; and
political, economic, environmental, and health risks relevant to specific foreign countries, including risks related to natural disasters or disease outbreaks, including the current coronavirus disease 2019, or COVID-19, pandemic.

We are early in our development efforts. Our primary product candidates are in the discovery and preclinical stages of development. We may encounter substantial delays or difficulties in commencement, enrollment or completion of our preclinical studies or clinical trials, or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing our current and future product candidates on a timely basis, if at all.

We are early in our development efforts, and our primary product candidates are in preclinical development. Before obtaining marketing approval from regulatory authorities for the sale of our current and future product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates. To conduct clinical trials, we must first complete preclinical testing and studies to support IND applications or similar applications in other jurisdictions. We cannot be certain of the timely completion or successful outcome of our preclinical testing and studies. Our ability to complete our preclinical testing and studies is contingent on our ability to source animals and other supplies required for the conduct of such testing and studies. If we are unable to obtain all necessary animals and other supplies required for the conduct of our preclinical testing and studies, we may be unable to complete such preclinical testing and studies in a timely manner or at all. For example, some of our IND-enabling toxicology and other studies require certain non-human primates that are customarily imported from the People’s Republic of China, or the PRC, and current trade relations between the United States and the PRC have made the sourcing of these non-human primates challenging. We have encountered, and may continue to encounter, delays in obtaining a sufficient supply of such non-human primates to enable the conduct of our preclinical studies and testing. In addition, we may need to conduct preclinical studies utilizing non-human primates located in testing facilities outside of the United States. Utilizing such facilities will require us to observe export control regulations for the shipment of vectors and transgenes and import controls for the shipment of samples to us for evaluation and storage, which controls we may not be to satisfy, or may result in delay or additional expense. Our inability to obtain access to a sufficient supply of these non-human primates in a timely manner or at all may impair our ability to complete preclinical testing and studies to support IND applications or similar applications in other jurisdictions or delay the submission of such applications.

Additionally, we cannot predict if the FDA or similar regulatory authorities outside the United States will accept our planned clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our preclinical and clinical programs.

58

For example, in September 2020, we submitted an IND to the FDA in connection with the proposed initiation of a planned Phase 1 and 2 clinical trial for VY-HTT01 in patients with Huntington’s disease. In October 2020, the FDA notified us that the IND application for VY-HTT01 was placed on clinical hold pending the resolution of certain CMC information requests. We provided a complete response to the additional requests from the FDA regarding the IND application for VY-HTT01 in the first quarter of 2021, and the FDA removed its clinical hold on the IND and confirmed that we could proceed with our planned VYTAL Phase 1 and 2 clinical trial in April 2021. Although we resolved the clinical hold, we decided in August 2021 not to initiate our planned VYTAL Phase 1 and 2 clinical trial. This delay and our subsequent decision to refocus our program for the treatment of Huntington’s disease on the development of a second-generation product candidate could increase our expenses and adversely impact our ability to commercialize a product candidate for the treatment of Huntington’s disease in a timely manner, if at all.

We also have very limited experience with clinical trials. The transfer of sponsorship of the VY-AADC Program to Neurocrine required Neurocrine to become the sponsor of the RESTORE-1 Phase 2 clinical trial in many sites. The sponsorship transition required additional regulatory filings with and review by regulatory officials, and led to additional costs and delays in the enrollment of patients in the RESTORE-1 Phase 2 clinical trial. Following Neurocrine’s termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program, Neurocrine remains the sponsor of the RESTORE-1 Phase 2 clinical trial and the holder of the applicable IND. If sponsorship of the RESTORE-1 Phase 2 clinical trial is transferred back to us at our request, such transition would require additional regulatory filings with and review by the FDA, and would likely lead to additional costs and delays in the enrollment of patients in any potential future clinical trials we or a collaboration partner would pursue in connection with the VY-AADC Program.

We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A clinical trial failure can occur at any stage of testing. Similarly, there may be delays or difficulties in our initiation of future clinical trials. Due to the additional regulatory uncertainties associated with gene therapy products, we did not initiate the RESTORE-1 Phase 2 clinical trial for VY-AADC (NBIb-1817) as a treatment for Parkinson’s disease until we met with OTAT to discuss our proposed trial design and overall development plan. While we received OTAT’s feedback and incorporated it as appropriate in our plans, the clinical trial as designed may not achieve the prospectively defined primary clinical endpoints or provide a favorable benefit to risk ratio to support a biologics license application, or BLA, filing or approval. In November 2020, the sponsor medical monitor and surgical core requested that the data safety and monitoring board, or DSMB, for the RESTORE-1 Phase 2 clinical trial review certain patient MRI abnormalities observed in some clinical trial participants in the ongoing clinical trial. Following this review, the DSMB requested additional patient-level data and recommended a pause in the dosing of patients in the RESTORE-1 Phase 2 clinical trial pending its review of these additional data. In response to the DSMB’s recommendation, we and Neurocrine decided to delay the planned resumption of patient screening in the RESTORE-1 Phase 2 clinical trial until Neurocrine had submitted the required expedited IND safety reports related to these matters and the DSMB was able to complete its evaluation. In December 2020, the FDA notified Neurocrine that it had placed a clinical hold on the RESTORE-1 Phase 2 clinical trial. In January 2021, the FDA informed Neurocrine of the information required to provide a complete response to the FDA in connection with the clinical hold. Information required by the FDA includes an assessment of how the investigational product may have given rise to the adverse findings, a mitigation plan to manage the adverse findings, and supportive data to justify that the product candidate continues to have a favorable benefit/risk profile. The DSMB met to review additional patient data in January 2021 and characterized the MRI abnormalities as having uncertain clinical significance and requested that Neurocrine provide additional information. The clinical implications of these observations are currently unknown. We intend to support Neurocrine, the clinical trial sponsor and IND holder, on ongoing matters related to the completion of imaging and clinical assessments requested by the DSMB and the provision of other information requested by the FDA for the RESTORE-1 Phase 2 clinical trial. We have decided that, if Neurocrine were to transfer sponsorship of the RESTORE-1 Phase 2 clinical trial back to us, we would not seek to advance the clinical trial without a partner. Our ability to establish such a collaboration regarding the VY-AADC Program will be subject to a number of factors, including, among other things, the additional information collected by Neurocrine in response to the DSMB requests.

Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner or at all pursuant to the requirements of the

59

FDA, EMA, or other regulatory authorities. Patient enrollment and trial completion are affected by many factors including:

perceived risks and benefits of AAV gene therapy approaches for the treatment of neurological and other diseases;
perceived risks of the delivery procedure, such as the intracranial infusions previously proposed for evaluation in connection with VY-AADC (NBIb-1817) and VY-HTT01;
formulation changes to our product candidates, which may require us to conduct additional clinical studies to bridge our modified product candidates to earlier versions;
size of the patient population and process for identifying patients;
design of the trial protocol;
eligibility and exclusion criteria;
patients with preexisting antibodies to the gene therapy vector that preclude their participation in the trial;
perceived risks and benefits of the product candidate under study;
availability of competing therapies and clinical trials;
severity of the disease under investigation;
availability of genetic testing for potential patients;
proximity and availability of clinical trial sites for prospective patients;
lack of adequate compensation of patients;
ability to obtain and maintain patient consent;
risk that enrolled patients will drop out before completion of the trial;
our ability to locate appropriately trained physicians to conduct such clinical trials, particularly for clinical trials requiring lengthy and highly complex surgical protocols, the performance of which may only be possible at major academic medical centers or specialized surgical centers;
willingness of patients to participate in a placebo-controlled trial;
patient referral practices of physicians; and
ability to monitor patients adequately during and after treatment.

Further, we plan to seek marketing approvals in the United States, the European Union and other jurisdictions, which may require that we conduct clinical trials in foreign countries. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:

60

difficulty in establishing or managing relationships with clinical research organizations, or CROs, and physicians;
different standards for the conduct of clinical trials;
absence in some countries of established groups with sufficient regulatory expertise for review of AAV gene therapy protocols;
our inability to locate qualified local partners or collaborators for such clinical trials; and
the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.

If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials in some or all localities, any of which would harm our business, financial condition, results of operations and prospects.

Other events that may prevent successful or timely completion of clinical development include:

delays in reaching a consensus with regulatory authorities or collaborators on trial design, implementation, management, or other aspects of the clinical trial;
delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;
delays in opening clinical trial sites or obtaining required IRB or independent ethics committee approval at each clinical trial site;
imposition of a clinical hold by regulatory authorities, such as the clinical hold that the FDA placed on the IND application for the RESTORE-1 Phase 2 clinical trial of VY-AADC (NBIb-1817) in Parkinson’s disease in December 2020;
as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites or the decision by us or our collaborators, such as the pause in screening and enrollment of patients in the RESTORE-1 Phase 2 clinical trial in Parkinson’s disease, or the requirement of regulators or IRBs to suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;
failure by us, our collaboration partners, any CROs we engage, or any other third parties to adhere to clinical trial protocols or regulatory requirements;
failure by us, our collaboration partners, any CROs we engage, or any other third parties to perform in accordance with the FDA’s good clinical practices, or GCPs, or applicable regulatory guidelines in the European Union;
failure by physicians to adhere to delivery protocols leading to variable results;
delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions;
insufficient or inadequate supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates;

61

delays in having patients complete participation in a trial or return for post-treatment follow-up;
clinical trial sites or patients dropping out of a trial at a rate higher than we anticipate;
selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;
receipt of negative or inconclusive clinical trial results;
occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;
occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors;
changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or
the cost of clinical trials of our product candidates may be greater than we anticipate.

Any inability to successfully initiate or complete preclinical studies and clinical trials could result in additional costs and potential delays to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. For example, our decision to refocus our Huntington’s Disease program means we must conduct new preclinical studies, prepare a new IND, submit it to the FDA, and resolve any potential FDA objections before enrolling our first patient in a new clinical trial. In addition, if we make manufacturing or formulation changes to our product candidates, such as our previous transition from an HEK 293-based production system to a baculovirus/Sf9 AAV production system or as a result of unanticipated clinical trial results, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.

Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or SAEs associated with our product candidates, we may:

be delayed in obtaining marketing approval for our product candidates, if we are able to do so at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
be subject to changes in the way the product is administered;
be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;
have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a Risk Evaluation and Mitigation Strategy, or REMS;
be subject to the addition of labeling statements, such as warnings or contraindications;

62

be sued or otherwise become party to dispute proceedings; or
experience damage to our reputation.

Our product candidates or the process for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.

In past clinical trials that were conducted by others with non-AAV gene therapy vectors, several significant side effects were caused by gene therapy treatments, including reported cases of leukemia and death. Other potential side effects could include an immunologic reaction and insertional oncogenesis, which is the process whereby the insertion of a functional gene near a gene that is important in cell growth or division results in uncontrolled cell division, which could potentially enhance the risk of malignant transformation. If our vectors demonstrate a similar adverse effect, or other adverse effects, we may be required to halt or delay further clinical development of our product candidates or withdraw the product from the market post-approval. For example, in a recently published review of patients with hepatocellular carcinomas, it was shown that a small subset contained an integrated genome sequence of wild-type AAV2 and it was suggested that AAV2 may be associated with insertional oncogenesis.

In addition to side effects caused by the product candidate, the administration process or related procedures also can cause side effects. VY-AADC (NBIb-1817) and VY-HTT01 were designed to be administered directly to the targeted areas and cells in the brain, requiring the patient to undergo brain surgery. There are risks associated with direct delivery of AAV gene therapy into the brain. In a previous Phase 1 clinical trial conducted by UCSF, three patients experienced hemorrhages caused by the surgical procedure for administering VY-AADC (NBIb-1817). Investigators in the PD-1101 Phase 1b clinical trial, the separate PD-1102 Phase 1 posterior trajectory trial, and the RESTORE-1 Phase 2 clinical trial of VY-AADC (NBIb-1817), have used the ClearPoint System to provide accurate placement of the cannula in the putamen and allow for real-time, intra-operative MRI to assist the physician in visualizing the delivery of VY-AADC (NBIb-1817) to the putamen and to avoid specific blood vessels during the duration of the surgical procedure, with the goal of reducing the risk of hemorrhages. One patient in the Phase 1b clinical trial experienced two SAEs, a pulmonary embolism, or blood clot in the lungs, and related heart arrhythmia, or irregular heartbeat, which were determined to be related to the surgical procedure and prolonged immobility, not VY-AADC (NBIb-1817). Limited clinical data are available for this route of administration. If other side effects were to occur in connection with this route of administration including the related surgical procedures or related devices, any clinical trials which we conduct utilizing intraparenchymal delivery could be suspended or terminated. While we intend to transition our product candidates away from direct delivery into the brain, our experience outside of direct delivery is limited, and we may not see the levels of results we hope for using alternative delivery methods such as intravenous delivery.

If in the future we are unable to demonstrate that such side effects were caused by the administration process or related procedures or are unable to modify the trial protocol adequately to address such side effects, the FDA, the European Commission, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. For products that “knock down” or reduce the expression of a gene or the production of its encoded protein, their effects on other parts of the body, or “off target” effects, could result in unforeseen toxicity. Even if we are able to demonstrate that any future SAEs are not product-related, and regulatory authorities do not order us to cease further development of our product candidates, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates and may harm our business, financial condition and prospects significantly.

Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits outweigh its risks. We believe that the likelihood of the FDA requiring a REMS may be higher for treatments with more invasive routes of administration such as direct delivery through brain surgery. Such REMS may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners or the limitation of the use of the product to specifically trained

63

neurosurgeons and/or certain centers. Furthermore, adverse events which were initially considered unrelated to the study treatment of the clinical trial may later be found to be caused by the study treatment. If we or others later identify undesirable side effects caused by our product candidate, several potentially significant negative consequences could result, including:

regulatory authorities may suspend or withdraw approvals of such product candidate;
regulatory authorities may require additional warnings on the label;
we may be required to change the way a product candidate is administered or conduct additional clinical trials;
we could be sued and held liable for harm caused to patients; and
our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly harm our business, prospects, financial condition and results of operations.

We may be unable to obtain orphan drug designation or exclusivity for any of our product candidates for which we seek such designation. If our competitors are able to obtain orphan drug exclusivity for products that constitute the “same drug” and treat the same indications as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time. For products for which we may obtain orphan drug designation or exclusivity, we may be unable to prevent the approval or marketing authorization of other similar products based upon regulatory decisions regarding product “sameness”.

Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, or the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biological product will be recovered from sales in the United States. In the European Union, EMA’s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, orphan designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biologic product.

Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the applicable regulatory authority from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we may be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and 10 years in the European Union. The exclusivity period in the United States can be extended by six months if the new drug application or BLA sponsor submits pediatric data that adequately respond to a written request from the FDA for such data. The exclusivity period in the European Union can be reduced to nine years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.

64

We believe that certain of our current programs may qualify for orphan drug designation. On March 15, 2019, we received notification from the FDA that VY-HTT01, an AAV gene therapy containing a transgene that encodes a microRNA targeting huntingtin messenger RNA, had been granted orphan drug designation for the treatment of Huntington’s disease. This designation, however, does not mean that we will be able to obtain orphan drug designation for any future or related product candidates for the treatment of Huntington’s disease, including our planned second-generation product candidate for Huntington’s disease. Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs or biological products can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve another drug or biological product for the same condition if the FDA concludes that the other drug or biological product is not the “same drug” or biological product or even if it is, the FDA determines that it is clinically superior in that it is shown to be safer or more effective or makes a major contribution to patient care. In September 2021, the FDA issued final guidance describing its current thinking on when a gene therapy product is the “same” as another product for purposes of orphan exclusivity. Under the guidance, if either the transgene or vector differs between two gene therapy products in a manner that does not reflect “minor” differences, the two products would be considered different drugs for orphan drug exclusivity purposes. The FDA will determine whether two vectors from the same viral class are the same on a case-by-case basis and may consider additional key features in assessing the sameness.

In the European Union, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:

the second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior;
the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or
the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.

On August 3, 2017, the Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA’s pre-existing regulatory interpretation to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority.

The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies, particularly in light of a decision from the U.S. Court of Appeals for the Eleventh Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term “same disease or condition” means the designated “rare disease or condition” and could not be interpreted by the FDA to mean the “indication or use.” Thus, the Court of Appeals concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the “indication or use.” We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.

A potential breakthrough therapy designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.

We have sought and may in the future seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug or biological product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence

65

indicates that the drug or biological product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biological products that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval.

Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the drugs or biological products no longer meet the conditions for qualification.

A potential regenerative medicine advanced therapy designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.

We have sought and may in the future seek a regenerative medicine advanced therapy, or RMAT, designation for some of our product candidates. Under the 21st Century Cures Act, or the Cures Act, to be eligible to receive RMAT designation from the FDA, a product candidate must be (i) considered a “regenerative medicine therapy” as defined in the Cures Act; (ii) intended to treat, modify, reverse, or cure one or more serious or life-threatening diseases or conditions; and (iii) indicated, in preliminary clinical evidence, to have the potential to address unmet medical needs for such diseases or conditions. Gene therapies, including genetically modified cells, that lead to a durable modification of cells or tissues may meet the definition in the Cures Act of a regenerative medicine therapy.

The RMAT program is intended to facilitate efficient development and expedite review of such therapies. A new drug application or a BLA for a product candidate that has received an RMAT designation may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A product candidate that has received an RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval.

In June 2018, the FDA granted RMAT designation for the VY-AADC (NBIb-1817) gene therapy treatment for Parkinson’s disease in patients with motor fluctuations that are refractory to medical management. The designation was based on data from the PD-1101 Phase 1b clinical trial.

RMAT designation is within the discretion of the FDA. Accordingly, even if we believe one of our other product candidates meets the criteria for RMAT designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of RMAT designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that a product candidate that received RMAT designation no longer meets the conditions for designation. Alternatively, we or our collaborative partners may decide not to proceed with the clinical development of a product candidate that has previously received RMAT designation or decide to pursue such product candidate for an indication for which it has not received RMAT designation.

66

Fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure FDA approval of our product candidate.

If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical need for this condition, the drug sponsor may apply for FDA fast track designation. VY-AADC (NBIb-1817) has been granted fast track designation by the FDA. We may seek such a designation for our other product candidates. A fast track designation does not ensure that the product candidate will receive marketing approval or that approval will be granted within any particular timeframe. Thus, fast track products may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from a product candidate’s clinical development program. Fast track designation alone does not guarantee qualification for the FDA’s priority review procedures.

Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of our product candidate.

If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the FDA’s goal to review an application is six months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.

Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we or any current or future collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they may not be able to commercialize our products, and our ability to generate revenue may be materially impaired.

Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and comparable regulatory authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process.

Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.

The process of obtaining marketing approvals, both in the United States and abroad, is expensive; may take many years if additional clinical trials are required, if approval is obtained at all and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. In the United States, for example, the application user fee to obtain FDA review of a marketing application is more than $3.1 million, and may be higher in the future. Changes in marketing approval policies during the development period, in or the enactment

67

of additional statutes or regulations, or in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any current or future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.

Accordingly, if we or any current or future collaborators experience delays in obtaining approval or if we or they fail to obtain or retain approval of our product candidates and devices, the commercial prospects for our product candidates may be harmed and our ability to generate revenues could be materially impaired.

Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight.

Even if we obtain any regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storing, advertising, promoting, sampling, record-keeping and submitting safety and other post-market information. Any regulatory approvals that we receive for our product candidates also may be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. FDA guidance advises that patients treated with some types of gene therapy undergo follow-up observations for potential adverse events for as long as 15 years. The holder of an approved BLA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.

In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practice, or cGMP, requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or such regulatory authority disagrees with the promotion, marketing or labeling of that product, the regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.

If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory authority may:

issue a warning letter asserting that we are in violation of the law;
seek an injunction or impose administrative, civil or criminal penalties or monetary fines;
suspend or withdraw regulatory approval;
suspend any ongoing clinical trials;
refuse to approve a pending BLA or comparable foreign marketing application, or any supplements thereto, submitted by us or our collaboration partners;
restrict the marketing or manufacturing of the product;

68

seize or detain the product or otherwise require the withdrawal of the product from the market;
refuse to permit the import or export of products; or
refuse to allow us to enter into supply contracts, including government contracts.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.

In addition, FDA policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would harm our business, financial condition, results of operations and prospects.

We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may harm our business and financial condition and our ability to successfully market or commercialize our product candidates.

The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. Any product candidates that we successfully develop into products and commercialize may compete with existing therapies and new therapies that may become available in the future. While we believe that our gene therapy platform, vectorized antibody platform, product programs, product candidates and scientific expertise in the fields of gene therapy and neuroscience provide us with competitive advantages, we face potential competition from various sources, including larger and better-funded pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions, governmental agencies and public and private research institutions.

We are aware of several companies focused on developing AAV gene therapies in various indications, including AavantiBio, Inc. (merger with Solid Biosciences, Inc., or Solid, announced), Abeona Therapeutics, Inc., Adverum Biotechnologies, Inc., Aevitas Therapeutics, Inc., Akouos, Inc. (acquisition by Eli Lilly and Company, or Eli Lilly, announced), Alcyone Therapeutics, Inc., Amicus Therapeutics, Inc., Apic Bio, Inc., Applied Genetic Technologies Corporation (acquisition by Syncona Limited announced), Asklepios BioPharmaceutical, Inc., or AskBio (acquired by Bayer), Audentes Therapeutics, Inc. (acquired by Astellas Pharma Inc.), Biogen, Inc., or Biogen, Brain Neurotherapy Bio, Inc. (merged with AskBio), BioMarin, Encoded Therapeutics, Inc., GenSight Biologics SA, Homology Medicines, Inc., LEXEO Therapeutics, Inc., LogicBio Therapeutics, Inc. (acquisition by AstraZeneca announced), Lysogene SA, MeiraGTx Ltd., or MeiraGTx, Neurogene, Inc., Novartis Gene Therapies, Inc. (formerly AveXis, Inc.), Passage Bio, Inc., Pfizer, Prevail Therapeutics Inc. (acquired by Eli Lilly), PTC, REGENXBio Inc., Sarepta Therapeutics, Inc., Sio Gene Therapies, Inc., Solid, Spark, StrideBio, Inc., Taysha Gene Therapies, Inc. and uniQure, as well as several companies addressing other methods for modifying genes and regulating gene expression. Any advances in gene therapy technology made by a competitor may be used to develop therapies that could compete against any of our product candidates.

We expect that our TRACER platform preclinical programs will compete with a variety of technologies and therapies in development, including:

Our TRACER discovery platform will potentially compete with a variety of companies developing AAV capsids, including: 4D Molecular Therapeutics, Inc., Affinia Therapeutics Inc., Apertura Gene Therapy,

69

LLC, Capsida Biotherapeutics, Inc., Capsigen Inc., Dyno Therapeutics, Inc., Kate Therapeutics, Inc., Shape Therapeutics, Inc., and StrideBio, Inc.
Our program for diseases linked to GBA1 mutations will potentially compete with AAV gene therapies being developed by Prevail Therapeutics Inc. (acquired by Eli Lilly), Freeline Therapeutics Holdings plc, Pfizer, Biogen, Lysogene SA, and Coave Therapeutics;
Our program for tauopathies including Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal dementia will potentially compete with tau antibodies being developed by Roche Genentech Inc. in collaboration with AC Immune SA, Eli Lilly, AbbVie, Biogen, Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., UCB S.A., and several other companies, as well as an antisense oligonucleotide program being developed by Ionis in collaboration with Biogen;
Our program for a monogenic form of ALS will potentially compete with BIIB067 (IONIS-SOD1Rx) being developed by Biogen, in collaboration with Ionis, and gene therapies being developed by Apic Bio, Inc. and Novartis Gene Therapies, Inc.;
Our program for Huntington’s disease will potentially compete with AMT-130, an AAV gene therapy being developed by uniQure, a gene therapy being developed by Spark, and TAK-686 being developed by Sangamo Therapeutics, Inc. in collaboration with Takeda Pharmaceutical Company Limited;
Our program for spinal muscular atrophy, or SMA, will potentially compete with Zolgensma being marketed by Novartis Gene Therapies, Inc., Spinraza being marketed by Biogen, and Evrysdi being marketed by Roche; and
Our FA Program will potentially compete with AAV gene therapies being developed by LEXEO Therapeutics, Inc., AavantiBio, Inc. (acquired by Solid), PTC, StrideBio, Inc. in collaboration with Takeda Pharmaceutical Company Limited, Pfizer, and Novartis Gene Therapies, Inc.

Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries, including recent transactions involving a number of gene therapy companies, may result in even more resources being concentrated among a smaller number of competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative agreements with large and established companies. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly or earlier than us or may obtain orphan drug or other marketing exclusivity, which could result in our competitors establishing a strong market position before we are able to enter the market or reducing the number of available subjects for enrollment in our clinical trials to support regulatory submissions and approvals of our product. Additionally, technologies developed or acquired by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. These third parties also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, and registering patients for clinical trials.

In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and scope of patents relating to our competitors’ products. The availability of our competitors’ products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. If we are not able to compete effectively against potential competitors, our business will not grow, and our financial condition and operations will be harmed.

70

Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and adversely affect our business.

Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the product candidates in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials or manufacturing control requirements. In many countries outside the United States, a product candidate must be separately approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. We intend to submit a marketing authorization application to EMA for approval of our product candidates in the European Union but obtaining such approval from the European Commission following the opinion of EMA is a lengthy and expensive process. Even if a product candidate is approved, the FDA or the European Commission may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and the European Union also have requirements for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.

Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Regulatory approval for any of our product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects will be harmed.

Additionally, on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the European Union on January 31, 2020, and a transition period to December 31, 2020, was established to allow the United Kingdom and the European Union to negotiate the United Kingdom’s withdrawal. Effective January 1, 2021, the United Kingdom is no longer part of the European Single Market and European Union Customs Union. A cooperation agreement was signed between the United Kingdom and the European Union in December 2020, which was applied provisionally beginning on January 1, 2021 and entered into force on May 1, 2021. The agreement addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. As both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal.

Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and regulations, the consequences of Brexit and the impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom remain unclear. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom’s withdrawal from the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.

71

We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.

Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Separately, in response to the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA’s inability to complete required inspections for their applications. The FDA announced, however, on February 2, 2022, that it would resume domestic inspections beginning on February 7, 2022. As for foreign inspections, the FDA indicated that it would continue planned inspections in countries that have received country clearance and are within the CDC’s level 1 or level 2 COVID-19 travel recommendation. The FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.

If approved, our product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.

The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as “interchangeable” based on its similarity to an approved biologic.

72

Under the BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as its BLA does not reply on the reference product, sponsor’s data or submit the application as a biosimilar application. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty, and any new policies or processes adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products.

We believe that any of the product candidates we develop as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. Nonetheless, the approval of a biosimilar to our product candidates would have a material adverse impact on our business due to increased competition and pricing pressure.

Risks Related to Third Parties

To date, all of our revenue has been derived from our ongoing collaboration with Neurocrine, our ongoing option and license arrangements Pfizer and Novartis, and from our prior collaborations with Sanofi Genzyme and AbbVie. If any ongoing or future collaboration or option and license agreements were to be terminated, our business financial condition, results of operations and prospects could be harmed.

In February 2015, we entered into the Sanofi Genzyme Collaboration Agreement to leverage our combined expertise and assets in gene therapy for neurological diseases. Under the Sanofi Genzyme Collaboration Agreement, we received an upfront commitment of approximately $100.0 million. Pursuant to the agreement, we granted Sanofi Genzyme an exclusive option to license, develop and commercialize (i) ex-U.S. rights to the VY-AADC Program, Friedreich’s ataxia program, or FA Program, and the Huntington’s disease program, or Huntington’s Program, and a future program, collectively, the Split Territory Programs, with an incremental option to co-commercialize the product candidate from our Huntington’s Program in the United States and (ii) worldwide rights to our spinal muscular atrophy program. In June 2019, we and Sanofi Genzyme executed a termination agreement to terminate the Sanofi Genzyme Collaboration Agreement, or the Sanofi Genzyme Termination Agreement. Under the terms of the Sanofi Genzyme Termination Agreement, Sanofi Genzyme relinquished its rights to its exclusive license options to the Huntington’s Program, FA Program and the unnamed future program described above, and we were relieved of our obligations to perform the research and development services under those programs under the Sanofi Genzyme Collaboration Agreement.

In February 2018, we entered into an exclusive collaboration and option agreement with AbbVie, which we refer to as the AbbVie Tau Collaboration Agreement, for the research, development, and commercialization of AAV gene therapy products for the treatment of diseases of the central nervous system and other neurodegenerative diseases related to defective or excess aggregation of tau protein in the human brain, including Alzheimer’s disease. Under the terms of the AbbVie Tau Collaboration Agreement, we received an upfront payment of $69.0 million and were eligible to receive option exercise payments, future development and regulatory milestone payments and royalties prior to the termination of the AbbVie Tau Collaboration Agreement, effective August 3, 2020.

In January 2019, we entered into the Neurocrine Collaboration Agreement for the research, development and commercialization of four programs including the VY-AADC Program, our FA Program, and two programs to be determined by us and Neurocrine at a later date, or the Discovery Programs. Under the terms of the agreement, we received an upfront payment of $115.0 million and may receive future development and regulatory milestones and royalties. In connection with the Neurocrine Collaboration Agreement, Neurocrine also paid us $50.0 million as

73

consideration for an equity purchase of 4,179,728 shares of our common stock. In June 2019, in conjunction with the termination of the Sanofi Genzyme Collaboration Agreement, we and Neurocrine amended the Neurocrine Collaboration Agreement to facilitate the transfer of the ex-U.S. rights to the FA Program which we acquired from Sanofi Genzyme to Neurocrine. In connection with the amendment, we received a $5.0 million payment from Neurocrine.

Under the terms of the Neurocrine Collaboration Agreement, subject to the rights retained by us thereunder, we have agreed to collaborate with Neurocrine on, and to grant, exclusive, royalty-bearing, non-transferable, sublicensable licenses to certain of our intellectual property rights for all human and veterinary diagnostic, prophylactic, and therapeutic uses for the research, development, and commercialization of gene therapy products, which we refer to as the Collaboration Products, under (i) the VY-AADC Program, on a worldwide basis; (ii) the FA Program, on a worldwide basis; and (iii) each Discovery Program, on a worldwide basis. We refer to each of these programs as a Neurocrine Program and, collectively, as the Neurocrine Programs. Subject to the terms and conditions of the Neurocrine Collaboration Agreement, we also have the option to co-develop and co-commercialize the FA Program with Neurocrine pursuant to which we and Neurocrine would agree to enter into a cost- and profit-sharing arrangement for such program and share in its costs, profits and losses, and we would forfeit certain milestones and royalties on net sales in the United States during the effective period of the applicable co-development and co-commercialization agreement.

On February 2, 2021, Neurocrine notified us that it had elected to terminate the Neurocrine Collaboration Agreement solely with regards to the VY-AADC Program. This termination became effective August 2, 2021, which we refer to as the Neurocrine VY-AADC Program Termination Effective Date. The Neurocrine Collaboration Agreement remains in full force and effect for each other program thereunder. Upon the termination of the VY-AADC Program, the license granted by us to Neurocrine regarding the VY-AADC Program expired, and we regained worldwide intellectual property rights to the VY-AADC Program in accordance with the collaboration agreement, and the restrictions on us to develop, manufacture or commercialize a gene therapy product directed to the targets specified in the VY-AADC Program terminated. If Neurocrine were to terminate the remainder of the Neurocrine Collaboration Agreement, we would become responsible for all research and development expenses relating to the remaining Neurocrine Programs and would not receive any future milestone payments or royalty payments under the Neurocrine Collaboration Agreement with respect to such programs.

In February 2019, we entered into a collaboration agreement, which we refer to as the AbbVie Alpha-Synuclein Collaboration Agreement, for the research, development, and commercialization of AAV gene therapy products directed against alpha-synuclein for indications including Parkinson’s disease and other synucleinopathies. Under the terms of the AbbVie Alpha-Synuclein Collaboration Agreement, we received an upfront payment of $65.0 million and were eligible to receive option exercise payments, future development and regulatory milestone payments and royalties prior to the termination of the AbbVie Alpha-Synuclein Collaboration Agreement, effective August 3, 2020.

On October 1, 2021, we entered into the Pfizer Agreement, pursuant to which we granted Pfizer options to receive an exclusive license to TRACER capsids to develop and commercialize certain AAV gene therapy candidates comprised of a TRACER capsid and specified transgenes to help treat respective central nervous system and cardiovascular diseases. Under the terms of the Pfizer Agreement, we received an upfront payment of $30.0 million in October 2021 and are eligible to receive future option exercise payments of $10.0 million upon each of up to two option exercises; specified development, regulatory, and commercialization milestone payments following each option exercise of up to an aggregate of $115.0 million for the first licensed product to achieve such milestones; specified sales milestone payments of up to an aggregate of $175.0 million per licensed product; and tiered, escalating royalties in the mid- to high-single digit percentages of annual net sales of each licensed product. Effective as of September 30, 2022, Pfizer exercised its option with respect to a capsid in connection with a gene therapy program for the potential treatment of an undisclosed rare neurologic, rare neurological disease, or the Pfizer Option Exercise. Pfizer did not exercise its option to license a capsid for a specified cardiovascular disease target under the Pfizer Agreement. As a result, all rights to capsids for that cardiovascular disease target under the Pfizer Agreement have expired and have reverted to us, and we are not eligible to receive any potential future development, regulatory, commercialization, or sales milestone payments or potential royalties pursuant to the Pfizer Agreement in connection with such target.

In March 2022, we entered into the Novartis Agreement, pursuant to which we granted Novartis options to receive an exclusive license to TRACER capsids to develop and commercialize certain AAV gene therapy candidates

74

comprised of a TRACER capsid and specified genetic payloads for specific genetic targets. Under the terms of the Novartis Agreement, we are entitled to receive an upfront payment of $54.0 million and are eligible to receive future option exercise payments of $12.5 million upon each option exercise; fees of $18.0 million for each of two potential expansions of the arrangement; specified development, regulatory, and commercialization milestone payments following each option exercise of up to an aggregate of $125.0 million for the first licensed product to achieve such milestones; specified sales milestone payments of up to an aggregate of $175.0 million per licensed product; and tiered, escalating royalties in the mid- to high-single digit percentages of annual net sales of each licensed product. If Novartis decided not to exercise its options or otherwise to terminate the Novartis Agreement, in whole or in part, we would not receive the applicable option exercise fees or future milestone payments or royalty payments.

Our current collaborators or any future collaborator might not be successful in obtaining approvals for the product candidates arising from our collaboration or commercializing or manufacturing the resulting products. Further, such collaborator’s objectives in connection with the collaboration may not be consistent with our best interests. With respect to the rights granted to a collaborator by us, the collaborator could take actions that may be averse to us, or it could halt, slow, or deprioritize its development and commercialization efforts under the collaboration. In any such instances, our business, financial condition, results of operations and prospects could be materially harmed.

We have used the ClearPoint System to deliver our product candidates to date. While other devices for delivery may be used in the future, any issues with the ClearPoint System or the manufacturer of the ClearPoint System may result in delays in the development and commercialization of certain of our product candidates, which could have an adverse impact on our business.

The surgical approach that we have used for VY-AADC (NBIb-1817) is similar, in some respects, to the stereotactic approach used for DBS. One primary difference with our approach is the ability to assist the physician in visualizing the delivery of VY-AADC (NBIb-1817) to the putamen using real-time, intra-operative, magnetic resonance imaging, or MRI, scans to avoid specific blood vessels to potentially reduce the risk of hemorrhages during the surgical procedure and to maximize the coverage of the putamen.

Investigators in the PD-1101 Phase 1b clinical trial, the separate PD-1102 Phase 1 posterior trajectory trial, and the RESTORE-1 Phase 2 clinical trial for VY-AADC (NBIb-1817) have used and may continue to use the real-time, intra-operative, MRI imaging system known as the ClearPoint System. We also considered using the ClearPoint System in our planned VYTAL Phase 1 and 2 clinical trial before we decided to refocus the Huntington’s disease program and withdraw our existing IND. The ClearPoint System is manufactured by CLPT. Not all neurosurgical units within the United States utilize the ClearPoint system and may employ other neuro-navigational systems that are not compatible with real-time MRI imaging. Investigators have used the ClearPoint System at certain sites in the RESTORE-1 Phase 2 clinical trial and may continue to use it in future clinical trials of VY-AADC (NBIb-1817) and any other of our product candidates that are injected directly into the brain. Therefore, any issues with the ClearPoint System, such as a finding that use of the ClearPoint System causes adverse events or a product recall, or issues with CLPT, the manufacturer of the ClearPoint System, such as bankruptcy or a decision to stop production of the system due to lack of profitability, could delay the development or commercialization of certain of our product candidates, including VY-AADC (NBIb-1817) and VY-HTT01, as there currently is no other manufacturer of the ClearPoint System. Outside the United States, the ClearPoint System is not widely available or utilized in neurosurgical units.

We have developed V-TAG as our real-time, intra-operative device that is compatible with MRI imaging and can be used with other neuro-navigational systems to dose VY-AADC (NBIb-1817) and for other surgical procedures. We believe that the experience we have gained from delivering VY-AADC (NBIb-1817) in our clinical trials to date and our work to develop V-TAG may inform AAV gene therapy delivery for our Huntington’s Program and other projects. In July 2018, we received 510(k) regulatory clearance of V-TAG from the CDRH. There are additional steps needed in making this device available for use, including the manufacture of the product and compliance with state and federal laws and regulations for medical devices.

We have relied on, and may in the future rely on, third parties in the development and manufacture of our potential delivery devices. In May 2018, we entered into a master services and supply agreement with CLPT for the development and manufacture of devices, including V-TAG. This agreement provides for CLPT to perform certain

75

manufacturing, supply, development and other services, including the supply of the ClearPoint System and cannula devices. In March 2019, we transferred our premarket notification (510(k)) clearance for the V-TAG device to CLPT and have worked with CLPT on the manufacturing and clinical supply of the device for relevant clinical trials.

We may seek to enter into collaborations, and out-licensing transactions in the future with other third parties. If we are unable to enter into such collaborations or out-licensing transactions, or if these collaborations or out-licensing transactions are not successful, our business could be adversely affected.

We may seek to enter into additional collaborations in the future, including sales, marketing, distribution, development, option, licensing, and/or broader collaboration agreements. For example, we entered into the Pfizer Agreement with Pfizer in October 2021 and the Novartis Agreement in March 2022. We believe there is significant opportunity for option and license transactions related to the TRACER capsids. To maximize the potential of TRACER capsids for our own programs and option and license transactions, we have retained to date, and expect to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with a particular optionee’s or licensee’s transgenes. Our likely collaborators, optionees, and licensees include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies, and medical device manufacturers. However, we may not be able to enter into additional collaborations or option and license transactions on favorable terms or at all. Our ability to generate revenues from our collaborations and option and license transactions will depend on our and our collaborators, optionees, and licensees’ abilities to successfully perform the functions assigned to each of us in these arrangements. In addition, our collaborators, optionees, and licensees might have the ability to abandon research or development projects and terminate applicable agreements. Moreover, an unsuccessful outcome in any clinical trial for which our collaborator, optionee, or licensee is responsible could be harmful to the public perception and prospects of our gene therapy and vectorized antibody platforms.

Our relationship with any current or future collaborators, optionees, or licensees may pose several risks, including the following:

collaborators, optionees, and licensees have significant discretion in determining the amount and timing of the efforts and resources that they will apply to these collaborations and option and license transactions;
collaborators, optionees, or licensees may not perform their obligations as expected or desired;
the preclinical studies and clinical trials conducted as part of these collaborations or by our licensees may not be successful;
collaborators, optionees, or licensees may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on preclinical study or clinical trial results, changes in the collaborators’, optionees’, or licensees’ strategic focus or available funding or external factors, such as an acquisition, which divert resources or create competing priorities;
collaborators, optionees, or licensees may delay preclinical studies and clinical trials, provide insufficient funding for preclinical studies and clinical trials, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new preclinical studies or clinical trials or require a new formulation of a product candidate for preclinical studies or clinical trials;
we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration or by a licensee and, consequently, may have limited ability to inform our stockholders about the status of such product candidates;
collaborators, optionees, or licensees could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators, optionees, or licensees

76

believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
product candidates developed in collaboration with us or by a licensee may be viewed by our collaborators or licensees as competitive with their own product candidates or products, which may cause collaborators or licensees to cease to devote resources to the commercialization of our product candidates;
a collaborator or licensee with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product candidate;
disagreements with collaborators, optionees, or licensees, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any product candidates, may cause delays or termination of the research, development or commercialization of such product candidates, may lead to additional responsibilities or expenses for us with respect to such product candidates (in the case of collaborations) or may result in litigation or arbitration, any of which would be time-consuming and expensive;
collaborators, optionees, or licensees may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
disputes may arise with respect to the ownership or inventorship of intellectual property developed pursuant to our collaborations or option and license transactions;
collaborators, optionees, or licensees may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;
the terms of our collaboration or license agreement may restrict us from entering into certain relationships with other third parties, thereby limiting our options; and
collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.

Collaboration and license agreements may not lead to the development or commercialization of product candidates in the most efficient manner, or at all. If our collaborations or option and license transactions do not result in the successful development and commercialization of products, or if one of our collaborators, optionees, or licensees terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration or option and license transactions. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed, and we may need additional resources to develop our product candidates. In the event we are unable to achieve milestones necessary to demonstrate progress on our programs relevant to the Neurocrine Collaboration Agreement, Neurocrine may be unwilling to fund these programs at the desired levels or at all, which could require us to fund these programs to a greater extent than we have expected, to decline to pursue certain program objectives or to discontinue one or more of the programs. Additionally, subject to its contractual obligations to us, if a collaborator, optionee, or licensee of ours were to be involved in a business combination, it might deemphasize or terminate the development or commercialization of any product candidate optioned or licensed to it by us. If one of our collaborators, optionees, or licensees terminates its agreement with us, we may find it more difficult to attract new collaborators, optionees, or licensees, and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this periodic report also apply to the activities of our collaborators, optionees, and licensees.

77

We will face significant competition in seeking appropriate collaborators, optionees, and licensees, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration or license agreement with any future collaborators, optionees, and licensees will depend, among other things, upon our assessment of the collaborator’s, optionee’s, or licensee’s resources and expertise, the terms and conditions of the proposed collaboration or option and license transactions and the proposed collaborator’s, optionee’s, or licensee’s evaluation of several factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator, optionee, or licensee may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration or option and license transaction could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators, optionees, or licensees. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators, optionees, and licensees.

If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations or option and license transactions and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our gene therapy and vectorized antibody platforms. If we license rights to product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.

We have relied, and we expect to continue to rely, on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if these third parties perform in an unsatisfactory manner, our business could be harmed.

We expect to rely on CROs, clinical trial sites, and other vendors to ensure our preclinical studies and clinical trials are conducted properly and on time. We may also engage third parties such as clinical data management organizations, medical institutions and clinical investigators to conduct or assist in our clinical trials or other preclinical and clinical research and development work. While we will have agreements governing their activities, we will have limited influence over their actual performance. We will control only certain aspects of our third-party service providers’ activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal, quality, regulatory and scientific standards. Our reliance on these third parties does not relieve us of our regulatory responsibilities. For example, the PD-1101 Phase 1b clinical trial of VY-AADC (NBIb-1817) and the separate PD-1102 Phase 1 clinical trial exploring the delivery of VY-AADC (NBIb-1817) using a posterior trajectory were conducted at several locations. The protocol for the RESTORE-1 Phase 2 clinical trial states that the clinical trial is intended to be conducted at over twenty clinical trial sites, including neurosurgical and neurology patient referral sites. Additionally, we had expected to initiate the planned VYTAL Phase 1 and 2 clinical trial for VY-HTT01 at multiple sites in the United States before our decision to refocus the Huntington’s disease program and develop a second-generate program candidate. If any locations terminate a particular clinical trial, we or our collaborators would be required to find other parties or locations to conduct such clinical trial. We may be unable to find a new party to conduct new trials of our product candidates or obtain clinical supply of our product candidates or AAV vectors for such trials. If we elect to internalize some or all activities related to the conduct of our preclinical studies or clinical trials that are currently performed by our third-party service providers, or if we are required to do so due to a service provider’s termination of our relationship, then we may be required to source additional technology and personnel in order to perform the relevant activities. We may be unsuccessful in our efforts to internalize some or all relevant activities, either on the desired timeline or at all.

78

We and our third-party service providers are required to comply with the FDA’s good laboratory practices, or GLPs, and GCPs for conducting, recording and reporting the results of IND-enabling preclinical studies and clinical studies to assure that the data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. The FDA enforces these GLPs and GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites, and laboratories at which the FDA may determine that our preclinical studies and clinical trials did not comply with GLPs or GCPs. If we, our collaborators, or our third-party service providers fail to comply with applicable GLPs or GCPs, the preclinical or clinical data generated in our future preclinical studies or clinical trials may be deemed unreliable and the FDA may require us to perform additional preclinical studies or clinical trials before approving the relevant INDs or marketing applications. In addition, our future clinical trials will require a sufficient number of patients to evaluate the safety and effectiveness of our product candidates. Accordingly, if we, our collaborators, or our third-party service providers fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such preclinical studies or clinical trials, which would delay the regulatory approval process. Failure to comply can also result in fines, adverse publicity, and civil and criminal sanctions.

Our third-party service providers are not our employees, and we are therefore unable to directly monitor whether or not they devote sufficient time, attention, expertise and resources to our clinical and nonclinical programs. These third-party service providers may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If our third-party service providers do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our preclinical studies or clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates could be harmed, our costs could increase, and our ability to generate revenues could be delayed.

Risks Related to Manufacturing

Our gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business.

The manufacture of gene therapy products is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for our clinical studies. To meet the requirements of our current and planned future trials we have developed a flexible manufacturing platform that is based on proprietary technology and provides a scalable process for preclinical and clinical AAV production. We are using HEK 293 cell manufacturing to support our preclinical research activities. We also have expertise with the baculovirus/Sf9 AAV production system, a technology for producing AAV gene therapy vectors at scale in insect-derived cells, which we have used for our clinical development activities in the past and may use in the future for clinical development activities. Both the HEK 293 cell manufacturing process and the baculovirus/Sf9 manufacturing process have been successfully transferred to our contract manufacturing organizations where it is used in manufacturing clinical materials in accordance with the FDA’s cGMPs. If we transition from the use of HEK 293 cell manufacturing for preclinical research activities to the use of the baculovirus/Sf9 AAV production system for clinical development activities, we could encounter transition-related difficulties such as the need to make manufacturing process adjustments, the need to change third-party contract manufacturers, issues with drug potency consistency, and adverse clinical reactions, which could lead us to incur additional costs or delays.

We presently contract with third parties for the manufacturing of our program materials. We have also built an onsite, state-of-the-art process research and development facility to enable the manufacturing of clinical quality AAV gene therapy vectors at research scale. We are currently assessing our manufacturing capabilities and, although we do not currently have our own clinical or commercial scale manufacturing, we may choose to build those capabilities. The

79

use of contracted manufacturing and reliance on collaboration partners is relatively cost-efficient and eliminates the need for our direct investment in manufacturing facilities and additional staff early in development. Although we rely on contract manufacturers, we have personnel with manufacturing and quality experience to oversee our contract manufacturers.

To date, our third-party manufacturers have met our manufacturing requirements for our program materials. We expect third-party manufacturers to be capable of providing sufficient quantities of our program materials to meet anticipated clinical trial scale demands. To meet our projected needs for commercial manufacturing, third parties with whom we currently work might need to increase their scale of production or we will need to secure alternate suppliers. We believe that there are alternate sources of supply for our program materials that can satisfy our clinical and commercial requirements, although we cannot be certain that identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional costs.

To date, our third-party manufacturers have met our quality standards for our program materials. The manufacturers of pharmaceutical products must comply with strictly enforced cGMP requirements, state and federal regulations, as well as foreign requirements when applicable. Any failure by us or our contract manufacturing organizations to adhere to or document compliance to such regulatory requirements could lead to a delay or interruption in the availability of our program materials for clinical study. If we or our manufacturers were to fail to comply with the FDA, EMA, or other regulatory authority, it could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates. Our potential future dependence upon others for the manufacture of our product candidates may also adversely affect our future profit margins and our ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis.

Biological products are inherently difficult to manufacture. Our program materials are manufactured using technically complex processes requiring specialized equipment and facilities, highly specific raw materials, cells, and reagents, and other production constraints. Several of these raw materials, cells, and reagents are provided by a limited number of suppliers. Even though we aim to have backup supplies and suppliers of raw materials, cells, and reagents whenever possible, we cannot be certain they will be sufficient if our primary sources are unavailable. A shortage of a critical raw material, cell line, or reagent, or a technical issue during manufacturing may lead to delays in clinical development or commercialization plans. Any changes in the manufacturing of components of the raw materials we use could result in unanticipated or unfavorable effects on our manufacturing processes, including delays.

Delays in obtaining regulatory approval of our or our collaborators’ manufacturing processes and facilities or disruptions in such manufacturing processes may delay or disrupt our commercialization efforts. Until recently, no cGMP gene therapy manufacturing facility in the United States had received approval from the FDA for the manufacture of an approved gene therapy product.

Before we can begin to commercially manufacture a product candidate in our own facility, or the facility of a collaborator, we must obtain regulatory approval from the FDA for our manufacturing process and our collaborator’s facility. A manufacturing authorization must also be obtained from the appropriate European Union regulatory authorities. Until recently, no cGMP gene therapy manufacturing facility in the United States had received approval from the FDA for the manufacture of an approved gene therapy product and, therefore, the timeframe required for us to obtain such approval is uncertain. In addition, we must pass a pre-approval inspection of our or our collaborator’s manufacturing facility by the FDA and other relevant regulatory authorities before any of our product candidates can obtain marketing approval. In order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other

80

requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any products that we may develop.

Failure to comply with ongoing regulatory requirements could cause us to suspend production or put in place costly or time-consuming remedial measures.

The regulatory authorities may, at any time, following approval of a product for sale, audit the manufacturing facilities for such product or institute biennial inspections. If any such inspection or audit identifies a failure to comply with applicable regulations, or if a violation of product specifications or applicable regulations occurs independent of such an inspection or audit, the relevant regulatory authority may require remedial measures that may be costly or time-consuming to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a manufacturing facility. Any such remedial measures imposed upon our third-party manufacturers, our collaborators, or us could harm our business, financial condition, results of operations and prospects.

If our third-party manufacturers, our collaborators, or we fail to comply with applicable cGMP regulations, FDA and foreign regulatory authorities can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate or suspension or revocation of a pre-existing approval. Such an occurrence may cause our business, financial condition, results of operations and prospects to be harmed.

Additionally, if supply from any third-party manufacturers is delayed or interrupted, there could be a significant disruption in the supply of our clinical or commercial material. We have agreements in place with our contract manufacturers pursuant to which we are collaborating on cGMP manufacturing processes and analytical methods for the manufacture of our AAV product candidates. Therefore, if we are unable to enter into an agreement with our contract manufacturers to manufacture clinical or commercial material for our product programs, or if our agreement with our contract manufacturers were terminated, we would have to find suitable alternative manufacturers. This could delay our or our collaborators’ ability to conduct clinical trials or commercialize our current and future product candidates. The regulatory authorities also may require additional trials if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and could result in a delay in our desired clinical and commercial timelines.

Any contamination in the manufacturing process for our products or product candidates, shortages of raw materials, cells or reagents, or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.

Given the nature of biologics manufacturing, there is a risk of contamination. Any contamination could adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage.

Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects.

Interruptions in the supply of product candidates or inventory loss may harm our operating results and financial condition.

Our product candidates and our product delivery devices are manufactured using technically complex processes requiring specialized facilities, highly specific raw materials and other production constraints. The complexity of these processes, as well as strict government standards for the manufacture and storage of our product candidates and delivery devices, subjects us to manufacturing risks. While product candidate batches released for use in clinical trials or for commercialization undergo sample testing, some defects may only be identified following product release. In addition, process deviations or unanticipated effects of approved process changes may result in these intermediate products not

81

complying with stability requirements or specifications. Our product candidates and delivery devices must be stored and transported at temperatures within a certain range and in sterile environments. If these temperature and environmental conditions deviate, the remaining shelf-life of a product candidate or utility of a device could be impaired or its efficacy and safety could be negatively impacted, making it no longer suitable for use.

The occurrence, or suspected occurrence, of manufacturing and distribution difficulties can lead to lost inventories and, in some cases, product recalls, with consequential reputational damage and the risk of product liability. The investigation and remediation of any identified problems can cause production delays, substantial expense, lost sales and delays of new product launches. Any interruption in the supply of finished products or the loss thereof could hinder our ability to timely distribute our products and satisfy customer demand. Any unforeseen failure in the storage of the product or loss in supply could delay our clinical trials and, if our product candidates are approved, result in a loss of our market share and negatively affect our business, financial condition, results of operations and prospects.

Failure to obtain access to or to protect intellectual property related to the manufacturing of our products or product candidates may result in changes, delays and/or inability to manufacture such products or product candidates.

The intellectual property related to the manufacture of biological products is complex. If we are unable to maintain control of manufacturing technology such as our trade secrets, or we are unable to protect ongoing improvements comprehensively and in a sufficient number of jurisdictions, it would impact our ability to produce products for commercial sale or product candidates for preclinical testing or clinical trials and our development timelines and operations timelines could be adversely affected.

We presently manufacture our products using either an insect cell AAV production system or a mammalian cell system. We are aware of third parties which also use these systems in the manufacture of their products and who hold intellectual property on their AAV manufacturing systems. If we determine that access to certain third-party intellectual property is necessary for the manufacturing of our products and product candidates and are unable to license or otherwise access this intellectual property, it would impact our ability to produce products for commercial sale or product candidates for preclinical testing or clinical trials and our development timelines and operations timelines could be adversely affected.

Risks Related to Our Business Operations

We may not be successful in our efforts to identify or discover additional product candidates and may fail to capitalize on programs or product candidates that may be a greater commercial opportunity, or for which there is a greater likelihood of success.

The success of our business depends upon our ability to identify, develop and commercialize product candidates generated through our gene therapy and vectorized antibody platforms. Research programs to identify new product candidates require substantial technical, financial and human resources. The only active clinical trial for a product candidate we have developed, the RESTORE-1 Phase 2 clinical trial, is currently on clinical hold. It is uncertain when, or if, the FDA might release the hold. Although our collaboration partner Neurocrine has terminated our collaboration regarding VY-AADC, Neurocrine remains the sponsor of the RESTORE-1 Phase 2 clinical trial. Our other product candidates are in preclinical development. Our portfolio of product candidates is subject to change as we continue to conduct preclinical testing and development of product candidates and prioritize or abandon product candidates based on such results and other factors. For example, in August 2022, we announced a re-prioritization of our portfolio based on a review evaluating our programs based on, among other things, their potential for competitive differentiation, supportive preclinical data, an efficient path to human proof of biology or proof of mechanism (reflecting the availability of validated biomarkers), unmet medical need, commercial opportunity, and alignment with our overall strategy. We may also fail to identify other product candidates for clinical development for several reasons. For example, our research may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects, may be commercially impracticable to manufacture or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.

82

Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our spending on current and future research and development programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, option and license, or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement. Several of our current preclinical programs have previously been part of collaborations with third parties. While we have invested significant resources in these programs, we may decide in the future to cease development activities on one or more of them.

If any of these events occur, we may be forced to abandon our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate, which could harm our business, financial condition, results of operations and prospects.

Our future success depends on our ability to retain key members of our management team, and to attract, retain and motivate qualified personnel.

We are highly dependent on the management, technical, and scientific expertise of principal members of our management, scientific, and clinical teams. While we have entered into employment agreements or offer letters with each of our executive officers, any of them could leave our employment at any time, as all of our employees are “at will” employees. We currently do not have “key person” insurance on any of our employees. The loss of the services of one or more of our current employees might impede the achievement of our research, development and commercialization objectives.

Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, is critical to our success. There currently is a shortage of skilled individuals with substantial gene therapy experience, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and vector manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms, if at all, given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. In addition, failure to succeed in preclinical or clinical trials or applications for marketing approval, the termination of relationships with collaborators, and the reduction of our workforce in connection with the development of a new portfolio and platform strategy may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of, certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and could harm our business, financial condition, results of operations and prospects.

If we are unable to manage expected growth in the scale and complexity of our operations, our performance may suffer.

If we are successful in executing our business strategy in connection with the August 2021 strategic restructuring, we will need to expand our managerial, operational, financial and other systems and resources to manage our operations, continue our research and development activities and, in the longer term, build a commercial infrastructure to support commercialization of any of our product candidates that are approved for sale. We can provide no assurances that we will have sufficient resources in the future to manage all of our planned programs. Future growth would impose significant added responsibilities on members of management, may lead to significant added costs, and may divert our management and business development resources. It is likely that our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and product candidates requires that we continue to develop more robust business processes and improve our systems and procedures in each of these areas and to attract and retain sufficient numbers of talented employees. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals.

83

Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants, collaborators, and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.

Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.

In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed.

In March 2010, President Obama signed the ACA into law. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.

Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the TCJA, which was signed by President Trump on December 22, 2017, Congress repealed the “individual mandate.” The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the Court of Appeals for the Fifth Circuit affirmed the lower court’s ruling that the individual mandate portion of

84

the ACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA. Thereafter, the U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November 10, 2020. On June 17, 2021, the U.S. Supreme Court dismissed this case after finding that plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.

The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans’ access to health care, and consider actions that will protect and strengthen that access. Under this Executive Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.

The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our drug products, if and when approved.

The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States and other jurisdictions. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, former President Trump issued several executive orders intended to lower the costs of prescription drug products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, the Centers for Medicare & Medicaid Services, or CMS, issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries’ access to evidence-based care.

In addition, in October 2020, the Department of Health and Human Services, or the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the U.S. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, in November 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which has been delayed until January 1, 2026 by the Infrastructure Investment and Jobs Act.

In July 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals. The order directed the HHS to create a plan within 45 days to combat “excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.” In September 2021, the HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by

85

supporting pharmaceutical price negotiations with manufacturers; (b) improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.

More recently, with passage of the Inflation Reduction Act in August 2022, Congress authorized Medicare beginning in 2026 to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year, and it only applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition are categorically excluded from price negotiation. Further, the new legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.

At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

In other countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our products or product candidates to other available therapies. If reimbursement of our products or product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.

These measures, as well as others adopted in the future, may result in additional downward pressure on the price that we receive for any approved product we or our collaborators might bring to market. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from that we, or our collaborators, may successfully develop and for which we, or they, may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.

We may be subject, directly or indirectly, to federal, state, and foreign healthcare laws and regulations, including fraud and abuse laws and false claims laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state laws and regulations, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims act, and the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed research and development, sales, marketing and educational programs. In addition, we may be subject to data privacy laws by both the federal government and the states in which we conduct our

86

business. Such laws that may constrain the business or financial arrangements and relationships through which we conduct our operations include, but are not limited to:

the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for either the referral of an individual for, or the purchase, recommendation, leasing or furnishing of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. Further, the ACA amended the intent requirement of the federal Anti-Kickback Statute. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;
the federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent, or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties. The ACA provided and recent government cases against pharmaceutical and medical device manufacturers support the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the civil False Claims Act;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit a person from knowingly and willfully executing or attempting to execute a scheme or from making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private);
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in January 2013, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers;
federal transparency laws, including the federal Physician Payments Sunshine Act, which is part of the ACA, that requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members, by the 90th day of each subsequent calendar year, and disclosure of such information is made by CMS on a publicly available website; and
state and/or foreign law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws that may apply to arrangements and claims involving health care items or services reimbursed by non-governmental third-party payors; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances, such as specific disease states.

87

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union and other countries. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws such as laws of individual European Union Member States or the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.

Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.

We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, European Union, and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.

There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.

In 2018, California passed into law the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA’s requirements are similar to those found in the European Union’s General Data Protection Regulation, or GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of “sales” of their personal information. The CCPA contains significant penalties for companies that violate its requirements. On November 3, 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or CPRA, which will significantly expand the CCPA to incorporate

88

additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. Most CPRA provisions are scheduled to take effect on January 1, 2023, though the obligations will apply to any personal information collected after January 1, 2022. These provisions may apply to some of our business activities. In addition, other states, including Virginia and Colorado, already have passed state privacy laws. Congress, at the federal level, and other states are expected to consider similar laws in the future. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.

The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to €20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR has been and will continue to be a rigorous and time-intensive process that has increased and will continue to increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we or our collaborators may be subject to fines and penalties, litigation, and reputational harm in connection with any European activities, which could adversely affect our business, prospects, financial condition and results of operations.

Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. Following Brexit, the Data Protection Act of 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. Privacy and data security laws in several other countries loosely follow GDPR as a model but often contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual commercialization and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions. Any failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop.

We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and may face an even greater risk if we commercialize any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for any product candidates that we may develop;
loss of revenue;
substantial monetary awards to trial participants or patients;

89

significant time and costs to defend the related litigation;
withdrawal of clinical trial participants;
the inability to commercialize any product candidates that we may develop; and
injury to our reputation and significant negative media attention.

Although we maintain clinical trial liability insurance in the amount of $10.0 million per occurrence and $10.0 million in the aggregate, this insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial.  In addition, if we successfully commercialize any product candidate, we will need to obtain product liability insurance.  Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

If we, our collaborators, or any third-party manufacturers engaged by us or our collaborators fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

We, our collaborators, and any third-party manufacturers we engage are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and regulations relating to occupational health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biologic and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials or from any other work-related injuries, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain general liability insurance and workers’ compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could harm our business, financial condition, results of operations and prospects.

Further, with respect to the operations of any current or future collaborators or third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products.

A widespread outbreak of an illness or other health issue could significantly disrupt our operations. The current coronavirus disease 2019 (COVID-19) pandemic and the response to it have had, and we expect they will continue to have, an adverse effect on our business, operations, and future results.

Health issues such as epidemics or other medical emergencies outside of our control could significantly disrupt our operations and negatively impact our business.

90

In December 2019, a novel strain of coronavirus called severe acute respiratory syndrome coronavirus 2, also referred to as SARS-CoV-2, which causes the coronavirus disease 2019, also referred to as COVID-19, began to be reported in China and other countries. The World Health Organization has declared the outbreak a pandemic and a global public health emergency. In addition to those who have been directly affected, millions more have been affected by local and national government efforts in the United States, the European Union and around the world to slow the spread of the pandemic through quarantines, travel restrictions, heightened border scrutiny and other measures.

The COVID-19 pandemic continues to evolve. Our corporate headquarters is in Massachusetts, a state particularly hard hit by the initial wave of the pandemic. We have and will continue to adhere to applicable guidelines and safety measures including guidelines and measures regarding stay-at-home policies and the reporting of only essential personnel for business continuity to ensure the safety of our employees, consultants, contractors, and staff. Although the entirety of our workforce has been permitted to return to the office for a portion of the work week, workplace safety measures still in effect continue to limit our workforce’s ability to collaborate as it did prior to the COVID-19 pandemic. Further, the COVID-19 pandemic has transformed the workplace, establishing as an expected business norm a hybrid working environment where employees who are able to perform their job responsibilities remotely will expect the flexibility to work in locations outside of our office facilities. This type of workplace environment could create potential challenges, including establishing equity and inclusiveness among employees who must work on-site and employees who can work remotely, sustaining a collaborative team environment and encouraging company loyalty and diminishing turnover. Our ability to develop strategies and practices to address these risks are unknown.

The current workplace safety measures that we have enacted in response to COVID-19 have required a reduction in on-site activity at our facilities in Massachusetts, including in our laboratories in which preclinical experiments are conducted. As a result, we have had to prioritize our preclinical experiments and terminate or delay some non-critical experiments in order to maintain critical experiments for our preclinical programs. If these measures must be maintained for an extended period of time, or if more restrictive workplace safety measures are recommended by federal and state authorities, we may need to delay or terminate other preclinical experiments, including critical experiments for our preclinical programs, which we expect could have a material adverse impact on our development and regulatory plans and timelines for our preclinical programs. To the extent that any preclinical experiments impacted in this manner relate to a collaboration program, our reimbursement revenues from collaborators for the relevant activities may decrease or be delayed.

The extent to which COVID-19 ultimately impacts our business, financial condition, and results of operations will depend on future developments such as the duration and scope of the pandemic and the response of policymakers, businesses and individuals that are highly uncertain and cannot be accurately predicted. In the future, there may be other material adverse impacts on our business and operations during the pandemic and once it subsides. Employees and other key personnel could become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. Disruptions in the supply chain for personal protective equipment and other supplies critical for laboratory operations and/or the maintenance of current or future workplace safety measures could limit our ability to maintain business continuity. Regulators could be delayed in inspections, reviews, and approvals of product candidates including INDs and BLAs. Quarantines and travel restrictions could impact the ability of our third-party manufacturers and other suppliers to deliver clinical supplies or raw materials to us in a timely manner. Restrictions imposed on the construction industry could cause delays in completing our potential construction projects, resulting in program delays, cost increases and disruption to our current laboratory activities and general operations. Prolonged stay-at-home policies and, as described above, a distributed workforce could inhibit our ability to restore operations to pre-COVID-19 pandemic norms and to attract, retain, and motivate qualified personnel, and consequently, to allow our operations to develop as anticipated and to make our expected organizational growth more difficult. We are dedicating financial resources towards mitigating operational adjustments arising from the COVID-19 pandemic. If we need to access the capital markets to address requirements arising from the impacts of COVID-19 pandemic, there is no assurance that financing will be available on attractive terms, if at all.

We will continue to monitor the issues raised by the global spread of COVID-19 and have put in place and will continue to put in place measures as appropriate and necessary for, or that we believe to be in the best interest of, our

91

business, employees, collaborators, stockholders, and the community. However, there is no assurance that the pandemic will not have a material adverse impact on our business, operations, and future results.

Risks Related to the Commercialization of Our Product Candidates

The affected populations for our product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.

Our projections of the number of people who have the diseases we are seeking to treat, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are estimates based on our knowledge and understanding of these diseases. The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The process we have used in developing an estimated prevalence range for the indications we are targeting has involved collating limited data from multiple sources. While we believe these sources are reliable, we have not independently verified the data. Accordingly, the prevalence estimates included in our periodic reports and other reports filed with or furnished to the Securities and Exchange Commission, or SEC, should be viewed with caution. Further, the data and statistical information used in such reports, including estimates derived from them, may differ from information and estimates made by our competitors or from current or future studies conducted by independent sources.

The use of such data involves risks and uncertainties, and such data is subject to change based on various factors. Our estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of the diseases we seek to address. The number of patients with the diseases we are targeting in the United States, the European Union and elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or access, all of which would harm our results of operations and our business. Additionally, because some patients with the diseases we are targeting in the United States, the European Union, and elsewhere may have increased susceptibility to COVID-19, the COVID-19 pandemic could limit the number of patients willing to participate in clinical trials related to our products or amenable to treatment with our products, which would harm our results of operations and our business.

If we are unable to establish sales, medical affairs and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any product revenue.

To successfully commercialize any products that may result from our clinical development programs, we will need to further develop these capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any products we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability.

Under the Neurocrine Collaboration Agreement, Neurocrine agreed to fund the clinical development through the readout of the RESTORE-1 Phase 2 clinical trial for VY-AADC (NBIb-1817). If Neurocrine had not terminated the Neurocrine Collaboration Agreement with respect to VY-AADC (NBIb-1817), after the data readout of the RESTORE-1 Phase 2 clinical trial, we would have had the option to either: (1) co-commercialize VY-AADC (NBIb-1817) with Neurocrine in the United States under a 50/50 cost- and profit-sharing arrangement and receive milestones and royalties based on ex-U.S. sales, or (2) retain the right to receive milestone payments and royalties based on global sales pursuant to the full global commercial rights granted to Neurocrine. Under the terms of the Neurocrine Collaboration Agreement for the FA Program, Neurocrine has agreed to fund the development through the Phase 1 clinical trial of VY-FXN01. After the data readout of the Phase 1 clinical trial, we have the option to either: (1) co-commercialize VY-FXN01 with Neurocrine in the United States under a 60/40 cost and profit-sharing arrangement, 60% to Neurocrine and 40% to us, or (2) retain the right to receive milestone payments and royalties based on global sales pursuant to the full global commercial rights granted to Neurocrine.

92

In the future, we may seek to enter into collaborations regarding other of our product candidates with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future collaborators do not commit sufficient resources to commercialize our products, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded medical affairs, marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. We might face unforeseen costs and expenses associated with creating an independent sales and marketing organization. Our sales personnel might also face difficulties obtaining access to physicians or being able to persuade adequate numbers of physicians to use or prescribe our products or selling our products if we lack complementary products, which could disadvantage us compared to companies with more extensive product lines. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our potential products. If any of our product candidates is approved but fails to achieve market acceptance among physicians, patients, or third-party payors, we will not be able to generate significant revenues from such product, which could harm our business, financial condition, results of operations and prospects.

The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.

We expect the cost of a single administration of gene therapy products, such as those we are developing, to be substantial, when and if they receive regulatory approval. We expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Coverage and reimbursement by a third-party payor may depend upon several factors, including the third-party payor’s determination that use of a product is:

a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient and the indication;
convenient and easy-to-administer compared to alternative treatments;
cost-effective compared to alternative treatments; and
neither experimental nor investigational.

No uniform policy requirement for coverage and reimbursement for biopharmaceutical products exists among third-party payors. Therefore, coverage and reimbursement for such products can differ significantly from payor to payor. As a result, obtaining coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide to each different payor supporting scientific, clinical and cost-effectiveness data, and to receive the support of medical associations and technology assessment committees. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be

93

adequate to realize a sufficient return on our investment including our research, development, manufacture, sales, and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to new product acceptance. Additionally, there may be significant delays in obtaining coverage and reimbursement for newly approved drugs and biologics, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities.

There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. In the United States, third-party payors, including government payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare and Medicaid programs increasingly are used as models for how private payors and government payors develop their coverage and reimbursement policies. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.

The CMS is responsible for determining whether a product should be approved for coverage and reimbursement under the Medicare program. It is difficult to predict what CMS will decide with respect to coverage and reimbursement for novel products such as ours, as there is no body of established practices and precedents for these types of products. Currently, no gene therapy product has been approved for coverage and reimbursement by the CMS. Moreover, reimbursement agencies in the European Union may be more conservative than CMS. For example, several cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European Union Member States. It is difficult to predict what third-party payors will decide with respect to the coverage and reimbursement for our product candidates, especially given that the cost of our product candidates is likely to be very high and pricing of such products is highly uncertain.

Outside the United States, international operations generally are subject to extensive government price controls and other market regulations, and increasing emphasis on cost-containment initiatives in the European Union, Canada and other countries may put pricing pressure on us. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable product revenues.

Moreover, increasing efforts by government and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Payors increasingly are considering new metrics as the basis for reimbursement rates, such as average sales price, or ASP, average manufacturer price, or AMP, and Actual Acquisition Cost. The existing data for reimbursement based on some of these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates, and CMS has begun making pharmacy National Average Drug Acquisition Cost and National Average Retail Price data publicly available on at least a monthly basis. The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug and device products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug

94

before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.

Therefore, it is difficult to project the impact of these evolving reimbursement metrics on the willingness of payors to cover candidate products that we or our partners are able to commercialize. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products such as ours.

The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community.

Ethical, social and legal concerns about gene therapy could result in additional regulations restricting or prohibiting our products. Even with the requisite approvals from the FDA in the United States, EMA in the European Union and other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on the support and acceptance of medical associations and technology assessment committees, physicians, patients and health care payors of gene therapy products in general, and our product candidates in particular, as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of gene therapy products and, in particular, our product candidates, if approved for commercial sale, will depend on several factors, including:

the efficacy and safety of such product candidates as demonstrated in clinical trials;
the potential and perceived advantages of product candidates over alternative treatments;
the cost of treatment relative to alternative treatments;
the clinical indications for which the product candidate is approved by the FDA or the European Commission, or other regulatory authorities;
patient awareness of, and willingness to seek, genotyping;
the willingness of physicians to prescribe new therapies;
the willingness of physicians to undergo specialized training with respect to administration of our product candidates;
the willingness of the target patient population to try new therapies;
the prevalence and severity of any side effects;

95

product labeling or product insert requirements of the FDA, EMA or other regulatory authorities, including any limitations or warnings contained in a product’s approved labeling or restrictions on the use of our products together with other medications;
relative convenience and ease of administration;
the strength of marketing and distribution support;
the timing of market introduction of competitive products;
publicity concerning our products or competing products and treatments; and
sufficient third-party payor coverage and reimbursement.

Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched.

Our gene therapy and vectorized antibody approaches utilize vectors derived from viruses that are selectively engineered, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.

Gene and vectorized antibody therapies remain novel technologies, with few gene therapy products approved to date in the United States and the European Union. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. Medical events such as the COVID-19 pandemic that emphasize harmful effects of certain viruses could also indirectly foster negative public perception of virus-based therapies. In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop.

For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of leukemia and death seen in other trials using non-AAV gene therapy vectors. Adverse events and SAEs in our clinical trials such as the MRI abnormalities detected in some patients dosed in the RESTORE-1 Phase 2 clinical trial, or other clinical trials involving gene therapy products or our competitors’ products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.

If we obtain approval to commercialize our product candidates outside of the United States, in particular in the United Kingdom or European Union, a variety of risks associated with international operations could harm our business.

We expect that we will be subject to additional risks in commercializing our product candidates outside the United States, including:

different regulatory requirements for approval of drugs and biologics in foreign countries;
reduced or loss of protection under our intellectual property rights;

96

unexpected changes in tariffs, trade barriers and regulatory requirements;
economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;
workforce uncertainty in countries where labor unrest is more common than in the United States;
shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
business interruptions resulting from geopolitical actions, including war and terrorism, from natural disasters including earthquakes, typhoons, floods and fires, or from economic, social, or political instability; and
greater difficulty with enforcing our contracts in jurisdictions outside of the United States.

We must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.

Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In many foreign countries, it is common for others to engage in business practices that are prohibited by U.S. laws and regulations applicable to us, including the FCPA. In addition, the FCPA presents particular challenges in the pharmaceutical industry because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions. Although we expect to implement policies and procedures designed to comply with these laws and policies, there can be no assurance that our employees, contractors and agents will comply with these laws and policies. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results could be harmed.

97

Risks Related to Our Intellectual Property

Our rights to develop and commercialize our product candidates are subject to, in part, the terms and conditions of licenses granted to us by others.

We are reliant upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. These licenses may also require us to grant back certain rights to licensors and to pay certain amounts relating to the use of the licensed intellectual property. For example, The Touchlight License Agreement obligates us to make future milestone and royalty payments if we, or our collaboration partners or TRACER capsid licensees, use a capsid created using certain DNA preparation processes licensed under the Touchlight License Agreement.

In some circumstances, particularly in-licenses with academic institutions, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce or defend the patents, covering technology that we license from third parties. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our licensors fail to maintain such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected. In certain circumstances, we have or may license technology from third parties on a non-exclusive basis. In such instances, other licensees may have the right to enforce our licensed patents in their respective fields, without our oversight or control. Those other licensees may choose to enforce our licensed patents in a way that harms our interest, for example, by advocating for claim interpretations or agreeing on invalidity positions that conflict with our positions or our interest. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we own or may own in the future.

Further, in many of our license agreements we are responsible for bringing any actions against any third party for infringing on the patents we have licensed. Certain of our license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products and minimum yearly diligence obligations in developing and commercializing the product. Certain of our license agreements contain “no challenge” clauses which preclude and prevent us from taking any action to limit or narrow the intellectual property of a licensor. In some cases, these limitations extend to any intellectual property of our licensor and not just that which is licensed to us. Such constraints may limit our ability to develop or commercialize products or to expand such efforts beyond the scope of any license. Disputes may arise regarding intellectual property subject to a licensing agreement, including:

the scope of rights granted under the license agreement and other interpretation-related issues;
the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
the sublicensing of patent and other rights under our collaborative development relationships;
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
the inventorship or ownership of inventions and know-how resulting from the creation or use of intellectual property by our licensors and us and our partners; and
the priority of invention of patented technology.

98

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.

If we fail to comply with our obligations under these license agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to develop, manufacture, or market products covered by the license or may face other penalties under the agreements. Termination of any of our agreements involving intellectual property or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Termination may also result in unfavorable terms associated with such termination or may result in obligations on our part to license or grant back intellectual property rights to prior licensors.

Furthermore, the research resulting in certain of our licensed patent rights and technology was funded by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive, royalty-free license authorizing the U.S. government, or a third party on its behalf, to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government, or a third party on its behalf, of such rights could harm our competitive position, business, financial condition, results of operations and prospects.

If we are unable to obtain and maintain patent protection for our products and technology, or if the scope of the patent protection obtained is not of sufficient breadth, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected.

Our success depends, in large part, on our and our licensors’ ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and manufacturing technology. We and our licensors have sought, and we intend to seek in the future, to protect our proprietary position by filing patent applications in the United States and abroad related to many of our technologies and product candidates that are important to our business.

The patent prosecution process is expensive, time-consuming and complex, and we may not have and may not in the future be able to file, prosecute, maintain, enforce, defend or license all necessary or desirable patent applications in some or all relevant jurisdictions at a reasonable cost or in a timely manner. For example, in some cases, the work of certain academic researchers in the gene therapy field has entered the public domain, which may compromise our ability to obtain patent protection for certain inventions related to or building upon such prior work. Consequently, we may not be able to obtain any such patents to prevent others from using our technology for, and developing and marketing competing products to treat, these indications. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In some cases, we may be able to obtain patent protection, but such protections may expire before we commercialize the product protected by those rights, leaving us no meaningful protection for our products. In other cases, where our intellectual property is being managed by a third-party collaborator, licensee or partner, that third party may fail to act diligently in prosecuting, maintaining, defending or enforcing our patents. Such conduct may result in the failure to maintain or obtain protections, loss of rights, loss of patent term or, in cases where a third party has acted negligently or inequitably, patents being found unenforceable.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the

99

issuance, scope, validity, enforceability and commercial value of our and our licensors’ patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. In particular, during prosecution of any patent application, the issuance of any patents based on the application may depend upon our ability to generate additional preclinical or clinical data that support the patentability of our proposed claims. We may not be able to generate sufficient additional data on a timely basis, or at all. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value, narrow the scope, or eliminate the enforceability of our and our licensors’ patent protection.

We may not be aware of all third-party intellectual property rights potentially relating to our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, only upon issuance or not at all. Therefore, we cannot be certain that we, or a licensor, were the first to make the inventions claimed in any owned or any licensed patents or pending patent applications, respectively, or which entity was the first to file for patent protection until such patent application publishes or issues as a patent. Databases for patents and publications, and methods for searching them, are inherently limited, so it is not practical to review and know the full scope of all issued and pending patent applications. As a result, the issuance, scope, validity, enforceability, and commercial value of our and our licensed patent rights are uncertain.

Even if the patent applications we license or may own in the future do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.

In spite of a legal presumption of validity, the issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity, or enforceability which may be challenged in the courts and patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology, resulting in termination of our access to such intellectual property, or increase our financial or other obligations to our licensors.

The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, result in loss of access, or increase what we believe to be our financial or other obligations under the relevant agreement, any of which could harm our business, financial condition, results of operations and prospects.

We may not be successful in obtaining necessary rights to our product candidates through acquisitions and in-licenses.

We currently have rights to certain intellectual property, through licenses from third parties, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business likely will depend, in part, on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to

100

license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical or technical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.

We currently co-own certain intellectual property rights with one or more third parties. We may not be able to obtain a license to the third parties’ interest such that we have exclusive access and control of such co-owned assets. In this case, and depending on the jurisdiction of the patent filing, we may not be able to license, enforce, or exploit the co-owned rights without the consent from, or an accounting to, the other co-owners.

We sometimes collaborate with non-profit and academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to develop our program. We may also decide not to exercise an option to such institutional rights.

If we decide not to obtain, or are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the United States Patent and Trademark Office, or USPTO, and various government patent agencies outside of the United States over the lifetime of our licensed patents and/or applications and any patent rights we may own in the future. We rely on our outside counsel or our licensors to pay these fees due to patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction, and may compromise the strength of other intellectual property in our portfolio. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.

On February 1, 2019 the government of Venezuela, in response to certain U.S. sanctions, began to require that foreign entities pay all official fees, including patent fees (either for pending matters or new petitions), in PETRO, a “cryptocurrency” created by the Nicolás Maduro administration in February 2018 as a way to collect U.S. dollars while avoiding American financial sanctions issued under an Executive Order of President Trump on March 19, 2018. The Executive Order banned transactions involving “any digital currency, digital coin, or digital token, that was issued by, for, or on behalf of the Government of Venezuela on or after January 9, 2018.” The prohibition is applicable to any U.S. entity unless exempted by license. We do not hold such a license and therefore may not be able to secure patents in Venezuela.

101

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. Our intellectual property rights may vary from country to country and foreign protections could be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products or methods of treatment, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, an April 2021 report from the Office of the United States Trade Representative identified a number of countries, including India and China, where challenges to the procurement and enforcement of patent rights have been reported. Several countries, including India and China, have been listed in the report every year since 1989. With Brexit, there is uncertainty associated with obtaining, defending, and enforcing intellectual property rights in the United Kingdom. International treaties and regulations promulgated as a result of this transition could impede or eliminate our ability to obtain or maintain meaningful intellectual property rights in the United Kingdom. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Issued patents covering our technology or product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court.

If one of our licenses or licensors or we initiate legal proceedings against a third party to enforce a patent covering our technology or one of our product candidates, the defendant could counterclaim that the patent covering such technology or product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that an individual connected with prosecution of the patent, including an inventor, an employee of the company, a collaborator or advisor, withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include pre-issuance submissions, ex parte re-examination, post-grant review, inter partes review and equivalent proceedings in foreign jurisdictions. Some of these mechanisms may even be exploited anonymously by third parties. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our technology or product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensees or licensors were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose part or, all of the patent protection on one or more of our product candidates or our supporting technology. Such a loss of patent protection could harm our business.

102

In addition to the protection afforded by patents, we rely on trade secret protection, nondisclosure, and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. Some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, collaborators, contractors, and other third parties. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.

Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm our business.

Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may become party to, or threatened with, infringement litigation claims regarding our products and technology, including claims from competitors or from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. Moreover, we may become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including ex parte re-examination, post-grant review and inter partes review before the USPTO or foreign patent offices. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of the merit of the claim.

On November 3, 2022, we and Touchlight entered into the Touchlight License Agreement to allow for our historical use a certain DNA preparation process, or the Subject DNA Preparation Process, and to authorize the prospective exploitation of TRACER Capsids that we have previously created using the Subject DNA Preparation Process. As previously referenced in the Risk Factor section of our prior periodic reports, Touchlight had made us aware earlier in 2022 that it believed its intellectual property rights could potentially be asserted against us, although we disagreed with this assessment. In connection with entering into the Touchlight License Agreement, Touchlight also agreed to release any potential claims against us regarding the alleged historical use of certain of Touchlight’s intellectual property rights and exploitation of TRACER Capsids created with the alleged use of such intellectual property rights.

There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize our product candidates or any other of our product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such asserted third-party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Similar challenges exist in other jurisdictions. If we are found to infringe a third-party’s valid and enforceable intellectual property rights, we could be required to obtain a license from such third-party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary

103

damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals, and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, reputation, financial condition, results of operations and prospects.

Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Competitors may infringe our intellectual property rights or the intellectual property rights of our licenses or licensors, or we may be required to defend against claims of infringement. To counter infringement or unauthorized use claims or to defend against claims of infringement can be expensive and time consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could adversely affect our ability to compete in the marketplace.

We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.

Many of our directors, employees, consultants, and advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that these individuals do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

In addition, while it is our policy to require our employees, consultants, advisors and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.

If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America

104

Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes several significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a “first-to-invent” system to a “first-inventor-to-file” system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-inventor-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO has promulgated regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-inventor-to-file provisions, became effective on March 16, 2013. The Leahy-Smith Act has resulted in an increased investment in filing applications earlier, and consequently has increased the uncertainties and costs surrounding the prosecution of our patent applications, and may increase the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects.

The administrative tribunal created by the Leahy-Smith Act, known as the Patent Trial and Appeals Board, or PTAB, may have an impact on the operation of our business in the future. For example, the initial results of patent challenge proceedings before the PTAB since its inception in 2013 have resulted in the invalidation of many U.S. patent claims. The availability of the PTAB as a lower-cost, faster and potentially more potent tribunal for challenging patents could therefore increase the likelihood that our own licensed patents will be challenged, thereby increasing the uncertainties and costs of maintaining and enforcing them. Moreover, if such challenges occur, we may not have the right to control the defense. In certain situations, we may be required to rely on our licensor to consider our suggestions and to defend such challenges, with the possibility that it may not do so in a way that best protects our interests.

We also may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in other contested proceedings such as opposition, derivation, reexamination, inter partes review, or post-grant review proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products.

The patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain as the courts address issues such as patenting genes or gene products. Recent guidance provided under Berkheimer v HP, Inc. (April 19, 2018) and Vanda Pharmaceuticals, Inc. v West-Ward Pharmaceuticals (June 7, 2018) instruct USPTO examiners on the ramifications of the court rulings as applied to method of treatment claims, natural products and principles including all naturally occurring nucleic acids. Patents for certain of our product candidates contain claims related to specific DNA sequences that are naturally occurring and, therefore, could be the subject of future challenges made by third parties. In addition, the recent USPTO guidance could make it impossible for us to pursue similar patent claims in patent applications we may prosecute in the future.

We cannot assure you that our efforts to seek patent protection for our technology and products will not be negatively impacted by the court decisions referenced above, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact decisions from the U.S. Supreme Court’s decisions in Mayo Collaborative Services v. Prometheus Laboratories and Molecular Pathology v. Myriad Genetics, Inc. or other applicable court decisions may have on the ability of life science companies to obtain or enforce patents relating to their products and technologies in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have an adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.

Moreover, although the U.S. Supreme Court has held that isolated segments of naturally occurring DNA are not patent-eligible subject matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent claims, and we may deem it necessary to defend ourselves against these claims by asserting non-infringement and/or invalidity positions, or paying to obtain a license to these claims. In any of the foregoing or in

105

other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, we could be forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter. Such outcomes could harm our business, financial condition, results of operations or prospects.

Outside the United States, other courts have also begun to address the patenting of genetic material. In August 2015, the Australian High Court ruled that isolated genes cannot be patented in Australia. The decision did not address methods of using genetic material. Any ruling of a similar scope in other countries could affect the scope of our intellectual property rights. The ambiguities and changing law in all countries as to patenting genetic material may directly affect our ability to secure and/or maintain patent protection for our products.

If we do not obtain patent term extension and data exclusivity for our product candidates, our business may be harmed.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars.

Depending upon the timing, duration and specifics of any FDA marketing approval of our product candidates, one or more of our U.S. patents, which may cover non-gene therapy compounds, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended per FDA-approved product, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Further, certain of our licenses currently or in the future may not provide us with the right to control decisions the licensor or its other licensees on Orange Book listings or patent term extension decisions under the Hatch-Waxman Act. Thus, if one of our important licensed patents is eligible for a patent term extension under the Hatch-Waxman Act, and it covers a product of another licensee in addition to our own product candidate, we may not be able to obtain that extension if the other licensee seeks and obtains that extension first. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements.

The BPCIA provides up to 12 years of market exclusivity for a reference biological product. We may not be able to obtain such exclusivity for our products. Moreover, the applicable time-period or the scope of patent protection afforded during any such extension could be less than we request. If we are unable to obtain patent term extension or the scope of term of any such extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be materially reduced.

If our trademarks and trade name are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

We own service mark registrations in the USPTO for the marks “VOYAGER THERAPEUTICS” and “VOYAGER THERAPEUTICS Logo” and European Community trademark registrations for the marks “V-TAG” and “VOYAGER TRAJECTORY ARRAY GUIDE.” Our trademarks or our trade name may be challenged, infringed, circumvented or declared generic or found to infringe prior third-party marks. We may not be able to protect our rights in our trademarks or in our trade name, which we need in order to build name recognition among potential partners or customers in our markets of interest. It is possible that competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of prior registered trademarks or trademarks

106

that incorporate variations of our registered or unregistered trademarks or trade name. Over the long term, if we are unable to establish name recognition based on our trademarks and trade name, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce and protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights and other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and such rights may not adequately protect our business or permit us to maintain our competitive advantage. For example:

others may be able to make gene therapy products that are similar to our product candidates but that are not covered by the claims of the patents that we own, license or may access in the future;
we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;
we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;
it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents;
issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we may not develop additional proprietary technologies that are patentable;
the patents of others may have an adverse effect on our business; and
we may choose not to file a patent for certain inventions, trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.

We may not be able to maintain sufficient control over our proprietary know-how or trade secrets when employees, consultants, advisors or persons with access to our proprietary information terminate their relationship with us.

Despite our efforts to protect our proprietary know-how and trade secrets, our competitors may discover this information, or obtain the benefit of this information, through a breach of confidentiality and/or non-competition obligations by persons who were formerly associated with us but who have established relationships as employees, contractors, consultants or advisors with other companies, including our competitors. The recent departures of certain executives, key employees, consultants or advisors, and the restructuring of our organization, may make it more difficult

107

to enforce our rights in protecting this information. Further, if discovered in a timely manner, our efforts to enforce rights to protect against these types of breaches may not be possible under law, or may not be successful if commenced.

It is also possible that, as we grow and establish ourselves in multiple geographic areas, alignment and/or compliance with company polices may not be consistently maintained. In any such cases, the risk of loss of control or proper management of our proprietary information could jeopardize our intellectual property.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we currently rely on certain third parties to manufacture all or part of our product candidates and to perform quality testing, and because we collaborate with various organizations and academic institutions for the advancement of our gene therapy and vectorized antibody platforms and pipeline, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may harm our business, financial condition, results of operations and prospects.

Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets by third parties. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.

Changes to national patent laws and diminished or limited access to United States and/or foreign patent counsel and the courts in response to the ongoing COVID-19 pandemic may compromise our ability to pursue, obtain, enforce or defend our intellectual property patent protections throughout the world.

In response to the ongoing COVID-19 pandemic, many national patent offices promulgated emergency measures and alternative procedures for filing, prosecuting and adjudicating disputes regarding intellectual property. While some of these new rules involve the provision of extensions for certain filing deadlines, none of these emergency-situation rules have been tested in a litigation setting or for their harmonization with the laws of other countries.

Access to the USPTO and other patent offices were, and may again in the future be, restricted by government mandated shelter-in-place or stay-home orders thereby limiting our ability to appear before any tribunal in support of our intellectual property. Should direct or electronic access to these tribunals be interrupted or become non-existent again in the future, we may not be able to secure, defend or enforce patent protections in all jurisdictions.

We also rely on United States and foreign patent counsel in the management of our intellectual property. Should our access to counsel be diminished or lost due to effects of COVID-19 on these service providers and their organizations, we may not be able to manage, maintain or secure our intellectual property position.

108

Risks Related to Ownership of Our Common Stock

Our executive officers, directors, principal stockholders and their affiliates exercise significant influence over our company.

The holdings of our executive officers, directors, principal stockholders and their affiliates, including investment funds affiliated with Third Rock Ventures, LLC, Neurocrine, EcoR1 Capital, LLC, and The Vanguard Group, Inc. represent beneficial ownership, in the aggregate, of approximately 43% of our outstanding common stock as of September 30, 2022. As a result, these stockholders, if they act together, will be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. In addition, this concentration of ownership might adversely affect the market price of our common stock by:

delaying, deferring or preventing a change of control of us;
impeding a merger, consolidation, takeover or other business combination involving us; or
discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.

An active trading market for our common stock may not be sustained.

Our shares of common stock began trading on the Nasdaq Global Select Market on November 11, 2015. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares.

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.

Persons who were our stockholders prior to our initial public offering continue to hold a substantial number of shares of our common stock. If such persons sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline.

In addition, shares of common stock that are either subject to outstanding options or restricted stock units, or RSUs, or reserved for future issuance under our stock incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933, as amended. We have also filed registration statements on Form S-8 permitting shares of common stock issued on exercise of options or the settlement of RSUs to be freely sold in the public market. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. We also have an effective registration statement on Form S-3 for the sale of up to $300.0 million in aggregate of an indeterminate number of shares of common stock and preferred stock, an indeterminate principal amount of debt securities, and an indeterminate number of warrants, of which we have reserved $100.0 million for the offering, issuance, and sale of common stock through at-the-market offerings or negotiated transactions under a sales agreement we entered into with Cowen and Company, LLC, or Cowen, on November 6, 2019.

Certain holders of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.

The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.

109

The price of our common stock is likely to be volatile and may fluctuate substantially. From July 1, 2022 through September 30, 2022, the sales price of our common stock ranged from a high of $7.56 to a low of $5.37 on the Nasdaq Global Select Market. As a result of this volatility, our stockholders may not be able to sell their common stock at or above the price at which they purchased it. The market price for our common stock may be influenced by many factors, including:

our success in commercializing any product candidates for which we obtain marketing approval;
regulatory action and results of clinical trials of our product candidates or those of our competitors;
the success of competitive products or technologies;
the results of clinical trials of our product candidates;
the results of clinical trials of product candidates of our competitors;
the commencement, termination, and success of our collaborations, including the ability or willingness of our collaboration partners to fulfill their obligations to us;
regulatory or legal developments in the United States and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel, including in connection with our strategic restructuring;
the level of expenses related to any of our product candidates or clinical development programs;
the results of our efforts to discover, develop, acquire or in-license additional product candidates or technologies, the cost of commercializing such product candidates, and the cost of development of any such product candidates or technologies;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
variations in our financial results or those of companies that are perceived to be similar to us;
the ability to secure third-party reimbursement for our product candidates;
changes in the structure of healthcare payment systems;
market conditions in the pharmaceutical and biotechnology sectors;
general economic, industry and market conditions; and
the other factors described in this “Risk Factors” section and elsewhere in this Quarterly Report on Form 10-Q.

If our operating results fall below the expectations of investors or securities analysts for a given period, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results from period to period may, in turn, cause the price of our stock to fluctuate substantially. We believe that such comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.

In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation often has been instituted against that company. We also may face securities class-action litigation if we cannot obtain regulatory approvals for or if we otherwise fail to commercialize our product candidates. We and certain of our

110

current and former officers and directors were previously named as defendants in a purported class action lawsuit. This proceeding and other similar litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management’s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.

We have broad discretion in how we apply our available funds, and we may not use these funds effectively, which could affect our results of operations and cause our stock price to decline.

Our management will have broad discretion in the application of our existing cash, cash equivalents and marketable securities and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply our available funds effectively could result in financial losses that could cause the price of our common stock to decline and delay the development of our product candidates and preclinical programs. Pending their use, we may invest our available funds in a manner that does not produce income or that loses value.

We are a “smaller reporting company” and the reduced disclosure requirements applicable to such companies may make our common stock less attractive to investors.

We are a “smaller reporting company,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We would cease to qualify as a smaller reporting company if we have (i) a non-affiliate public float in excess of $250 million and annual revenues in excess of $100 million during our last fiscal year, or (ii) a non-affiliate public float in excess of $700 million, in each case determined on an annual basis as of the last business day of our second quarter. As a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not smaller reporting companies. These exemptions include:

being permitted to provide only two years of audited consolidated financial statements in this Annual Report on Form 10-K, with correspondingly reduced “Management's Discussion and Analysis of Financial Condition and Results of Operations” disclosure;

reduced disclosure obligations regarding executive compensation; and

not being required to furnish a stock performance graph in our annual report.

We expect to take advantage of some or all of the available exemptions until we cease to be a smaller reporting company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

We have recently been, and could in the future be, subject to legal actions and proceedings related to the decline in our stock price, which could distract our management and could result in substantial costs or large judgments against us.

The market prices of securities of companies in the biotechnology and pharmaceutical industry, including the market price of our common stock, have been extremely volatile and have experienced fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. On January 22, 2021, a putative class action lawsuit was filed in the U.S. District Court for the Eastern District of New York (later transferred to the U.S. District Court for the District of Massachusetts) against us and certain of our current and former officers and directors. The complaint sought, among other things, unspecified compensatory damages, interest, attorneys’ and expert fees and costs. On July 2, 2021, the lead plaintiff voluntarily dismissed the action without prejudice against all defendants and as to all claims, and this action is no longer pending. Nonetheless, due to the volatility in, or the unfulfilled expectations of stockholders for, our stock price, we may be the target of similar litigation in the future.

In connection with such legal proceedings, we could incur substantial costs and such costs and any related settlements or judgments may not be covered by insurance. We could also suffer an adverse impact on our reputation and

111

a diversion of management’s attention and resources, which could cause serious harm to our business, operating results and financial condition.

We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.

As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and rules subsequently implemented by the SEC and The Nasdaq Stock Market have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly. For example, these rules and regulations have made it more difficult and more expensive for us to obtain director and officer liability insurance, and we have been required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers.

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. To remain compliant with Section 404, we must continue to engage in the process of documenting and evaluating our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

Provisions in our amended and restated certificate of incorporation and bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:

establish a classified board of directors such that only one of three classes of members of the board is elected each year;
allow the authorized number of our directors to be changed only by resolution of our board of directors;
limit the manner in which stockholders can remove directors from the board;
establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;

112

require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
limit who may call stockholder meetings;
authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called “poison pill,” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our amended and restated certificate of incorporation or bylaws.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. This choice of forum provision is inapplicable to actions arising under the Securities Exchange Act of 1934, as amended, and we likewise do not intend to apply this choice of forum provision to actions arising under the Securities Act of 1933, as amended.

This choice of forum provision may limit a stockholder’s ability to bring a claim that is not arising under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, in a judicial forum that he, she or it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs and business interruption that could have a material adverse effect on our business, financial condition or results of operations.

113

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gain.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.

General Risk Factors

Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including inflation and supply disruption. A domestic or global financial crisis can cause extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, which could result from an event like the COVID-19 pandemic or the recent global sanctions imposed by countries against Russia following Russia’s military intervention in the Ukraine, could result in a variety of risks to our business, including weakened demand for our product candidates, our inability to purchase necessary supplies on acceptable terms, if at all, and our inability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.

The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes in tax law (which may have retroactive application) may adversely affect our stockholders or our business or financial condition. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. On December 22, 2017, the U.S. government enacted the TCJA, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The TCJA, among other things, contained significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for net interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses, or NOLs, to 80% of current year taxable income and elimination of NOL carrybacks, in each case, for losses arising in taxable years beginning after December 31, 2017 (though any such NOLs may be carried forward indefinitely), imposition of a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits. Beginning in 2022, the TCJA eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. Congress is considering legislation that would defer the amortization requirement to future periods, however, we have no assurance that the provision will be repealed or otherwise modified.

As part of Congress’ response to the COVID-19 pandemic, the Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, the CARES Act was enacted on March 27, 2020 and COVID-19 relief provisions were included in the Consolidated Appropriations Act, 2021 or CAA, which was enacted on December 27, 2020. All contain numerous tax provisions. In particular, the CARES Act retroactively and temporarily (for taxable years beginning before January 1, 2021) suspends application of the 80%-of-income limitation on the use of NOLs, which was enacted as part of the TCJA. It also provides that NOLs arising in any taxable year beginning after December

114

31, 2017, and before January 1, 2021, are generally eligible to be carried back up to five years. The CARES Act also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30% to 50% of adjusted taxable income.

Regulatory guidance under the TCJA, the FFCR Act, the CARES Act and the CAA is and continues to be forthcoming, and such guidance could ultimately increase or lessen impact of these laws on our business and financial condition. It is also possible that Congress will enact additional legislation in connection with the COVID-19 pandemic, and as a result of the changes in the U.S. presidential administration and control of the U.S. Senate, additional tax legislation may also be enacted; any such additional legislation could have an impact on us. In addition, it is uncertain if and to what extent various states will conform to the TCJA, the FFCR Act, the CARES Act or the CAA.

We might not be able to utilize a significant portion of our net operating loss carryforwards.

As of December 31, 2021, we had both federal and state NOL carryforwards of $210.8 million and $198.9 million, respectively, which expire beginning in 2033. These NOL carryforwards could expire unused and be unavailable to offset our future income tax liabilities. As described above under the heading “Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,” the TCJA, as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing NOL carryforwards that may significantly impact our ability to utilize our NOLs to offset taxable income in the future. Nor is it clear how various states will respond to the TCJA, the FFCR Act or the CARES Act. In addition, state NOLs generated in one state cannot be used to offset income generated in another state. Furthermore, the use of NOL carryforwards may become subject to an annual limitation under Section 382 of the Code and similar state provisions in the event of certain cumulative changes in the ownership interest of significant shareholders in excess of 50 percent over a three-year period. This could limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of a company immediately prior to the ownership change. Our company has completed several transactions since its inception which resulted in an ownership change under Section 382 of the Code. In addition, future changes in our stock ownership, some of which are outside of our control, could result in ownership changes in the future. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes.

Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.

Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, ransom requests, sabotage, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or the operations of those third parties with which we contract, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions, and could require a substantial expenditure of resources to remedy. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in our information systems and networks, including personal information of our employees. Outside parties may attempt to penetrate our systems or those of the third parties with which we contract or to fraudulently induce our employees or employees of such third parties to disclose sensitive information to gain access to our data or to use such access to request cash compensation in the form of a ransom for the return of such data.

The number and complexity of these threats continue to increase over time. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated. Despite our efforts, the possibility of these events occurring cannot be eliminated entirely. Although we maintain cyber risk insurance for certain costs we may incur due to a cyber-related event, this insurance may not provide adequate

115

coverage against potential liabilities. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, or a loss of cash in response to ransom threats, we could incur liability, our competitive and financial position and the market perception of the effectiveness of our security measures could be harmed, our credibility could be damaged, and the further development and commercialization of our product candidates could be delayed.

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. If no or few analysts maintain coverage of us, the trading price of our stock would likely decrease. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.

116

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Inducement Grant Awards

On September 19, 2022, we issued to two executives non-statutory stock options to purchase an aggregate of 276,000 shares of our common stock at an exercise price of $4.40 per share. The options were granted outside of our 2015 Stock Option Plan, in each case, as an inducement material to such executive’s acceptance of an offer of employment with us in accordance with Nasdaq Listing Rule 5635(c)(4). We intend to file a registration statement on a Form S-8 to register the shares of common stock underlying the stock options prior to the time at which the shares underlying the options become exercisable.

Repurchases of Common Stock

The following table sets forth information with respect to repurchases of shares of our common stock during the three months ended September 30, 2022.

Period

Total Number of Shares Purchased

Average Price Paid per Share

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs

Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs

July 1 – July 31, 2022

72,647 (1)

$0.0425

-

-

August 1 – August 31, 2022

-

-

-

-

September 1 – September 30, 2022

-

-

-

-

Total

72,647

$0.0425

-

-

(1)During the three months ended September 30, 2022, we modified one of our founder’s performance awards, repurchasing 72,647 shares of common stock previously issued thereunder.

ITEM 5. OTHER INFORMATION

On November 3, 2022, we and Touchlight entered into a license agreement, or the Touchlight License Agreement, to allow for the historical use by us of a certain DNA preparation process, or the Subject DNA Preparation Process, and to authorize the prospective exploitation of TRACER Capsids that we have previously created using the Subject DNA Preparation Process.

The terms of the Touchlight License Agreement include a one-time, non-refundable technology access fee of $5.0 million, payable to Touchlight during the fourth quarter of 2022. As of September 30, 2022, we determined that this technology access fee was a probable liability that could be reasonably estimated in accordance with ASC 450 Contingencies as of such date. The Company recorded the $5.0 million charge during the third quarter of 2022, accordingly.

In connection with entering into the Touchlight License Agreement, Touchlight also agreed to release any potential claims against us regarding the historical use of certain of Touchlight’s intellectual property rights.

If we or any of our therapeutic program licensees choose to move forward with the exploitation of TRACER Capsids created with the historical use of the Subject DNA Preparation Process, the Touchlight License Agreement obligates us to pay Touchlight future milestone payments of up to an aggregate of $850,000 per developed product utilizing such TRACER Capsids and low single-digit royalties on net sales. Unless earlier terminated, these obligations

117

under the Touchlight License Agreement shall expire on the earlier to occur of January 17, 2031 or a final decision by an applicable patent authority or court of competent jurisdiction invalidating or otherwise rendering the licensed patent unenforceable. The Touchlight License Agreement also obligates us to pay Touchlight low single-digit royalties on future payments received by Voyager from third parties in connection with licensing of TRACER Capsids created with the historical use of the Subject DNA Preparation Process (other than the licensing of such TRACER Capsids in the context of licensing of or collaboration on our therapeutic programs). The royalty obligations to Touchlight on payments received under agreements entered with third parties prior January 17, 2031 or the expiration or invalidation of the licensed patent are subject to step-down provisions, and no other payment obligations under the Touchlight License Agreement in relation to licensing of the relevant TRACER Capsids to third parties shall continue following January 17, 2031 or a final decision by an applicable patent authority or court of competent jurisdiction invalidating or otherwise rendering the licensed patent unenforceable.

The foregoing description of the Touchlight License Agreement is qualified in its entirety by the text of such agreement, a copy of which we expect to file as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2022.

ITEM 6.EXHIBITS

The exhibits filed or furnished as part of this Quarterly Report are set forth on the Exhibit Index, which is incorporated herein by reference.

INDEX TO EXHIBITS

Incorporated by Reference to:

Exhibit
No.

    

Description

    

Form or
Schedule

    

Exhibit
No.

    

Filing
Date with
SEC

    

SEC File
Number

    

Filed
Herewith

10.1

Employment Agreement by and between the Registrant and Peter Pfreundschuh, effective as of September 7, 2022

8-K

10.1

09/07/2022

001-37625

10.2

Second Amended and Restated Employment Agreement by and between the Registrant and Todd Carter, Ph.D., effective as of September 7, 2022

8-K

10.2

09/07/2022

001-37625

31.1

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14 or 15d-14.

X

31.2

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14 or 15d-14.

X

32.1+

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rules 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350.

X

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

X

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

X

118

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

X

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

X

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

X

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

X

104

Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

+

The certification furnished in Exhibit 32.1 hereto is deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

119

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 8, 2022

VOYAGER THERAPEUTICS, INC.

By:

/s/ Alfred Sandrock, M.D., Ph.D.

Alfred Sandrock, M.D., Ph.D.

Chief Executive Officer, President, and Director

(Principal Executive Officer)

By:

/s/ Peter P. Pfreundschuh

Peter P. Pfreundschuh

Chief Financial Officer

(Principal Financial and Accounting Officer)

120

EX-31.1 2 vygr-20220930xex31d1.htm EX-31.1

Exhibit 31.1

Certification

I, Alfred Sandrock, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2022 of Voyager Therapeutics, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 8, 2022

/s/ Alfred Sandrock, M.D., Ph.D.

Alfred Sandrock, M.D., Ph.D.

Chief Executive Officer, President, and Director

(Principal Executive Officer)


EX-31.2 3 vygr-20220930xex31d2.htm EX-31.2

Exhibit 31.2

Certification

I, Peter P. Pfreundschuh, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2022 of Voyager Therapeutics, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2022

/s/ Peter P. Pfreundschuh

Peter P. Pfreundschuh

Chief Financial Officer

(Principal Financial and Accounting Officer)


EX-32.1 4 vygr-20220930xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Voyager Therapeutics, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that to his or her knowledge:

 

1)the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 8, 2022

 

/s/ Alfred Sandrock, M.D., Ph.D.

 

Alfred Sandrock, M.D., Ph.D.

 

Chief Executive Officer, President, and Director

(Principal Executive Officer)

Date: November 8, 2022

 

/s/ Peter P. Pfreundschuh

 

Peter P. Pfreundschuh

 

Chief Financial Officer

(Principal Financial and Accounting Officer)


GRAPHIC 5 vygr-20220930x10q006.jpg GRAPHIC begin 644 vygr-20220930x10q006.jpg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end GRAPHIC 6 vygr-20220930x10q008.jpg GRAPHIC begin 644 vygr-20220930x10q008.jpg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vygr-20220930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair value measurements - Assets and liabilities measured on a recurring basis - (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, Cash Equivalents, and Marketable Securities - (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Other liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Net income (loss) per share - Basic and diluted weighted average shares outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accrued expenses link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Net income (loss) per share link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accrued expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Net income (loss) per share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of business (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Lease obligation (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Commitments and contingencies - Neurocrine Collaboration Agreement - (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Commitments and contingencies - Collaboration receivables and contract liabilities - (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Commitments and contingencies - Pfizer Option and License Agreement - (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Commitments and contingencies - Novartis Option and License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Commitments and Contingencies - Touchlight IP Ltd License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40806 - Disclosure - Commitments and contingencies - Other Agreements - (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stock-based compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Stock-based compensation - Compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Stock-based compensation - Restricted Stock - (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Stock-based compensation - Stock Options - (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Related party transactions (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Lease obligation link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Other liabilities link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Lease obligation (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Other liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Lease obligation - Operating sublease income (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vygr-20220930_cal.xml EX-101.CAL EX-101.DEF 9 vygr-20220930_def.xml EX-101.DEF EX-101.LAB 10 vygr-20220930_lab.xml EX-101.LAB EX-101.PRE 11 vygr-20220930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2022
Nov. 04, 2022
Document and Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2022  
Entity File Number 001-37625  
Entity Registrant Name Voyager Therapeutics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 46-3003182  
Entity Address, Address Line One 64 Sidney Street  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02139  
City Area Code 857  
Local Phone Number 259-5340  
Title of 12(b) Security Common Stock, $0.001 par value  
Trading Symbol VYGR  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001640266  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Entity Common Stock, Shares Outstanding   38,607,346
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 96,860 $ 117,433
Marketable securities, current 34,778 15,106
Accounts receivable 10,000  
Related party collaboration receivable 225 732
Prepaid expenses and other current assets 5,079 3,427
Total current assets 146,942 136,698
Property and equipment, net 18,082 21,920
Deposits and other non-current assets 1,515 1,779
Operating lease, right-of-use asset 15,941 33,458
Total assets 182,480 193,855
Current liabilities:    
Accounts payable 1,337 574
Accrued expenses 12,529 10,950
Other current liabilities 2,746 5,571
Deferred revenue, current 56,630 33,886
Total current liabilities 73,242 50,981
Deferred revenue, non-current 7,391 8,210
Other non-current liabilities 22,024 39,609
Total liabilities 102,657 98,800
Commitments and contingencies (see note 8)
Stockholders' equity:    
Preferred stock $0.001 par value: 5,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.001 par value: 120,000,000 shares authorized at September 30, 2022 and December 31, 2021; 38,520,336 and 37,918,395 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively 38 38
Additional paid-in capital 450,008 442,259
Accumulated other comprehensive loss (337) (138)
Accumulated deficit (369,886) (347,104)
Total stockholders' equity 79,823 95,055
Total liabilities and stockholders' equity $ 182,480 $ 193,855
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Condensed Consolidated Balance Sheets    
Preferred Stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred Stock, Shares Authorized 5,000,000 5,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common Stock, Shares Authorized 120,000,000 120,000,000
Common Stock, Shares, Issued 38,520,336 37,918,395
Common Stock, Shares, Outstanding 38,520,336 37,918,395
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)        
Collaboration revenue $ 41,086 $ 1,482 $ 42,457 $ 9,342
Operating expenses:        
Research and development 19,337 17,914 46,213 59,767
General and administrative 7,307 8,714 22,518 28,895
Total operating expenses 26,644 26,628 68,731 88,662
Operating income (loss) 14,442 (25,146) (26,274) (79,320)
Other income, net:        
Interest income 545 121 816 253
Other income (expensive) 2,637 (112) 2,676 2,161
Total other income, net 3,182 9 3,492 2,414
Net income (loss) 17,624 (25,137) (22,782) (76,906)
Other comprehensive income (loss)        
Net unrealized (loss) gain on available-for-sale securities 27 (2) (199) 6
Total other comprehensive income (loss) 27 (2) (199) 6
Comprehensive income (loss) $ 17,651 $ (25,139) $ (22,981) $ (76,900)
Net income (loss) per share, basic $ 0.46 $ (0.67) $ (0.59) $ (2.04)
Net income (loss) per share, diluted $ 0.45 $ (0.67) $ (0.59) $ (2.04)
Weighted-average common shares outstanding, basic 38,507,542 37,780,547 38,292,497 37,623,309
Weighted-average common shares outstanding, diluted 39,570,394 37,780,547 38,292,497 37,623,309
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2020 $ 37 $ 430,324 $ (134) $ (275,907) $ 154,320
Shares, Outstanding, Beginning Balance at Dec. 31, 2020 37,368,027        
Exercises of vested stock options $ 1 27     28
Exercises of vested stock options (in shares) 3,811        
Vesting of restricted stock units (in shares) 184,217        
Stock based compensation expense   3,498     3,498
Unrealized gain (loss) on available-for-sale securities, net of tax     11   11
Net income (loss)       (21,649) (21,649)
Stockholders' Equity, Ending Balance at Mar. 31, 2021 $ 38 433,849 (123) (297,556) 136,208
Shares, Outstanding, Ending Balance at Mar. 31, 2021 37,556,055        
Stockholders' Equity, Beginning Balance at Dec. 31, 2020 $ 37 430,324 (134) (275,907) 154,320
Shares, Outstanding, Beginning Balance at Dec. 31, 2020 37,368,027        
Unrealized gain (loss) on available-for-sale securities, net of tax         6
Net income (loss)         (76,906)
Stockholders' Equity, Ending Balance at Sep. 30, 2021 $ 38 440,325 (128) (352,813) 87,422
Shares, Outstanding, Ending Balance at Sep. 30, 2021 37,781,786        
Stockholders' Equity, Beginning Balance at Mar. 31, 2021 $ 38 433,849 (123) (297,556) 136,208
Shares, Outstanding, Beginning Balance at Mar. 31, 2021 37,556,055        
Vesting of restricted stock units (in shares) 114,412        
Issuance of common stock under ESPP   580     580
Issuance of common stock under ESPP (in shares) 101,752        
Stock based compensation expense   3,871     3,871
Unrealized gain (loss) on available-for-sale securities, net of tax     (3)   (3)
Net income (loss)       (30,120) (30,120)
Stockholders' Equity, Ending Balance at Jun. 30, 2021 $ 38 438,300 (126) (327,676) 110,536
Shares, Outstanding, Ending Balance at Jun. 30, 2021 37,772,219        
Vesting of restricted stock units (in shares) 9,567        
Stock based compensation expense   2,025     2,025
Unrealized gain (loss) on available-for-sale securities, net of tax     (2)   (2)
Net income (loss)       (25,137) (25,137)
Stockholders' Equity, Ending Balance at Sep. 30, 2021 $ 38 440,325 (128) (352,813) 87,422
Shares, Outstanding, Ending Balance at Sep. 30, 2021 37,781,786        
Stockholders' Equity, Beginning Balance at Dec. 31, 2021 $ 38 442,259 (138) (347,104) 95,055
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 37,918,395        
Exercises of vested stock options   12     12
Exercises of vested stock options (in shares) 11,484        
Vesting of restricted stock units (in shares) 312,090        
Stock based compensation expense   2,268     2,268
Unrealized gain (loss) on available-for-sale securities, net of tax     (85)   (85)
Net income (loss)       (21,319) (21,319)
Stockholders' Equity, Ending Balance at Mar. 31, 2022 $ 38 444,539 (223) (368,423) 75,931
Shares, Outstanding, Ending Balance at Mar. 31, 2022 38,241,969        
Stockholders' Equity, Beginning Balance at Dec. 31, 2021 $ 38 442,259 (138) (347,104) $ 95,055
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 37,918,395        
Exercises of vested stock options (in shares)         79,837
Unrealized gain (loss) on available-for-sale securities, net of tax         $ (199)
Net income (loss)         (22,782)
Stockholders' Equity, Ending Balance at Sep. 30, 2022 $ 38 450,008 (337) (369,886) 79,823
Shares, Outstanding, Ending Balance at Sep. 30, 2022 38,520,336        
Stockholders' Equity, Beginning Balance at Mar. 31, 2022 $ 38 444,539 (223) (368,423) 75,931
Shares, Outstanding, Beginning Balance at Mar. 31, 2022 38,241,969        
Exercises of vested stock options   575     575
Exercises of vested stock options (in shares) 63,012        
Vesting of restricted stock units (in shares) 32,165        
Issuance of common stock under ESPP   313     313
Issuance of common stock under ESPP (in shares) 102,105        
Stock based compensation expense   2,460     2,460
Unrealized gain (loss) on available-for-sale securities, net of tax     (141)   (141)
Net income (loss)       (19,087) (19,087)
Stockholders' Equity, Ending Balance at Jun. 30, 2022 $ 38 447,887 (364) (387,510) 60,051
Shares, Outstanding, Ending Balance at Jun. 30, 2022 38,439,251        
Exercises of vested stock options   15     15
Exercises of vested stock options (in shares) 5,341        
Vesting of restricted stock units (in shares) 75,744        
Stock based compensation expense   2,106     2,106
Unrealized gain (loss) on available-for-sale securities, net of tax     27   27
Net income (loss)       17,624 17,624
Stockholders' Equity, Ending Balance at Sep. 30, 2022 $ 38 $ 450,008 $ (337) $ (369,886) $ 79,823
Shares, Outstanding, Ending Balance at Sep. 30, 2022 38,520,336        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flow from operating activities    
Net loss $ (22,782) $ (76,906)
Adjustments to reconcile net loss (income) to net cash used in operating activities:    
Stock-based compensation expense 6,998 9,670
Depreciation 5,357 3,683
Amortization of premiums and discounts on marketable securities (23) 324
Other non-cash items (2,468) (2,460)
Changes in operating assets and liabilities:    
Accounts receivable (10,000)  
Related party collaboration receivable 507 6,847
Prepaid expenses and other current assets (1,652) 1,731
Operating lease, right-of-use asset 3,005 2,265
Other non-current assets   69
Accounts payable 763 (42)
Accrued expenses 1,536 (2,912)
Operating lease liabilities (3,280) (2,348)
Other non-current liabilities (151)  
Deferred revenue 21,925 (4,641)
Net cash used in operating activities (265) (64,720)
Cash flow from investing activities    
Purchases of property and equipment (1,558) (1,262)
Purchases of marketable securities (54,848)  
Proceeds from sales and maturities of marketable securities 35,000 72,632
Net cash (used in) provided by investing activities (21,406) 71,370
Cash flow from financing activities    
Proceeds from the exercise of stock options 602 28
Proceeds from the purchase of common stock under ESPP 232 357
Net cash provided by financing activities 834 385
Net (decrease) increase in cash, cash equivalents, and restricted cash (20,837) 7,035
Cash, cash equivalents, and restricted cash beginning of period 119,212 106,219
Cash, cash equivalents, and restricted cash end of period 98,375 113,254
Supplemental disclosure of cash and non-cash activities    
Capital expenditures incurred but not yet paid $ 40 $ 22
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nature of business
9 Months Ended
Sep. 30, 2022
Nature of business  
Nature of business

1. Nature of business

Voyager Therapeutics, Inc. (the “Company”) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines, with the goal of either halting or slowing disease progression or reduce symptom severity, therefore providing clinically meaningful impact to patients. The Company’s gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (“AAV”) based gene therapies that it believes have the potential to safely provide durable efficacy. The Company’s team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which the Company believes an AAV gene therapy or other biological therapy will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. The Company then engineers and optimizes an AAV vector or other biological therapy for activity in, efficacy in, or delivery to, the targeted tissue or cells.

The Company is identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. The Company’s team has developed a proprietary AAV capsid discovery platform called TRACERTM (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (“BBB”). The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The Company believes that the capsids it discovers through its TRACER discovery platform (“TRACER Capsids”) have the potential to significantly enhance the efficacy and safety of its single dose gene therapies, which it expects to be delivered with targeted surgical delivery or systemic infusions, as compared with conventional capsids.

In addition to leveraging TRACER capsids in potential licensing arrangements, the Company is advancing its own proprietary pipeline of drug candidates for neurological diseases. The Company's three prioritized pipeline programs include: GBA1 gene therapy for Parkinson’s disease, SOD1 gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease. The Company plans to identify lead development candidates for all three programs between the fourth quarter of 2022 and the first half of 2023, with investigational new drug (IND) filings expected in 2024 and 2025.

In addition to these three lead programs, the Company has a collaboration ongoing with Neurocrine Biosciences, Inc. (“Neurocrine”) to develop a gene therapy for Friedreich's ataxia, which Neurocrine is funding through Phase 1. At that point, the Company has an option to either (1) co-develop and co-commercialize the asset with Neurocrine in the United States under a 60/40 cost and profit-sharing arrangement, 60% to Neurocrine and 40% to the Company, or (2) retain the right to receive milestone payments and royalties based on global sales pursuant to the full global commercial rights granted to Neurocrine.

The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy and other biological therapy programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy and antibody development and manufacturing. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in specific geographies with collaborators, as the Company has demonstrated through its ongoing collaboration with Neurocrine under a collaboration agreement that became effective in January 2019 (the “Neurocrine Collaboration Agreement”), or out-licensing activities including option and license agreements related to the TRACER capsids such as the Company’s October 2021 option and license agreement with Pfizer Inc. (“Pfizer”), pursuant to which Pfizer exercised an option effective as of September 30, 2022, and the Company’s March 2022 option and license agreement with Novartis Pharma AG (“Novartis”). The Company believes there is an ongoing opportunity for option and license transactions related to the TRACER capsids. To maximize the potential of TRACER capsids for the Company’s own

programs and option and license transactions, the Company has retained to date, and expects to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with a particular optionee’s or licensee’s transgenes.

The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products.

The Company has a history of incurring annual net operating losses. As of September 30, 2022, the Company had an accumulated deficit of $369.9 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from fees, milestone payments, and cost reimbursements associated with its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”) and AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaboration with Neurocrine, its option and license agreement with Pfizer, and its option and license agreement with Novartis.

As of September 30, 2022, the Company had cash, cash equivalents, and marketable securities of $131.6 million. Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable securities at September 30, 2022, together with amounts expected to be received as reimbursement for development costs under the Neurocrine Collaboration Agreement, and the Pfizer option exercise payment of $10.0 million received in the fourth quarter of 2022 will be sufficient to meet the Company’s planned operating expenses and capital expenditure requirements into 2024.

There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of significant accounting policies
9 Months Ended
Sep. 30, 2022
Summary of significant accounting policies  
Summary of significant accounting policies

2. Summary of significant accounting policies and basis of presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (“SEC”) on March 8, 2022. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Principles of Consolidation

The unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiary as disclosed in Note 2, under the heading “Summary of Significant Accounting Policies - Basis of

Presentation”, within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.

Summary of Significant Accounting Policies

There have been no changes in the Company's significant accounting policies as described in Note 2, “Summary of Significant Accounting Policies,” within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair value measurements
9 Months Ended
Sep. 30, 2022
Fair value measurements  
Fair value measurements

3. Fair value measurements

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 are as follows:

Quoted Prices

Significant

 

in Active

Other

Significant

 

Markets for

Observable

Unobservable

 

Identical Assets

Inputs

Inputs

Assets

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

September 30, 2022

(in thousands)

 

Money market funds included in cash and cash equivalents

    

$

93,043

    

$

93,043

    

$

    

$

Marketable securities - U.S. Treasury notes

 

34,778

 

34,778

 

 

Total

$

127,821

$

127,821

$

$

December 31, 2021

Money market funds included in cash and cash equivalents

    

$

100,305

    

$

100,305

    

$

    

$

Marketable securities - U.S. Treasury notes

15,106

15,106

Total

$

115,411

$

115,411

$

$

The Company measures the fair value of money market funds and U.S. Treasury notes based on quoted prices in active markets for identical securities.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cash, cash equivalents, restricted cash, and available-for-sale marketable securities
9 Months Ended
Sep. 30, 2022
Cash, cash equivalents, restricted cash, and available-for-sale marketable securities  
Cash, cash equivalents, restricted cash, and available-for-sale marketable securities

4. Cash, cash equivalents, restricted cash, and available-for-sale marketable securities

Cash, cash equivalents, and marketable securities included the following at September 30, 2022 and December 31, 2021:

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

(in thousands)

As of September 30, 2022

    

    

    

    

    

    

    

    

Money market funds included in cash and cash equivalents

$

93,043

$

$

$

93,043

Marketable securities - U.S. Treasury notes

 

34,987

(209)

34,778

Total money market funds and marketable securities

$

128,030

$

$

(209)

$

127,821

As of December 31, 2021

    

    

    

    

    

    

    

    

Money market funds included in cash and cash equivalents

$

100,305

$

$

$

100,305

Marketable securities - U.S. Treasury notes

15,117

(11)

15,106

Total money market funds and marketable securities

$

115,422

$

$

(11)

$

115,411

All of the Company’s marketable securities as of September 30, 2022 have a contractual maturity of one year or less.

The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. In connection with these investments, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the condensed consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the condensed consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.

The Company held $30.0 million and $15.1 million marketable securities that were in an unrealized loss position as of September 30, 2022 and December 31, 2021, respectively, and held $5.0 million marketable securities that were in an unrealized gain position as of September 30, 2022. No marketable securities were in an unrealized gain position as of December 31, 2021. The unrealized losses at September 30, 2022 and December 31, 2021 were attributable to changes in interest rates and the unrealized losses do not represent credit losses. The Company does not intend to sell these securities and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:

As of September 30, 

As of December 31, 

2022

    

2021

(in thousands)

Cash and cash equivalents

$

96,860

$

117,433

Restricted cash included in deposits and other non-current assets

1,515

1,779

Total cash, cash equivalents, and restricted cash

$

98,375

$

119,212

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued expenses
9 Months Ended
Sep. 30, 2022
Accrued expenses  
Accrued expenses

5. Accrued expenses

Accrued expenses as of September 30, 2022 and December 31, 2021 consist of the following:

As of September 30, 

As of December 31, 

    

2022

    

2021

 

(in thousands)

Employee compensation costs

$

3,585

$

5,022

Research and development costs

7,768

3,719

Professional services

 

675

 

727

Accrued goods and services

501

1,482

Total

$

12,529

$

10,950

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease obligation
9 Months Ended
Sep. 30, 2022
Lease obligation  
Lease obligation

6. Lease obligation

Operating Leases

As of September 30, 2022, the Company has a lease for office and laboratory space at 64 Sidney Street in Cambridge, Massachusetts through November 30, 2026 and a lease for additional laboratory and office space at 75 Hayden Avenue in Lexington, Massachusetts through January 31, 2031.

In September 2021, the Company entered into an agreement with BioNTech US, Inc. (“BioNTech US”) to sublease part of the office and laboratory space leased by the Company at 75 Sidney Street in Cambridge, Massachusetts (the “Sublease Agreement”) at that time. The sublease term was for approximately 3.3 years. The sublease did not relieve the Company of its original obligation under the lease, and therefore the Company did not adjust the operating lease right-of-use asset as a result of the sublease and accounted for the sublease as a separate lease.

On June 22, 2022 the Company entered into a Lease Termination Agreement (the “Lease Termination Agreement”) and terminated the lease for office and laboratory space at 75 Sidney Street (the “75 Sidney Street Lease”), effective immediately. The 75 Sidney Street Lease was previously scheduled to terminate, in accordance with its terms, on November 30, 2026. In connection with the Lease Termination Agreement, the Company also entered into a Sublease Termination Agreement (the “Sublease Termination Agreement”) and terminated the Sublease Agreement with BioNTech US. The Company did not incur any termination penalties in connection with the Lease Termination Agreement or Sublease Termination Agreement. The Company derecognized the related right-of-use asset of approximately $14.5 million and the operating lease liabilities of $17.0 million, accordingly, resulting in a gain of $2.5 million in the three-month period ended June 30, 2022.

The Company’s lease agreements require the Company to maintain a cash deposit or irrevocable letter of credit in the aggregate amount of $1.5 million payable to its landlords as security for the performance of its obligations under the leases. These amounts are recorded as restricted cash and are included in deposits and other non-current assets in the accompanying condensed consolidated balance sheets.

During the three and nine months ended September 30, 2022, the Company incurred lease expenses of $1.0 million and $3.8 million, respectively, for operating leases. During the three and nine months ended September 30, 2021, the Company incurred lease expenses of $1.7 million and $5.4 million, respectively, for operating leases. As of September 30, 2022, the weighted average remaining lease term was 6.3 years and the weighted average incremental borrowing rate used to determine the operating lease liability was 7.4%.

The following table summarizes the operating sublease income generated under the Sublease Agreement for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2022

    

2021

2022

    

2021

(in thousands)

Operating sublease income

$

$

204

$

1,380

$

204

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other liabilities
9 Months Ended
Sep. 30, 2022
Other liabilities  
Other liabilities

7. Other liabilities

As of September 30, 2022 and December 31, 2021, other current and non-current liabilities consisted of the following:

As of September 30, 

As of December 31, 

2022

    

2021

(in thousands)

Other current liabilities

Lease liability

2,746

5,571

Total other current liabilities

$

2,746

$

5,571

Other non-current liabilities

Lease liability

$

21,024

$

38,608

Other

1,000

1,001

Total other non-current liabilities

$

22,024

$

39,609

Strategic Restructuring

On August 6, 2021, the board of directors of the Company approved a strategic restructuring plan to eliminate a portion of its workforce as part of an initiative to reduce expenses and enhance operations. The strategic restructuring plan was approved in connection with its portfolio reevaluation efforts and its strategic shift to invest additional resources in the Company’s TRACER capsid development efforts.

During the year ended December 31, 2021, the Company incurred restructuring costs of approximately $2.6 million, which consists of severance-related costs. Substantially all costs have been paid as of September 30, 2022.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and contingencies
9 Months Ended
Sep. 30, 2022
Commitments and contingencies  
Commitments and contingencies

8. Commitments and contingencies

Significant Agreements

Neurocrine Collaboration Agreement

Summary of Agreement

In March 2019, the Company entered into the Neurocrine Collaboration Agreement for the research, development and commercialization of certain of its AAV gene therapy products. Under the Neurocrine Collaboration Agreement, the Company agreed to collaborate on the conduct of four collaboration programs (the “Neurocrine Programs”) which include: (i) VY-AADC (NBIb-1817) for Parkinson’s disease (the “VY-AADC Program”), (ii) VY-FXN01 for Friedreich’s ataxia (the “FA Program”) (collectively, with the VY-AADC Program, the “Legacy Programs”), and (iii) two programs to be determined by the Company and Neurocrine at a later date (the “Discovery Programs”).

In June 2019, in conjunction with the termination of the collaboration agreement with Sanofi Genzyme (the “Sanofi Genzyme Collaboration Agreement”), the Company gained ex-U.S. rights to the FA Program. The Company’s

ex-U.S. rights to the FA Program were subsequently transferred to Neurocrine under the terms of the Neurocrine Collaboration Agreement. To facilitate the transfer of the ex-U.S. rights to the FA Program to Neurocrine, the Company and Neurocrine executed an amendment to the Neurocrine Collaboration Agreement (the “June 2019 Modification”), and Neurocrine paid $5.0 million to the Company. There were no other changes in pricing or scope of the obligations required to be performed under the Neurocrine Collaboration Agreement.

In February 2021, Neurocrine notified the Company that it had elected to terminate the Neurocrine Collaboration Agreement solely with regards to the VY-AADC Program, effective August 2, 2021 (the “Neurocrine VY-AADC Program Termination Effective Date”). The Neurocrine Collaboration Agreement remains in full force and effect for each other program thereunder. As a result of the termination, Neurocrine is no longer obligated to reimburse the Company for research and development activities related to the VY-AADC Program.

Under the terms of the Neurocrine Collaboration Agreement, the Company originally agreed to collaborate with Neurocrine on, and to grant, exclusive, royalty-bearing, non-transferable, sublicensable licenses to certain of its intellectual property rights, for all human and veterinary diagnostic, prophylactic, and therapeutic uses, for the research, development, and commercialization of gene therapy products (the “Collaboration Products”) on a worldwide basis under (i) the VY-AADC Program; (ii) the FA Program; and (iii) each Discovery Program. As a result of the termination of the Neurocrine Collaboration Agreement with regards to the VY-AADC Program, in accordance with the terms of the Neurocrine Collaboration Agreement, the licenses granted by the Company to Neurocrine regarding the VY-AADC Program have expired, and the Company has regained worldwide intellectual property rights regarding the VY-AADC Program, in each case as of the VY-AADC Termination Effective Date.

Pursuant to development plans agreed by the parties, which are overseen by a joint steering committee (“JSC”), the Company has operational responsibility, subject to certain exceptions, for the conduct of each Neurocrine Program prior to the occurrence of a specified event for such Neurocrine Program (a “Transition Event”), as described below, and is required to use commercially reasonable efforts to develop the corresponding Collaboration Products. Neurocrine has agreed to be responsible for all costs incurred by the Company in conducting these activities for each Neurocrine Program, in accordance with an agreed budget for each Neurocrine Program. If the Company breaches its development responsibilities or in certain circumstances upon a change in control, Neurocrine has the right but not the obligation to assume the activities under such Neurocrine Program.

Upon the occurrence of a Transition Event for each Neurocrine Program, Neurocrine has agreed to assume responsibility for development, manufacturing and commercialization activities for such Neurocrine Program from the Company and to pay milestones and royalties on future net sales as described further below. As a result of Neurocrine’s termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program, the Transition Event with respect to the VY-AADC Program is no longer applicable. The Transition Events for the remaining programs are (i) with respect to the FA Program, the Company’s receipt of topline data for the initial Phase 1 clinical trial for an FA Program product candidate; and (ii) with respect to each Discovery Program, the preparation by the Company and the approval by Neurocrine of an IND application to be filed with the U.S. Food and Drug Administration (the “FDA”) by Neurocrine for the first development candidate in such Discovery Program. For the FA Program, the Company was granted the option (the “FA Co-Co Option”) to co-develop and co-commercialize the FA Program upon the occurrence of a specified event (a “FA Co-Co Trigger Event”). The Company agreed, upon its exercise of the FA Co-Co Option, to enter into a cost- and profit-sharing arrangement with Neurocrine (the “FA Co-Co Agreement”), and (i) jointly develop and commercialize the Collaboration Products for the FA Program (“FA Collaboration Products”), (ii) share in its costs, profits and losses, and (iii) forfeit certain milestones and royalties on net sales in the United States during the effective period of the FA Co-Co Agreement. The FA Co-Co Trigger Event is the receipt of topline data for the initial Phase 1 clinical trial for an FA Program product candidate.

Under the Neurocrine Collaboration Agreement, subject to exceptions specified therein, the Company and Neurocrine agreed that profits and losses under the Company’s FA Co-Co Option would be allocated 60% to Neurocrine and 40% to the Company for any FA Collaboration Product. The parties agreed that FA Co-Co Agreement would provide the Company the right to terminate for any reason upon prior written notice to Neurocrine and Neurocrine the right to terminate in certain circumstances upon change of control.

The Company’s research and development activities under the Neurocrine Collaboration Agreement are conducted pursuant to plans agreed to by the parties, on a program-by-program basis, and overseen by the JSC, as detailed in the Neurocrine Collaboration Agreement.

Under the Neurocrine Collaboration Agreement, the parties committed to agree on a list of up to eight target genes (the “Targets”) from which Neurocrine had the right to nominate Targets for the two Discovery Programs. The Company and Neurocrine completed the nomination process, and the JSC has approved the two Targets for development under the Discovery Programs. The two Targets are currently under development.

The Neurocrine Collaboration Agreement provides for an upfront non-refundable payment of $115.0 million, as well as for aggregate development and regulatory milestone payments from Neurocrine to the Company for Collaboration Products under (i) the VY-AADC Program of up to $170.0 million, which the Company is no longer eligible to receive in light of the partial termination of the Neurocrine Collaboration Agreement; (ii) the FA Program of up to $195.0 million, and (iii) each of the two Discovery Programs of up to $130.0 million per Discovery Program. The Company may be entitled to receive aggregate commercial milestone payments for each Collaboration Product of up to $275.0 million, subject to an aggregate cap on commercial milestone payments across all Neurocrine Programs of $1.1 billion. Furthermore, in connection with the Neurocrine Collaboration Agreement, Neurocrine purchased 4,179,728 shares of the Company’s common stock at a price of $11.9625 per share, for an aggregate purchase price of $50.0 million.

Neurocrine also agreed to pay the Company royalties, based on future net sales of the Collaboration Products. Such royalty percentages, for net sales in and outside the United States, as applicable, range (i) for the VY-AADC Program, from the mid-teens to low thirties and the low-teens to low twenties, respectively; (ii) for the FA Program, from the low-teens to high-teens and high-single digits to mid-teens, respectively; and (iii) for each Discovery Program, from the high-single digits to mid-teens and mid-single digits to low-teens, respectively. On a country-by-country and program-by-program basis, royalty payments would commence on the first commercial sale of a Collaboration Product and terminate on the later of (a) the expiration of the last patent covering the Collaboration Product or its method of use in such country, (b) ten years from the first commercial sale of the Collaboration Product in such country and (c) the expiration of regulatory exclusivity in such country (the “Royalty Term”). Royalty payments may be reduced by up to 50% in specified circumstances, including expiration of patents rights related to a Collaboration Product, approval of biosimilar products in a given country or required payment of licensing fees to third parties related to the development and commercialization of any Collaboration Product. As a result of Neurocrine’s termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program, the Company is no longer entitled to receive royalties related to the VY-AADC Program. Additionally, the licenses granted to Neurocrine shall automatically convert to fully paid-up, non-royalty bearing, perpetual, irrevocable, exclusive licenses on a country-by-country and product-by-product basis upon the expiration of the Royalty Term applicable to such Collaboration Product in such country.

Under the terms of the Neurocrine Collaboration Agreement and subject to specified exceptions therein, each party owns the entire right, title and interest in and to all intellectual property rights made solely by its employees or agents in the course of the collaboration. The parties jointly own all rights, title and interest in and to all intellectual property rights made or invented jointly by employees or agents of both parties.

During the term of the Neurocrine Collaboration Agreement, neither party nor any of its respective affiliates is permitted to directly or indirectly exploit any AAV-based gene therapy products directed to a Target to which a Collaboration Product is directed, subject to specified exceptions, including the parties’ conduct of basic research activities.

Unless earlier terminated, the Neurocrine Collaboration Agreement expires on the later of (i) the expiration of the last to expire royalty term with respect to a Collaboration Product in all countries in the relevant territory or (ii) the expiration or termination of any FA Co-Co Agreement. Neurocrine may terminate the Neurocrine Collaboration Agreement in its entirety or on a program-by-program or country-by-country basis by providing at least (x) 180-day advance notice if such notice is provided prior to the first commercial sale of the Collaboration Product to which the termination applies or (y) one-year advance notice if such notice is provided after the first commercial sale of the Collaboration Product to which the termination applies. The Company may terminate the Neurocrine Collaboration Agreement, subject to specified conditions, if Neurocrine challenges the validity or enforceability of certain of the

Company’s intellectual property rights. Subject to a cure period, either party may terminate the Neurocrine Collaboration Agreement in the event of a material breach by the other party in whole or in part, subject to specified conditions.

Upon termination in certain cases, Neurocrine has agreed to grant to the Company licenses to certain Neurocrine intellectual property, subject to a negotiation between the parties to establish royalty rates for use of such intellectual property. In the event of a breach by the Company with respect to a Neurocrine Program, if such termination were to occur after a Transition Event, then (i) with respect to the FA Program, if an FA Co-Co Agreement is in effect, Neurocrine can terminate the FA Co-Co Agreement for such program and the Company would no longer have co-development and co-commercialization rights with respect to the FA Collaboration Products and (ii) subject to any license agreements, Neurocrine would no longer have any obligations with respect to any Collaboration Products resulting from such program.

Termination of VY-AADC Program

As described above, as of the Neurocrine VY-AADC Program Termination Effective Date, the license granted by the Company to Neurocrine thereunder regarding the VY-AADC Program expired, the Company regained worldwide intellectual property rights regarding the VY-AADC Program, and the restrictions on the Company to develop, manufacture or commercialize a gene therapy product directed to the target of the VY-AADC Program terminated, in each case in accordance with the terms of the Neurocrine Collaboration Agreement. As of the Neurocrine VY-AADC Program Termination Effective Date, Neurocrine no longer is obligated to reimburse the Company for research and development activities related to the VY-AADC Program, and the Company is no longer entitled to receive future milestone or royalty payments related to the VY-AADC Program. The Company is supporting Neurocrine, the study sponsor and IND holder, on ongoing matters related to the completion of imaging and clinical assessments requested by the Data Safety and Monitoring Board (the “DSMB”), and the provision of other information requested by the FDA for the RESTORE-1 Phase 2 clinical trial.

Accounting Analysis

At inception, the Neurocrine Collaboration Agreement included the following performance obligations: (i) research and development services for each Legacy Program combined with a development and commercialization license for each such program and (ii) research and development services for each Discovery Program combined with a development and commercialization license for each program. The research services and license on a program-by-program basis are not distinct as Neurocrine cannot benefit from such license on its own or from other resources commonly available in the industry, without the corresponding research services due to the unique and specialized expertise of the Company that is not readily available in the marketplace.

The Company identified $92.4 million of fixed transaction price consisting of the $115.0 million upfront fee and $5.0 million payment from the June 2019 Modification, offset by a discount of $27.6 million related to the $50.0 million equity investment of 4,179,728 shares when measured at fair value on the date of issuance. The Company is also entitled to reimbursement of costs incurred by the Company prior to the Transition Events associated with each Neurocrine Program. These amounts are determinable based on program plans and budgets, and the Company has a contractual right to the payment of cost incurred under the agreed upon program plans. The Company utilized the most likely amount approach and estimated the expected cost reimbursement to be $431.1 million at inception. The Company concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Company considers this estimate at each reporting date and updates the estimate based on information available. During the fourth quarter of 2021, the Company further revised the estimate of the expected reimbursement to approximately $80.0 million based on expectations resulting from decisions made at the JSC meeting in the fourth quarter of 2021, which are expected to result in significantly less research and development services being provided by the Company under the Neurocrine Collaboration Agreement. As of September 30, 2022, the estimate of the expected reimbursement is $79.4 million based on expectations as of such date. Additional consideration to be paid to the Company upon reaching certain milestones are excluded from the transaction price at inception due to the uncertainty of achieving the development and regulatory milestones.

The Company allocated the fixed transaction price to the separate performance obligations based on the relative standalone selling price of each performance obligation or in the case of certain variable consideration to one or more performance obligations. The estimated standalone selling prices for performance obligations, which include a license

and research services, were developed using the estimated selling price of the license, using comparable and market data, and an estimate of the overall effort to perform the research services along with a reasonable profit for research services.

The Company concluded that the variable consideration related to the cost reimbursement of each program will be allocated to each respective program as the cost reimbursement relates specifically to the respective program services being performed under the Neurocrine Collaboration Agreement. The reimbursement of research services is considered to be at a market rate and the allocation of the fixed consideration to all of the performance obligations depicts the estimated amounts in which it would expect to receive for these obligations, absent the variable consideration related to the research reimbursement. The total variable consideration allocated to each program related to the expected cost reimbursement was as follows as of September 30, 2022:

Performance Obligation

Amount

(in thousands)

Variable Consideration

VY-AADC Program

$

53,863

FA Program

16,938

Discovery Program 1

5,236

Discovery Program 2

3,372

Total

$

79,409

Based on the relative standalone selling price allocation, the allocation of the transaction price, exclusive of the variable consideration allocated to the individual performance obligations, to the separate performance obligations was as follows:

Performance Obligation

Amount

(in thousands)

Fixed Consideration

VY-AADC Program

$

49,045

FA Program

20,647

Discovery Program 1

14,443

Discovery Program 2

8,247

Total

$

92,382

The Company recognizes the transaction price associated with each performance obligation on a proportional performance basis over the period of service using input-based measurements such as costs incurred to date, to estimate proportion performed, and remeasures its progress towards completion at the end of each reporting period.

The Company determined the partial termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program represented a modification of the arrangement under ASC 606 and that the remaining fixed transaction price at the Neurocrine VY-AADC Program Termination Effective Date of $42.2 million should be re-allocated to the FA Program and Discovery Program 1 and 2 based on their standalone selling prices. Accordingly, the Company recorded a cumulative adjustment to revenue of approximately $0.9 million on the partially satisfied remaining performance obligations, as the remaining services to be performed under each of the performance obligations are not distinct from the services prior to the modification. The Company determined that reasonable changes to the Company’s estimates of standalone selling prices for the FA Program, Discovery Program 1 and Discovery Program 2 performance obligations did not have a material impact on the re-allocation or the amount of revenue recorded pursuant to the cumulative catch-up adjustment.

During the three and nine months ended September 30, 2022, the Company recognized $1.1 million and $2.5 million, respectively, of revenue associated with its collaboration with Neurocrine related to research and development services performed during the period and the corresponding cost reimbursement receivable. During the three and nine months ended September 30, 2021, the Company recognized $1.5 million and $9.3 million of revenue, respectively, associated with its collaboration with Neurocrine related to research and development services performed during the period and the corresponding cost reimbursement receivable.

The following table presents changes in the balances of the Company’s related party collaboration receivables and contract liabilities during the nine months ended September 30, 2022:

Balance at

    

Balance at

December 31, 2021

Additions

Deductions

September 30, 2022

(in thousands)

Related party collaboration receivable

$

732

$

583

$

(1,090)

$

225

Contract liabilities:

Deferred revenue

$

12,096

$

-

$

(2,075)

$

10,021

The change in the receivable balance for the nine months ended September 30, 2022 is primarily driven by amounts owed to the Company for research and development services provided, offset by amounts collected from Neurocrine during the period.

Costs incurred relating to the Company’s collaboration programs under the Neurocrine Collaboration Agreement consist of internal and external research and development costs, which primarily include: salaries and benefits, laboratory supplies, preclinical research studies, clinical studies, consulting services, and commercial development. These costs are included in research and development expenses in the Company’s condensed consolidated statements of operations during the three and nine months ended September 30, 2022.

The Company incurred approximately $0.8 million of costs to obtain the Neurocrine Collaboration Agreement which were payable only upon the close of the deal and therefore considered incremental costs of obtaining a contract with a customer and capitalized. The costs are recorded in prepaid expenses and other non-current assets and are being amortized over the period in which the research services will be provided.

Pfizer Option and License Agreement

Summary of Agreement

On October 1, 2021, the Company entered into an option and license agreement with Pfizer (the “Pfizer Agreement”), pursuant to which the Company has granted Pfizer options to receive an exclusive license (the “Pfizer License Options”) to certain TRACER capsids to develop and commercialize certain AAV gene therapy candidates comprised of a capsid and specified Pfizer transgenes (the “Pfizer Transgenes”). Under the terms of the Pfizer Agreement, during an initial research term that ended as of October 1, 2022 (the “Pfizer Research Term”) Pfizer had the right to evaluate the potential use of the capsids in combination with up to two Pfizer Transgenes to help treat respective central nervous system (“CNS”) and cardiovascular diseases.

During the Pfizer Research Term, the Company agreed to provide Pfizer with certain quantities of materials encoding specified existing capsids for Pfizer’s evaluation. Further, during the Pfizer Research Term the Company agreed to disclose to Pfizer, on a rolling basis, the performance characteristics identified during the Pfizer Research Term for all such capsid candidates. Pfizer had the right, in its sole discretion, to select any capsid candidate for evaluation to determine its interest in exercising a Pfizer License Option with respect to such capsid candidate. Pfizer had the right to exercise up to two Pfizer License Options, provided that it could exercise only one Pfizer License Option for each Pfizer Transgene.

Effective as of September 30, 2022, Pfizer exercised its Pfizer License Option with respect to a capsid for the specified Pfizer Transgene for potential treatment of a rare neurological disease. Pfizer did not exercise its option to license a capsid for the potential treatment of a cardiovascular disease. As result, Pfizer’s right to exercise a Pfizer License Option for a cardiovascular disease has terminated in accordance with the terms of the Pfizer Agreement and all rights to capsids for that cardiovascular disease have reverted to the Company. Pfizer’s exercise of a Pfizer License Option extends the Pfizer Research Term to October 1, 2024, during which period the Company may, at its sole discretion and expense, conduct additional research activities to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of the rare neurological disease associated with the exercise of the applicable Pfizer License Option.

Pursuant to the exercise of the Pfizer License Option, the Company granted Pfizer an exclusive, worldwide license, with the right to sublicense, under certain of the Company’s intellectual property, the rights to develop and commercialize rare neurological disease products utilizing the capsid candidate and incorporating the corresponding Pfizer Transgene (the “Pfizer Licensed CNS Products”). Until October 1, 2024, while the Company is not obligated to conduct additional research activities to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of rare neurological diseases, it has agreed to continue to disclose to Pfizer, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available. Pfizer may, during the Pfizer Research Term, conduct additional evaluations of such capsid candidates and has the right to substitute any other capsid candidate for the capsid it previously elected to license when it exercised the Pfizer License Option.

Under the Pfizer Agreement, Pfizer is solely responsible for, and has sole decision-making authority with respect to, development and commercialization of the Pfizer Licensed CNS Products. Pfizer is required to use commercially reasonable efforts to develop and obtain regulatory approval for at least one Pfizer Licensed CNS Product for which Pfizer has exercised its Pfizer License Option in (i) the United States and (ii) at least one of the following countries: the United Kingdom, France, Germany, Italy, Spain and Japan (each of which is referred to as a “Pfizer Major Market Country”), subject to certain limitations. Pfizer is also required to use commercially reasonable efforts to commercialize each Pfizer Licensed CNS Product in the United States and at least one Pfizer Major Market Country where Pfizer or its designated affiliates or sublicensees has received regulatory approval for such Pfizer Licensed CNS Product, subject to certain limitations.

Under the terms of the Pfizer Agreement, Pfizer paid the Company an upfront payment of $30.0 million in October 2021. Following the exercise of the Pfizer License Option, Pfizer is obligated to pay the Company a fee of $10.0 million and the Company is also eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $115.0 million for the first corresponding Pfizer Licensed CNS Product to achieve the corresponding milestone. On a Pfizer Licensed CNS Product-by-Pfizer Licensed CNS Product basis, the Company is also eligible to receive (a) specified sales milestone payments of up to an aggregate of $175.0 million per Pfizer Licensed CNS Product and (b) tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Pfizer Licensed CNS Product. The royalties are subject to potential reductions in customary circumstances including patent claim expiration, payments for certain third-party licenses, and biosimilar market penetration, subject to specified limits.

Under the terms of the Pfizer Agreement, each the Company and Pfizer owns the entire right, title, and interest in and to all patents or know-how controlled by such party and existing as of or before the effective date of the Pfizer Agreement, or invented, developed, created, generated or acquired solely by or on behalf of such party after such effective date.

Subject to certain specified exceptions, any patents and know-how that are invented or otherwise developed jointly by or on behalf of the parties during the term of the Pfizer Agreement and in the course of the Company’s and Pfizer’s activities under the Pfizer Agreement will follow inventorship under U.S. patent law. Subject to certain limitations and exceptions, the Company agreed (i) during the Pfizer Research Term, not to conduct any internal program or program on behalf of a third party that is directed to development or commercialization of any capsid candidates, or grant any third party or affiliate any right or license under the Company’s rights in such capsid candidates to exploit any therapeutic product, in combination with any Pfizer Transgene in any indication for therapeutic, diagnostic and prophylactic human and veterinary use; and (ii) after Pfizer’s exercise of a Pfizer License Option, not to grant any third party or affiliate any right or license under the Company’s patents to exploit any licensed capsid in combination with any Pfizer Transgene.

Unless earlier terminated, the Pfizer Agreement expires on the expiration of the last-to-expire royalty term with respect to all Pfizer Licensed CNS Products in all countries. Subject to a cure period, either party may terminate the Pfizer Agreement, in whole or in part, subject to specified conditions, in the event of the other party’s uncured material breach. Pfizer may also terminate the Pfizer Agreement, in whole or in part, subject to specified conditions, for the Company’s insolvency, the occurrence of a violation of global trade control laws, or for the Company’s noncompliance with certain anti-bribery or anti-corruption covenants. Pfizer may also terminate the Pfizer Agreement, in whole or in part, for any or no reason upon ninety days’ written notice to us.

Upon certain terminations for cause by Pfizer, the licenses that the Company has granted to Pfizer under the Pfizer Agreement shall become irrevocable and perpetual, and all milestone payments and royalties that would have otherwise been payable by Pfizer under such licenses had the Pfizer Agreement remained in effect would be substantially reduced.

Accounting Analysis

The Company assessed the promised goods and services under the Pfizer Agreement, in accordance with ASC 606, and determined that the Pfizer Agreement contains two performance obligations consisting of two material rights, one for each of the Pfizer License Options. The Company concluded that each Pfizer License Option provides a material right as consideration for each option is less than the amount that the Company would otherwise have expected to receive outside the context of the contract. The promises at inception do not include the underlying goods or services that would be delivered upon exercise of the option, but rather represent the value to the customer of having the right to exercise the Pfizer License Option at the specified exercise fee. Upon the exercise of a Pfizer License Option, until October 1, 2024, while the Company is not obligated to conduct additional research activities upon option exercise to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of central nervous system or cardiovascular diseases, it has agreed to continue to disclose to Pfizer, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available. Pfizer may, conduct additional evaluations of such capsid candidates and has the right to substitute any other capsid candidate for the capsid it previously elected to license when it exercised the Pfizer License Option. The Company determined that this promise to provide Pfizer the ability to evaluate and potentially substitute other capsid candidates for the capsid it previously elected to license when it exercised the Pfizer License Option, if and when available, is an additional performance obligation in the arrangement (“the Pfizer Substitution Right Performance Obligation”).

The Company received a nonrefundable, upfront payment of $30.0 million as consideration under the Pfizer Agreement, which represents the transaction price at inception. Additional consideration to be paid to the Company upon exercise of the Pfizer License Option or upon reaching certain milestones are excluded from the transaction price as they relate to option fees and milestones that could only be achieved subsequent to an option exercise.

The Company allocated the transaction price to the two material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be willing to pay an equal amount for each Pfizer License Option on a standalone basis. The Company reached this conclusion after considering (i) the downstream economics including option fees, milestones and royalties related to each Pfizer License Option being identical and (ii) comparable market data. The Company determined the standalone selling price for the Pfizer Substitution Right Performance Obligation was insignificant to the allocation of the transaction price using the relative standalone selling price model and, accordingly, did not allocate any transaction price to the Pfizer Substitution Right Performance Obligation. This determination was supported by qualitative and quantitative assessments of the standalone selling price that considered the cost of identifying other potential capsid candidates and the likelihood of license substitution. As such, based on the relative standalone selling price for each of the two material rights, the allocation of the transaction price to the separate performance obligations is $15.0 million for each material right.

The amount allocated to each material right was initially recorded as deferred revenue.

During the three and nine months ended September 30, 2022, the Company recognized $40.0 million in collaboration revenue related to the Pfizer Agreement. Of this $40.0 million, $25.0 million is attributable to the exercise of the first material right for the Pfizer License Option for a rare neurological disease and includes the option exercise fee of $10.0 million. The remaining $15.0 million is attributable to the expiration of the second material right associated with the Pfizer License Option for a cardiovascular disease.

Novartis Option and License Agreement

Summary of Agreement

On March 4, 2022 (the “Novartis Effective Date”), the Company entered into an option and license agreement with Novartis (the “Novartis Agreement”). Pursuant to the Novartis Agreement, the Company has granted Novartis options (the “Novartis License Options”) to license TRACER capsids (“Novartis Licensed Capsids”) for exclusive use with certain targets to develop and commercialize adeno-associated virus gene therapy candidates comprised of Novartis Licensed Capsids and payloads directed to such targets (the “Novartis Payloads”).

During the period commencing on the Novartis Effective Date and ending on the first anniversary thereof or, in the event Novartis exercises a Novartis License Option, the third anniversary thereof (the “Novartis Research Term”), the Company has granted Novartis a non-exclusive research license to evaluate the Company’s TRACER capsids for potential use, in combination with Novartis Payloads, in programs targeting three specified genes (the “Initial Novartis Targets”). Upon the payment of additional fees, Novartis may also assess the Company’s TRACER capsids for use with two other targets (the “Additional Novartis Targets”), subject to certain conditions including that such target is not part of, or reasonably competitive with, the Company’s current development programs (the Initial Novartis Targets and the Additional Novartis Targets collectively, the “Novartis Targets”). During the Novartis Research Term, the Company may, at its sole discretion and expense, conduct further research activities to identify additional TRACER capsids. If the Company elects to do so, the Company has agreed to disclose performance characteristics of such new TRACER capsids to Novartis on a rolling basis.

During the Novartis Research Term, Novartis may exercise up to three Novartis License Options—or up to five Novartis License Options if Novartis is evaluating the Additional Novartis Targets—in the aggregate, provided that Novartis may only exercise one Novartis License Option for each Novartis Target. Upon the exercise of any Novartis License Option, the Company has agreed to grant Novartis a target-exclusive, worldwide license, with the right to sublicense, under certain of the Company’s intellectual property, the rights to develop and commercialize the applicable Novartis Licensed Capsid as incorporated into products containing the corresponding Novartis Payload (the “Novartis Licensed Products”). Upon the exercise of a Novartis License Option, the Company has agreed to provide certain additional know-how to enable Novartis to exploit the Novartis Licensed Capsid and the corresponding Novartis Payload for use in a Novartis Licensed Product. Novartis may, during the Novartis Research Term but following the exercise of a Novartis License Option, conduct additional evaluation of the Company’s capsid candidates and has the right to substitute any other TRACER capsid for a Novartis Licensed Capsid.

Subject to the Company’s disclosure obligations described above, the Company and Novartis have agreed to conduct their respective research and evaluation activities independently, with communications being managed by two alliance managers comprised of a designee from each of the Company and Novartis.

Under the Novartis Agreement, Novartis is solely responsible for, and has sole decision-making authority with respect to, development and commercialization of the Novartis Licensed Products. In the event Novartis exercises a Novartis License Option, Novartis is required to use commercially reasonable efforts to develop and obtain regulatory approval for at least one Novartis Licensed Product for each Novartis Target for which it has exercised a Novartis License Option in (i) the United States and (ii) at least three of the following countries: the United Kingdom, France, Germany, Italy, Spain and Japan (each of which, a “Novartis Major Market Country”), subject to certain limitations. Novartis is also required to use commercially reasonable efforts to commercialize each Novartis Licensed Product in the United States and at least three Novartis Major Market Countries where Novartis or its designated affiliates or sublicensees has received regulatory approval for such Novartis Licensed Product, subject to certain limitations.

During the Novartis Research Term, the Company has agreed to provide plasmids to Novartis for the production of TRACER capsids for evaluation upon request. The Company has also granted Novartis a non-exclusive license, effective upon an exercise of a Novartis License Option and in addition to its options for target-exclusive licenses under certain of the Company’s intellectual property described above, on a Novartis Licensed Capsid-by-Novartis Licensed Capsid basis, under certain of the Company’s know-how to exploit the applicable Novartis Licensed Capsid as incorporated into Novartis Licensed Products containing the corresponding Novartis Payload.

Under the terms of the Novartis Agreement, Novartis paid the Company an upfront payment of $54.0 million. Novartis has also agreed to pay the Company a fee of $18.0 million per Additional Novartis Target it elects to add to the collaboration and, upon each exercise of a Novartis License Option, an option exercise fee of $12.5 million. Following each exercise of a Novartis License Option, the Company is also eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $125.0 million for the first corresponding Novartis Licensed Product to achieve the corresponding milestone. On a Novartis Licensed Product-by-Novartis Licensed Product basis, the Company is also eligible to receive (a) specified sales milestone payments of up to an aggregate of $175.0 million per Novartis Licensed Product and (b) tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Novartis Licensed Product. The royalties are subject to potential reductions in customary circumstances including patent claim expiration, payments for certain third-party licenses, and biosimilar market penetration, subject to specified limits.

Under the terms of the Novartis Agreement, each party owns the entire right, title, and interest in and to all patents or know-how controlled by such party and existing as of or before the Novartis Effective Date, or invented, developed, created, generated or acquired solely by or on behalf of such party after the Novartis Effective Date. Subject to certain specified exceptions, any patents and know-how that are invented or otherwise developed jointly by or on behalf of the parties during the term of the Novartis Agreement and in the course of the parties’ activities under the Novartis Agreement will follow inventorship under U.S. patent law.

Subject to certain limitations and exceptions, the Company has agreed (i) during the Novartis Research Term, not to conduct any internal program or program on behalf of a third party that is directed to the development or commercialization of any Company’s capsids, or grant any third party or affiliate any right or license under the Company’s rights in such capsids, to exploit any therapeutic product containing a capsid in combination with a payload designed to have therapeutic effect on any of the Novartis Targets; and (ii) after Novartis’s exercise of any Novartis License Option, not to grant any third party or affiliate any right or license under the Company’s patents to exploit any Novartis Licensed Capsid for the applicable Novartis Target.

Unless earlier terminated, the Novartis Agreement expires on the earlier to occur of (i) the first anniversary of the Novartis Effective Date , if no Novartis License Option is exercised, and (ii) the expiration of the last-to-expire royalty term with respect to all Novartis Licensed Products in all countries if at least one Novartis License Option is exercised. Subject to a cure period, either party may terminate the Novartis Agreement, in whole or in part, subject to specified conditions, in the event of the other party’s uncured material breach. Novartis may also terminate the Novartis Agreement, in whole or in part, subject to specified conditions, for the Company’s insolvency, the occurrence of a violation of global trade control laws, or for the Company’s non-compliance with certain anti-bribery or anti-corruption covenants. Novartis may terminate the Novartis Agreement, in whole or in part, for any or no reason upon ninety days’ written notice to the Company.

Upon certain terminations for cause by Novartis, the licenses granted by the Company to Novartis under the Novartis Agreement shall become irrevocable and perpetual, and all milestone payments and royalties that would have otherwise been payable by Novartis under such licenses had the Novartis Agreement remained in effect would be substantially reduced.

Accounting Analysis

The Company assessed the promised goods and services under the Novartis Agreement, in accordance with ASC 606, and determined that the Novartis Agreement contains three performance obligations consisting of three material rights, one for each of the Novartis License Options. The Company concluded that each Novartis License Option provides a material right as consideration for each option is less than the amount that the Company would otherwise have expected to receive outside the context of the contract. The promises at inception do not include the underlying goods or services that would be delivered upon exercise of the option, but rather represent the value to the customer of having the right to exercise the Novartis License Option at the specified exercise fee. Upon the exercise of a Novartis License Option, until March 4, 2025, while the Company is not obligated to conduct additional research activities upon any option exercise to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of central nervous system or cardiovascular diseases, it has agreed to continue to disclose to Novartis, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available.

Novartis may conduct additional evaluation of such capsid candidates and has the right to substitute any other capsid candidate for the Novartis Licensed Capsid it previously elected to license when it exercised the Novartis License Option. The Company determined that this promise to provide Novartis the ability to evaluate and potentially substitute other capsid candidates for the Novartis Licensed Capsid it previously elected to license when it exercised the Novartis License Option, if and when available, is an additional performance obligation in the arrangement (the “Novartis Substitution Right Performance Obligation”). The Company concluded the options for Additional Novartis Targets are not material rights as the price reflects the standalone selling price of the options. The Company will therefore account for the options for Additional Novartis Targets separately, if exercised.

The Company received a nonrefundable, upfront payment of $54.0 million as consideration under the Novartis Agreement, which represents the transaction price at inception. Additional consideration to be paid to the Company upon exercise of the Novartis License Options or upon reaching certain milestones are excluded from the transaction price as they relate to option fees and milestones that could only be achieved subsequent to an option exercise.

The Company allocated the transaction price to the three material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be willing to pay an equal amount for each Novartis License Option on a standalone basis. The Company reached this conclusion after considering (i) the downstream economics including option fees, milestones and royalties related to each Novartis License Option being identical and (ii) comparable market data. The Company determined the standalone selling price for the Novartis Substitution Right Performance Obligation was insignificant to the allocation of the transaction price using the relative standalone selling price model and did not allocate any transaction price to the Novartis Substitution Right Performance Obligation, accordingly. This determination was supported by qualitative and quantitative assessments of the standalone selling price that considered the cost of identifying other potential capsid candidates and the likelihood of license substitution. As such, based on the relative standalone selling price for each of the three material rights, the allocation of the transaction price to the separate performance obligations is $18.0 million for each material right.

The amount allocated to each material right was recorded as deferred revenue and will be recognized either upon exercise of the Novartis License Option or upon expiration of the Novartis License Option.

During the three and nine months ended September 30, 2022, the Company did not recognize any revenue related to the Novartis Agreement. As of September 30, 2022, the entire transaction price of $54.0 million is recorded as deferred revenue, current in the accompanying consolidated balance sheet.

License Agreement with Touchlight IP Limited

On November 3, 2022, the Company and Touchlight IP Limited (“Touchlight”) entered into a license agreement (the “Touchlight License Agreement”) to authorize historical use by the Company of a certain DNA preparation process (“Subject DNA Preparation Process”), and to authorize the prospective exploitation of TRACER Capsids created with the use of the Subject DNA Preparation Process.

The terms of the Touchlight License Agreement include a one-time, non-refundable technology access fee of $5.0 million, payable to Touchlight during the fourth quarter of 2022. As of September 30, 2022, the Company determined that this technology access fee was a probable liability that could be reasonably estimated in accordance with ASC 450 Contingencies as of such date. The Company recorded the $5.0 million charge during the third quarter of 2022, accordingly.

The terms of the Touchlight License Agreement also include future milestone payments and low single-digit royalties payable to Touchlight if the Company or its program collaborators or licensees choose to utilize in a therapeutic product TRACER Capsids that were created with the historical use of the Subject DNA Preparation Process. Additionally, the Company is obligated to pay low single-digit royalties to Touchlight on future payments the Company receives in connection with licensing of TRACER capsids that were created with the historical use of the Subject DNA Preparation Process, excluding the licensing of or collaboration on any Company therapeutic programs.

Other Agreements

During the year ended December 31, 2016, the Company entered into a research and development funding arrangement with a non-profit organization that provides up to $4.0 million in funding to the Company upon the achievement of clinical and development milestones. The agreement provides that the Company repay amounts received under certain circumstances including termination of the agreement, and to pay an amount up to 2.6 times the funding received upon successful development and commercialization of any products developed. During the year ended December 31, 2017, the Company earned a milestone payment of $1.0 million. The Company has evaluated the arrangement and has concluded that it represents a research and development financing arrangement as it is probable that the Company will repay amounts received under the arrangement. As a result, the $1.0 million earned to date is recorded as a non-current liability in the condensed consolidated balance sheet.

Litigation

The Company was not a party to any material legal matters or claims as of September 30, 2022 or December 31, 2021. The Company did not have contingency reserves established for any litigation liabilities as of September 30, 2022 or December 31, 2021.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based compensation
9 Months Ended
Sep. 30, 2022
Stock-based compensation  
Stock-based compensation

9. Stock-based compensation

Founder Awards

In January 2014, the Company issued 1,188,233 shares of restricted stock to its founders (each, a “Founder”) at an original issuance price of $0.0425 per share. Of the total restricted shares awarded to the Founders, 835,292 shares generally vest over one to four years, based on each Founder’s continued service to the Company in varying capacities as a Scientific Advisory Board member, consultant, director, officer or employee, as set forth in each grantee’s individual restricted stock purchase agreement.

The remaining 352,941 of the shares issued were subject to vesting upon the achievement of certain performance objectives as well as continued service to the Company, as set forth in the agreements. These performance conditions were tied to certain milestone events specific to the Company’s corporate goals, including but not limited to preclinical and clinical development milestones related to the Company’s product candidates. Stock-based compensation expense associated with these performance-based awards is recognized when the achievement of the performance condition is considered probable, using management’s best estimates. Management concluded that the achievement of the performance milestone associated with the performance-based award for one Founder had been met during 2016.

In December 2019, the Company modified one of the remaining Founder performance awards, repurchasing 58,823 shares of common stock previously issued to this Founder. Additionally, the Company modified the award to vest solely based on time rather than on performance. The Company revalued the award at the modification date and is recognizing expense on a straight-line basis over the three-year vesting period from the modification date.

In July 2022, the Company modified the last remaining Founder performance award, repurchasing 72,647 shares of common stock previously issued to this Founder. Additionally, the Company modified the award to vest solely based on time rather than on performance. The Company revalued the award at the modification date and is recognizing expense on a straight-line basis over the two-year vesting period. Stock-based compensation related to the modification of this award was less than $0.1 million for both the three and nine months ended September 30, 2022.

Inducement Awards

During the three and nine months ended September 30, 2022, the Company issued to two executives non-statutory stock options to purchase an aggregate of 276,000 shares of the Company’s common stock outside of the Company’s 2015 Stock Option Plan as an inducement material to such executive’s acceptance of an offer of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option vests over a four-year period, with 25% of the shares underlying the option award vesting on the first anniversary of the effective date of the award and the remaining 75% of the shares underlying the award vesting in 36 equal monthly installments following the first anniversary of the effective date of the award.

Stock-Based Compensation Expense

Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations and comprehensive income (loss) is as follows:

Three Months Ended

Nine Months Ended

September 30, 

 

September 30, 

 

    

2022

    

2021

 

2022

    

2021

 

(in thousands)

 

Research and development

$

588

$

702

$

2,170

$

3,409

General and administrative

 

1,601

 

1,375

 

4,828

 

6,261

Total stock-based compensation expense

$

2,189

$

2,077

$

6,998

$

9,670

Stock-based compensation expense by type of award included within the condensed consolidated statements of operations and comprehensive income (loss) was as follows:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2022

    

2021

2022

    

2021

(in thousands)

Stock options

$

1,357

$

1,372

$

4,452

$

6,375

Restricted stock awards and units

748

651

2,382

3,018

Employee stock purchase plan awards

 

84

 

54

164

277

Total stock-based compensation expense

$

2,189

$

2,077

6,998

9,670

Restricted Stock Units

A summary of the status of and changes in unvested restricted stock unit activity under the Company’s equity award plans for the nine months ended September 30, 2022 was as follows:

    

    

Weighted

Average

Grant Date

Fair Value

    

Units

    

Per Unit

Unvested restricted stock units as of December 31, 2021

 

806,379

$

7.26

Granted

 

770,580

$

3.89

Vested

 

(419,999)

6.71

Forfeited

 

(215,685)

$

4.96

Unvested restricted stock units as of September 30, 2022

 

941,275

$

5.27

Stock-based compensation of restricted stock units is based on the fair value of the Company’s common stock on the date of grant and is recognized over the vesting period. Restricted stock units granted by the Company typically vest in equal amounts, annually over three years. All of the restricted stock units granted in the nine months ended September 30, 2022 vest in equal amounts, annually over three years. The stock-based compensation expense related to

restricted stock units and awards was $0.7 million and $2.4 million for the three and nine months ended September 30, 2022, respectively. The stock-based compensation expense related to restricted stock units and awards was $0.7 million and $3.0 million for the three and nine months ended September 30, 2021, respectively.

As of September 30, 2022, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $3.3 million, which is expected to be recognized over the remaining average vesting period of 1.9 years.

Stock Options

The following is a summary of stock option activity for the nine months ended September 30, 2022:

    

    

Weighted

    

Remaining

    

Aggregate

Average

Contractual

Intrinsic

Exercise

Life

Value

    

Shares

    

Price

    

(in years)

    

(in thousands)

Outstanding at December 31, 2021

 

5,013,193

$

12.69

5.6

$

1,165

Granted

 

3,504,675

$

5.14

Exercised

 

(79,837)

$

7.56

Cancelled or forfeited

 

(2,358,960)

$

13.22

Outstanding at September 30, 2022

 

6,079,071

$

8.20

 

8.1

$

5,693

Exercisable at September 30, 2022

 

2,581,363

$

10.85

 

6.4

$

1,838

As of September 30, 2022, the Company had unrecognized stock-based compensation expense related to its unvested stock options of $13.5 million which is expected to be recognized over the remaining weighted-average vesting period of 3.1 years.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net income (loss) per share
9 Months Ended
Sep. 30, 2022
Net income (loss) per share  
Net income (loss) per share

10. Net income (loss) per share

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net income (loss) per share because to include them would be anti-dilutive:

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2022

    

2021

2022

    

2021

Unvested restricted common stock awards

 

64,608

156,863

64,608

156,863

Unvested restricted common stock units

523,627

947,265

941,275

947,265

Outstanding stock options

 

5,433,867

5,406,072

6,079,071

5,406,072

Total

 

6,022,102

6,510,200

7,084,954

6,510,200

Basic net income (loss) and diluted weighted-average shares outstanding are as follows for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended September 30, 

Nine Months Ended September 30, 

2022

    

2021

2022

    

2021

(in thousands, except share data)

Numerator:

Net income (loss)

$

17,624

$

(25,137)

$

(22,782)

$

(76,906)

Denominator for basic net income (loss) per share:

Weighted average shares outstanding-basic

38,507,542

37,780,547

38,292,497

37,623,309

Denominator for diluted net income (loss) per share:

Weighted average shares outstanding-basic

38,507,542

37,780,547

38,292,497

37,623,309

Common stock options and restricted stock units

1,062,852

Weighted average shares outstanding-diluted

39,570,394

37,780,547

38,292,497

37,623,309

Basic net loss per share for the nine months ended September 30, 2022 and 2021, and for the three months ended September 30, 2021, is the same as diluted net loss per share as shown on the Company’s condensed consolidated statement of operations.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related party transactions
9 Months Ended
Sep. 30, 2022
Related party transactions  
Related party transactions

11. Related-party transactions

During the three and nine months ended September 30, 2022, the Company received scientific advisory board and other scientific advisory services from one of its prior executives, Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Sah for services provided during the three and nine months ended September 30, 2022, was $93,600 and $185,925, respectively. The total amount of fees paid to Dr. Sah for services provided during the three and nine months ended September 30, 2021 was $30,000 and $120,000, respectively.

During the nine months ended September 30, 2022, the Company received advisory services related to strategic planning, operations, and management from Alfred Sandrock, M.D., Ph.D., the Company’s current President and Chief Executive Officer and a member of the Company’s Board of Directors, before he commenced service in the capacity of President and Chief Executive Officer in March 2022. The total amount of fees paid to Dr. Sandrock for services provided was $60,000 for the nine months ended September 30, 2022.

Under the Neurocrine Collaboration Agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization activities for certain of the Company’s AAV gene therapy products (Note 8). Amounts due from Neurocrine are reflected as related party collaboration receivables. As of September 30, 2022, the Company had approximately $0.2 million in related party collaboration receivables associated with Neurocrine.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of significant accounting policies (Policies)
9 Months Ended
Sep. 30, 2022
Summary of significant accounting policies  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (“SEC”) on March 8, 2022. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Principles of Consolidation

Principles of Consolidation

The unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiary as disclosed in Note 2, under the heading “Summary of Significant Accounting Policies - Basis of

Presentation”, within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Intercompany accounts and transactions have been eliminated.

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

There have been no changes in the Company's significant accounting policies as described in Note 2, “Summary of Significant Accounting Policies,” within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair value measurements (Tables)
9 Months Ended
Sep. 30, 2022
Fair value measurements  
Assets and liabilities measured at fair value on a recurring basis

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 are as follows:

Quoted Prices

Significant

 

in Active

Other

Significant

 

Markets for

Observable

Unobservable

 

Identical Assets

Inputs

Inputs

Assets

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

September 30, 2022

(in thousands)

 

Money market funds included in cash and cash equivalents

    

$

93,043

    

$

93,043

    

$

    

$

Marketable securities - U.S. Treasury notes

 

34,778

 

34,778

 

 

Total

$

127,821

$

127,821

$

$

December 31, 2021

Money market funds included in cash and cash equivalents

    

$

100,305

    

$

100,305

    

$

    

$

Marketable securities - U.S. Treasury notes

15,106

15,106

Total

$

115,411

$

115,411

$

$

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables)
9 Months Ended
Sep. 30, 2022
Cash, cash equivalents, restricted cash, and available-for-sale marketable securities  
Schedule of money market funds and marketable securities

Cash, cash equivalents, and marketable securities included the following at September 30, 2022 and December 31, 2021:

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

(in thousands)

As of September 30, 2022

    

    

    

    

    

    

    

    

Money market funds included in cash and cash equivalents

$

93,043

$

$

$

93,043

Marketable securities - U.S. Treasury notes

 

34,987

(209)

34,778

Total money market funds and marketable securities

$

128,030

$

$

(209)

$

127,821

As of December 31, 2021

    

    

    

    

    

    

    

    

Money market funds included in cash and cash equivalents

$

100,305

$

$

$

100,305

Marketable securities - U.S. Treasury notes

15,117

(11)

15,106

Total money market funds and marketable securities

$

115,422

$

$

(11)

$

115,411

Reconciliation of cash, cash equivalents, and restricted cash

As of September 30, 

As of December 31, 

2022

    

2021

(in thousands)

Cash and cash equivalents

$

96,860

$

117,433

Restricted cash included in deposits and other non-current assets

1,515

1,779

Total cash, cash equivalents, and restricted cash

$

98,375

$

119,212

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued expenses (Tables)
9 Months Ended
Sep. 30, 2022
Accrued expenses  
Schedule of accrued expenses

As of September 30, 

As of December 31, 

    

2022

    

2021

 

(in thousands)

Employee compensation costs

$

3,585

$

5,022

Research and development costs

7,768

3,719

Professional services

 

675

 

727

Accrued goods and services

501

1,482

Total

$

12,529

$

10,950

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease obligation (Tables)
9 Months Ended
Sep. 30, 2022
Lease obligation  
Summary of operating sublease income

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2022

    

2021

2022

    

2021

(in thousands)

Operating sublease income

$

$

204

$

1,380

$

204

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other liabilities (Tables)
9 Months Ended
Sep. 30, 2022
Other liabilities  
Summary of other current and non-current liabilities

As of September 30, 

As of December 31, 

2022

    

2021

(in thousands)

Other current liabilities

Lease liability

2,746

5,571

Total other current liabilities

$

2,746

$

5,571

Other non-current liabilities

Lease liability

$

21,024

$

38,608

Other

1,000

1,001

Total other non-current liabilities

$

22,024

$

39,609

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and contingencies (Tables)
9 Months Ended
Sep. 30, 2022
Schedule of collaboration receivables and contract liabilities

Balance at

    

Balance at

December 31, 2021

Additions

Deductions

September 30, 2022

(in thousands)

Related party collaboration receivable

$

732

$

583

$

(1,090)

$

225

Contract liabilities:

Deferred revenue

$

12,096

$

-

$

(2,075)

$

10,021

Neurocrine Collaboration Agreement  
Schedule of allocation of variable consideration

Performance Obligation

Amount

(in thousands)

Variable Consideration

VY-AADC Program

$

53,863

FA Program

16,938

Discovery Program 1

5,236

Discovery Program 2

3,372

Total

$

79,409

Schedule of allocation of fixed consideration

Performance Obligation

Amount

(in thousands)

Fixed Consideration

VY-AADC Program

$

49,045

FA Program

20,647

Discovery Program 1

14,443

Discovery Program 2

8,247

Total

$

92,382

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based compensation (Tables)
9 Months Ended
Sep. 30, 2022
Stock-based compensation  
Compensation cost recognized for all stock-based compensation awards

Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations and comprehensive income (loss) is as follows:

Three Months Ended

Nine Months Ended

September 30, 

 

September 30, 

 

    

2022

    

2021

 

2022

    

2021

 

(in thousands)

 

Research and development

$

588

$

702

$

2,170

$

3,409

General and administrative

 

1,601

 

1,375

 

4,828

 

6,261

Total stock-based compensation expense

$

2,189

$

2,077

$

6,998

$

9,670

Summary of stock-based compensation expense by type of award

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2022

    

2021

2022

    

2021

(in thousands)

Stock options

$

1,357

$

1,372

$

4,452

$

6,375

Restricted stock awards and units

748

651

2,382

3,018

Employee stock purchase plan awards

 

84

 

54

164

277

Total stock-based compensation expense

$

2,189

$

2,077

6,998

9,670

Summary of status and changes in unvested restricted stock

A summary of the status of and changes in unvested restricted stock unit activity under the Company’s equity award plans for the nine months ended September 30, 2022 was as follows:

    

    

Weighted

Average

Grant Date

Fair Value

    

Units

    

Per Unit

Unvested restricted stock units as of December 31, 2021

 

806,379

$

7.26

Granted

 

770,580

$

3.89

Vested

 

(419,999)

6.71

Forfeited

 

(215,685)

$

4.96

Unvested restricted stock units as of September 30, 2022

 

941,275

$

5.27

Summary of stock option activity

The following is a summary of stock option activity for the nine months ended September 30, 2022:

    

    

Weighted

    

Remaining

    

Aggregate

Average

Contractual

Intrinsic

Exercise

Life

Value

    

Shares

    

Price

    

(in years)

    

(in thousands)

Outstanding at December 31, 2021

 

5,013,193

$

12.69

5.6

$

1,165

Granted

 

3,504,675

$

5.14

Exercised

 

(79,837)

$

7.56

Cancelled or forfeited

 

(2,358,960)

$

13.22

Outstanding at September 30, 2022

 

6,079,071

$

8.20

 

8.1

$

5,693

Exercisable at September 30, 2022

 

2,581,363

$

10.85

 

6.4

$

1,838

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net income (loss) per share (Tables)
9 Months Ended
Sep. 30, 2022
Net income (loss) per share  
Outstanding potentially dilutive securities excluded in the calculation of diluted net income (loss) per share

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net income (loss) per share because to include them would be anti-dilutive:

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2022

    

2021

2022

    

2021

Unvested restricted common stock awards

 

64,608

156,863

64,608

156,863

Unvested restricted common stock units

523,627

947,265

941,275

947,265

Outstanding stock options

 

5,433,867

5,406,072

6,079,071

5,406,072

Total

 

6,022,102

6,510,200

7,084,954

6,510,200

Schedule of weighted average number of shares, basic and diluted

Three Months Ended September 30, 

Nine Months Ended September 30, 

2022

    

2021

2022

    

2021

(in thousands, except share data)

Numerator:

Net income (loss)

$

17,624

$

(25,137)

$

(22,782)

$

(76,906)

Denominator for basic net income (loss) per share:

Weighted average shares outstanding-basic

38,507,542

37,780,547

38,292,497

37,623,309

Denominator for diluted net income (loss) per share:

Weighted average shares outstanding-basic

38,507,542

37,780,547

38,292,497

37,623,309

Common stock options and restricted stock units

1,062,852

Weighted average shares outstanding-diluted

39,570,394

37,780,547

38,292,497

37,623,309

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nature of business (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 01, 2021
USD ($)
Mar. 31, 2019
item
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Program
Dec. 31, 2021
USD ($)
Number of pipeline programs | Program       3  
Accumulated deficit     $ (369,886) $ (369,886) $ (347,104)
Cash, cash equivalents, and marketable debt securities     131,600 $ 131,600  
Neurocrine Collaboration Agreement | FA Program          
Percentage of profit or loss under co-co option   40.00%   40.00%  
Neurocrine | Neurocrine Collaboration Agreement          
Number of pipeline programs | item   4      
Neurocrine | Neurocrine Collaboration Agreement | FA Program          
Percentage of profit or loss under co-co option   60.00%   60.00%  
Pfizer | Option and license agreement          
Aggregate milestone payments, if exercise rights $ 10,000   $ 10,000 $ 10,000  
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair value measurements - Assets and liabilities measured on a recurring basis - (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Assets, Fair Value Disclosure [Abstract]    
Cash and cash equivalents $ 96,860 $ 117,433
Fair Value, Measurements, Recurring    
Assets, Fair Value Disclosure [Abstract]    
Total assets measured at fair value 127,821 115,411
Level 1 | Fair Value, Measurements, Recurring    
Assets, Fair Value Disclosure [Abstract]    
Total assets measured at fair value 127,821 115,411
U.S. Treasury notes | Fair Value, Measurements, Recurring    
Assets, Fair Value Disclosure [Abstract]    
Marketable securities 34,778 15,106
U.S. Treasury notes | Level 1 | Fair Value, Measurements, Recurring    
Assets, Fair Value Disclosure [Abstract]    
Marketable securities 34,778 15,106
Money market funds    
Assets, Fair Value Disclosure [Abstract]    
Cash and cash equivalents 93,043 100,305
Money market funds | Fair Value, Measurements, Recurring    
Assets, Fair Value Disclosure [Abstract]    
Cash and cash equivalents 93,043 100,305
Money market funds | Level 1 | Fair Value, Measurements, Recurring    
Assets, Fair Value Disclosure [Abstract]    
Cash and cash equivalents $ 93,043 $ 100,305
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, Cash Equivalents, and Marketable Securities - (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Amortized Cost Basis [Abstract]    
Cash and Cash Equivalents, at Carrying Value $ 96,860 $ 117,433
Total money market funds and marketable securities 128,030 115,422
Fair Value Disclosure [Abstract]    
Total money market funds and marketable securities 127,821 115,411
Unrealized Gain and Loss [Abstract]    
Total money market funds and marketable securities (209) (11)
Debt securities, unrealized loss position 30,000 15,100
Debt securities, unrealized gain position 5,000 0
Money market funds    
Amortized Cost Basis [Abstract]    
Cash and Cash Equivalents, at Carrying Value 93,043 100,305
U.S. Treasury notes    
Amortized Cost Basis [Abstract]    
Marketable securities, amortized cost 34,987 15,117
Fair Value Disclosure [Abstract]    
Marketable securities, fair value 34,778 15,106
Unrealized Gain and Loss [Abstract]    
Marketable securities, unrealized losses $ (209) $ (11)
Maximum    
Unrealized Gain and Loss [Abstract]    
Debt securities, contractual maturity period 1 year  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Cash, cash equivalents, restricted cash, and available-for-sale marketable securities        
Cash and cash equivalents $ 96,860 $ 117,433    
Restricted cash included in deposits and other noncurrent assets $ 1,515 $ 1,779    
Restricted Cash, Statement of Financial Position [Extensible Enumeration] Deposits And Other Non-Current Assets Deposits And Other Non-Current Assets    
Total cash, cash equivalents, and restricted cash $ 98,375 $ 119,212 $ 113,254 $ 106,219
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Accrued expenses    
Employee compensation costs $ 3,585 $ 5,022
Research and development costs 7,768 3,719
Professional services 675 727
Accrued goods and services 501 1,482
Total $ 12,529 $ 10,950
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease obligation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Operating lease, right-of-use asset     $ 3,005 $ 2,265  
Operating lease liabilities     (3,280) (2,348)  
Restricted cash included in deposits and other noncurrent assets $ 1,515   1,515   $ 1,779
Lease expense $ 1,000 $ 1,700 $ 3,800 $ 5,400  
Weighted average remaining lease term 6 years 3 months 18 days   6 years 3 months 18 days    
Weighted average incremental borrowing rate 7.40%   7.40%    
75 Sidney Street          
Lease term   3 years 3 months 18 days   3 years 3 months 18 days  
Operating lease, right-of-use asset $ 14,500        
Operating lease liabilities 17,000        
Gain on termination of lease 2,500        
Restricted cash included in deposits and other noncurrent assets $ 1,500   $ 1,500    
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease obligation - Operating sublease income (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Lease obligation      
Operating sublease income $ 204 $ 1,380 $ 204
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Sep. 30, 2022
Other current liabilities    
Lease liability $ 5,571 $ 2,746
Total other current liabilities 5,571 2,746
Other non-current liabilities    
Lease liability 38,608 21,024
Other 1,001 1,000
Total other non-current liabilities 39,609 $ 22,024
Restructuring costs $ 2,600  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and contingencies - Neurocrine Collaboration Agreement - (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
item
$ / shares
shares
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Program
Sep. 30, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Number of collaboration programs | Program           3  
Allocation of Transaction Price              
Revenue recognized           $ 2,075  
Neurocrine Collaboration Agreement | FA Program              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of profit or loss under co-co option   40.00%       40.00%  
Neurocrine Collaboration Agreement | Neurocrine              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Number of collaboration programs | item   4          
Number of discovery programs | item   2          
Programs added later | item   2          
Discovery programs under development | item   2          
Number of targets | item   8          
Upfront payment $ 115,000 $ 115,000          
Purchase of common stock, shares | shares 4,179,728 4,179,728          
Purchase of common stock $ 5,000 $ 50,000          
Price per share | $ / shares   $ 11.9625          
Aggregate maximum milestone payments to be received from collaborative partner   $ 170,000          
Estimated cost reimbursement 431,100     $ 80,000   $ 79,400  
Termination period   10 years          
Period of advance notice for termination prior to first commercial sale   180 days          
Period of advance notice for termination after first commercial sale   1 year          
Discount related to equity investment 27,600            
Equity investment 50,000            
Allocation of Transaction Price              
Allocation of variable consideration     $ 79,409     79,409  
Allocation of fixed consideration 92,400   92,382     92,382  
Cumulative catch up of revenue recognized           900  
Costs to obtain collaboration agreement     800     800  
Consideration received $ 5,000            
Revenue recognized     1,100   $ 1,500 2,500 $ 9,300
Neurocrine Collaboration Agreement | Neurocrine | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of reduction in royalty payments   50.00%          
Neurocrine Collaboration Agreement | Neurocrine | VY-AADC              
Allocation of Transaction Price              
Allocation of variable consideration     53,863     53,863  
Allocation of fixed consideration     49,045     $ 49,045  
Neurocrine Collaboration Agreement | Neurocrine | FA Program              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of profit or loss under co-co option   60.00%       60.00%  
Allocation of Transaction Price              
Allocation of variable consideration     16,938     $ 16,938  
Allocation of fixed consideration     20,647     20,647  
Neurocrine Collaboration Agreement | Neurocrine | Discovery and FA Programs              
Allocation of Transaction Price              
Allocation of fixed consideration     42,200     42,200  
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 1              
Allocation of Transaction Price              
Allocation of variable consideration     5,236     5,236  
Allocation of fixed consideration     14,443     14,443  
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 2              
Allocation of Transaction Price              
Allocation of variable consideration     3,372     3,372  
Allocation of fixed consideration     $ 8,247     $ 8,247  
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | FA Program              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate maximum milestone payments to be received from collaborative partner   $ 195,000          
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | Discovery program 1              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate maximum milestone payments to be received from collaborative partner   130,000          
Neurocrine Collaboration Agreement | Neurocrine | Commercial Milestone              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Per Milestone, maximum milestone payments to be received from collaborative partner   275,000          
Aggregate maximum milestone payments to be received from collaborative partner   $ 1,100,000          
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and contingencies - Collaboration receivables and contract liabilities - (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2022
USD ($)
Commitments and contingencies  
Related party collaboration receivables, beginning balance $ 732
Additions 583
Deductions (1,090)
Related party collaboration receivables, ending balance 225
Deferred revenue, beginning balance 12,096
Deductions (2,075)
Deferred revenue, ending balance $ 10,021
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and contingencies - Pfizer Option and License Agreement - (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 01, 2021
USD ($)
item
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Mar. 04, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaboration revenue   $ 41,086 $ 1,482 $ 42,457 $ 9,342  
Pfizer | Option and license agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of transgenes | item 2          
Number of options | item 1          
Number of performance obligations | item 2          
Number of material rights | item 2          
Upfront payment $ 30,000          
Number of license options | item 1          
Allocation of transaction price           $ 15,000
Aggregate milestone payments, if exercise rights $ 10,000 10,000   10,000    
Number of days written notice required by reporting entity to terminate agreement 90 days          
Collaboration revenue   40,000   40,000    
Pfizer | First Material Right            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Allocation of transaction price   25,000   25,000    
Pfizer | Second Material Right            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Allocation of transaction price   $ 15,000   $ 15,000    
Pfizer | Development, regulatory and commercialization milestone | Option and license agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Aggregate maximum milestone payments to be received from collaborative partner $ 115,000          
Pfizer | Sales milestone | Option and license agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Aggregate maximum milestone payments to be received from collaborative partner $ 175,000          
Minimum | Pfizer | Option and license agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of countries received regulatory approval | item 1          
Number of major market countries received regulatory approval | item 1          
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and contingencies - Novartis Option and License Agreement (Details)
$ in Thousands
9 Months Ended
Mar. 04, 2022
USD ($)
item
Sep. 30, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Revenue recognized | $   $ 2,075
Novartis Pharma, AG | Novartis License Agreement    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of transgenes 3  
Number of additional targets 2  
Upfront payment | $ $ 54,000  
Additional fee agreed to pay | $ 18,000  
Aggregate maximum milestone payments to be received from collaborative partner | $ 125,000  
Aggregate milestone payments, if exercise rights | $ $ 12,500  
Number of license options 3  
Number of license options on additional targets 5  
Number of license option exercise for each target 1  
Number of Alliance Managers 2  
Number of options 1  
Number of major market countries received regulatory approval 3  
Number of options exercised 0  
Number of days written notice required by reporting entity to terminate agreement 90 days  
Number of performance obligations 3  
Number of material rights 3  
Allocation of transaction price | $ $ 18,000  
Revenue recognized | $   $ 54,000
Novartis Pharma, AG | Novartis License Agreement | Maximum    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of options exercised 1  
Novartis Pharma, AG | Sales milestone | Novartis License Agreement    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Aggregate maximum milestone payments to be received from collaborative partner | $ $ 175,000  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Touchlight IP Ltd License Agreement (Details) - Touchlight IP Ltd License Agreement - Touchlight IP Ltd
$ in Millions
3 Months Ended
Sep. 30, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Non-refundable technology access fee payable $ 5.0
Non-refundable technology access fee $ 5.0
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and contingencies - Other Agreements - (Details) - Non-profit organization agreement
$ in Millions
12 Months Ended
Dec. 31, 2016
USD ($)
multiple
Dec. 31, 2017
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Maximum funding $ 4.0  
Funding multiple | multiple 2.6  
Milestone payment liability   $ 1.0
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based compensation (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2022
shares
Dec. 31, 2019
shares
Jan. 31, 2014
$ / shares
shares
Sep. 30, 2022
USD ($)
individual
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
individual
$ / shares
shares
Sep. 30, 2021
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation.       $ 2,189 $ 2,077 $ 6,998 $ 9,670
Stock options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation.       $ 1,357 1,372 $ 4,452 6,375
Stock options | Inducement Awards              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period       4 years   4 years  
Stock options | Inducement Awards | Vesting period, tranche one              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage       25.00%   25.00%  
Stock options | Inducement Awards | Vesting period, tranche two              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period       36 months   36 months  
Vesting percentage       75.00%   75.00%  
Unvested restricted common stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation.       $ 748 651 $ 2,382 3,018
Vesting period           3 years  
Restricted stock granted, original issued price (in dollars per share) | $ / shares           $ 3.89  
Performance based milestone awards              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Remaining number of shares authorized to be repurchased | shares 72,647 58,823          
Vesting period 2 years 3 years          
Performance based milestone awards | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation.       $ 100   $ 100  
Founders restricted stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Restricted stock granted (in shares) | shares     1,188,233        
Restricted stock granted, original issued price (in dollars per share) | $ / shares     $ 0.0425        
Founders restricted stock | Vesting period, tranche one              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Restricted stock granted (in shares) | shares     835,292        
Founders restricted stock | Vesting period, tranche two              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Restricted stock granted (in shares) | shares     352,941        
Founders restricted stock | Minimum | Vesting period, tranche one              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period     1 year        
Founders restricted stock | Maximum | Vesting period, tranche one              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period     4 years        
Non-statutory stock options | Inducement Awards              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of executives issued options | individual       2   2  
New stock options issued | shares       276,000   276,000  
Research and development              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation.       $ 588 702 $ 2,170 3,409
General and administrative              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation.       $ 1,601 $ 1,375 $ 4,828 $ 6,261
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based compensation - Compensation expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation $ 2,189 $ 2,077 $ 6,998 $ 9,670
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation 1,357 1,372 4,452 6,375
Restricted stock awards and units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation 748 651 2,382 3,018
Employee stock purchase plan awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation 84 54 164 277
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation 588 702 2,170 3,409
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation $ 1,601 $ 1,375 $ 4,828 $ 6,261
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based compensation - Restricted Stock - (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Restricted stock disclosures        
Stock-based compensation. $ 2,189 $ 2,077 $ 6,998 $ 9,670
Unvested restricted common stock units        
Shares        
Balance, beginning (in shares)     806,379  
Granted (in shares)     770,580  
Vested (in shares)     (419,999)  
Forfeited (in shares)     (215,685)  
Balance, ending (in shares) 941,275   941,275  
Weighted Average Grant Date Fair Value Per Share        
Balance, beginning (in dollars per share)     $ 7.26  
Granted (in dollars per share)     3.89  
Vested (in dollars per share)     6.71  
Forfeited (in dollars per share)     4.96  
Balance, ending (in dollars per share) $ 5.27   $ 5.27  
Restricted stock disclosures        
Vesting period     3 years  
Stock-based compensation. $ 748 $ 651 $ 2,382 $ 3,018
Unrecognized stock-based compensation expense $ 3,300   $ 3,300  
Remaining weighted-average remaining vesting period     1 year 10 months 24 days  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based compensation - Stock Options - (Details)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]    
Outstanding, beginning balance (in shares) | shares 5,013,193  
Granted (in shares) | shares 3,504,675  
Exercised (in shares) | shares (79,837)  
Cancelled or forfeited (in shares) | shares (2,358,960)  
Outstanding, ending balance (in shares) | shares 6,079,071 5,013,193
Exercisable (in shares) | shares 2,581,363  
Weighted Average Exercise Price    
Outstanding (in dollars per share) | $ / shares $ 12.69  
Granted (in dollars per share) | $ / shares 5.14  
Exercised (in dollars per share) | $ / shares 7.56  
Cancelled or forfeited (in dollars per share) | $ / shares 13.22  
Outstanding (in dollars per share) | $ / shares 8.20 $ 12.69
Exercisable (in dollars per share) | $ / shares $ 10.85  
Remaining Contractual Life    
Outstanding 8 years 1 month 6 days 5 years 7 months 6 days
Exercisable 6 years 4 months 24 days  
Aggregate Intrinsic Value    
Outstanding | $ $ 5,693 $ 1,165
Exercisable | $ 1,838  
Stock options    
Options disclosures    
Unrecognized stock-based compensation expense | $ $ 13,500  
Remaining weighted-average remaining vesting period 3 years 1 month 6 days  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net income (loss) per share (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities 6,022,102 6,510,200 7,084,954 6,510,200
Unvested restricted common stock awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities 64,608 156,863 64,608 156,863
Unvested restricted common stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities 523,627 947,265 941,275 947,265
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities 5,433,867 5,406,072 6,079,071 5,406,072
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net income (loss) per share - Basic and diluted weighted average shares outstanding (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Numerator:        
Net income (loss) $ 17,624 $ (25,137) $ (22,782) $ (76,906)
Denominator for basic net income (loss) per share:        
Weighted average shares outstanding-basic 38,507,542 37,780,547 38,292,497 37,623,309
Denominator for diluted net income (loss) per share:        
Weighted average shares outstanding-basic 38,507,542 37,780,547 38,292,497 37,623,309
Common stock options and restricted stock units 1,062,852      
Weighted average shares outstanding-diluted 39,570,394 37,780,547 38,292,497 37,623,309
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related party transactions (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
individual
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
individual
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Related party transactions          
Related party collaboration receivable $ 225,000   $ 225,000   $ 732,000
Dr. Sah | Board and scientific advisory services          
Related party transactions          
Number of individuals providing services | individual 1   1    
Total amount of services received $ 93,600 $ 30,000 $ 185,925 $ 120,000  
Dr. Sandrock | Consulting and advisor services          
Related party transactions          
Total amount of services received     60,000    
Neurocrine | Collaboration arrangement          
Related party transactions          
Related party collaboration receivable $ 200,000   $ 200,000    
XML 59 vygr-20220930x10q_htm.xml IDEA: XBRL DOCUMENT 0001640266 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001640266 vygr:PfizerMember vygr:SecondMaterialRightMember 2022-09-30 0001640266 vygr:PfizerMember vygr:FirstMaterialRightMember 2022-09-30 0001640266 vygr:PfizerMember vygr:OptionAndLicenseAgreementMember 2022-03-04 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:VyaadcProgramMember vygr:NeurocrineCollaborativeArrangementMember 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:FaProgramMember vygr:NeurocrineCollaborativeArrangementMember 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:DiscoveryProgramTwoMember vygr:NeurocrineCollaborativeArrangementMember 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:DiscoveryProgramOneMember vygr:NeurocrineCollaborativeArrangementMember 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:DiscoveryAndFaProgramsMember vygr:NeurocrineCollaborativeArrangementMember 2022-09-30 0001640266 vygr:NeurocrineCollaborativeArrangementMember 2022-01-01 2022-09-30 0001640266 vygr:NonProfitAgreementMember 2016-01-01 2016-12-31 0001640266 vygr:NonProfitAgreementMember 2016-12-31 0001640266 vygr:NonProfitAgreementMember 2017-12-31 0001640266 vygr:PfizerMember vygr:OptionAndLicenseAgreementMember 2021-10-01 0001640266 vygr:NovartisPharmaAgMember srt:MaximumMember vygr:NovartisLicenseAgreementMember 2022-03-04 0001640266 vygr:NovartisPharmaAgMember vygr:NovartisLicenseAgreementMember 2022-03-04 0001640266 vygr:PfizerMember srt:MinimumMember vygr:OptionAndLicenseAgreementMember 2021-10-01 0001640266 vygr:TouchlightIpLtdMember vygr:TouchlightIpLtdLicenseAgreementMember 2022-09-30 0001640266 vygr:TouchlightIpLtdMember vygr:TouchlightIpLtdLicenseAgreementMember 2022-07-01 2022-09-30 0001640266 srt:MaximumMember 2022-01-01 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember srt:MaximumMember vygr:NeurocrineCollaborativeArrangementMember 2019-03-01 2019-03-31 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:FaProgramMember vygr:NeurocrineCollaborativeArrangementMember 2022-01-01 2022-09-30 0001640266 vygr:FaProgramMember vygr:NeurocrineCollaborativeArrangementMember 2022-01-01 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:FaProgramMember vygr:NeurocrineCollaborativeArrangementMember 2019-03-01 2019-03-31 0001640266 vygr:FaProgramMember vygr:NeurocrineCollaborativeArrangementMember 2019-03-01 2019-03-31 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2022-09-30 0001640266 vygr:PfizerMember vygr:OptionAndLicenseAgreementMember 2021-10-01 2021-10-01 0001640266 vygr:NovartisPharmaAgMember vygr:NovartisLicenseAgreementMember vygr:SalesMilestoneMember 2022-03-04 2022-03-04 0001640266 vygr:PfizerMember vygr:OptionAndLicenseAgreementMember vygr:SalesMilestoneMember 2021-10-01 2021-10-01 0001640266 vygr:PfizerMember vygr:OptionAndLicenseAgreementMember vygr:DevelopmentRegulatoryAndCommercializationMilestoneMember 2021-10-01 2021-10-01 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:FaProgramMember vygr:NeurocrineCollaborativeArrangementMember vygr:DevelopmentAndRegulatoryMilestonesMember 2019-03-01 2019-03-31 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:DiscoveryProgramOneMember vygr:NeurocrineCollaborativeArrangementMember vygr:DevelopmentAndRegulatoryMilestonesMember 2019-03-01 2019-03-31 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember vygr:CommercialMilestoneMember 2019-03-01 2019-03-31 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2021-10-01 2021-12-31 0001640266 vygr:NovartisPharmaAgMember vygr:NovartisLicenseAgreementMember 2022-03-04 2022-03-04 0001640266 vygr:PerformanceBasedMilestoneAwardsMember 2022-07-31 0001640266 vygr:PerformanceBasedMilestoneAwardsMember 2019-12-31 0001640266 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001640266 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001640266 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001640266 vygr:FoundersRestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2014-01-01 2014-01-31 0001640266 vygr:FoundersRestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-01-01 2014-01-31 0001640266 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001640266 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2019-06-01 2019-06-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2019-03-01 2019-03-31 0001640266 us-gaap:RetainedEarningsMember 2022-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001640266 us-gaap:RetainedEarningsMember 2022-06-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001640266 2022-06-30 0001640266 us-gaap:RetainedEarningsMember 2022-03-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001640266 2022-03-31 0001640266 us-gaap:RetainedEarningsMember 2021-12-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001640266 us-gaap:RetainedEarningsMember 2021-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001640266 us-gaap:RetainedEarningsMember 2021-06-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001640266 2021-06-30 0001640266 us-gaap:RetainedEarningsMember 2021-03-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001640266 2021-03-31 0001640266 us-gaap:RetainedEarningsMember 2020-12-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001640266 us-gaap:CommonStockMember 2022-09-30 0001640266 us-gaap:CommonStockMember 2022-06-30 0001640266 us-gaap:CommonStockMember 2022-03-31 0001640266 us-gaap:CommonStockMember 2021-12-31 0001640266 us-gaap:CommonStockMember 2021-09-30 0001640266 us-gaap:CommonStockMember 2021-06-30 0001640266 us-gaap:CommonStockMember 2021-03-31 0001640266 us-gaap:CommonStockMember 2020-12-31 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2019-03-31 0001640266 vygr:NonStatutoryStockOptionsMember vygr:InducementStockOptionAwardsMember 2022-07-01 2022-09-30 0001640266 vygr:NonStatutoryStockOptionsMember vygr:InducementStockOptionAwardsMember 2022-01-01 2022-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001640266 vygr:FoundersRestrictedStockMember 2014-01-01 2014-01-31 0001640266 us-gaap:EmployeeStockOptionMember vygr:InducementStockOptionAwardsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-07-01 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember vygr:InducementStockOptionAwardsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-01-01 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember vygr:InducementStockOptionAwardsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-07-01 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember vygr:InducementStockOptionAwardsMember 2022-07-01 2022-09-30 0001640266 vygr:PerformanceBasedMilestoneAwardsMember 2022-07-01 2022-07-31 0001640266 us-gaap:EmployeeStockOptionMember vygr:InducementStockOptionAwardsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-01-01 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember vygr:InducementStockOptionAwardsMember 2022-01-01 2022-09-30 0001640266 vygr:PerformanceBasedMilestoneAwardsMember 2019-12-01 2019-12-31 0001640266 srt:MinimumMember vygr:FoundersRestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-01-01 2014-01-31 0001640266 srt:MaximumMember vygr:FoundersRestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-01-01 2014-01-31 0001640266 vygr:PfizerMember vygr:OptionAndLicenseAgreementMember 2022-07-01 2022-09-30 0001640266 vygr:PfizerMember vygr:OptionAndLicenseAgreementMember 2022-01-01 2022-09-30 0001640266 vygr:Sidney75StreetMember 2022-09-30 0001640266 vygr:RelatedPartyTransactionBoardAndScientificAdvisoryServicesMember vygr:DrDinahSahMember 2022-07-01 2022-09-30 0001640266 vygr:RelatedPartyTransactionConsultingAndManagementServicesMember vygr:DrAlfredSandrockMember 2022-01-01 2022-09-30 0001640266 vygr:RelatedPartyTransactionBoardAndScientificAdvisoryServicesMember vygr:DrDinahSahMember 2022-01-01 2022-09-30 0001640266 vygr:RelatedPartyTransactionBoardAndScientificAdvisoryServicesMember vygr:DrDinahSahMember 2021-07-01 2021-09-30 0001640266 vygr:RelatedPartyTransactionBoardAndScientificAdvisoryServicesMember vygr:DrDinahSahMember 2021-01-01 2021-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001640266 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001640266 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001640266 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001640266 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001640266 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001640266 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001640266 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001640266 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001640266 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001640266 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001640266 vygr:Sidney75StreetMember 2021-09-30 0001640266 vygr:Sidney75StreetMember 2022-07-01 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2019-06-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2022-07-01 2022-09-30 0001640266 vygr:NovartisPharmaAgMember vygr:NovartisLicenseAgreementMember 2022-01-01 2022-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2021-07-01 2021-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2021-01-01 2021-09-30 0001640266 vygr:NeurocrineBiosciencesIncMember vygr:NeurocrineCollaborativeArrangementMember 2022-01-01 2022-09-30 0001640266 vygr:RelatedPartyTransactionCollaborationArrangementMember vygr:NeurocrineBiosciencesIncMember 2022-09-30 0001640266 2021-09-30 0001640266 2020-12-31 0001640266 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001640266 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001640266 us-gaap:MoneyMarketFundsMember 2022-09-30 0001640266 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001640266 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001640266 us-gaap:MoneyMarketFundsMember 2021-12-31 0001640266 2021-01-01 2021-12-31 0001640266 us-gaap:USTreasurySecuritiesMember 2022-09-30 0001640266 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001640266 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001640266 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001640266 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001640266 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001640266 us-gaap:RestrictedStockMember 2022-07-01 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001640266 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001640266 us-gaap:RestrictedStockMember 2021-07-01 2021-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001640266 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001640266 srt:MaximumMember vygr:PerformanceBasedMilestoneAwardsMember 2022-07-01 2022-09-30 0001640266 us-gaap:StockCompensationPlanMember 2022-07-01 2022-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001640266 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001640266 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001640266 srt:MaximumMember vygr:PerformanceBasedMilestoneAwardsMember 2022-01-01 2022-09-30 0001640266 us-gaap:StockCompensationPlanMember 2022-01-01 2022-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001640266 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001640266 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001640266 us-gaap:StockCompensationPlanMember 2021-07-01 2021-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001640266 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001640266 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001640266 us-gaap:StockCompensationPlanMember 2021-01-01 2021-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001640266 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001640266 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001640266 2022-07-01 2022-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001640266 2022-04-01 2022-06-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001640266 2022-01-01 2022-03-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001640266 2021-07-01 2021-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001640266 2021-04-01 2021-06-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001640266 2021-01-01 2021-03-31 0001640266 2021-01-01 2021-09-30 0001640266 2022-09-30 0001640266 2021-12-31 0001640266 2022-11-04 0001640266 2022-01-01 2022-09-30 shares iso4217:USD iso4217:USD shares pure vygr:item vygr:Program vygr:multiple vygr:individual 38520336 2400000 http://www.voyagertherapeutics.com/20220930#DepositsAndOtherNonCurrentAssets http://www.voyagertherapeutics.com/20220930#DepositsAndOtherNonCurrentAssets false 0001640266 --12-31 2022 Q3 37918395 0 0 P1Y 10-Q true 2022-09-30 false 001-37625 Voyager Therapeutics, Inc. DE 46-3003182 64 Sidney Street Cambridge MA 02139 857 259-5340 Common Stock, $0.001 par value VYGR NASDAQ Yes Yes Accelerated Filer true false false 38607346 96860000 117433000 34778000 15106000 10000000 225000 732000 5079000 3427000 146942000 136698000 18082000 21920000 1515000 1779000 15941000 33458000 182480000 193855000 1337000 574000 12529000 10950000 2746000 5571000 56630000 33886000 73242000 50981000 7391000 8210000 22024000 39609000 102657000 98800000 0.001 0.001 5000000 5000000 0 0 0.001 0.001 120000000 120000000 38520336 37918395 38000 38000 450008000 442259000 -337000 -138000 -369886000 -347104000 79823000 95055000 182480000 193855000 41086000 1482000 42457000 9342000 19337000 17914000 46213000 59767000 7307000 8714000 22518000 28895000 26644000 26628000 68731000 88662000 14442000 -25146000 -26274000 -79320000 545000 121000 816000 253000 2637000 -112000 2676000 2161000 3182000 9000 3492000 2414000 17624000 -25137000 -22782000 -76906000 27000 -2000 -199000 6000 27000 -2000 -199000 6000 17651000 -25139000 -22981000 -76900000 0.46 -0.67 -0.59 -2.04 0.45 -0.67 -0.59 -2.04 38507542 37780547 38292497 37623309 39570394 37780547 38292497 37623309 37368027 37000 430324000 -134000 -275907000 154320000 3811 1000 27000 28000 184217 3498000 3498000 11000 11000 -21649000 -21649000 37556055 38000 433849000 -123000 -297556000 136208000 114412 101752 580000 580000 3871000 3871000 -3000 -3000 -30120000 -30120000 37772219 38000 438300000 -126000 -327676000 110536000 9567 2025000 2025000 -2000 -2000 -25137000 -25137000 37781786 38000 440325000 -128000 -352813000 87422000 37918395 38000 442259000 -138000 -347104000 95055000 11484 12000 12000 312090 2268000 2268000 -85000 -85000 -21319000 -21319000 38241969 38000 444539000 -223000 -368423000 75931000 63012 575000 575000 32165 102105 313000 313000 2460000 2460000 -141000 -141000 -19087000 -19087000 38439251 38000 447887000 -364000 -387510000 60051000 5341 15000 15000 75744 2106000 2106000 27000 27000 17624000 17624000 38520336 38000 450008000 -337000 -369886000 79823000 -22782000 -76906000 6998000 9670000 5357000 3683000 23000 -324000 2468000 2460000 10000000 -507000 -6847000 1652000 -1731000 -3005000 -2265000 -69000 763000 -42000 1536000 -2912000 -3280000 -2348000 -151000 21925000 -4641000 -265000 -64720000 1558000 1262000 54848000 35000000 72632000 -21406000 71370000 602000 28000 232000 357000 834000 385000 -20837000 7035000 119212000 106219000 98375000 113254000 40000 22000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a<span style="font-size:11pt;"> </span>biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines, with the goal of<span style="font-family:'Segoe UI';"> </span>either halting or slowing disease progression or reduce symptom severity, therefore providing clinically meaningful impact to patients. The Company’s gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (“AAV”) based gene therapies that it believes have the potential to safely provide durable efficacy. The Company’s team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which the Company believes an AAV gene therapy or other biological therapy will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. The Company then engineers and optimizes an AAV vector or other biological therapy for activity in, efficacy in, or delivery to, the targeted tissue or cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. The Company’s team has developed a proprietary AAV capsid discovery platform called TRACER<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (“BBB”). The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid <i style="font-style:italic;">in vivo</i> evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The Company believes that the capsids it discovers through its TRACER discovery platform (“TRACER Capsids”) have the potential to significantly enhance the efficacy and safety of its single dose gene therapies, which it expects to be delivered with targeted surgical delivery or systemic infusions, as compared with conventional capsids.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to leveraging TRACER capsids in potential licensing arrangements, the Company is advancing its own proprietary pipeline of drug candidates for neurological diseases. The Company's three prioritized pipeline programs include: GBA1 gene therapy for Parkinson’s disease, SOD1 gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease. The Company plans to identify lead development candidates for all three programs between the fourth quarter of 2022 and the first half of 2023, with investigational new drug (IND) filings expected in 2024 and 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to these three lead programs, the Company has a collaboration ongoing with <span style="background:#ffffff;">Neurocrine Biosciences, Inc. (“Neurocrine”) </span>to develop a gene therapy for Friedreich's ataxia, which Neurocrine is funding through Phase 1. At that point, the Company has an option to either (1) co-develop and co-commercialize the asset with Neurocrine in the United States under a 60/40 cost and profit-sharing arrangement, 60% to Neurocrine and 40% to the Company, or (2) retain the right to receive milestone payments and royalties based on global sales pursuant to the full global commercial rights granted to Neurocrine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy and other biological therapy programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy and antibody development and manufacturing. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in specific geographies with collaborators, as the Company has demonstrated through its ongoing <span style="background:#ffffff;">collaboration with Neurocrine under a collaboration agreement that became effective in January 2019 (the “Neurocrine Collaboration Agreement”), or out-licensing activities including option and license agreements related to the TRACER capsids such as the Company’s October 2021 option and license agreement with Pfizer Inc. </span>(“Pfizer”), pursuant to which Pfizer exercised an option effective as of September 30, 2022, and the Company’s March 2022 option and license agreement with Novartis Pharma AG (“Novartis”). The Company believes there is an ongoing opportunity for option and license transactions related to the TRACER capsids. To maximize the potential of TRACER capsids for the Company’s own </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">programs and option and license transactions, the Company has retained to date, and expects to retain in the future, all rights associated with such TRACER capsids other than the rights specific to their use in combination with a particular optionee’s or licensee’s transgenes. <span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring annual net operating losses. As of September 30, 2022, the Company had an accumulated deficit of $369.9 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from fees, milestone payments, and cost reimbursements associated with its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”) and AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaboration with Neurocrine, <span style="font-family:'Times';">its option and license agreement with Pfizer, and its option and license agreement with Novartis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company had cash, cash equivalents, and marketable securities of $131.6 million. Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable securities at September 30, 2022, together with amounts expected to be received as reimbursement for development costs under the Neurocrine Collaboration Agreement, and the Pfizer option exercise payment of $10.0 million received in the fourth quarter of 2022 will be sufficient to meet the Company’s planned operating expenses and capital expenditure re<span style="background:#ffffff;">quirements</span> into 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </p> 3 3 3 0.60 0.40 -369900000 131600000 10000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of significant accounting policies and basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Basis of Presentation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (“SEC”) on March 8, 2022. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Principles of Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">The unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiary as disclosed in Note 2, under the heading “Summary of Significant Accounting Policies - Basis of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;">Presentation”, within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Intercompany accounts and transactions have been eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Summary of Significant Accounting Policies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no changes in the Company's significant accounting policies as described in Note 2, “Summary of Significant Accounting Policies,” within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Basis of Presentation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (“SEC”) on March 8, 2022. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Principles of Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">The unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiary as disclosed in Note 2, under the heading “Summary of Significant Accounting Policies - Basis of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;">Presentation”, within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Intercompany accounts and transactions have been eliminated.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Certain reclassifications have been made to prior periods to conform to current period presentation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Summary of Significant Accounting Policies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no changes in the Company's significant accounting policies as described in Note 2, “Summary of Significant Accounting Policies,” within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Fair value measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - U.S. Treasury notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - U.S. Treasury notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company measures the fair value of money market funds and U.S. Treasury notes based on quoted prices in active markets for identical securities. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - U.S. Treasury notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:45.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - U.S. Treasury notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 93043000 93043000 34778000 34778000 127821000 127821000 100305000 100305000 15106000 15106000 115411000 115411000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">4. Cash, cash equivalents, restricted cash, and available-for-sale marketable securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Cash, cash equivalents, and marketable securities included the following at September 30, 2022 and December 31, 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - U.S. Treasury notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (209)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total money market funds and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 128,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (209)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - U.S. Treasury notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total money market funds and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All of the Company’s marketable securities as of September 30, 2022 have a contractual maturity of one year or less. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. In connection with these investments, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the condensed consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the condensed consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company held $30.0 million and $15.1 million marketable securities that were in an unrealized loss position as of September 30, 2022 and December 31, 2021, respectively, and held $5.0 million marketable securities that were in an unrealized gain position as of September 30, 2022. No marketable securities were in an unrealized gain position as of December 31, 2021. The unrealized losses at September 30, 2022 and December 31, 2021 were attributable to changes in interest rates and the unrealized losses do not represent credit losses. The Company does not intend to sell these securities and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 96,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 117,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_h_OgR02KwEmlXHP1AGXahw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restricted cash included in deposits and other non-current assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 98,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Cash, cash equivalents, and marketable securities included the following at September 30, 2022 and December 31, 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - U.S. Treasury notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (209)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total money market funds and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 128,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (209)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:49.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - U.S. Treasury notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total money market funds and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 115,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 93043000 93043000 34987000 209000 34778000 128030000 209000 127821000 100305000 100305000 15117000 11000 15106000 115422000 11000 115411000 P1Y 30000000.0 15100000 5000000.0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 96,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 117,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_h_OgR02KwEmlXHP1AGXahw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restricted cash included in deposits and other non-current assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 98,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 119,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 96860000 117433000 1515000 1779000 98375000 119212000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Accrued expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses as of September 30, 2022 and December 31, 2021 consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:51.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation costs</p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs</p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:51.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional services</p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued goods and services</p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:51.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation costs</p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development costs</p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:51.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional services</p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued goods and services</p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 3585000 5022000 7768000 3719000 675000 727000 501000 1482000 12529000 10950000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">6. Lease obligation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">As of September 30, 2022, the Company has a lease for office and laboratory space at 64 Sidney Street in Cambridge, Massachusetts through November 30, 2026 and a lease for additional laboratory and office space at 75 Hayden Avenue in Lexington, Massachusetts through January 31, 2031. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In September 2021, the Company entered into an agreement with BioNTech US, Inc. (“BioNTech US”) to sublease part of the office and laboratory space leased by the Company at 75 Sidney Street in Cambridge, Massachusetts (the “Sublease Agreement”) at that time. The sublease term was for approximately 3.3 years. The sublease did not relieve the Company of its original obligation under the lease, and therefore the Company did not adjust the operating lease right-of-use asset as a result of the sublease and accounted for the sublease as a separate lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On June 22, 2022 the Company entered into a Lease Termination Agreement (the “Lease Termination Agreement”) and terminated the lease for office and laboratory space at 75 Sidney Street (the “75 Sidney Street Lease”), effective immediately. The 75 Sidney Street Lease was previously scheduled to terminate, in accordance with its terms, on November 30, 2026. In connection with the Lease Termination Agreement, the Company also entered into a Sublease Termination Agreement (the “Sublease Termination Agreement”) and terminated the Sublease Agreement with BioNTech US. The Company did not incur any termination penalties in connection with the Lease Termination Agreement or Sublease Termination Agreement. The Company derecognized the related right-of-use asset of approximately $14.5 million and the operating lease liabilities of $17.0 million, accordingly, resulting in a gain of $2.5 million in the three-month period ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company’s lease agreements require the Company to maintain a cash deposit or irrevocable letter of credit in the aggregate amount of $1.5 million payable to its landlords as security for the performance of its obligations under the leases. These amounts are recorded as restricted cash and are included in deposits and other non-current assets in the accompanying condensed consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the three and nine months ended September 30, 2022, the Company incurred lease expenses of $1.0 million and $3.8 million, respectively, for operating leases. During the three and nine months ended September 30, 2021, the Company incurred lease expenses of $1.7 million and $5.4 million, respectively, for operating leases. As of September 30, 2022, the weighted average remaining lease term was 6.3 years and the weighted average incremental borrowing rate used to determine the operating lease liability was 7.4%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the operating sublease income generated under the Sublease Agreement for the three and nine months ended September 30, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:74.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Operating sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 204</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> P3Y3M18D -14500000 17000000.0 2500000 1500000 1000000.0 3800000 1700000 5400000 P6Y3M18D 0.074 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:74.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Operating sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 204</p></td></tr></table> 204000 1380000 204000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">7. Other liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2022 and December 31, 2021, other current and non-current liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:51.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39,609</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Strategic Restructuring</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On August 6, 2021, the board of directors of the Company approved a strategic restructuring plan to eliminate a portion of its workforce as part of an initiative to reduce expenses and enhance operations. The strategic restructuring plan was approved in connection with its portfolio reevaluation efforts and its strategic shift to invest additional resources in the Company’s TRACER capsid development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2021, the Company incurred restructuring costs of approximately $2.6 million, which consists of severance-related costs. Substantially all costs have been paid as of September 30, 2022.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:51.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39,609</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 2746000 5571000 2746000 5571000 21024000 38608000 1000000 1001000 22024000 39609000 2600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Significant Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Neurocrine Collaboration Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Summary of Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:36pt;margin:0pt;">In March 2019, the Company entered into the Neurocrine Collaboration Agreement for the research, development and commercialization of certain of its AAV gene therapy products. Under the Neurocrine Collaboration Agreement, the Company agreed to collaborate on the conduct of four collaboration programs (the “Neurocrine Programs”) which include: <span style="background:#ffffff;">(i) VY-AADC (NBIb-1817) for Parkinson’s disease (the “VY-AADC Program”), (ii) VY-FXN01 for Friedreich’s ataxia (the “FA Program”) (collectively, with the VY-AADC Program, the “Legacy Programs”), and (iii) </span><span style="background:#ffffff;">two</span><span style="background:#ffffff;"> programs to be determined by the Company and Neurocrine at a later date (the “Discovery Programs”)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In June 2019, in conjunction with the termination of the collaboration agreement with Sanofi Genzyme (the “Sanofi Genzyme Collaboration Agreement”), the Company gained ex-U.S. rights to the FA Program. The Company’s </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">ex-U.S. rights to the FA Program were subsequently transferred to Neurocrine under the terms of the Neurocrine Collaboration Agreement. To facilitate the transfer of the ex-U.S. rights to the FA Program to Neurocrine, the Company and Neurocrine executed an amendment to the Neurocrine Collaboration Agreement (the “June 2019 Modification”), and Neurocrine paid $5.0 million to the Company. There were no other changes in pricing or scope of the obligations required to be performed under the Neurocrine Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021, Neurocrine notified the Company that it had elected to terminate the Neurocrine Collaboration Agreement solely with regards to the VY-AADC Program, effective August 2, 2021 (the “Neurocrine VY-AADC Program Termination Effective Date”). The Neurocrine Collaboration Agreement remains in full force and effect for each other program thereunder. <span style="background:#ffffff;">As a result of the termination, Neurocrine is no longer obligated to reimburse the Company for research and development activities related to the VY-AADC Program. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Neurocrine Collaboration Agreement, the Company originally agreed to collaborate with Neurocrine on, and to grant, exclusive, royalty-bearing, non-transferable, sublicensable licenses to certain of its intellectual property rights, for all human and veterinary diagnostic, prophylactic, and therapeutic uses, for the research, development, and commercialization of gene therapy products (the “Collaboration Products”) on a worldwide basis under (i) the VY-AADC Program; (ii) the FA Program; and (iii) each Discovery Program. As a result of the termination of the Neurocrine Collaboration Agreement with regards to the VY-AADC Program, in accordance with the terms of the Neurocrine Collaboration Agreement, the licenses granted by the Company to Neurocrine regarding the VY-AADC Program have expired, and the Company has regained worldwide intellectual property rights regarding the VY-AADC Program, in each case as of the VY-AADC Termination Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">Pursuant to development plans agreed by the parties, which are overseen by a joint steering committee (“JSC”), the Company has operational responsibility, subject to certain exceptions, for the conduct of each Neurocrine Program prior to the occurrence of a specified event for such Neurocrine Program (a “Transition Event”), as described below, and is required to use commercially reasonable efforts to develop the corresponding Collaboration Products. Neurocrine has agreed to be responsible for all costs incurred by the Company in conducting these activities for each Neurocrine Program, in accordance with an agreed budget for each Neurocrine Program. If the Company breaches its development responsibilities or in certain circumstances upon a change in control, Neurocrine has the right but not the obligation to assume the activities under such Neurocrine Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Upon the occurrence of a Transition Event for each Neurocrine Program, Neurocrine has agreed to assume responsibility for development, manufacturing and commercialization activities for such Neurocrine Program from the Company and to pay milestones and royalties on future net sales as described further below. As a result of Neurocrine’s termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program, the Transition Event with respect to the VY-AADC Program is no longer applicable. The Transition Events for the remaining programs are (i) with respect to the FA Program, the Company’s receipt of topline data for the initial Phase 1 clinical trial for an FA Program product candidate; and (ii) <span style="white-space:pre-wrap;">with respect to each Discovery Program, the preparation by the Company and the approval by Neurocrine of an IND application to be filed with the U.S. Food and Drug Administration (the “FDA”) by Neurocrine for the first development candidate in such Discovery Program. For the FA Program, the Company was granted the option (the “FA Co-Co Option”) to co-develop and co-commercialize the FA Program upon the occurrence of a specified event (a “FA Co-Co Trigger Event”). The Company agreed, upon its exercise of the FA Co-Co Option, to enter into a cost- and profit-sharing arrangement with Neurocrine (the “FA Co-Co Agreement”), and (i) jointly develop and commercialize the Collaboration Products for the FA Program (“FA Collaboration Products”), (ii) share in its costs, profits and losses, and (iii) forfeit certain milestones and royalties on net sales in the United States during the effective period of the FA Co-Co Agreement. The FA Co-Co Trigger Event is the receipt of topline data for the initial Phase 1 clinical trial for an FA Program product candidate. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Neurocrine Collaboration Agreement, subject to exceptions specified therein, the Company and Neurocrine agreed that profits and losses under the Company’s FA Co-Co Option would be allocated 60% to Neurocrine and 40% to the Company for any FA Collaboration Product. The parties agreed that FA Co-Co Agreement would provide the Company the right to terminate for any reason upon prior written notice to Neurocrine and Neurocrine the right to terminate in certain circumstances upon change of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s research and development activities under the Neurocrine Collaboration Agreement are conducted pursuant to plans agreed to by the parties, on a program-by-program basis, and overseen by the JSC, as detailed in the Neurocrine Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Under the Neurocrine Collaboration Agreement, the parties committed to agree on a list of up to eight target genes (the “Targets”) from which Neurocrine had the right to nominate Targets for the two Discovery Programs. The Company and Neurocrine completed the nomination process, and the JSC has approved the two Targets for development under the Discovery Programs. The two Targets are currently under development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Neurocrine Collaboration Agreement provides for an upfront non-refundable payment of $115.0 million, as well as for aggregate development and regulatory milestone payments from Neurocrine to the Company for Collaboration Products under (i) the VY-AADC Program of up to $170.0 million, which the Company is no longer eligible to receive in light of the partial termination of the Neurocrine Collaboration Agreement; (ii) the FA Program of up to $195.0 million, and (iii) each of the two Discovery Programs of up to $130.0 million per Discovery Program. The Company may be entitled to receive aggregate commercial milestone payments for each Collaboration Product of up to $275.0 million, subject to an aggregate cap on commercial milestone payments across all Neurocrine Programs of $1.1 billion. Furthermore, in connection with the Neurocrine Collaboration Agreement, Neurocrine purchased 4,179,728 shares of the Company’s common stock at a price of $11.9625 per share, for an aggregate purchase price of $50.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Neurocrine also agreed to pay the Company royalties, based on future net sales of the Collaboration Products. Such royalty percentages, for net sales in and outside the United States, as applicable, range (i) for the VY-AADC Program, from the mid-teens to low thirties and the low-teens to low twenties, respectively; (ii) for the FA Program, from the low-teens to high-teens and high-single digits to mid-teens, respectively; and (iii) for each Discovery Program, from the high-single digits to mid-teens and mid-single digits to low-teens, respectively. On a country-by-country and program-by-program basis, royalty payments would commence on the first commercial sale of a Collaboration Product and terminate on the later of (a) the expiration of the last patent covering the Collaboration Product or its method of use in such country, (b) ten years from the first commercial sale of the Collaboration Product in such country and (c) the expiration of regulatory exclusivity in such country (the “Royalty Term”). Royalty payments may be reduced by up to 50% in specified circumstances, including expiration of patents rights related to a Collaboration Product, approval of biosimilar products in a given country or required payment of licensing fees to third parties related to the development and commercialization of any Collaboration Product. As a result of Neurocrine’s termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program, the Company is no longer entitled to receive royalties related to the VY-AADC Program. Additionally, the licenses granted to Neurocrine shall automatically convert to fully paid-up, non-royalty bearing, perpetual, irrevocable, exclusive licenses on a country-by-country and product-by-product basis upon the expiration of the Royalty Term applicable to such Collaboration Product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Under the terms of the Neurocrine Collaboration Agreement and subject to specified exceptions therein, each party owns the entire right, title and interest in and to all intellectual property rights made solely by its employees or agents in the course of the collaboration. The parties jointly own all rights, title and interest in and to all intellectual property rights made or invented jointly by employees or agents of both parties<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the term of the Neurocrine Collaboration Agreement, neither party nor any of its respective affiliates is permitted to directly or indirectly exploit any AAV-based gene therapy products directed to a Target to which a Collaboration Product is directed, subject to specified exceptions, including the parties’ conduct of basic research activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Unless earlier terminated, the Neurocrine Collaboration Agreement expires on the later of (i) the expiration of the last to expire royalty term with respect to a Collaboration Product in all countries in the relevant territory or (ii) the expiration or termination of any FA Co-Co Agreement. Neurocrine may terminate the Neurocrine Collaboration Agreement in its entirety or on a program-by-program or country-by-country basis by providing at least (x) 180-day advance notice if such notice is provided prior to the first commercial sale of the Collaboration Product to which the termination applies or (y) one-year advance notice if such notice is provided after the first commercial sale of the Collaboration Product to which the termination applies. The Company may terminate the Neurocrine Collaboration Agreement, subject to specified conditions, if Neurocrine challenges the validity or enforceability of certain of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Company’s intellectual property rights. Subject to a cure period, either party may terminate the Neurocrine Collaboration Agreement in the event of a material breach by the other party in whole or in part, subject to specified conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Upon termination in certain cases, Neurocrine has agreed to grant to the Company licenses to certain Neurocrine intellectual property, subject to a negotiation between the parties to establish royalty rates for use of such intellectual property. In the event of a breach by the Company with respect to a Neurocrine Program, if such termination were to occur after a Transition Event, then (i) with respect to the FA Program, if an FA Co-Co Agreement is in effect, Neurocrine can terminate the FA Co-Co Agreement for such program and the Company would no longer have co-development and co-commercialization rights with respect to the FA Collaboration Products and (ii) subject to any license agreements, Neurocrine would no longer have any obligations with respect to any Collaboration Products resulting from such program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Termination of VY-AADC Program</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As described above, as of the Neurocrine VY-AADC Program Termination Effective Date, the license granted by the Company to Neurocrine thereunder regarding the VY-AADC Program expired, the Company regained worldwide intellectual property rights regarding the VY-AADC Program, and the restrictions on the Company to develop, manufacture or commercialize a gene therapy product directed to the target of the VY-AADC Program terminated, in each case in accordance with the terms of the Neurocrine Collaboration Agreement. As of the Neurocrine VY-AADC Program Termination Effective Date, <span style="background:#ffffff;">Neurocrine no longer is obligated to reimburse the Company for research and development activities related to the VY-AADC Program, and the Company is no longer entitled to receive future milestone or royalty payments related to the VY-AADC Program. </span>The Company is supporting Neurocrine, the study sponsor and IND holder, on ongoing matters related to the completion of imaging and clinical assessments requested by the Data Safety and Monitoring Board (the “DSMB”), and the provision of other information requested by the FDA for the RESTORE-1 Phase 2 clinical trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounting Analysis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">At inception, the Neurocrine Collaboration Agreement included the following performance obligations: (i) research and development services for each Legacy Program combined with a development and commercialization license for each such program and (ii) research and development services for each Discovery Program combined with a development and commercialization license for each program. The research services and license on a program-by-program basis are not distinct as Neurocrine cannot benefit from such license on its own or from other resources commonly available in the industry, without the corresponding research services due to the unique and specialized expertise of the Company that is not readily available in the marketplace. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company identified $92.4 million of fixed transaction price consisting of the $115.0 million upfront fee and $5.0 million payment from the June 2019 Modification, offset by a discount of $27.6 million related to the $50.0 million equity investment of 4,179,728 shares when measured at fair value on the date of issuance. The Company is also entitled to reimbursement of costs incurred by the Company prior to the Transition Events associated with each Neurocrine Program. These amounts are determinable based on program plans and budgets, and the Company has a contractual right to the payment of cost incurred under the agreed upon program plans. The Company utilized the most likely amount approach and estimated the expected cost reimbursement to be $431.1 million at inception. The Company concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Company considers this estimate at each reporting date and updates the estimate based on information available. During the fourth quarter of 2021, the Company further revised the estimate of the expected reimbursement to approximately $80.0 million based on expectations resulting from decisions made at the JSC meeting in the fourth quarter of 2021, which are expected to result in significantly less research and development services being provided by the Company under the Neurocrine Collaboration Agreement. As of September 30, 2022, the estimate of the expected reimbursement is $79.4 million based on expectations as of such date. Additional consideration to be paid to the Company upon reaching certain milestones are excluded from the transaction price at inception due to the uncertainty of achieving the development and regulatory milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company allocated the fixed transaction price to the separate performance obligations based on the relative standalone selling price<span style="background:#ffffff;"> of each performance obligation or in the case of certain variable consideration to one or more performance obligations. The estimated standalone selling prices for performance obligations, which include a license </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">and research services, were developed using the estimated selling price of the license, using comparable and market data, and an estimate of the overall effort to perform the research services along with a reasonable profit for research services. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company concluded that the variable consideration related to the cost reimbursement of each program will be allocated to each respective program as the cost reimbursement relates specifically to the respective program services being performed under the Neurocrine Collaboration Agreement. The reimbursement of research services is considered to be at a market rate and the allocation of the fixed consideration to all of the performance obligations depicts the estimated amounts in which it would expect to receive for these obligations, absent the variable consideration related to the research reimbursement. The <span style="background:#ffffff;">total variable consideration allocated to each program related to the expected cost reimbursement was as follows as of September 30, 2022</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:32.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:32.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable Consideration</p></td><td style="vertical-align:bottom;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:32.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">VY-AADC Program</p></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">FA Program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Discovery Program 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Discovery Program 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Based on the relative standalone selling price allocation, the allocation of the transaction price, exclusive of the variable consideration allocated to the individual performance obligations, to the separate performance obligations was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:32.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:32.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed Consideration</p></td><td style="vertical-align:bottom;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:32.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">VY-AADC Program</p></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">FA Program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Discovery Program 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Discovery Program 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 92,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the transaction price associated with each performance obligation on a proportional performance basis over the period of service using input-based measurements such as costs incurred to date, to estimate proportion performed, and remeasures its progress towards completion at the end of each reporting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined the partial termination of the Neurocrine Collaboration Agreement with respect to the VY-AADC Program represented a modification of the arrangement under ASC 606 and that the remaining fixed transaction price at the Neurocrine VY-AADC Program Termination Effective Date of $42.2 million should be re-allocated to the FA Program and Discovery Program 1 and 2 based on their standalone selling prices. Accordingly, the Company recorded a cumulative adjustment to revenue of approximately $0.9 million on the partially satisfied remaining performance obligations, as the remaining services to be performed under each of the performance obligations are not distinct from the services prior to the modification. The Company determined that reasonable changes to the Company’s estimates of standalone selling prices for the FA Program, Discovery Program 1 and Discovery Program 2 performance obligations did not have a material impact on the re-allocation or the amount of revenue recorded pursuant to the cumulative catch-up adjustment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three and nine months ended September 30, 2022, the Company recognized $1.1 million and $2.5 million, respectively, of revenue associated with its collaboration with Neurocrine related to research and development services performed during the period and the corresponding cost reimbursement receivable. During the three and nine months ended September 30, 2021, the Company recognized $1.5 million and $9.3 million of revenue, respectively, associated with its collaboration with Neurocrine related to research and development services performed during the period and the corresponding cost reimbursement receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The following table presents changes in the balances of the Company’s related party collaboration receivables and contract liabilities during the nine months ended September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Related party collaboration receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,096</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,075)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,021</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The change in the receivable balance for the nine months ended September 30, 2022 is primarily driven by amounts owed to the Company for research and development services provided, offset by amounts collected from Neurocrine during the period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs incurred relating to the Company’s collaboration programs under the Neurocrine Collaboration Agreement consist of internal and external research and development costs, which primarily include: salaries and benefits, laboratory supplies, preclinical research studies, clinical studies, consulting services, and commercial development. These costs are included in research and development expenses in the Company’s condensed consolidated statements of operations during the three and nine months ended September 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company incurred approximately $0.8 million of costs to obtain the Neurocrine Collaboration Agreement which were payable only upon the close of the deal and therefore considered incremental costs of obtaining a contract with a customer and capitalized. The costs are recorded in prepaid expenses and other non-current assets and are being amortized over the period in which the research services will be provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pfizer Option and License Agreement</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Summary of Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On October 1, 2021, the Company entered into an option and license agreement with Pfizer (the “Pfizer Agreement”), pursuant to which the Company has granted Pfizer options to receive an exclusive license (the “Pfizer License Options”) to certain TRACER capsids to develop and commercialize certain AAV gene therapy candidates comprised of a capsid and specified Pfizer transgenes (the “Pfizer Transgenes”). Under the terms of the Pfizer Agreement, during an initial research term that ended as of October 1, 2022 (the “Pfizer Research Term”) Pfizer had the right to evaluate the potential use of the capsids in combination with up to two Pfizer Transgenes to help treat respective central nervous system (“CNS”) and cardiovascular diseases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the Pfizer Research Term, the Company agreed to provide Pfizer with certain quantities of materials encoding specified existing capsids for Pfizer’s evaluation. Further, during the Pfizer Research Term the Company agreed to disclose to Pfizer, on a rolling basis, the performance characteristics identified during the Pfizer Research Term for all such capsid candidates. Pfizer had the right, in its sole discretion, to select any capsid candidate for evaluation to determine its interest in exercising a Pfizer License Option with respect to such capsid candidate. Pfizer had the right to exercise up to two Pfizer License Options, provided that it could exercise only one Pfizer License Option for each Pfizer Transgene. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Effective as of September 30, 2022, Pfizer exercised its Pfizer License Option with respect to a capsid for the specified Pfizer Transgene for potential treatment of a rare neurological disease. Pfizer did not exercise its option to license a capsid for the potential treatment of a cardiovascular disease. As result, Pfizer’s right to exercise a Pfizer License Option for a cardiovascular disease has terminated in accordance with the terms of the Pfizer Agreement and all rights to capsids for that cardiovascular disease have reverted to the Company. Pfizer’s exercise of a Pfizer License Option extends the Pfizer Research Term to October 1, 2024, during which period the Company may, at its sole discretion and expense, conduct additional research activities to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of the rare neurological disease associated with the exercise of the applicable Pfizer License Option. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the exercise of the Pfizer License Option, the Company granted Pfizer an exclusive, worldwide license, with the right to sublicense, under certain of the Company’s intellectual property, the rights to develop and commercialize rare neurological disease products utilizing the capsid candidate and incorporating the corresponding Pfizer Transgene (the “Pfizer Licensed CNS Products”). Until October 1, 2024, while the Company is not obligated to conduct additional research activities to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of rare neurological diseases, it has agreed to continue to disclose to Pfizer, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available. Pfizer may, during the Pfizer Research Term, conduct additional evaluations of such capsid candidates and has the right to substitute any other capsid candidate for the capsid it previously elected to license when it exercised the Pfizer License Option. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the Pfizer Agreement, Pfizer is solely responsible for, and has sole decision-making authority with respect to, development and commercialization of the Pfizer Licensed CNS Products. Pfizer is required to use commercially reasonable efforts to develop and obtain regulatory approval for at least one Pfizer Licensed CNS Product for which Pfizer has exercised its Pfizer License Option in (i) the United States and (ii) at least one of the following countries: the United Kingdom, France, Germany, Italy, Spain and Japan (each of which is referred to as a “Pfizer Major Market Country”), subject to certain limitations. Pfizer is also required to use commercially reasonable efforts to commercialize each Pfizer Licensed CNS Product in the United States and at least one Pfizer Major Market Country where Pfizer or its designated affiliates or sublicensees has received regulatory approval for such Pfizer Licensed CNS Product, subject to certain limitations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Pfizer Agreement, Pfizer paid the Company an upfront payment of $30.0 million in October 2021. Following the exercise of the Pfizer License Option, Pfizer is obligated to pay the Company a fee of $10.0 million and the Company is also eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $115.0 million for the first corresponding Pfizer Licensed CNS Product to achieve the corresponding milestone. On a Pfizer Licensed CNS Product-by-Pfizer Licensed CNS Product basis, the Company is also eligible to receive (a) specified sales milestone payments of up to an aggregate of $175.0 million per Pfizer Licensed CNS Product and (b) tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Pfizer Licensed CNS Product. The royalties are subject to potential reductions in customary circumstances including patent claim expiration, payments for certain third-party licenses, and biosimilar market penetration, subject to specified limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Pfizer Agreement, each the Company and Pfizer owns the entire right, title, and interest in and to all patents or know-how controlled by such party and existing as of or before the effective date of the Pfizer Agreement, or invented, developed, created, generated or acquired solely by or on behalf of such party after such effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Subject to certain specified exceptions, any patents and know-how that are invented or otherwise developed jointly by or on behalf of the parties during the term of the Pfizer Agreement and in the course of the Company’s and Pfizer’s activities under the Pfizer Agreement will follow inventorship under U.S. patent law. Subject to certain limitations and exceptions, the Company agreed (i) during the Pfizer Research Term, not to conduct any internal program or program on behalf of a third party that is directed to development or commercialization of any capsid candidates, or grant any third party or affiliate any right or license under the Company’s rights in such capsid candidates to exploit any therapeutic product, in combination with any Pfizer Transgene in any indication for therapeutic, diagnostic and prophylactic human and veterinary use; and (ii) after Pfizer’s exercise of a Pfizer License Option, not to grant any third party or affiliate any right or license under the Company’s patents to exploit any licensed capsid in combination with any Pfizer Transgene.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Unless earlier terminated, the Pfizer Agreement expires on the expiration of the last-to-expire royalty term with respect to all Pfizer Licensed CNS Products in all countries. Subject to a cure period, either party may terminate the Pfizer Agreement, in whole or in part, subject to specified conditions, in the event of the other party’s uncured material breach. Pfizer may also terminate the Pfizer Agreement, in whole or in part, subject to specified conditions, for the Company’s insolvency, the occurrence of a violation of global trade control laws, or for the Company’s noncompliance with certain anti-bribery or anti-corruption covenants. Pfizer may also terminate the Pfizer Agreement, in whole or in part, for any or no reason upon ninety days’ written notice to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Upon certain terminations for cause by Pfizer, the licenses that the Company has granted to Pfizer under the Pfizer Agreement shall become irrevocable and perpetual, and all milestone payments and royalties that would have otherwise been payable by Pfizer under such licenses had the Pfizer Agreement remained in effect would be substantially reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounting Analysis </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company assessed the promised goods and services under the Pfizer Agreement, in accordance with ASC 606, and determined that the Pfizer Agreement contains two performance obligations consisting of two material rights, one for each of the Pfizer License Options. The Company concluded that each Pfizer License Option provides a material right as consideration for each option is less than the amount that the Company would otherwise have expected to receive outside the context of the contract. The promises at inception do not include the underlying goods or services that would be delivered upon exercise of the option, but rather represent the value to the customer of having the right to exercise the Pfizer License Option at the specified exercise fee. Upon the exercise of a Pfizer License Option, until October 1, 2024, while the Company is not obligated to conduct additional research activities upon option exercise to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of central nervous system or cardiovascular diseases, it has agreed to continue to disclose to Pfizer, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available. Pfizer may, conduct additional evaluations of such capsid candidates and has the right to substitute any other capsid candidate for the capsid it previously elected to license when it exercised the Pfizer License Option. The Company determined that this promise to provide Pfizer the ability to evaluate and potentially substitute other capsid candidates for the capsid it previously elected to license when it exercised the Pfizer License Option, if and when available, is an additional performance obligation in the arrangement (“the Pfizer Substitution Right Performance Obligation”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company received a nonrefundable, upfront payment of $30.0 million as consideration under the Pfizer Agreement, which represents the transaction price at inception. Additional consideration to be paid to the Company upon exercise of the Pfizer License Option or upon reaching certain milestones are excluded from the transaction price as they relate to option fees and milestones that could only be achieved subsequent to an option exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company allocated the transaction price to the two material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be willing to pay an equal amount for each Pfizer License Option on a standalone basis. The Company reached this conclusion after considering (i) the downstream economics including option fees, milestones and royalties related to each Pfizer License Option being identical and (ii) comparable market data. The Company determined the standalone selling price for the Pfizer Substitution Right Performance Obligation was insignificant to the allocation of the transaction price using the relative standalone selling price model and, accordingly, did not allocate any transaction price to the Pfizer Substitution Right Performance Obligation. This determination was supported by qualitative and quantitative assessments of the standalone selling price that considered the cost of identifying other potential capsid candidates and the likelihood of license substitution. As such, based on the relative standalone selling price for each of the two material rights, the allocation of the transaction price to the separate performance obligations is $15.0 million for each material right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The amount allocated to each material right was initially recorded as deferred revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the three and nine months ended September 30, 2022, the Company recognized $40.0 million in collaboration revenue related to the Pfizer Agreement. Of this $40.0 million, $25.0 million is attributable to the exercise of the first material right for the Pfizer License Option for a rare neurological disease and includes the option exercise fee of $10.0 million. The remaining $15.0<span style="white-space:pre-wrap;"> million is attributable to the expiration of the second material right associated with the Pfizer License Option for a cardiovascular disease. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Novartis Option and License Agreement </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Summary of Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On March 4, 2022 (the “Novartis Effective Date”), the Company entered into an option and license agreement with Novartis (the “Novartis Agreement”). Pursuant to the Novartis Agreement, the Company has granted Novartis options (the “Novartis License Options”) to license TRACER capsids (“Novartis Licensed Capsids”) for exclusive use with certain targets to develop and commercialize adeno-associated virus gene therapy candidates comprised of Novartis Licensed Capsids and payloads directed to such targets (the “Novartis Payloads”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the period commencing on the Novartis Effective Date and ending on the first anniversary thereof or, in the event Novartis exercises a Novartis License Option, the third anniversary thereof (the “Novartis Research Term”), the Company has granted Novartis a non-exclusive research license to evaluate the Company’s TRACER capsids for potential use, in combination with Novartis Payloads, in programs targeting three specified genes (the “Initial Novartis Targets”). Upon the payment of additional fees, Novartis may also assess the Company’s TRACER capsids for use with two other targets (the “Additional Novartis Targets”), subject to certain conditions including that such target is not part of, or reasonably competitive with, the Company’s current development programs (the Initial Novartis Targets and the Additional Novartis Targets collectively, the “Novartis Targets”). During the Novartis Research Term, the Company may, at its sole discretion and expense, conduct further research activities to identify additional TRACER capsids. If the Company elects to do so, the Company has agreed to disclose performance characteristics of such new TRACER capsids to Novartis on a rolling basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the Novartis Research Term, Novartis may exercise up to three Novartis License Options—or up to five Novartis License Options if Novartis is evaluating the Additional Novartis Targets—in the aggregate, provided that Novartis may only exercise one Novartis License Option for each Novartis Target. Upon the exercise of any Novartis License Option, the Company has agreed to grant Novartis a target-exclusive, worldwide license, with the right to sublicense, under certain of the Company’s intellectual property, the rights to develop and commercialize the applicable Novartis Licensed Capsid as incorporated into products containing the corresponding Novartis Payload (the “Novartis Licensed Products”). Upon the exercise of a Novartis License Option, the Company has agreed to provide certain additional know-how to enable Novartis to exploit the Novartis Licensed Capsid and the corresponding Novartis Payload for use in a Novartis Licensed Product. Novartis may, during the Novartis Research Term but following the exercise of a Novartis License Option, conduct additional evaluation of the Company’s capsid candidates and has the right to substitute any other TRACER capsid for a Novartis Licensed Capsid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Subject to the Company’s disclosure obligations described above, the Company and Novartis have agreed to conduct their respective research and evaluation activities independently, with communications being managed by two alliance managers comprised of a designee from each of the Company and Novartis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the Novartis Agreement, Novartis is solely responsible for, and has sole decision-making authority with respect to, development and commercialization of the Novartis Licensed Products. In the event Novartis exercises a Novartis License Option, Novartis is required to use commercially reasonable efforts to develop and obtain regulatory approval for at least one Novartis Licensed Product for each Novartis Target for which it has exercised a Novartis License Option in (i) the United States and (ii) at least three of the following countries: the United Kingdom, France, Germany, Italy, Spain and Japan (each of which, a “Novartis Major Market Country”), subject to certain limitations. Novartis is also required to use commercially reasonable efforts to commercialize each Novartis Licensed Product in the United States and at least three Novartis Major Market Countries where Novartis or its designated affiliates or sublicensees has received regulatory approval for such Novartis Licensed Product, subject to certain limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the Novartis Research Term, the Company has agreed to provide plasmids to Novartis for the production of TRACER capsids for evaluation upon request. The Company has also granted Novartis a non-exclusive license, effective upon an exercise of a Novartis License Option and in addition to its options for target-exclusive licenses under certain of the Company’s intellectual property described above, on a Novartis Licensed Capsid-by-Novartis Licensed Capsid basis, under certain of the Company’s know-how to exploit the applicable Novartis Licensed Capsid as incorporated into Novartis Licensed Products containing the corresponding Novartis Payload.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Novartis Agreement, Novartis paid the Company an upfront payment of $54.0 million. Novartis has also agreed to pay the Company a fee of $18.0 million per Additional Novartis Target it elects to add to the collaboration and, upon each exercise of a Novartis License Option, an option exercise fee of $12.5 million. Following each exercise of a Novartis License Option, the Company is also eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $125.0 million for the first corresponding Novartis Licensed Product to achieve the corresponding milestone. On a Novartis Licensed Product-by-Novartis Licensed Product basis, the Company is also eligible to receive (a) specified sales milestone payments of up to an aggregate of $175.0 million per Novartis Licensed Product and (b) tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Novartis Licensed Product. The royalties are subject to potential reductions in customary circumstances including patent claim expiration, payments for certain third-party licenses, and biosimilar market penetration, subject to specified limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the Novartis Agreement, each party owns the entire right, title, and interest in and to all patents or know-how controlled by such party and existing as of or before the Novartis Effective Date, or invented, developed, created, generated or acquired solely by or on behalf of such party after the Novartis Effective Date. Subject to certain specified exceptions, any patents and know-how that are invented or otherwise developed jointly by or on behalf of the parties during the term of the Novartis Agreement and in the course of the parties’ activities under the Novartis Agreement will follow inventorship under U.S. patent law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Subject to certain limitations and exceptions, the Company has agreed (i) during the Novartis Research Term, not to conduct any internal program or program on behalf of a third party that is directed to the development or commercialization of any Company’s capsids, or grant any third party or affiliate any right or license under the Company’s rights in such capsids, to exploit any therapeutic product containing a capsid in combination with a payload designed to have therapeutic effect on any of the Novartis Targets; and (ii) after Novartis’s exercise of any Novartis License Option, not to grant any third party or affiliate any right or license under the Company’s patents to exploit any Novartis Licensed Capsid for the applicable Novartis Target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Unless earlier terminated, the Novartis Agreement expires on the earlier to occur of (i) the first anniversary of the Novartis Effective Date , if no Novartis License Option is exercised, and (ii) the expiration of the last-to-expire royalty term with respect to all Novartis Licensed Products in all countries if at least one Novartis License Option is exercised. Subject to a cure period, either party may terminate the Novartis Agreement, in whole or in part, subject to specified conditions, in the event of the other party’s uncured material breach. Novartis may also terminate the Novartis Agreement, in whole or in part, subject to specified conditions, for the Company’s insolvency, the occurrence of a violation of global trade control laws, or for the Company’s non-compliance with certain anti-bribery or anti-corruption covenants. Novartis may terminate the Novartis Agreement, in whole or in part, for any or no reason upon ninety days’ written notice to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Upon certain terminations for cause by Novartis, the licenses granted by the Company to Novartis under the Novartis Agreement shall become irrevocable and perpetual, and all milestone payments and royalties that would have otherwise been payable by Novartis under such licenses had the Novartis Agreement remained in effect would be substantially reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounting Analysis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company assessed the promised goods and services under the Novartis Agreement, in accordance with ASC 606, and determined that the Novartis Agreement contains three performance obligations consisting of three material rights, one for each of the Novartis License Options. The Company concluded that each Novartis License Option provides a material right as consideration for each option is less than the amount that the Company would otherwise have expected to receive outside the context of the contract. The promises at inception do not include the underlying goods or services that would be delivered upon exercise of the option, but rather represent the value to the customer of having the right to exercise the Novartis License Option at the specified exercise fee. Upon the exercise of a Novartis License Option, until March 4, 2025, while the Company is not obligated to conduct additional research activities upon any option exercise to identify additional proprietary capsids that may be useful for AAV gene therapies for the treatment of central nervous system or cardiovascular diseases, it has agreed to continue to disclose to Novartis, on a rolling basis, the performance characteristics identified for all such capsid candidates, if and when available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Novartis may conduct additional evaluation of such capsid candidates and has the right to substitute any other capsid candidate for the Novartis Licensed Capsid it previously elected to license when it exercised the Novartis License Option. The Company determined that this promise to provide Novartis the ability to evaluate and potentially substitute other capsid candidates for the Novartis Licensed Capsid it previously elected to license when it exercised the Novartis License Option, if and when available, is an additional performance obligation in the arrangement (the “Novartis Substitution Right Performance Obligation”). The Company concluded the options for Additional Novartis Targets are not material rights as the price reflects the standalone selling price of the options. The Company will therefore account for the options for Additional Novartis Targets separately, if exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company received a nonrefundable, upfront payment of $54.0 million as consideration under the Novartis Agreement, which represents the transaction price at inception. Additional consideration to be paid to the Company upon exercise of the Novartis License Options or upon reaching certain milestones are excluded from the transaction price as they relate to option fees and milestones that could only be achieved subsequent to an option exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company allocated the transaction price to the three material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be willing to pay an equal amount for each Novartis License Option on a standalone basis. The Company reached this conclusion after considering (i) the downstream economics including option fees, milestones and royalties related to each Novartis License Option being identical and (ii) comparable market data. The Company determined the standalone selling price for the Novartis Substitution Right Performance Obligation was insignificant to the allocation of the transaction price using the relative standalone selling price model and did not allocate any transaction price to the Novartis Substitution Right Performance Obligation, accordingly. This determination was supported by qualitative and quantitative assessments of the standalone selling price that considered the cost of identifying other potential capsid candidates and the likelihood of license substitution. As such, based on the relative standalone selling price for each of the three material rights, the allocation of the transaction price to the separate performance obligations is $18.0 million for each material right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The amount allocated to each material right was recorded as deferred revenue and will be recognized either upon exercise of the Novartis License Option or upon expiration of the Novartis License Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the three and nine months ended September 30, 2022, the Company did not recognize any revenue related to the Novartis Agreement. As of September 30, 2022, the entire transaction price of $54.0 million is recorded as deferred revenue, current in the accompanying consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">License Agreement with Touchlight IP Limited</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>On November 3, 2022, the Company and Touchlight IP Limited (“Touchlight”) entered into a license agreement (the “Touchlight License Agreement”) to authorize historical use by the Company of a certain DNA preparation process (“Subject DNA Preparation Process”), and to authorize the prospective exploitation of TRACER Capsids created with the use of the Subject DNA Preparation Process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The terms of the Touchlight License Agreement include a one-time, non-refundable technology access fee of $5.0 million, payable to Touchlight during the fourth quarter of 2022. As of September 30, 2022, the Company determined that this technology access fee was a probable liability that could be reasonably estimated in accordance with ASC 450 <i style="font-style:italic;">Contingencies</i> as of such date. The Company recorded the $5.0 million charge during the third quarter of 2022, accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>The terms of the Touchlight License Agreement also include future milestone payments and low single-digit royalties payable to Touchlight if the Company or its program collaborators or licensees choose to utilize in a therapeutic product TRACER Capsids that were created with the historical use of the Subject DNA Preparation Process. Additionally, the Company is obligated to pay low single-digit royalties to Touchlight on future payments the Company receives in connection with licensing of TRACER capsids that were created with the historical use of the Subject DNA Preparation Process, excluding the licensing of or collaboration on any Company therapeutic programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2016, the Company entered into a research and development funding arrangement with a non-profit organization that provides up to $4.0 million in funding to the Company upon the achievement of clinical and development milestones. The agreement provides that the Company repay amounts received under certain circumstances including termination of the agreement, and to pay an amount up to 2.6 times the funding received upon successful development and commercialization of any products developed. During the year ended December 31, 2017, the Company earned a milestone payment of $1.0 million. The Company has evaluated the arrangement and has concluded that it represents a research and development financing arrangement as it is probable that the Company will repay amounts received under the arrangement. As a result, the $1.0 million earned to date is recorded as a non-current liability in the condensed consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company was not a party to any material legal matters or claims as of September 30, 2022 or December 31, 2021. The Company did not have contingency reserves established for any litigation liabilities as of September 30, 2022 or December 31, 2021.</p> 4 2 5000000.0 0.60 0.40 8 2 2 2 115000000.0 170000000.0 195000000.0 2 130000000.0 275000000.0 1100000000 4179728 11.9625 50000000.0 P10Y 0.50 P180D P1Y 92400000 115000000.0 5000000.0 27600000 50000000.0 4179728 431100000 80000000.0 79400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:32.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:32.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable Consideration</p></td><td style="vertical-align:bottom;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:32.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">VY-AADC Program</p></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">FA Program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Discovery Program 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Discovery Program 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 53863000 16938000 5236000 3372000 79409000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Performance Obligation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:32.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:32.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed Consideration</p></td><td style="vertical-align:bottom;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:32.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">VY-AADC Program</p></td><td style="vertical-align:bottom;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">FA Program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Discovery Program 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Discovery Program 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 92,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 49045000 20647000 14443000 8247000 92382000 42200000 900000 1100000 2500000 1500000 9300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Related party collaboration receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,096</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,075)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,021</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 732000 583000 1090000 225000 12096000 2075000 10021000 800000 2 2 1 1 1 1 30000000.0 10000000.0 115000000.0 175000000.0 P90D 2 2 1 30000000.0 2 2 15000000.0 40000000.0 40000000.0 40000000.0 40000000.0 25000000.0 25000000.0 10000000.0 10000000.0 15000000.0 15000000.0 3 2 3 5 1 2 1 3 3 54000000.0 18000000.0 12500000 125000000.0 175000000.0 0 1 P90D 3 3 1 54000000.0 3 3 18000000.0 54000000.0 5000000.0 5000000.0 4000000.0 2.6 1000000.0 1000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">9. Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Founder Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">In January 2014, the Company issued </span><span style="font-size:10pt;">1,188,233</span><span style="font-size:10pt;"> shares of restricted stock to its founders (each, a “Founder”) at an original issuance price of </span><span style="font-size:10pt;">$0.0425</span><span style="font-size:10pt;"> per share. Of the total restricted shares awarded to the Founders, </span><span style="font-size:10pt;">835,292</span><span style="font-size:10pt;"> shares generally vest over </span><span style="-sec-ix-hidden:Hidden_p1cIZyZWsUqbTrCBVf5Y8g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">four years</span><span style="font-size:10pt;">, based on each Founder’s continued service to the Company in varying capacities as a Scientific Advisory Board member, consultant, director, officer or employee, as set forth in each grantee’s individual restricted stock purchase agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;background:#ffffff;margin:0pt;">The remaining 352,941 of the shares issued were subject to vesting upon the achievement of certain performance objectives as well as continued service to the Company, as set forth in the agreements. These performance conditions were tied to certain milestone events specific to the Company’s corporate goals, including but not limited to preclinical and clinical development milestones related to the Company’s product candidates. Stock-based compensation expense associated with these performance-based awards is recognized when the achievement of the performance condition is considered probable, using management’s best estimates. Management concluded that the achievement of the performance milestone associated with the performance-based award for one Founder had been met during 2016.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">In December 2019, the Company modified one of the remaining Founder performance awards, repurchasing </span><span style="font-size:10pt;">58,823</span><span style="font-size:10pt;"> shares of common stock previously issued to this Founder. Additionally, the Company modified the award to vest solely based on time rather than on performance. The Company revalued the award at the modification date and is recognizing expense on a straight-line basis over the </span><span style="font-size:10pt;">three-year</span><span style="font-size:10pt;"> vesting period from the modification date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">In July 2022, the Company modified the last remaining Founder performance award, repurchasing </span><span style="font-size:10pt;">72,647</span><span style="font-size:10pt;"> shares of common stock previously issued to this Founder. Additionally, the Company modified the award to vest solely based on time rather than on performance. The Company revalued the award at the modification date and is recognizing expense on a straight-line basis over the </span><span style="font-size:10pt;">two-year</span><span style="font-size:10pt;"> vesting period. Stock-based compensation related to the modification of this award was less than </span><span style="font-size:10pt;">$0.1</span><span style="font-size:10pt;"> million for both the three and nine months ended September 30, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Awards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>During the three and nine months ended September 30, 2022, the Company issued to two executives non-statutory stock options to purchase an aggregate of 276,000 shares of the Company’s common stock outside of the Company’s 2015 Stock Option Plan as an inducement material to such executive’s acceptance of an offer of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option vests over a four-year period, with 25% of the shares underlying the option award vesting on the first anniversary of the effective date of the award and the remaining 75% of the shares underlying the award vesting in 36 equal monthly installments following the first anniversary of the effective date of the award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations and comprehensive income (loss) is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense by type of award included within the condensed consolidated statements of operations and comprehensive income (loss) was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of the status of and changes in unvested restricted stock unit activity under the Company’s equity award plans for the nine months ended September 30, 2022 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 806,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 770,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (419,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (215,685)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units as of September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 941,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation of restricted stock units is based on the fair value of the Company’s common stock on the date of grant and is recognized over the vesting period. Restricted stock units granted by the Company typically vest in equal amounts, annually over three years. All of the restricted stock units granted in the nine months ended September 30, 2022 vest in equal amounts, annually over three years. The stock-based compensation expense related to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">restricted stock units and awards was $0.7 million and $<span style="-sec-ix-hidden:Hidden_xRfp_jLVfUeudXYorI3q_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4</span></span> million for the three and nine months ended September 30, 2022, respectively. The stock-based compensation expense related to restricted stock units and awards was $0.7 million and $3.0 million for the three and nine months ended September 30, 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $3.3 million, which is expected to be recognized over the remaining average vesting period of 1.9 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity for the nine months ended September 30, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(in years)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,013,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,504,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (79,837)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled or forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,358,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,079,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,581,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2022, the Company had unrecognized stock-based compensation expense related to its unvested stock options of $13.5 million which is expected to be recognized over the remaining weighted-average vesting period of 3.1 years.</p> 1188233 0.0425 835292 P4Y 352941 58823 P3Y 72647 P2Y 100000 100000 2 2 276000 276000 P4Y P4Y 0.25 0.25 0.75 0.75 P36M P36M <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations and comprehensive income (loss) is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 588000 702000 2170000 3409000 1601000 1375000 4828000 6261000 2189000 2077000 6998000 9670000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock awards and units</p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan awards</p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 1357000 1372000 4452000 6375000 748000 651000 2382000 3018000 84000 54000 164000 277000 2189000 2077000 6998000 9670000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of the status of and changes in unvested restricted stock unit activity under the Company’s equity award plans for the nine months ended September 30, 2022 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 806,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 770,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (419,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (215,685)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units as of September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 941,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 806379 7.26 770580 3.89 419999 6.71 215685 4.96 941275 5.27 P3Y P3Y 700000 700000 3000000.0 3300000 P1Y10M24D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity for the nine months ended September 30, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(in years)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,013,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,504,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (79,837)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled or forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,358,960)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,079,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,581,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 5013193 12.69 P5Y7M6D 1165000 3504675 5.14 79837 7.56 2358960 13.22 6079071 8.20 P8Y1M6D 5693000 2581363 10.85 P6Y4M24D 1838000 13500000 P3Y1M6D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Net income (loss) per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net income (loss) per share because to include them would be anti-dilutive:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted common stock awards</p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 64,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 156,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 64,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 156,863</p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted common stock units</p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 523,627</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 947,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 941,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 947,265</p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,433,867</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,406,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,079,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,406,072</p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,022,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,510,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,084,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,510,200</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="color:#242424;background:#ffffff;">Basic net income (loss) and diluted weighted-average shares outstanding are as follows for the three and nine months ended September 30, 2022 and 2021:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands, except share data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,624</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,782)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (76,906)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator for basic net income (loss) per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares outstanding-basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,507,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,780,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,292,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,623,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator for diluted net income (loss) per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares outstanding-basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,507,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,780,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,292,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,623,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock options and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,062,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares outstanding-diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,570,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,780,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,292,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,623,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Basic net loss per share for the nine months ended September 30, 2022 and 2021, and for the three months ended September 30, 2021, is the same as diluted net loss per share as shown on the Company’s condensed consolidated statement of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net income (loss) per share because to include them would be anti-dilutive:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:30.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted common stock awards</p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 64,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 156,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 64,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 156,863</p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted common stock units</p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 523,627</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 947,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 941,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 947,265</p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,433,867</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,406,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,079,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,406,072</p></td></tr><tr><td style="vertical-align:bottom;width:33.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,022,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,510,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,084,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,510,200</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 64608 156863 64608 156863 523627 947265 941275 947265 5433867 5406072 6079071 5406072 6022102 6510200 7084954 6510200 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands, except share data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,624</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,137)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,782)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (76,906)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator for basic net income (loss) per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares outstanding-basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,507,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,780,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,292,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,623,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator for diluted net income (loss) per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares outstanding-basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,507,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,780,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,292,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,623,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock options and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,062,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares outstanding-diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,570,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,780,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,292,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,623,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 17624000 -25137000 -22782000 -76906000 38507542 37780547 38292497 37623309 38507542 37780547 38292497 37623309 1062852 39570394 37780547 38292497 37623309 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">11. Related-party transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three and nine months ended September 30, 2022, the Company received scientific advisory board and other scientific advisory services from one of its prior executives, Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Sah for services provided during the three and nine months ended September 30, 2022, was $93,600 and $185,925, respectively<span style="color:#212529;background:#ffffff;">. </span>The total amount of fees paid to Dr. Sah for services provided during the three and nine months ended September 30, 2021 was $30,000 and $120,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, the Company received advisory services related to strategic planning, operations, and management from Alfred Sandrock, M.D., Ph.D., the Company’s current President and Chief Executive Officer and a member of the Company’s Board of Directors, before he commenced service in the capacity of President and Chief Executive Officer in March 2022. The total amount of fees paid to Dr. Sandrock for services provided was $60,000 for the nine months ended September 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Neurocrine Collaboration Agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization activities for certain of the Company’s AAV gene therapy products (Note 8). Amounts due from Neurocrine are reflected as related party collaboration receivables. As of September 30, 2022, the Company had approximately $0.2 million in related party collaboration receivables associated with Neurocrine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p> 1 1 93600 185925 30000 120000 60000 200000 EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

]$]F>\T'M?/"_.VC0 M*'@P#/'P8%F:4;Z'_5[[N@QK=<-.=79=VC0-&]D\C ]W2FL0;E&PO=V]R:W-H965T)NOAL4FY^%R7RB)A]9HY V3,$H'L\O] M9[?Y[#+;EG&4\MO<*+9)$N:/-SS.'JX&YN#I@_?1:EU6'PQGEYMPQ3_P\M/F M-A?OAD?*,DIX6D19:N3\_FIP;5XP;U(5V!_Q6\0?BI/71M64NRS[7+WY97DU M&%4UXC%?E!4B%/_M^)S'<442]?B]A@Z.,:N"IZ^?Z&3?>-&8N[#@\RS^5[0L MUU>#R9 G9=P#Z/8#U3P*D+.%T+N'4!MVL!KR[@G16P MG_N6QG6!<=<(D[K 7B[#P\^Q_RW]L QGEWGV8.35T8)6O=@+8E]:_(116FGW M0YF+OT:B7#F;9TD2E4*,96&$Z=)89&D9I2N>+B)>&#\;O_)MGBUR4"=JM2Z,(%WR94MY7U_>?JD\U9>?:LH/ MQ?=]_-*MIR_]QM("_[Y-WQKVZ(UACF#;_SXPT_U]]92O;F>]B[,!ZFI93_063*#'^'SQ5$G+U&!(]]KH,/05C3)N\VR5 MATD+CGUUK12=V,>3T]YS[6=/SN,9M^/&=9Z'XLSK[0FOXSA; M'/0D!/91='Q%>)C\WN;1@K9D6VJ#K5-C-H ?<5X@$U/AIK16T<=:7QDP )(T@8[?!5 M,%! 13KF2&8X1U\_[,J#6O.3V@A]U0.E^5!: *41*(U":0Q%4U5YDG&Z=,EW/,XV]67&LS*#NA4U32LSJ D!I1$HC4)I M#$5392:="%-O1J=-^%CU4JU2&C>\%=-T1Z.1JH!YQ^-\?8UZ*P5J%T!I%$IC M*)JJ%&D9F-HD[^QVFR_68<$/UW])(B[\BC);?'[SM,CLC^>7F=W4;.6*S1Q/ MQ];D7$0=#_3UM>VM(F@>'TJC4!I#T505R5R^^4(R_QD5M8IFVNA0VKJ=]J,: MO0XT)0^E$2B-0FD,15/7RLK\O:7/W^]7^!@;,>W9=RZBDY'+6MLTH\?UG??4 M---4QK2W4\\Z6UK@0^,&4!J!TBB4QE T55XR$6]I4Z:SZ]4JYZNPY-6R^BC9 M)D82Q5ST2"E_FA(51ID9=_L%0#S:\:4A)DS):09T5QV:ERG/6P4)SVA'M*[A]%7R1P9CSS,V^\E@2;%H30"I5$HC:%HJLID4MQZ M(2F^5U8U(0^7NS 5TZTT*ZM9UWV6&^6I!,5Q>34:WD>YZ)VJZ3O/%U$8&T48 MMRZ=T$?N+4U].\S)R%B&C^W2A";6H30"I5$HC:%HJC1E8MW2)]8[2S.\KYR< M[KJ$9MQ?:(2Y[S%;50G-PT-I!$JC4!I#T515RCR\I<_#[^V>;5K-S^+]9$UT MB?SW;50^&E&Z$U*&, MQ=K8;BIMY)WNVM6S^W8J4)H/I050&H'2:$U3A-;(Q*)"JC*3B7E;GYB?9\7! M",KNRC!*SQ; AT_W$K6*#+KT'4KS[:9_,#G_Z@-H2 *ET2X-8*B0JG9.]O'1 MI\SGIR/4T49LE8K=9<&#/EQO"6"WVL'NM8/=; >[V\ZW2-K;,FEOZY/=W;:E MT$-Z]SU(FE_33D_=IG,90&.2FJ;8Y^YY3-I2,ZMQ%&MA3>V3H]0?5J:\;7VV MN.<-J^+-N\/*A=;?'YKGAM)\*"V T@B41J$TAJ*I^I3);]O3II'^C&WIH&O7 MH30?2@N@- *E42B-H6BJ:F4VW=9GT]4])'*^W!Y2GV(JGV>/85P^'I=[M2H2 MNO5.35.W33A?4 @-&4!I!$JC4!I#T52AR2R[K5\EWW_X_NW?/U]?^_-6V4'S M[U":#Z4%4!J!TBB4QE T59\R_VY/T2Z0#4V]0VD^E!9 :01*HU :0]'4S6)E M(M_ID\CO[@+IL7VE"*7Y3C-?[MH3[VPCU0 :E$!IM%L3&"JH*AZ9\G=>6+/_ M&A=(S^RM'&BJWVDFP)WIR''/E0/-X4-IU&G>E]#2!(8*JBI'9O&=%S:PZ3TY MTV_(J0_76U30U#Z4%D!I!$JC4!I#T52)2K/ ^>Z[_CO0^P6@-!]*"Z T J51 M*(VA:*IJ3W;_U[L1@"TZ]1%ZJ])I2;%X9RD6:,@ 2B-0&NWR=3!42%5#TOAP MX+O\.U![ TKSH;0 2B-0&H72&(JFJE#:&XY^;?^KKTRAG@64YCO-VPY,;VI/ MSJ\OH&8$E$:=YO[^+4U@J*"J>*3+X.A=AM==F4*]!2C-=YKW%U@CSQF?*P?J M+D!IM%L3&"JHJAQI&SAHVT#N.5==&,CKU%;_2A^]M\:@1@*4%D!I!$JC4!I# MT53%2B/!@1L)#M1(@-)\*"V T@B41J$TAJ*I#P:31H+[#>X(T#/[ZA!*\]UF M"MZQK,:R.&A0 J71;DU@J*"JM=7@VS55U0IP%*\Z&T $HC M4!J%TAB*IFI5^A:NA1YK7:@U :7Y4%H I1$HC4)I#$5352BM"5=_'\-K4R-Z M;&\I0OT&M[G5OVO9WOEH"_41H#3:J04,%5.5CO0'7+T_\+II&M01@-+\FJ:D MU!S'.5_L 0U*H#3:K0D,%515SLFC?]&W0S2G:5:KNK"/",8^(QC[D&#L4X*Q MCPG&/B?X6W@'KO0.7/VM$:^9ID%M RC-A]("*(U :11*8RB:JD)I0KA]3(@> MTS2H#P&E^6XSB6_;X_/=%* Q"91&.[6 H6*JTI$NA*MW(5XW38-Z"U":7].4 MO66MAGT%C4F@--JI!0P54]6-] )<_:8^KYBDG3P8J?*O+Z2WVU>DL/:BA :0&41J T"J4Q%$V1LB<-!6^DGLO/:C] *7Y4%H MI1$HC4)I#$5352O-#.][/\9 7X'>HFUYC,&TY5%1T*@!E$:@- JE,11-E:/T M*SST?19=YP,=/3A]_7JK%>I^0&D!E$:@- JE,11-U;1T/[SO?F.&!S5*H#0? M2@N@- *E42B-H6BJ:J7QXKU@O'S[B0'4I?%:3 F[Y?E&T*@!E$:@- JE,11- ME:-T=XWWVG*P]J M_T!I/I060&D$2J-0&D/15-5*^\=[<:4U39=J:](6/4+O78'2")1&H32&HAWT M."S6G)=^6(:S2S%97/$YC^/"V#^CJ0IR\JG0UWWUD.J+:VLP;'Q^8U[,S9;/ M??."M'U.S0NV_WPHP\XN-^&*OPOS59061LSO115&;\>B:\NCU?KXILPV5P-S M8-QE99DE^Y=K'BYY7AT@_GZ?9>73FRK 0Y9_WC=S]G]02P,$% @ TSAH M53UBS_?/ @ &0@ !D !X;"]W;W)K&ULK59; M;]HP%/XK5E9-G=0VCBFW#B*5LFE[J%25=7LVR0&L.G9F.]#^^QTG(64CT-U> MB.V<[W+.B6U&&VT>[0K D:=,*CL.5L[E5V%HDQ5DW%[H'!2^66B3<8=3LPQM M;H"G)2B3(:.T%V9E6MW)A[IPDFAX,X06V09-\\3D'HS#J)@NW OEBOG M%\)XE/,ES, ]Y'<&9V'#DHH,E!5:$0.+<7 =74TBZ@%EQ%;3U GU/5\B9:V_"6;.I8&)"FLTUD-1@>94-63/]6%V $P M=@# :@ K?5="I&;TAQD4[\K,&7PK$.?B&YUEPF&9 MG25H@T6EDC!YT(*5X%.I^"X MD/8=.2%"D2\K75@,MZ/0H64O'":UO4EECQVP-R2W*+&RY(-*(?T9'V*J3;YL MF^^$'26<07Y!.O2,,,H8>9A-R>G)NR.\G::.G9*W\S=U;,N[HKMLI_-[\E4 KS MP"]?IZGP;EHK5T&[.WK=0:== MK]?H]8[J32$MDH."O3W!\X@.:;MDOY'L_Y\>@$I?:4!_SQ]CW79W@\;=X)6" M+, 8M&=@#:J W_P4!GM.(D:'O78OP\;+\!^:,]QO#J/] ^E'].58I']8@-?[ M4%/N[H2(4A;]XB7<.:TS,,OR3K+X"13*50=WL]K<>]?5:?\27EV:M]Q@5RR1 ML$ HO>AC'4QU#U43I_/R[)]KAS=).5SAW0W&!^#[A=9N._$"S;^!^ =02P,$ M% @ TSAH59(]G1&)!P &ULQ9Q=;]LV&(7_"N$50P=TM25_)5EB(+5$K4"S%LVZ70R[8&S:UBJ) M*D7GH^B/'_5AR4P4QNH.EEPDELSW(>7WA*]T1.OT1LC/V89S16[C*,G.>ANE MTI-^/UML>,RRUR+EB7YG)63,E-Z4ZWZ62LZ615 <]=W!8-*/69CT9J?%O@]R M=BJV*@H3_D&2;!O'3-Z]X9&X.>LYO=V.C^%ZH_(=_=EIRM;\DJM/Z0>IM_HU M91G&/,E"D1#)5V>]<^+L]Z@WQ$/.(+ ME2.8_G/-YSR*QY<*VJO[S /W7^_HM#AX?3!7+.-S$?T9+M7FK'?4(TN^ M8MM(?10WO_+J@,8Y;R&BK/A-;JJV@QY9;#,EXBI8CR .D_(ONZT^B+T =_I( M@%L%N/<#W$<"AE7 \-" 414P.C1@7 6,#PV85 &30P.F5<"T2%;YZ1:I\9AB MLU,I;HC,6VM:_J+(;Q&M,Q(FN10OE=3OACI.S>8BCD.EM:4RPI(E68A$A@6[\*%5B(GYVO)>1ZH6[WTN&)AE/U$7I P(;]O MQ#;3;;/3OM)CS'OJ+ZKQS,OQN(^,9T@N] @V&?&3)5^VQ/OV^&-+?%]_-O4' MY.X^H#>N%?A^H5Z3@?.*N /7(9\N/?+RQ4\D5#QN.S@[ZY*GK\EP4+#<':L% MXQV.<2P8'S,:BAE-8,=<,*D_YY%M-$;^AK7 AP5W^*C HXA="WWZO-EKI:L,28@;]]4XSR5N=\NSOE@-[4PY@U#Z O):<9"E;\+.> M+A89E]>\-_OQ!VC_]#ULYHR/7;.2WH-S1>&JVH@];'0]' M]U !Z!"-/(SK/(RM>:@*U;?]4A55I8KM2E5;7JS8KGE!PCPDS$?"*!(6@&"& M:B:U:B;/71TF2'TA81X2YB-A% D+0#!#7]-:7U/KK/3;-K[2LA$KHK24,GU> MK<^JOSUV^OBFA(WW9ME[4^SJAD_I2@I]:IFRN\D4LNC50Q0ZQ%*\Z T'TJC4%I0T0R?;;P_ M29N":)Q%QVXMGJ_7DNL314[B,.*9$@G?U8KL%0E7A-]RN0CUM%&>1+0JI,4# M;"L@HX>SRL-FGGW G7-Z4*<4VFF HIDY;5Q*QVY3-E/^DMUEY$:&2O&$)$+I M?W$B^9=M*/F27-WIUZF0^;TXHO,=JCNB!-'GC'&8Y(JP6II/C.%X4'3>.@5 M#4PHS8?2*)06H&BFJAH7T[&:6(??A+!S.A>,R8-_X%';K $U&@_KE$([#5 T M,[^-B^C8;<3ZY@8-9:;(Q>[BL5@YTIIGI($VA](\*,V'TBB4%J!HIFH:Z]$Y M>NZ;&P[2JIM#:1Z4YD-I%$H+4#139XW)Z=A=SN^Y<$&:>G.GQ2L=M]0AJ,=Y M6*<4VFF HIE+H1K_TK7[EW4=NN0+H>>0IPN1'=@UT5":!Z7Y4!J%T@(4S91- M8W2ZSG,7(A?I"\ZA- ]*\Z$T"J4%*)JIL\9/=>U^ZG<4(CNQLV[<)YR@2A!0 M2_6P3BFTTP!%,S/=>*6NW2NM"Y&GKW4CD>:3QRM]X;O>1DP)>5>M98[CW"!C M4?BU5$7CHW5?)V8?46>E0+U6*,V'TBB4%J!HINX:2]8=/7LE0]J=QBVW ')#^"KWC!=L[;UUK* MI$JX;)79^&'5:"D;<_M .PL(Z@A#:11*"U T4T"-(^S:'>'F2HUIW?RWP@?U MC*$T#TKSH30*I04HFJFGQH%VI\]>^*">-93F06D^E$:AM !%,W76>-:N?;WL M_U#XCAX6OFE;X8.:T5":#Z51*"U T4P!-6:T:S>C+\*DD,TW\MW?"++WT'DB M@B[3A=)\*(U":0&*9GYKM+&ZAX/G+GA#J#<.I7E0F@^E42@M0-%,G37>^-"^ M"+A9$+00VT3)_&OW=67;-[325(IK%EF6AE8]V9:&V@?362108QM*HU!:@**9 M(FF,[>&A"X5C]H^0^K?\S!5 ,4\O)K:/K+-BH,XWE$:AM !%*Q73WWO"1\SE MNGAX2U8*H'P60KVW?D#,>?%8E'O[Y\Z)Y[3L]YT36C[^I<&73Z.Y8'(=)AF) M^$IW-7@]U6J1Y0->R@TETN+Y(E="*1$7+S><+;G,&^CW5T*HW4;>0?V8G=F_ M4$L#!!0 ( -,X:%6U(9D%MP4 ',> 9 >&PO=V]R:W-H965TT M=+:Y2J)*TG$S[,/O*"FB9,ET;-CKFT22Q>/][LCCG]1X+>0GM030Y$L2I^JJ MM]0Z>^UY*EQ"PM29R"#%7^9")DSCK5QX*I/ HKQ1$GO4]X=>PGC:FXSS9W=R M,A8K'?,4[B11JR1A\O$:8K&^Z@6]IPU:=I6+]^LOY3#H\P,Z;@1L1_\$@OKWJ7/1+!G*UB_4&L M?X$2:&#LA2)6^5^R+M_U>R1<*2V2LC%ZD/"T^,^^E(&H-: 76QK0L@'=;$"W M-.B7#?HY:.%9CO6&:3892[$FTKR-ULQ%'IN\-=+PU*3Q7DO\E6,[/;D12<(U MYD4KPM*(A"+5/%U &G)0Y'ORJWA@4G-%WF=%V/&==SS$/ *9+B2 :4I>O@'- M>*R^(R\(3\EO2[%2^*8:>QI]-#UY8>G/3>$/W>+/B-RB!TM%?DPCB)KM/62K M .D3X#5U&KQE\HSXYZ\(]2DE'^_?D)8M8ZJ\. ML.O"@?-N!TRM>*TR%L)5#XN! OD ON*!W)6"-6YU6LSEW6)Q_@ M =(58 D)Q2+E_T!$_B4ONI"==O9%+HP-P+>21CC6 ,JV ,O_8<&!XS5D/L[T":444S+LZD"0P+>2P'>B3&TZY@"$F?H3$2T,VS:NTF0].\%E&\S=\Z%D-;$3N,D6 MR+)@&HR$XLDJ04D5 XHLK!MEXI0!G>7K"V!1B0BF-4%95"\T&1;H%(?NME@$ M[5C004&@QJ@T&?&XQ6$%X1/B?P!63(<0621@NKK;BT-:9SW$U:IS>' MTEJ)%3A52:W:Q.6Z*G)%VUEJ2ENNRNGN[E ACL70G>'AP)9>1(\5Y^XYEA;G;3R<@IY$EA]$CQ7H"3L M;QQH"9.?0.-:L$JU--OC:HW .KJ*F1;RD; LDZC@XT[DMH1IE953:)C BIC MK6):F:NF6M0)-&H!M<8D) MG#WB=2:D.?L@N !R_6AT@ :9\-0LDQN]M#L:RRH6YE4Y^XF$*.ZV A83IQZ&Z< M4T@7:J4+=4L77!5$F.>CVO*QXA TDV84;]%EI=6&+NN0Y.[.#X6S0H8>ZSS' M;6C?_3MMG^@T=V)-'JM9Z'$/=?#'VV(OTLE\U/.=8UEKAL;J'/K5CWCH4<]X MCF6M&2\KH^B>,LJ]&-/=@LK=X:% 5E#1'8*JG M$"C Z^NISY$B*K(S7*?1=W^J[_HZSJO_E1*=THK&47G24?"6=":Y'DETM@$4CS OX^%T(_W9@.JN_,D_\ 4$L#!!0 ( -,X M:%52GJ4F@@( -\% 9 >&PO=V]R:W-H965TK)2N&-E0 M%Z&I-;+<@RH1QE%T$5:,RR!-_-Y ME.0VPC2I68$+I/MZKFT4]BPYKU :KB1H7(V#R?GE=.3R?<(WCANSLP;G9*G4 M@PNN\W$0.4$H,"/'P.QGC3,4PA%9&;\ZSJ"_T@%WUUOVC]Z[];)D!F=*?./@70 YKE@CZ$YM/F'GQPO,E##^%S9=;A1 UAA250>V"BHNVR][[.JP XCC M%P!Q!XB][O8BK_**$4L3K3:@7;9E@XWE,,-S^R;($P*C>B <'R%Q+@P)_^8 MOR_K"+B$6RZ$?2J3A&2M.8%AUMF8MC;B%VP,X-8*+PU\D#GFS_&A+4E?EWA; MEVE\D'"!]1D,HC<01W$,]XLK.#XZ.< [Z.L]\+R#%^LM!%LJS=R?$29:,UML M7Q57_=WX"Y6H@4HFX3GHQXWEA&O"ROS<5ZE6P'"_ -?DEZ9F&8X#V\4&]1J# M]/6K\XOH_0%[P][>\!![^EG)4]M6CZ M3WO+?N'9W3Q9IZ,D7.\1-.H%C?Y;T#XAH[\*"7>:KD)=^-%B(%.-I+;_^MU^ M>DW:IOV3WHZ^6Z8++@T(7%EH=/;6WJ[;<=(&I&K?PDM%=B#X96DG,&J78,]7 M2M$VLK_SWJV7.=$XD>P+S4TQ#%X'D.."K)BYEIOW6/LYE R0TH%VW9W,+GQJ.M&RI<%6^,LE^IQ9ET(CFGQI;%:" BATP*0\42 M1491PRE\,@4J&"T58A5T"L=3-(0R?6+7'Z4X+95<4 .VDXB@/TA5G2T CH * MF%'&[+$>A,9J=C>'6:UO7.F+#^B+8IA9286&MR+'_#%!:,TVCN.MXW'2X(HOB'3=Q)WGBI_7&9_I) M&C])>T$H0SN[;/>5Y,$W*:-D3ADU#_O\M)+]:R,F?U0Z:C)3F0EWYB5'M?3/ MB+:S;R5,-3J;T^:E&OD!'?X.KYZY&5%+*C0P7%AHMW-NLZZJIZ/:&%GZZ3N7 MQLYRORSL:XO*!=CO"RG-=N,N:-[O]!=02P,$% @ TSAH5=Z?T-LD"P M/(H !D !X;"]W;W)K&ULQ9UMC]HZ&H;_2L0> MK5JIIY W7F9GD-JQ8W>UK:IV>_;#:C]DP -10\))PDR[ZH]?)V0P#L&0F5O+ MEQ8R]O4X\0V/\6TGUX]I]CU?"E%8/U9QDM_TED6QONKW\]E2K,+\;;H6B?S+ M?9JMPD*^S1;]?)V)<%Y56L5]9S 8]E=AE/2FU]6QS]GT.MT4<92(SYF5;U:K M,/OY7L3IXTW/[CT=^!(MED5YH#^]7H<+\544W]:?,_FNOZ/,HY5(\BA-K$S< MW_3>V5?<]\L*58D_(O&8[[VVRE.Y2]/OY9L/\YO>H&R1B,6L*!&A_.]!W(HX M+DFR'7_6T-XN9EEQ__43/:A.7I[,79B+VS3^5S0OEC>]<<^:B_MP$Q=?TDL7T:Y'.OO]> M]O[ M)O/\NE_(MI3$_JR.^WX;USD2U[8^IDFQS"V:S,6\I3XUUW=/U6?F^A-#_;Z\ MAKL+Z3Q=R/>.$?CW3?S61$6\)D1_'V M^^\HD)J!7\5: @?UR7W[2JQ7O[V6"IA'#]%\$\;'P<'Y8/L)W-:;+VS?.=> MO[BIFG#+O_"7R796&R$#)1%-;=3VN_W.?P9W7XW6.8 MS:U__T,BK0^%6.7_:?LD;N-[[?'+Y'B5K\.9N.G)[)>+[$'TIG_]BST<_*U- MOT@80<(H$A8@80P)XR"8IE5OIU7/1#^:+=ZVR2Z_[ OIY9"@]%(+\0."PTGD[%>B!\6F@Q'@UTAK5O]7;?ZI[O52M=E M5[;FW0Z.:H MTP7WQBKDE^)L*:PT$:WJ,T;LK#XDC4!I%$H+H#0&I7$435>IHU3J7#A!UPU MB19)(U :A=("*(U!:1Q%TT6K3 3;..^[GZ=G4HCAHOW;$FH%0&D$2J,U;;+W MRW'PUO$;/U2A,=E9,3DJIBX4-8-OGS&%_\P<7#RFK:J"SO1#:01*HU!: *4Q M*(VC:+I*E2%A^Y?.P5!/ THC4!J%T@(HC4%I'$731:NL#=LX&WW.;V6H.0&E M$2B-GKA4[M!:5>MO6B4&M2->T!*.:HDN*.4_V&8#XLQ!'=1Z@-((E$9KFC[ M&AT,ZI QV5DQ.2JF+A3E:-AF2^-;\B"E(G.@A!=9-"NVCI44MI57X[U-N6JO M53Q08P-*(U :A=("*(U!:1Q%T\6H_ W[T@:'#74XH#0"I5$H+8#2&)3&431] M\:[R.1SSI'DGK]_,ZJH_*(U :;2F[;OT(Z^Q)"VH"VDNO6\W[/X6DN..FWY_ M"\H=V.-VP]]1QH-C-AY.C\S-@,Y="O41H#0*I050&CO1C>YQ9PO5#EU@RC-P MC-.[TR]JW+4=<"UDJI/OWEAI%BVB)(RM*,\W\L]K64Q8KZ+$FJ=Q+,^F%.5V M4?IKZ]?>0O56E4*- RB-0&D42@N@-%;3QOM?4F^;2WXY*J:N2&4(.&9#X+/( MJIUMB53;-JVMHEBJ-)4CJ_#H,B^W'#(FF]6=3-#I_=/^ ML7!3+&52_Z^4:9%:=\+*Q'J3S9:5<'^9DK=_,+8=.4.OL7CVMJ68/QX[KEZ, MF$^@L["@'@&4QJ TCJ+IPE(>@?-2C^ $P#DZ!KX]4?/XZ)F8:W86$W1O I3& MH#2.HNEB4OZ 8_8'3H_QY!?2Q_!'M-JL6J4&=0Z@- *E42@M@-(8E,91-%V2 MRHEPQI<>[4$="RB-0&D42@N@- :E<11-%ZUR+!SCY'+'R5^H^0"E$2B-UC1M ML]=@T)S\A7H*YX3DJ)#Z[1J45>":K8(@W21SD>7[9FLUZ=>F%C.KJUJ@- *E M42@M@-(8E,91-%U_RLQP[0NG6!=JAD!I!$JC4%H I3$HC:-HNFB50>(^SR"I MG)#MG,EKX^R)F=]9DU#KHZ9I&Y[M5T!T94!JI:?O#RK'K.Q.GF<"A?@N4QJ TCJ+I:E-^BVOV M6YZ3P(_LF31'ZJP[J/4"I5$H+8#2&)3&431=GW4S@T%T>4!J#TCB*IM^] M6%DWWC.MFW*=1)24ZR2Z_Q8WQ^RJ0"B-0&D42@N@- :E<11-UZFR>+Q+6SP> MU.*!T@B41J&T $IC4!I'T731*HO',UL\IY\')&\H:Z-U :.7%RQ^^(2Z'M M"* T!J5Q%$T7F')J/+-3\RE-?L^+L-@4:?:SSML=[\%OCM!9@5"O!DJC4%H MI3$HC:-HNBJ5H^.-+IVKH48/E$:@- JE!5 :@](XBJ:+5AD]GOEN7Y]V6U+% M#S';E ]_S9^6LZFO5/7TPU990JT<*(U :;2F[4_".\VGLT']F=,!.2J@+B!E MNGAFT^63>&QDX%H])J/%S.RL&*C1 J51[]"V<4;#P<'6%VA4=F94CHJJ/RE0 M62B^V4+Y(IEA-EM:83*WYN)!Q.FZ3(=MDC&CNDH&2B-0&H72 BB-06D<1=/E MIYP1_]+.B ]U1J T J51*"V TAB4QE$T7;3*&?'-YD&G_:5F5F?]04T2*(W6 MM/W-GOZX>7-!_W!OS6C0?)9@"\FQ1\W,V8)RO<'DR+-SE2_AFWT))A*1A7&5 M$,/Y*DJBO,C"VKU0PP%*(U :A=("*(U!:1Q%TP6H# ?_TH:##S4-GYT3L \BQ3R#'/H+E92REO[#0?*-]2:N@,[496[.=+(0H2%N'T>B6RA;@5<9S+GMLD17GR>T>M M3-R7=PF_>N?T^@?'W]M7Q&XY3NVKH.TXLZ]X=;ROPDZOU^%"? RS193D5BSN M91/*F_+WK"Q:+'=OBG1]TY,CO[NT*-)5]7(IPKG(R@+R[_=I6CR]*0,\IMGW MZC2G_P-02P,$% @ TSAH54JC7K&D! G!T !D !X;"]W;W)K&ULQ9EM;ZLV%,>_BL6NIGNEW8)Y"G1)I#:P[4J[4M7N M;B^FO7"#FZ "9K:3M-]^MD,)#RYK-DM]TV!SSL\^/N9?#IX?"'UD6XPY>"J+ MBBVL+>?UI6VS]1:7B%V0&E?BS@.A)>*B23.F[SS9;+#GLYK]$&WV'^K;ZAHF6W ME"PO<<5R4@&*'Q;6%;Q,82P=E,7O.3ZPSC60H=P3\B@;7[*%Y<@9X0*ON40@ M\;/'*UP4DB3F\7<#M=HQI6/W^H7^DPI>!'./&%Z1XH\\X]N%%5D@PP]H5_!; MFH6HN,@.'H'MW%PAP[^ M*PY>X^"]=02_YF)>DV^MF#M?'.;BOS,$#7TG%MPRD588SC7\R M[1]/^-MB/=I%<5\6Y=J=!-[A^@)XS@_ =5Q7,Y_5V]VA+IS_-WKZGT?O+8;7 M[A!/\;S7>%M$<;-#>EOBBE)4;;!0#0[NGT'7[@8]J^ZK Z(9^/-7@01?."[9 M7[K=<1S?UX\OE?*2U6B-%Y:00H;I'EO+[[^#H?.C+C4F88E)6&H(UDNBWR;1 MGZ*_^ICKTG$DA8HD_\_LERZ,XKF][RZSQLB9S?I&R=@HC..H;Y2.C>)PYK1& MO7"#-MS@W\,%I)8A:@5ITOW<+6<2EIB$I89@O1R$;0["=]:-T&023<(2D[#4 M$*R7Q%F;Q)DQW3B2@LZ##+U@( DKG=','>C&V,CW@X%1.C8*O5F@UXVH#3>: M#/<6,T[S-1?1,B4A2&Y$!L1[#=A5.==JR23RW&UH$I:8A*6&8+V\Q&U>XG?6 MDMAD$DW"$I.PU!"LET3HG&H-QYB:-*CN\SWS!^\.*XU1&,"!FFB,7"\:RHG& MRG-@I-<3V"FOX&3(:5D7Y!GC1D_J'5UO1?R@+E#5J(LV^DGJN?O1*"TQ2DM- MT?KY<4_Y<=]969H)F$JE25IBE)::HO53>:I3X60%=9ZZ>*.G/?*'XC*V"?RA MMHQM8.@/I65LY'9JI7ZXIXH.3I=TXET%(Z$FZN4DPWMB%$;O+2I&:UBCM,0H+35%ZZ?R5,?"R0KK/%&) M1U]&Q3S@4%4T5MWO(,TBCJW\R!U^BM58A6X(![)B=TZ;2DPWZIB/B7!V%3\> M*[2][5'BE3I &_1?P\L5U/0G\NA1G6Z=\,=SRZ^(;O**@0(_B*&&PO=V]R:W-H965TRT2%O!%, MNAD^4,?Q>8[/8_O$3YS9D;)GOB5$@),X# W2F(3699C)CA*C<4LK[MEBQG=BSA*R2T#?)\DF+TN24R/ MLK$>")J6Q[$$2I<4O?BF):!A(G'X#5!J@KL'X P.[-+ [!N@C#^/28#S4PZ0T MR$,WB]ASXGPL\&+&Z!&PK+5$RPHY^[FUY"M*LXFR$DS>C:2=6*P$73]?9E2' M8$T3.?\XSD?P$MP1+EBT%O).WDI6G?E$X"CFY[)\O_+!V;=S\ V8@&\Q(QQ$ M*;A/(\$O9*4L_[6E>X[3D,],(;N:.3379;>61;?0!]VRP0^:BBT'01J2L,?> M5]M/%?:FI*CB";WQM$1*P!79C8!M70!D(=33GYOAYK OG/_G/?C/WEMDV-6D ML7,\^P.\QLS@^LO MT+%^ZR-:)YBO$RS0!-8:DG$U)&,5^H?K>-0W'@64DT-E3Y+# D%O.C,/39Y[ M&EFNVV[DOV_D3*=>NU'POM'4<:VJ42O>217O1!GO?7J0DU &R^JY*.-.9.8J MIN0^2T1]P2MQ3YV,.L%\G6"!)K#6X#C5X#C*_+#*'P=]Y#LZR=<)YNL$"S2! MM/8=:V)9W4XUN2S MQ?&TXGBJY/BA2/6?4*S$.)5BG6#^]!W%EV,XE7\=CC4Y;7$,K5H)6$J6I?!Z M(M$ HM4XIS*M%$- GI.!U,,$?,<1 P\X MWA-P2QC(=R:]!".M#1]EUR^0G?"6GC"@EK?M$*M.E,KFJ\5+="%UAZ86I'"SR5I-L?EO(YHWP'%4@UP M\E!H%:2?!&>#5R(7;2_M7Z%14:U1D5JCGO2:N\1JOGAVQYV7TS<]C9Q)YW'F M]S1"MHOPZ4I7>SEU MI6M%\S]A .8K'4 +),5Y*1J#$+_V+GU='2L&RVR<62>$;?*/!;B1 M56WU0<)U?@S?J5_"JQO84^_#JZ#XW*"&+[Y^^(&9E)X9@^JSCL6_4$L#!!0 ( -,X M:%79,I; 3@4 $0: 9 >&PO=V]R:W-H965T]>3'OA@).@ YS93M).^^-G M P$"Q*4HZ8N&'_;CY^/']O.U&>\I^\'7A CP$H4QG_360FQN#8-[:Q)AWJ<; M$LLW2\HB+.0M6QE\PPCVDTI1:"#3=(P(!W%O.DZ>/;#IF&Y%&,3D@0&^C2+, M7N](2/>3'NP='CP&J[50#XSI>(-7Y(F(Y\T#DW=&;L4/(A+S@,: D>6D-X.W M<^2H"DF);P'9\](U4"@+2G^HFR_^I&\!4:6E-721]D]26-$&LPO@DF'P;R'IB^B2H]^-&=80//!K)T<%QTK\W('D% M_MBH6R[OK^Z)P$'(/X(/P !\C1GA((C!SSL2&D=ZH- MP\L\N4L]02<\&8&O-!9K#C[%/O$;ZL_U]2'2&#!DM^1]@PY]T%I_(I@\L M\QH@$R'P_'0/KCX.?E M\,X8P_&*R DIP.(5E,L]X-?D\6R/F7]]& #R8BNXD+$-XA7XZY&&(9 3297Y MNRG8J5^#9K_4XG3+-]@CDYYH80XUU$+-U= +0PE%&9"Y?$F"]\1M6"=$ENV.'+/" MJ/6B(Z.;,[KMYQU)EYWW3CJW!NJ8PY$YA!7.>KGJY#Q"&.4(HS9C#R_"]BZ/ M:JX@VX664UTGM"UW# TT"]5@:O/*]T0>R2$WVQ$FY1XX3#/PP */-&9_\YP9 MX5S6COE+J@FV'9Q)9'V9#C'C8$-8&EL5Y"*A-_9'VH);BC1$?6=4B;/>D:Z@ MJ !%K5-"%\C4.K3*4ZL/!U5(K1-=(0N1!+4"HI(CNF!:=A+*!I82!JHUS3GF*EVG=3MP]'17Y7:?F-V'^,4 M:@:VDC-Y2NF"X]1=,_MN5;3I'>D:MT+AP*$VPSP2=0BAHC:7NSHFM_M;'(+? M@V5S38X>(8&IR$O(910(9207BC-5BM&5E@0\$6. MXB#F@0>^X7#;B(W.*I'.9>V8O)!(J+U$DDM2(V]JP2F+ Z>V(VXH!:%C-Z^D MJ% V2*]LRBOI*?]038Q#UW*K_EU"O*!"O""]>$F/Z6AZ2M-(<=:CF'-9.Z8M M- P::.?3X3C2#[@74KX]D>/0F41'QGP)"8,*"8/T$N8Y9L2CJSCX5ZHU?NK MEKRHZ]-CV:[/(LLVJSM^O2M=40MY@_3RILCZ^VR'>8.S'2;+7^T(%^I7:IZ M-IT4W[W1BM4Z1>H-O;<[C-(Y?438*OE\P648M[%(C^SSI_DGDEGR8< HBJ?? M5[YBMI+9!(1D*:N:_:&,&TL_6:0W@FZ24_\%%8)&R>6:8)\P54"^7U(J#C>J M@?S#T?1_4$L#!!0 ( -,X:%5DKH^!U , !D5 9 >&PO=V]R:W-H M965TXP%N"_R MDB^MO1#5I6WS=(\+Q"]HA4OY9$M9@82Z$6[-6B0CN\P>)S="C_QD#)0IMY3>J:Y(\AS_M5"KVU,IGHX?Z']IXZ4QMXCC-HCH7G^CQ M/6X-"A0OI3G7G^#8RD(+I#47M&B5Y0D*4C;?Z+YUQ(F"Y(PKN*V".U3PGU#P M6@7OI3OXK8+_TAV"5D&;;C>V:\?%2*#5@M$C8$I:TM1 >U]K2W^14B7*1C#Y ME$@]L?I'YB(I4UI@\%M..?\=5%CFT1XQN1!C@4@NU_YL5OC"%G)/I6FG+?^Z MX;M/\#WPD99BST%29C@;T8^G]><3^K:TM3/8?3#XVIT$;G!U 3SX!W"AZXZ< M9_UR=6?,G)_;/?G?N_>X)W50J2D;Q6+RO8X+1F1! LG7V?YK7T M-]@R6H U+:I:(/UBTRU($"M)N>/@1F;*1F?*OW]+,/@@<,&_C>5(J'TNU#Z4_1^*'D7RK%H M-*! @]0/R6$5RFQTH$S(PZFC1^0"*05A7RX^EXO@S)\'?E\N>9[7LSSH+ \F M+?]<'C 7,EFE4P4CJ1K*@E;(;)7E,[T#Z(A8-NJ)2?!K\](D+#8)2PS!>M$) MN^B$;Z+$A"9#:1(6FX0EAF"]4$9=*"-3)28Z?]7]$,X&!>9@-ZLN+ M8,FSL)[-L\[FV<\5E[HD8M0%D]S7)J1)6&P2EAB"]8(S[X(S?Q.U96XRE"9A ML4E88@C6"Z4#'R\BT%1U:4FG[WK@>J$;#>K+B-S>MZ55GQSLN*[WFS\*RNC G"$$;NL+"<"TJI.8R<865Y MGMC8;Y^T>@K,=KK'QN5?DKH4S;V_6^WZ>%>Z>S58OW8NU\[(>JSZ?KJU](AO MFH8?$=N1DH,<;^56\"*2IV5-'ZZ9"%KI1M,M%8(6>KC'*,-,"&PO=V]R:W-H M965T,5D3#E>ULTG)),@ZK2=C$.[8H4M;5:Z+5[OEJP M5I9%3>\Y$FU5$?[WFI;LN+09/;!D145K M4; :<;I;6A^<^=;!"J M_BSH49R-D3K*(V-/:O);MK2P\HB6-)6*@L#/@6YH M62HF\..OGM0:]E3 \_&)_1=]>#C,(Q%TP\HO12;SI36S4$9WI"WE)W;\E?8' M"A1?RDJA_Z)C;XLME+9"LJH'@P=547>_Y&L?B#, \)@!;@]PKP'^"P"O!WBO MW<'O ?YK=PAZ@#ZZW9U=!RXADJP6G!T15]; I@8Z^AH-\2IJ)90'R>%K 3BY M^AVT6-0IJRBZ*9D0[U%#04F^X*>'/K):Y@)MZXQF!GPRCH]'\#;$; B<>PK#V<5Q@^&XP:C>$EHS MN R5XA \ENJI@'NJ?ODN,^HRF%*74Y(E4Y)M)R*[2%0X)"H67?W\N;G7R M3/GIJ(,S[7BS $>!?R6RC<$PBF8X\*]%:V)T8]>/KPRW)L;0]3PD M&P_QB$?CL6%5!94]5*3I$V*-*O.%+@TA*)(7J0I5][&M"VDL\>)GKCDX=&?! M=5!&'7FK(*M4/ND.[6E\[\XUC6$]4;ZO;IV_T M76/\D?!] ;HNZ0ZVPG<1N,N[7K.;2-;H9NJ126C-]#"'_IQR90#?=XS)TT1M M,'3\JW\ 4$L#!!0 ( -,X:%5!#ET*- 0 D; 9 >&PO=V]R:W-H M965T/S'-NO?0[8TR/CKV)'B$0_LC07 M,V,G9?%DFB+>D0R+!U:07#W9,)YAJ6[YUA0%)S@IC;+4="S+-S-, M^7S*]C*E.7GF2.RS#/.W!4G9<6;8QJG@A6YW4A>8\VF!MV1%Y/?BF:L[LZ$D M-".YH"Q'G&QFQF?[*;)'VJ"L\0]=69-19DR=(_:2)W,V-LH(1L\#Z5+^SX MA=0=\C0O9JDH?]&QJNN-#!3OA619;:Q:D-&\^L<_ZH%H&;CN.P9.;>!<&#C. M.P9N;>#>ZF%4&XQN]>#5!MZM!GYMX)=C7PU6.=(!EG@^Y>R(N*ZM:/JBE*NT M5@-, 2$Q3\7%J2N5)US?C MFKJHJ,X[5!=]9;G<"13F"4EZ[(-A^\F O:EZV'33.75SX0P"5Z1X0*[U"3F6 MXZ#OJP!]^/DCHGE"#S39X[2GB>67/?N"=!U2OJ4KKA^R=7I\#!W',^RK*EY M:&LXZ/Y>#6_S&4+ZC*Y]/KI.VV=GW+UFW+W!<0_X UKA'?H;+1CF"<)Y@D1, M22[IAL8()P!@0J.%.7--\V*UDM^<&WA47E MQFL%'/LBI@XVY%XU_]5=".DN H)U)!HW$HT')?K&)$X1SM@^EUJH1I(JT_6^ M^"[&5_%_XOI7:>ZZEFM=):;@NI8]]B:.=S'@/=6<:UHTV-G_.)239B@G-^2O M/.$L?E4S>JF"F/HTU/-<9[(Z?0UFKT'^O?$-$A9 PD)(6 0$ZRAN6^5P ^Z6\C:O M(:C7"(I6B62V=NHSPK?EF8I0@Z_28[6'VI0VYS:?R].*B_*%_;2T>\H#^RFL M3F7.^.J0Z"OF6YH+E)*-&PO MD&XS%+C;MW1 VO$E"9SSJ]WQ\\L M<$Y"K^C5 :(7K18N#" F'A\FOD\;D^YN2]OIIT;($4\Q6L]#,U'63.A@Y.3 M7.U/%K:D;LOK;<.9)89UL0S[62'7-1,1-V"4:F(Z=; =?0$'=OE^6QN%4T66[J&D9TP(>[@(?^5;6DOLHT]LSLF MFZ8Q5#>=C.N _J::T]Z4O7R5;E#RQT)_G9OE2-N'.F.WBF5\8?N+K#& J;=Q M=5J68OE%\*G,F5O\P0&'?;KB!;-"\2<3#4IE8@:8(L$C4YI/-D?^*%K>LX5> ME=,BPSUWCM#SO\WSE$FFJ-@T;6K_/6?YU8ZC[EM9MM\JNX:]'NLW]WLW>74, M)N-C,'D4-=D[!I/)$9CLOMFWYN$FH_>9R+ ^"6TC*T['Y!FO)SH@AV%?.&/<$XDB08 K7HK]$X1K(3P\>_ M/]A3$D5)XD< \SN((@R!IQ%', ?@ 4.BR+X'=]Y'X>H]%:[_ASE\!E!+ P04 M " #3.&A5EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_ MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+ MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D M5XA-/E_G;@ M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/ M['X 4$L#!!0 ( -,X:%5NF QWX0, +D? / >&PO=V]R:V)O;VLN M>&ULQ9E;;],P%(#_BI6G3:*TN:RPB2+!QF42VM"*>$6N<[I:<^Q@.QOPZSE. MJ7!8=\2+FY>VL1/WRW%\/MMY]6#LWFQ8T MUJR-;;C'0WL[=:T%7KL-@&_4M)C-YM.&2YV]?K5KZ[.=Q@?&@_#2:"P,!5\E M/+B_]>&0W4LG5U))_W.1];\59*R16C;R%]2+;)8QMS$/'XV5OXSV7"V%-4HM MLGQ;\16LE^)1\3) ?N$KUY=XOKKA"++(YC-L<"VM\_T9??L<&>\!3]X>==Z\ ME\J#O> >/EC3M5+?AF;P+J;1;?1QV'UO@WAF_R>,9KV6 BZ,Z!K0?AM'"RH M:K>1K@\0N];8I/#?<*?[U9;V]:X^X40SMF<0*>UGW MX.D@SXVN03NH&?YR1LD:.6KVEBNN!; (LB @BQ$AOQ419$E EJ- +@,.7AI! M5@1D-2+D()(G!.3)F)!E!#DG(.=I(:^X[RPPLV:KSDD-SD5<+PBN%VFYEEW3 MQD,.$L)TF(,BR)<$Y,NTD.^YM.R>JPY8 ]QA(,,%<01/";C3 MQ(\?=YMG3. G@^^=1,S ]HQ9<-Y*$>?M&96X9VDQWPAA.QP6\*,-@R4.7DX* M);%1/F&'XKA8*7G[R'.40_+$$KGV&[!,2=[/5^0P8)0W\N3B:!KI^P'03Q4$ M3I1PS@):_ -)>2-/+(ZE-^)NLN(A*PO3A$?N4>]2RL@3.^,*VY4:R8 =*>/< M,6NQM]V&6X@1*6'DB8UQ$PHQ?"VW.!/TEF,(^_GUH),I=>1CNF,P.\@I>>3C MV(,=X2) #8<,I9%\3(\,HEE0'BD.[)%=&(]C0$HHQ8&%LA>07)T>,2;EFF(\UP32&)/R37'P%0H[N@#/I1H^F)1QBL3& M>2J53]@;Y\#'F)1QBL3&H5-YO"(M*.,4HQJGBO=)*..4!S?.GL>RI)13'EPY M^P@IYY2)G?.(<,*N,0OQD-:9ZV),]CDIQJ3D4R66SY.8$^S_IHTQ*0-5B0U$8-[@?"/& MI Q4)380@1FJ8DSRO4QB"Y%KBHMXZ5-1%JI&7/I,V-L8D[)0-=I66S_68TS* M0E5OH>GN57$-:UQ&U5?X%P[+!5?BLV7A:[NY79V$_:9UI]0YEEWK3X;7NS?/ MN[?FKW\#4$L#!!0 ( -,X:%6Y(]HWL@$ %0< : >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'/-V3MNPD 4A>&M("\@PWU 0A12I:&-V( %PT,! M;'DF"NP^" HX5HHT:$YES5B^_JM/UOCM,^[JO&T.:;-MT^"XWQW2M-KDW+Z& MD!:;N*_34]/&P_G.JNGV=3XONW5HZ\57O8Y!A\-QZ.YG5.]O]S,'\U,;_S.Q M6:VVB_C1++[W\9#_&!Q^FNXK;6+,U6!>=^N8IU4X[F[;*5PN\G2>7 UFRVG5 MS992A=)!"D%:/L@@R,H'.01Y^: 1!(W*!XTA:%P^Z!F"GLL'O4#02_F@"01- MR@?)$&4<$B3UL";06I!K(?!:$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N M(;!;$&\AT%M1;R706U%O)=!;>Q_;!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJ MK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>EOOL(1 ;T.]C4!O0[V-0&]# MO8U ;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O[QUV$^CM MJ+<3Z.VHMQ/H[:BW/U+OE$^[F&X]US6^_Y%4Y_.S\?;ZR_*ZV6/G@G. GXCO MOU!+ P04 " #3.&A59>&9M;UW7VSI;#)^VUKRO4U=-7Z2%"'8!\9\5E"M?6HL-7%D;ERM0WQT M"V9UMM0+8F(X'+',-(&:, AMC60Z?J*Y7E6A][R)KWUIFDGBJ/))[W$WL3?4@;[A#2N[.;XHK2^'RC3S>9E1;K)5'9>DWCK2N2^(0EVENZ+]\\DA[C#M MKOSJ_*[,N< X<^:,]?'$'%T>=SB2=O7 QD+D0GG^$X^)L?35WT?M:>>4_S([ M;N^'<&PO=&AE;64O=&AE;64Q M+GAM;%!+ 0(4 Q0 ( -,X:%5Y<((TR@4 /H> 8 " M@0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ TSAH55(,[\W@ @ % H !@ M ("!9!0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ TSAH52?]W5WB!@ .!X !@ ("!VBD 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ TSAH5<]KB#YY M P $@L !@ ("!X4 'AL+W=O&UL4$L! A0#% @ TSAH M54REC=F] @ 10< !D ("!\TL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ TSAH5=9?4 9(P 8XD M !D ("!:5D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ TSAH59EKN%L9! , H !D M ("!%XL 'AL+W=O@$4& #S$0 &0 @(%GCP >&PO=V]R:W-H965T M.5 !X;"]W;W)K&UL4$L! A0# M% @ TSAH59K7U1F^ P # T !D ("!8ID 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ TSAH53DX M55^8 @ 6@< !D ("!Q:( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ TSAH564K.7&PO M=V]R:W-H965T&UL4$L! A0#% @ TSAH56(9T:+)! R!< !D ("! ME+P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ TSAH55P:9YF!! NQD !D ("!^,< 'AL+W=O&UL4$L! A0#% @ TSAH58QSAMG2 M#0 VZ@ !D ("!8]( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ TSAH5;4AF06W!0 &PO=V]R M:W-H965T&UL M4$L! A0#% @ TSAH5=Z?T-LD"P /(H !D ("!X_8 M 'AL+W=O ML:0$ "<'0 &0 @($^ @$ >&PO=V]R:W-H965T&UL4$L! A0#% @ MTSAH5=DREL!.!0 1!H !D ("!N0P! 'AL+W=O&POXB 0!X;"]W;W)K8F]O:RYX;6Q0 M2P$"% ,4 " #3.&A5N2/:-[(! !4' &@ @ '\)@$ M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #3.&A59>&9 MM; XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 198 254 1 false 51 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Sheet http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Nature of business Sheet http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusiness Nature of business Notes 7 false false R8.htm 10201 - Disclosure - Summary of significant accounting policies Sheet http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 8 false false R9.htm 10301 - Disclosure - Fair value measurements Sheet http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurements Fair value measurements Notes 9 false false R10.htm 10401 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities Sheet http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecurities Cash, cash equivalents, restricted cash, and available-for-sale marketable securities Notes 10 false false R11.htm 10501 - Disclosure - Accrued expenses Sheet http://www.voyagertherapeutics.com/role/DisclosureAccruedExpenses Accrued expenses Notes 11 false false R12.htm 10601 - Disclosure - Lease obligation Sheet http://www.voyagertherapeutics.com/role/DisclosureLeaseObligation Lease obligation Notes 12 false false R13.htm 10701 - Disclosure - Other liabilities Sheet http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilities Other liabilities Notes 13 false false R14.htm 10801 - Disclosure - Commitments and contingencies Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 14 false false R15.htm 10901 - Disclosure - Stock-based compensation Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensation Stock-based compensation Notes 15 false false R16.htm 11001 - Disclosure - Net income (loss) per share Sheet http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShare Net income (loss) per share Notes 16 false false R17.htm 11101 - Disclosure - Related party transactions Sheet http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactions Related party transactions Notes 17 false false R18.htm 20202 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 18 false false R19.htm 30303 - Disclosure - Fair value measurements (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsTables Fair value measurements (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurements 19 false false R20.htm 30403 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesTables Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecurities 20 false false R21.htm 30503 - Disclosure - Accrued expenses (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesTables Accrued expenses (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureAccruedExpenses 21 false false R22.htm 30603 - Disclosure - Lease obligation (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationTables Lease obligation (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureLeaseObligation 22 false false R23.htm 30703 - Disclosure - Other liabilities (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesTables Other liabilities (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilities 23 false false R24.htm 30803 - Disclosure - Commitments and contingencies (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and contingencies (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingencies 24 false false R25.htm 30903 - Disclosure - Stock-based compensation (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables Stock-based compensation (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensation 25 false false R26.htm 31003 - Disclosure - Net income (loss) per share (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareTables Net income (loss) per share (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShare 26 false false R27.htm 40101 - Disclosure - Nature of business (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails Nature of business (Details) Details http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusiness 27 false false R28.htm 40301 - Disclosure - Fair value measurements - Assets and liabilities measured on a recurring basis - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Fair value measurements - Assets and liabilities measured on a recurring basis - (Details) Details 28 false false R29.htm 40401 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, Cash Equivalents, and Marketable Securities - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, Cash Equivalents, and Marketable Securities - (Details) Details 29 false false R30.htm 40402 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details) Details 30 false false R31.htm 40501 - Disclosure - Accrued expenses (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails Accrued expenses (Details) Details http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesTables 31 false false R32.htm 40601 - Disclosure - Lease obligation (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails Lease obligation (Details) Details http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationTables 32 false false R33.htm 40602 - Disclosure - Lease obligation - Operating sublease income (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationOperatingSubleaseIncomeDetails Lease obligation - Operating sublease income (Details) Details 33 false false R34.htm 40701 - Disclosure - Other liabilities (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails Other liabilities (Details) Details http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesTables 34 false false R35.htm 40801 - Disclosure - Commitments and contingencies - Neurocrine Collaboration Agreement - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails Commitments and contingencies - Neurocrine Collaboration Agreement - (Details) Details 35 false false R36.htm 40802 - Disclosure - Commitments and contingencies - Collaboration receivables and contract liabilities - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationReceivablesAndContractLiabilitiesDetails Commitments and contingencies - Collaboration receivables and contract liabilities - (Details) Details 36 false false R37.htm 40803 - Disclosure - Commitments and contingencies - Pfizer Option and License Agreement - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails Commitments and contingencies - Pfizer Option and License Agreement - (Details) Details 37 false false R38.htm 40804 - Disclosure - Commitments and contingencies - Novartis Option and License Agreement (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails Commitments and contingencies - Novartis Option and License Agreement (Details) Details 38 false false R39.htm 40805 - Disclosure - Commitments and Contingencies - Touchlight IP Ltd License Agreement (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails Commitments and Contingencies - Touchlight IP Ltd License Agreement (Details) Details 39 false false R40.htm 40806 - Disclosure - Commitments and contingencies - Other Agreements - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails Commitments and contingencies - Other Agreements - (Details) Details 40 false false R41.htm 40901 - Disclosure - Stock-based compensation (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails Stock-based compensation (Details) Details http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables 41 false false R42.htm 40902 - Disclosure - Stock-based compensation - Compensation expense (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails Stock-based compensation - Compensation expense (Details) Details 42 false false R43.htm 40903 - Disclosure - Stock-based compensation - Restricted Stock - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails Stock-based compensation - Restricted Stock - (Details) Details 43 false false R44.htm 40904 - Disclosure - Stock-based compensation - Stock Options - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails Stock-based compensation - Stock Options - (Details) Details 44 false false R45.htm 41001 - Disclosure - Net income (loss) per share (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails Net income (loss) per share (Details) Details http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareTables 45 false false R46.htm 41002 - Disclosure - Net income (loss) per share - Basic and diluted weighted average shares outstanding (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails Net income (loss) per share - Basic and diluted weighted average shares outstanding (Details) Details http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareTables 46 false false R47.htm 41101 - Disclosure - Related party transactions (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails Related party transactions (Details) Details http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactions 47 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:AllocatedShareBasedCompensationExpense, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockSharesOutstanding, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - vygr-20220930x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 3 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies, us-gaap:RestrictedCashAssetStatementOfFinancialPositionExtensibleList - vygr-20220930x10q.htm 9 vygr-20220930x10q.htm vygr-20220930.xsd vygr-20220930_cal.xml vygr-20220930_def.xml vygr-20220930_lab.xml vygr-20220930_pre.xml vygr-20220930xex31d1.htm vygr-20220930xex31d2.htm vygr-20220930xex32d1.htm vygr-20220930x10q006.jpg vygr-20220930x10q008.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vygr-20220930x10q.htm": { "axisCustom": 1, "axisStandard": 17, "contextCount": 198, "dts": { "calculationLink": { "local": [ "vygr-20220930_cal.xml" ] }, "definitionLink": { "local": [ "vygr-20220930_def.xml" ] }, "inline": { "local": [ "vygr-20220930x10q.htm" ] }, "labelLink": { "local": [ "vygr-20220930_lab.xml" ] }, "presentationLink": { "local": [ "vygr-20220930_pre.xml" ] }, "schema": { "local": [ "vygr-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 403, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 12, "http://xbrl.sec.gov/dei/2022": 5, "total": 17 }, "keyCustom": 60, "keyStandard": 194, "memberCustom": 30, "memberStandard": 18, "nsprefix": "vygr", "nsuri": "http://www.voyagertherapeutics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities", "role": "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecurities", "shortName": "Cash, cash equivalents, restricted cash, and available-for-sale marketable securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Accrued expenses", "role": "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpenses", "shortName": "Accrued expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Lease obligation", "role": "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligation", "shortName": "Lease obligation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Other liabilities", "role": "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilities", "shortName": "Other liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Commitments and contingencies", "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Stock-based compensation", "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Net income (loss) per share", "role": "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShare", "shortName": "Net income (loss) per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Related party transactions", "role": "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related party transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of significant accounting policies (Policies)", "role": "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Fair value measurements (Tables)", "role": "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair value measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesTables", "shortName": "Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Accrued expenses (Tables)", "role": "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Lease obligation (Tables)", "role": "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationTables", "shortName": "Lease obligation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Other liabilities (Tables)", "role": "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesTables", "shortName": "Other liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Commitments and contingencies (Tables)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Stock-based compensation (Tables)", "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Net income (loss) per share (Tables)", "role": "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareTables", "shortName": "Net income (loss) per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": "INF", "first": true, "lang": null, "name": "vygr:CollaborativeArrangementNumberOfPrograms", "reportCount": 1, "unitRef": "Unit_Standard_Program_u7Yd7fEse0m1I4BK-Hj5xQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of business (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "shortName": "Nature of business (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Fair value measurements - Assets and liabilities measured on a recurring basis - (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "Fair value measurements - Assets and liabilities measured on a recurring basis - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_x707Ocwxv0e44Bvrv1PU5Q", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, Cash Equivalents, and Marketable Securities - (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "shortName": "Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, Cash Equivalents, and Marketable Securities - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "lang": null, "name": "vygr:MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_WSO-PlpgD0e-3o0AEv7iNA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_WSO-PlpgD0e-3o0AEv7iNA", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Accrued expenses (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": "-3", "first": true, "lang": null, "name": "vygr:IncreaseDecreaseInRightOfUseAssets", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Lease obligation (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "shortName": "Lease obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_xhMRF81DDkC5RrCYm5GuBw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Lease obligation - Operating sublease income (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationOperatingSubleaseIncomeDetails", "shortName": "Lease obligation - Operating sublease income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_xhMRF81DDkC5RrCYm5GuBw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_Fz8zlfYLU0m2RHlVIUJ2fA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Other liabilities (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails", "shortName": "Other liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_Fz8zlfYLU0m2RHlVIUJ2fA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": "INF", "first": true, "lang": null, "name": "vygr:CollaborativeArrangementNumberOfPrograms", "reportCount": 1, "unitRef": "Unit_Standard_Program_u7Yd7fEse0m1I4BK-Hj5xQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Commitments and contingencies - Neurocrine Collaboration Agreement - (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "shortName": "Commitments and contingencies - Neurocrine Collaboration Agreement - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_3_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_vygr_NeurocrineBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_vygr_NeurocrineCollaborativeArrangementMember_I8QJvU7ZXkaZkwyQ_nOJgg", "decimals": "INF", "lang": null, "name": "vygr:CollaborativeArrangementNumberOfDiscoveryPrograms", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_IrfbZf4fokO5pWfWqTbfKA", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_Fz8zlfYLU0m2RHlVIUJ2fA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Commitments and contingencies - Collaboration receivables and contract liabilities - (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationReceivablesAndContractLiabilitiesDetails", "shortName": "Commitments and contingencies - Collaboration receivables and contract liabilities - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": "-3", "lang": null, "name": "vygr:AdditionsToContractWithCustomerAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Commitments and contingencies - Pfizer Option and License Agreement - (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "shortName": "Commitments and contingencies - Pfizer Option and License Agreement - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_10_1_2021_srt_CounterpartyNameAxis_vygr_PfizerMember_us-gaap_TypeOfArrangementAxis_vygr_OptionAndLicenseAgreementMember_VTNEc96tC0moRaZmYkEo2A", "decimals": "INF", "lang": null, "name": "vygr:LicenseAgreementNumberOfTransgenes", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_IrfbZf4fokO5pWfWqTbfKA", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40804 - Disclosure - Commitments and contingencies - Novartis Option and License Agreement (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "shortName": "Commitments and contingencies - Novartis Option and License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_3_4_2022_To_3_4_2022_srt_CounterpartyNameAxis_vygr_NovartisPharmaAgMember_us-gaap_TypeOfArrangementAxis_vygr_NovartisLicenseAgreementMember_iOfAC_jVGUyHEtlUHTfUsQ", "decimals": "INF", "lang": null, "name": "vygr:NumberOfTransgenes", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_IrfbZf4fokO5pWfWqTbfKA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_srt_CounterpartyNameAxis_vygr_TouchlightIpLtdMember_us-gaap_TypeOfArrangementAxis_vygr_TouchlightIpLtdLicenseAgreementMember_ySdjiNwtLke2JUJ6DaN5uQ", "decimals": "-5", "first": true, "lang": null, "name": "vygr:LicenseAgreementNonRefundableTechnologyAccessFeePayable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40805 - Disclosure - Commitments and Contingencies - Touchlight IP Ltd License Agreement (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails", "shortName": "Commitments and Contingencies - Touchlight IP Ltd License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_srt_CounterpartyNameAxis_vygr_TouchlightIpLtdMember_us-gaap_TypeOfArrangementAxis_vygr_TouchlightIpLtdLicenseAgreementMember_ySdjiNwtLke2JUJ6DaN5uQ", "decimals": "-5", "first": true, "lang": null, "name": "vygr:LicenseAgreementNonRefundableTechnologyAccessFeePayable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_12_31_2016_us-gaap_TypeOfArrangementAxis_vygr_NonProfitAgreementMember_3gXhmiYkO0iIRTziFR69Ow", "decimals": "-5", "first": true, "lang": null, "name": "vygr:NonProfitOrganizationResearchAndDevelopmentMaximumFundingCapacity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40806 - Disclosure - Commitments and contingencies - Other Agreements - (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails", "shortName": "Commitments and contingencies - Other Agreements - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_12_31_2016_us-gaap_TypeOfArrangementAxis_vygr_NonProfitAgreementMember_3gXhmiYkO0iIRTziFR69Ow", "decimals": "-5", "first": true, "lang": null, "name": "vygr:NonProfitOrganizationResearchAndDevelopmentMaximumFundingCapacity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Stock-based compensation (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "shortName": "Stock-based compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vygr_InducementStockOptionAwardsMember_eULfm-LyxEq6NpQSsxfnlw", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Stock-based compensation - Compensation expense (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "shortName": "Stock-based compensation - Compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_IeU9PhIZR0yiDTZIlm-n4A", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Stock-based compensation - Restricted Stock - (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "shortName": "Stock-based compensation - Restricted Stock - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2fYEABICWUyWQbr764UhHw", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Yye1e9zJMUGxwaeOPHIrjg", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_Fz8zlfYLU0m2RHlVIUJ2fA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_Yye1e9zJMUGxwaeOPHIrjg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Stock-based compensation - Stock Options - (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "shortName": "Stock-based compensation - Stock Options - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Yye1e9zJMUGxwaeOPHIrjg", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Yye1e9zJMUGxwaeOPHIrjg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Net income (loss) per share (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails", "shortName": "Net income (loss) per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Yye1e9zJMUGxwaeOPHIrjg", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Net income (loss) per share - Basic and diluted weighted average shares outstanding (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails", "shortName": "Net income (loss) per share - Basic and diluted weighted average shares outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_niKlo_HOFkKgUho6nx-OLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_dww89AOl2U-nQ1i_KANEvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Related party transactions (Details)", "role": "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related party transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "vygr:NumberOfIndividualsProvidingServicesInRelatedPartyTransactions", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_vygr_RelatedPartyTransactionBoardAndScientificAdvisoryServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_vygr_DrDinahSahMember_S40dPi4dlkeIhEIjDgGibQ", "decimals": "INF", "lang": null, "name": "vygr:NumberOfIndividualsProvidingServicesInRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_individual_TEO2MXxZ70O0BxEKOcMNGA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__vKHw4JfJECBFgd5mryuGA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__gVyqIE6wUWbVpTwIKhVuA", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_HlVX0PZkk0y-TRF_YLUY-g", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of business", "role": "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusiness", "shortName": "Nature of business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of significant accounting policies", "role": "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Fair value measurements", "role": "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurements", "shortName": "Fair value measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "vygr-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_mT8nwuWxREW7JrUpp_2bfg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 51, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r25", "r27", "r66", "r67", "r183", "r190" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r182", "r189", "r214", "r215", "r328", "r329", "r330", "r331", "r332", "r333", "r352", "r392", "r394", "r403", "r404" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r182", "r189", "r214", "r215", "r328", "r329", "r330", "r331", "r332", "r333", "r352", "r392", "r394", "r403", "r404" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r126", "r167", "r168", "r200", "r203", "r355", "r391", "r393" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r126", "r167", "r168", "r200", "r203", "r355", "r391", "r393" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r161", "r166", "r167", "r168", "r169", "r182", "r189", "r204", "r214", "r215", "r246", "r247", "r248", "r328", "r329", "r330", "r331", "r332", "r333", "r352", "r392", "r394", "r403", "r404" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r161", "r166", "r167", "r168", "r169", "r182", "r189", "r204", "r214", "r215", "r246", "r247", "r248", "r328", "r329", "r330", "r331", "r332", "r333", "r352", "r392", "r394", "r403", "r404" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r26", "r27", "r66", "r67", "r183", "r190" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of significant accounting policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued expenses" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r17", "r321" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r56" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and discounts on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r12", "r30", "r31", "r32", "r382", "r399", "r400" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r29", "r32", "r39", "r40", "r41", "r69", "r70", "r71", "r274", "r310", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r10", "r321" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r69", "r70", "r71", "r258", "r259", "r260", "r280" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition", "terseLabel": "Stock based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by operating activities:", "terseLabel": "Adjustments to reconcile net loss (income) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r251" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock-based compensation.", "terseLabel": "Stock-based compensation.", "verboseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share (in common stock equivalent shares)", "terseLabel": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r7", "r64", "r114", "r118", "r124", "r144", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r268", "r275", "r291", "r319", "r321", "r369", "r380" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Abstract", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r16", "r64", "r144", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r268", "r275", "r291", "r319", "r321" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current Abstract", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r283" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure, Total", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets, Fair Value Disclosure [Abstract]" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r135" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Marketable securities, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r132", "r151" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "totalLabel": "Marketable securities, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "auth_ref": [ "r134" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "terseLabel": "Debt securities, unrealized gain position" } } }, "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amortized Cost Basis [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r130", "r133", "r151", "r371" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities, Debt Securities", "terseLabel": "Marketable securities, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r58", "r59", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capital expenditures incurred but not yet paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, cash equivalents, restricted cash, and available-for-sale marketable securities" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r5", "r57" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Cash, cash equivalents, restricted cash, and available-for-sale marketable securities" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "verboseLabel": "Cash, cash equivalents, and restricted cash" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents, and marketable debt securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r52", "r57", "r61" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r52", "r292" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r372", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (see note 7)", "terseLabel": "Commitments and contingencies (see note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r163", "r164", "r165", "r170", "r402" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r69", "r70", "r280" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r192" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r9", "r321" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value: 120,000,000 shares authorized at June 30, 2019 and December 31, 2018; 36,677,608 and 32,364,895 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively", "terseLabel": "Common stock, $0.001 par value: 120,000,000 shares authorized at September 30, 2022 and December 31, 2021; 38,520,336 and 37,918,395 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r35", "r37", "r38", "r43", "r375", "r389" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r63", "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of collaboration receivables and contract liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r194", "r196", "r201" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, Net, Current", "periodEndLabel": "Related party collaboration receivables, ending balance", "periodStartLabel": "Related party collaboration receivables, beginning balance", "terseLabel": "Related party collaboration receivable" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationReceivablesAndContractLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r194", "r195", "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred revenue, ending balance", "periodStartLabel": "Deferred revenue, beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationReceivablesAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": { "auth_ref": [ "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract", "terseLabel": "Cumulative catch up of revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r194", "r195", "r201" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Deferred revenue, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r194", "r195", "r201" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "verboseLabel": "Deferred revenue, non-current" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r202" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedTerseLabel": "Deductions", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationReceivablesAndContractLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r138", "r152", "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Debt securities, unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt securities" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r55", "r157" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r219", "r220", "r252", "r253", "r255", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income (loss) per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r44", "r74", "r75", "r76", "r77", "r78", "r82", "r85", "r91", "r92", "r93", "r98", "r99", "r281", "r282", "r376", "r390" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r44", "r74", "r75", "r76", "r77", "r78", "r85", "r91", "r92", "r93", "r98", "r99", "r281", "r282", "r376", "r390" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Reconciliation [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "EarningsPerShareReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r94", "r96", "r97", "r100" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee compensation costs" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Remaining weighted-average remaining vesting period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r39", "r40", "r41", "r69", "r70", "r71", "r73", "r79", "r81", "r102", "r145", "r192", "r193", "r258", "r259", "r260", "r263", "r264", "r280", "r293", "r294", "r295", "r296", "r297", "r298", "r310", "r395", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r6", "r115", "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r184", "r186", "r187", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r284", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r283", "r284", "r285", "r286", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r184", "r205", "r206", "r211", "r213", "r284", "r325" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r184", "r186", "r187", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r288", "r290" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r287", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r136", "r137", "r140", "r141", "r142", "r146", "r147", "r148", "r149", "r150", "r153", "r154", "r155", "r156", "r185", "r191", "r279", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r411", "r412", "r413", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "terseLabel": "Gain on termination of lease" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r160", "r162" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r54" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r54" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r54" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r54", "r353" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r54", "r304" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r54" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r54" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r86", "r87", "r88", "r93", "r218" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Common stock options and restricted stock units" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosure [Abstract]" } } }, "localname": "InvestmentsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease obligation" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease obligation" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r64", "r119", "r144", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r269", "r275", "r276", "r291", "r319", "r320" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r64", "r144", "r291", "r321", "r370", "r384" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity Abstract", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r4", "r21", "r64", "r144", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r269", "r275", "r276", "r291", "r319", "r320", "r321" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current Abstract", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r373" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities.", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current.", "terseLabel": "Marketable securities, current" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Schedule of money market funds and marketable securities" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r103", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r52" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r52" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r52", "r53", "r56" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r33", "r36", "r41", "r42", "r56", "r64", "r72", "r74", "r75", "r76", "r77", "r80", "r81", "r89", "r114", "r117", "r120", "r123", "r125", "r144", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r282", "r291", "r374", "r388" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r74", "r75", "r76", "r77", "r82", "r83", "r90", "r93", "r114", "r117", "r120", "r123", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net loss attributable to common stockholders", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Debt Expense", "totalLabel": "Total other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest and Debt Expense [Abstract]", "terseLabel": "Other income, net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Summary of status and changes in unvested restricted stock" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r114", "r117", "r120", "r123", "r125" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r101", "r308", "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Operating sublease income" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationOperatingSubleaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r101", "r309" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Summary of operating sublease income" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r301" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r301" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r300" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease, right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r34", "r37", "r266", "r267", "r273" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r28", "r30" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Net unrealized (loss) gain on available-for-sale securities", "verboseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r19", "r321" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Total other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other liabilities" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "totalLabel": "Total other non-current liabilities", "verboseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other liabilities.", "label": "Summary of other current and non-current liabilities" } } }, "localname": "OtherLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other financing expense", "terseLabel": "Other income (expensive)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r131" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r49" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r8", "r188" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r8", "r188" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r8" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred stock $0.001 par value: 5,000,000 shares authorized at June 30, 2019 and December 31, 2018; no shares issued and outstanding at June 30, 2019 and December 31, 2018", "terseLabel": "Preferred stock $0.001 par value: 5,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r50", "r257" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options", "terseLabel": "Proceeds from the purchase of common stock under ESPP" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r50", "r257" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r33", "r36", "r41", "r51", "r64", "r72", "r80", "r81", "r114", "r117", "r120", "r123", "r125", "r144", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r266", "r271", "r272", "r277", "r278", "r282", "r291", "r377" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r159", "r321", "r379", "r386" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r321", "r385", "r401" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Accounts receivable" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r212", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r313", "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Total amount of services received" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r212", "r313", "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related party transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r212", "r313", "r316", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r311", "r312", "r314", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r262", "r354", "r405" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r5", "r61", "r368", "r381" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "verboseLabel": "Restricted cash included in deposits and other noncurrent assets" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage.", "label": "Restricted Cash, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "RestrictedCashAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Unvested restricted common stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Unvested restricted common stock units", "terseLabel": "Restricted stock awards and units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r11", "r193", "r321", "r383", "r398", "r400" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r69", "r70", "r71", "r73", "r79", "r81", "r145", "r258", "r259", "r260", "r263", "r264", "r280", "r395", "r397" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r112", "r113", "r116", "r121", "r122", "r126", "r127", "r128", "r199", "r200", "r355" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration revenue", "verboseLabel": "Collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuePerformanceObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Allocation of Transaction Price" } } }, "localname": "RevenuePerformanceObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Outstanding potentially dilutive securities excluded in the calculation of diluted net income (loss) per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "terseLabel": "Summary of stock-based compensation expense by type of award" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Compensation cost recognized for all stock-based compensation awards" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r216", "r217", "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r224", "r239", "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of weighted average number of shares, basic and diluted" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r54" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted stock disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Restricted stock granted, original issued price (in dollars per share)", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Restricted stock granted, original issued price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Balance, beginning (in shares)", "periodEndLabel": "Balance, ending (in shares)", "periodStartLabel": "Balance, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Balance, ending (in dollars per share)", "periodStartLabel": "Balance, beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Vested (in shares)", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Cancelled or forfeited (in shares)", "negatedLabel": "Cancelled or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Cancelled or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Outstanding (in dollars per share)", "periodEndLabel": "Outstanding (in dollars per share)", "periodStartLabel": "Outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "New stock options issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting period, tranche one" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting period, tranche two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Estimated future value at closing", "verboseLabel": "Price per share" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r62", "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r24", "r39", "r40", "r41", "r69", "r70", "r71", "r73", "r79", "r81", "r102", "r145", "r192", "r193", "r258", "r259", "r260", "r263", "r264", "r280", "r293", "r294", "r295", "r296", "r297", "r298", "r310", "r395", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables", "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statement of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r69", "r70", "r71", "r102", "r355" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables", "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Employee stock purchase plan", "terseLabel": "Employee stock purchase plan awards" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r9", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Purchase of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r8", "r9", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock under ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross", "verboseLabel": "Restricted stock granted (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r9", "r192", "r193", "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercises of vested stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r8", "r9", "r192", "r193" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Purchase of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r8", "r9", "r193", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r24", "r192", "r193" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercises of vested stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased", "terseLabel": "Remaining number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r9", "r13", "r14", "r64", "r129", "r144", "r291", "r321" ], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Stockholders' Equity, Ending Balance", "periodStartLabel": "Stockholders' Equity, Beginning Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent Abstract", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental disclosure of cash and non-cash activities" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r136", "r137", "r140", "r141", "r142", "r185", "r191", "r279", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r411", "r412", "r413", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r65", "r205", "r213", "r378" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U.S. Treasury notes" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r104", "r105", "r106", "r107", "r108", "r109", "r110" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r220", "r221", "r222", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r84", "r93" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted", "totalLabel": "Weighted average shares outstanding-diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator for diluted net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r82", "r93" ], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic", "verboseLabel": "Weighted average shares outstanding-basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator for basic net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureNetIncomeLossPerShareBasicAndDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "vygr_AccruedGoodsAndServicesCurrent": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of expenses incurred but not paid for goods and services, due within one year or the normal operating cycle, if longer.", "label": "Accrued Goods And Services Current", "terseLabel": "Accrued goods and services" } } }, "localname": "AccruedGoodsAndServicesCurrent", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "vygr_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs . Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research And Development Costs Current", "verboseLabel": "Research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "vygr_AdditionalFeeAgreedToPayUnderCollaborativeArrangement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of additional fee agreed to pay under collaborative arrangement..", "label": "Additional Fee Agreed To Pay Under Collaborative Arrangement", "terseLabel": "Additional fee agreed to pay" } } }, "localname": "AdditionalFeeAgreedToPayUnderCollaborativeArrangement", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_AdditionsToContractWithCustomerAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to contract with customer assets during the reporting period.", "label": "Additions To Contract With Customer Assets", "terseLabel": "Additions" } } }, "localname": "AdditionsToContractWithCustomerAssets", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationReceivablesAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vygr_AggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValueAbstract", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "vygr_CollaborativeAgreementEstimatedCostReimbursement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated cost reimbursement in a collaboration agreement.", "label": "Collaborative Agreement Estimated Cost Reimbursement", "terseLabel": "Estimated cost reimbursement" } } }, "localname": "CollaborativeAgreementEstimatedCostReimbursement", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_CollaborativeArrangementAggregateMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "In the aggregate, the maximum milestone payments to be received from the collaborative partner.", "label": "Collaborative Arrangement Aggregate Maximum Milestone Payments To Be Received From Collaborative Partner", "verboseLabel": "Aggregate maximum milestone payments to be received from collaborative partner" } } }, "localname": "CollaborativeArrangementAggregateMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_CollaborativeArrangementAggregateMilestonePaymentsIfExerciseRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of aggregate milestone payments if exercise rights under collaborative arrangement.", "label": "Collaborative Arrangement Aggregate Milestone Payments if Exercise Rights", "terseLabel": "Aggregate milestone payments, if exercise rights" } } }, "localname": "CollaborativeArrangementAggregateMilestonePaymentsIfExerciseRights", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "vygr_CollaborativeArrangementConsiderationReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of consideration received under the collaborative agreements.", "label": "Collaborative Arrangement, Consideration Received", "terseLabel": "Consideration received" } } }, "localname": "CollaborativeArrangementConsiderationReceived", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_CollaborativeArrangementCostsToObtainContract": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of costs incurred to enter collaborative arrangement.", "label": "Collaborative Arrangement, Costs to Obtain Contract", "terseLabel": "Costs to obtain collaboration agreement" } } }, "localname": "CollaborativeArrangementCostsToObtainContract", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_CollaborativeArrangementDiscountRelatedToEquityInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of discount related to equity investment.", "label": "Collaborative Arrangement, Discount Related to Equity Investment", "terseLabel": "Discount related to equity investment" } } }, "localname": "CollaborativeArrangementDiscountRelatedToEquityInvestment", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_CollaborativeArrangementNumberOfDaysWrittenNoticeRequiredByReportingEntityToTerminateAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of days written notice required by reporting entity to terminate agreement.", "label": "Collaborative Arrangement Number Of Days Written Notice Required By Reporting Entity To Terminate Agreement", "verboseLabel": "Number of days written notice required by reporting entity to terminate agreement" } } }, "localname": "CollaborativeArrangementNumberOfDaysWrittenNoticeRequiredByReportingEntityToTerminateAgreement", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "durationItemType" }, "vygr_CollaborativeArrangementNumberOfDiscoveryPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of discovery programs under collaborative arrangement.", "label": "Collaborative Arrangement Number of Discovery Programs", "terseLabel": "Number of discovery programs" } } }, "localname": "CollaborativeArrangementNumberOfDiscoveryPrograms", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_CollaborativeArrangementNumberOfDiscoveryProgramsUnderDevelopment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of discovery programs under collaborative arrangement that is under development.", "label": "Collaborative Arrangement Number Of Discovery Programs Under Development", "terseLabel": "Discovery programs under development" } } }, "localname": "CollaborativeArrangementNumberOfDiscoveryProgramsUnderDevelopment", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_CollaborativeArrangementNumberOfPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of programs under collaborative arrangement.", "label": "Collaborative Arrangement Number of Programs", "terseLabel": "Number of collaboration programs", "verboseLabel": "Number of pipeline programs" } } }, "localname": "CollaborativeArrangementNumberOfPrograms", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "integerItemType" }, "vygr_CollaborativeArrangementNumberOfTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of targets parties have right to nominate.", "label": "Collaborative Arrangement, Number of Targets", "terseLabel": "Number of targets", "verboseLabel": "Number of additional targets" } } }, "localname": "CollaborativeArrangementNumberOfTargets", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_CollaborativeArrangementPerMilestoneMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Per milestone, the maximum milestone payments to be received from the collaborative partner.", "label": "Collaborative Arrangement Per Milestone Maximum Milestone Payments To Be Received From Collaborative Partner", "verboseLabel": "Per Milestone, maximum milestone payments to be received from collaborative partner" } } }, "localname": "CollaborativeArrangementPerMilestoneMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_CollaborativeArrangementPercentageOfProfitOrLossUnderCoCoOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of profit or loss under co-co option under collaborative arrangement.", "label": "Collaborative Arrangement Percentage of Profit or Loss Under Co Co Option", "terseLabel": "Percentage of profit or loss under co-co option" } } }, "localname": "CollaborativeArrangementPercentageOfProfitOrLossUnderCoCoOption", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "percentItemType" }, "vygr_CollaborativeArrangementPercentageOfReductionInRoyaltyPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of reduction in royalty payments under collaborative arrangement.", "label": "Collaborative Arrangement Percentage of Reduction in Royalty Payments", "terseLabel": "Percentage of reduction in royalty payments" } } }, "localname": "CollaborativeArrangementPercentageOfReductionInRoyaltyPayments", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "percentItemType" }, "vygr_CollaborativeArrangementPeriodOfAdvanceNoticeForTerminationAfterFirstCommercialSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the period of advance notice for termination after first commercial sale under collaborative arrangement.", "label": "Collaborative Arrangement Period of Advance Notice for Termination After First Commercial Sale", "terseLabel": "Period of advance notice for termination after first commercial sale" } } }, "localname": "CollaborativeArrangementPeriodOfAdvanceNoticeForTerminationAfterFirstCommercialSale", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "durationItemType" }, "vygr_CollaborativeArrangementPeriodOfAdvanceNoticeForTerminationPriorToFirstCommercialSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the period of advance notice for termination prior to first commercial sale under collaborative arrangement.", "label": "Collaborative Arrangement Period of Advance Notice for Termination Prior to First Commercial Sale", "terseLabel": "Period of advance notice for termination prior to first commercial sale" } } }, "localname": "CollaborativeArrangementPeriodOfAdvanceNoticeForTerminationPriorToFirstCommercialSale", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "durationItemType" }, "vygr_CollaborativeArrangementTerminationPeriodFromFirstCommercialSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the termination period from first commercial sale under collaborative arrangement.", "label": "Collaborative Arrangement Termination Period from First Commercial Sale", "terseLabel": "Termination period" } } }, "localname": "CollaborativeArrangementTerminationPeriodFromFirstCommercialSale", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "durationItemType" }, "vygr_CollaborativeArrangementUpfrontPaymentToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of upfront payment to be received under collaborative arrangement.", "label": "Collaborative Arrangement Upfront Payment to be Received", "terseLabel": "Upfront payment" } } }, "localname": "CollaborativeArrangementUpfrontPaymentToBeReceived", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_CommercialMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to commercial milestone.", "label": "Commercial Milestone" } } }, "localname": "CommercialMilestoneMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_DebtSecuritiesContractualMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual maturity period of a marketable debt security.", "label": "Debt Securities Contractual Maturity Period", "terseLabel": "Debt securities, contractual maturity period" } } }, "localname": "DebtSecuritiesContractualMaturityPeriod", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "durationItemType" }, "vygr_DeductionsToContractWithCustomerAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to contract with customer assets during the reporting period.", "label": "Deductions To Contract With Customer Assets", "negatedTerseLabel": "Deductions" } } }, "localname": "DeductionsToContractWithCustomerAssets", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationReceivablesAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vygr_DepositsAndOtherNonCurrentAssets": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits and other assets that are expected to be realized or consumed after one year.", "label": "Deposits And Other Non-Current Assets", "terseLabel": "Deposits and other non-current assets" } } }, "localname": "DepositsAndOtherNonCurrentAssets", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vygr_DevelopmentAndRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development and regulatory milestone achieved.", "label": "Development and regulatory milestones" } } }, "localname": "DevelopmentAndRegulatoryMilestonesMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_DevelopmentRegulatoryAndCommercializationMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to development, regulatory, and commercialization milestones achieved.", "label": "Development, regulatory and commercialization milestone" } } }, "localname": "DevelopmentRegulatoryAndCommercializationMilestoneMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_DiscoveryAndFaProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Discovery and FA programs.", "label": "Discovery and FA Programs" } } }, "localname": "DiscoveryAndFaProgramsMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_DiscoveryProgramOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to discovery program one.", "label": "Discovery program 1" } } }, "localname": "DiscoveryProgramOneMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_DiscoveryProgramTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to discovery program two.", "label": "Discovery program 2" } } }, "localname": "DiscoveryProgramTwoMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_DrAlfredSandrockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Person designated as Dr. Alfred Sandrock, M.D., Ph.D.", "label": "Dr. Sandrock" } } }, "localname": "DrAlfredSandrockMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vygr_DrDinahSahMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Person designated as former Chief Scientific Officer, Dr. Dinah Sah, Ph.D.", "label": "Dr. Sah" } } }, "localname": "DrDinahSahMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vygr_FaProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to FA program.", "label": "FA Program" } } }, "localname": "FaProgramMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "vygr_FirstMaterialRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to First material right.", "label": "First Material Right [Member]", "terseLabel": "First Material Right" } } }, "localname": "FirstMaterialRightMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_FormerExecutivesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to former executives of the entity.", "label": "Former Executives" } } }, "localname": "FormerExecutivesMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vygr_FoundersRestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock granted to Founders that includes a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Founders restricted stock" } } }, "localname": "FoundersRestrictedStockMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "vygr_IncreaseDecreaseInCollaborationReceivables": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from Collaboration agreements.", "label": "Increase (Decrease) in Collaboration Receivables", "negatedLabel": "Related party collaboration receivable" } } }, "localname": "IncreaseDecreaseInCollaborationReceivables", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vygr_IncreaseDecreaseInRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in operating lease, right-of-use assets.", "label": "Increase Decrease In Right Of Use Assets", "negatedTerseLabel": "Operating lease, right-of-use asset" } } }, "localname": "IncreaseDecreaseInRightOfUseAssets", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vygr_InducementStockOptionAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Inducement Awards" } } }, "localname": "InducementStockOptionAwardsMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "vygr_LicenseAgreementNonRefundableTechnologyAccessFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of non refundable technology license fee charged during the reporting period.", "label": "License Agreement, Non Refundable Technology Access Fee", "terseLabel": "Non-refundable technology access fee" } } }, "localname": "LicenseAgreementNonRefundableTechnologyAccessFee", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_LicenseAgreementNonRefundableTechnologyAccessFeePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of non refundable technology license fee payable in a license agreement.", "label": "License Agreement, Non Refundable Technology Access Fee Payable", "terseLabel": "Non-refundable technology access fee payable" } } }, "localname": "LicenseAgreementNonRefundableTechnologyAccessFeePayable", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_LicenseAgreementNumberOfAllianceManagers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of alliance managers in license agreement.", "label": "License Agreement, Number of Alliance Managers", "terseLabel": "Number of Alliance Managers" } } }, "localname": "LicenseAgreementNumberOfAllianceManagers", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_LicenseAgreementNumberOfCountriesReceivedRegulatoryApproval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of countries received regulatory approval under the license agreement.", "label": "License Agreement, Number of Countries Received Regulatory Approval", "terseLabel": "Number of countries received regulatory approval" } } }, "localname": "LicenseAgreementNumberOfCountriesReceivedRegulatoryApproval", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_LicenseAgreementNumberOfLicenseOptionExerciseForEachTarget": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of license options can be exercised for each target on license agreement.", "label": "License Agreement, Number of License Option Exercise for Each Target", "terseLabel": "Number of license option exercise for each target" } } }, "localname": "LicenseAgreementNumberOfLicenseOptionExerciseForEachTarget", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_LicenseAgreementNumberOfLicenseOptionsOnAdditionalTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of license option exercise for additional targets on license agreement.", "label": "License Agreement, Number of License Options on Additional Targets", "terseLabel": "Number of license options on additional targets" } } }, "localname": "LicenseAgreementNumberOfLicenseOptionsOnAdditionalTargets", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_LicenseAgreementNumberOfMajorMarketCountriesReceivedRegulatoryApproval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of major market countries received regulatory approval under the license agreement.", "label": "License Agreement, Number of Major Market Countries Received Regulatory Approval", "terseLabel": "Number of major market countries received regulatory approval" } } }, "localname": "LicenseAgreementNumberOfMajorMarketCountriesReceivedRegulatoryApproval", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_LicenseAgreementNumberOfOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options exercised under the license agreement.", "label": "License Agreement, Number of Options Exercised", "terseLabel": "Number of options exercised" } } }, "localname": "LicenseAgreementNumberOfOptionsExercised", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_LicenseAgreementNumberOfTransgenes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of transgenes in license agreement.", "label": "License Agreement Number of Transgenes", "terseLabel": "Number of transgenes" } } }, "localname": "LicenseAgreementNumberOfTransgenes", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_MilestoneAchievementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by categories of milestones achieved.", "label": "Milestone Achievement [Axis]" } } }, "localname": "MilestoneAchievementAxis", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "stringItemType" }, "vygr_MilestoneAchievementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Categories of milestones achieved.", "label": "Milestone Achievement [Domain]" } } }, "localname": "MilestoneAchievementDomain", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_MiscellaneousOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of miscellaneous liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Miscellaneous Other Liabilities Noncurrent", "terseLabel": "Other" } } }, "localname": "MiscellaneousOtherLiabilitiesNoncurrent", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vygr_MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the value of money market funds and marketable securities on amortized cost basis.", "label": "Money Market Funds And Marketable Securities, Amortized Cost Basis", "totalLabel": "Total money market funds and marketable securities" } } }, "localname": "MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vygr_MoneyMarketFundsAndMarketableSecuritiesFairValue": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vygr_MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the fair value of money market funds and marketable securities.", "label": "Money Market Funds And Marketable Securities Fair Value", "terseLabel": "Total money market funds and marketable securities" } } }, "localname": "MoneyMarketFundsAndMarketableSecuritiesFairValue", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vygr_MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vygr_MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the gross unrealized loss before tax from money market funds and marketable securities.", "label": "Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax", "negatedLabel": "Total money market funds and marketable securities" } } }, "localname": "MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vygr_NeurocrineBiosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Neurocrine Biosciences Inc.", "label": "Neurocrine" } } }, "localname": "NeurocrineBiosciencesIncMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vygr_NeurocrineCollaborativeArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Neurocrine Collaboration Agreement.", "label": "Neurocrine Collaboration Agreement" } } }, "localname": "NeurocrineCollaborativeArrangementMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "vygr_NonProfitAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement made with a non-profit organization.", "label": "Non-profit organization agreement" } } }, "localname": "NonProfitAgreementMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails" ], "xbrltype": "domainItemType" }, "vygr_NonProfitOrganizationMilestonePaymentLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the value of the milestone payment received from the non-profit organization recognized as a liability as it is probable that the Company will repay the amount.", "label": "Non Profit Organization Milestone Payment Liability", "terseLabel": "Milestone payment liability" } } }, "localname": "NonProfitOrganizationMilestonePaymentLiability", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vygr_NonProfitOrganizationResearchAndDevelopmentMaximumFundingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the amount of maximum funding available from non-profit organization, for research and development under arrangement.", "label": "Non Profit Organization Research And Development Maximum Funding Capacity", "terseLabel": "Maximum funding" } } }, "localname": "NonProfitOrganizationResearchAndDevelopmentMaximumFundingCapacity", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vygr_NonProfitOrganizationResearchAndDevelopmentMultiple": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reflects the multiple to be used for future funding following successful development and commercialization.", "label": "Non Profit Organization Research And Development Multiple", "terseLabel": "Funding multiple" } } }, "localname": "NonProfitOrganizationResearchAndDevelopmentMultiple", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesOtherAgreementsDetails" ], "xbrltype": "decimalItemType" }, "vygr_NonStatutoryStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to non-statutory stock options.", "label": "Non-statutory stock options" } } }, "localname": "NonStatutoryStockOptionsMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "vygr_NovartisLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Novartis License Agreement.", "label": "Novartis License Agreement" } } }, "localname": "NovartisLicenseAgreementMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_NovartisPharmaAgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Novartis Pharma, AG.", "label": "Novartis Pharma, AG" } } }, "localname": "NovartisPharmaAgMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_NumberOfExecutivesReceivingStockBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of executives receiving some form of stock-based compensation.", "label": "Number of Executives Receiving Stock-based Compensation", "terseLabel": "Number of executives issued options" } } }, "localname": "NumberOfExecutivesReceivingStockBasedCompensation", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "integerItemType" }, "vygr_NumberOfIndividualsProvidingServicesInRelatedPartyTransactions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of individuals who are involved or provide services in related party transactions.", "label": "Number Of Individuals Providing Services In Related Party Transactions", "terseLabel": "Number of individuals providing services" } } }, "localname": "NumberOfIndividualsProvidingServicesInRelatedPartyTransactions", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "vygr_NumberOfLicenseOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of license options.", "label": "Number Of License Options", "terseLabel": "Number of license options" } } }, "localname": "NumberOfLicenseOptions", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_NumberOfOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of exercise options associated with a collaboration agreement.", "label": "Number Of Options", "terseLabel": "Number of options" } } }, "localname": "NumberOfOptions", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_NumberOfTransgenes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of transgenes associated with a collaboration agreement.", "label": "Number Of Transgenes", "terseLabel": "Number of transgenes" } } }, "localname": "NumberOfTransgenes", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_OperatingLeaseWeightedAverageIncrementalBorrowingRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average incremental borrowing rate for operating lease.", "label": "Operating Lease Weighted Average Incremental Borrowing Rate", "terseLabel": "Weighted average incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageIncrementalBorrowingRate", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "percentItemType" }, "vygr_OptionAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to an option and license arrangement.", "label": "Option and license agreement" } } }, "localname": "OptionAndLicenseAgreementMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "vygr_PerformanceBasedMilestoneAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Performance based milestone awards" } } }, "localname": "PerformanceBasedMilestoneAwardsMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "vygr_PfizerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to Pfizer, Inc.", "label": "Pfizer" } } }, "localname": "PfizerMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "vygr_ProceedsFromMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromMaturityOfMarketableSecurities", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vygr_ProgramsAddedAtLaterDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of programs which will be added at a later date.", "label": "Programs Added At A Later Date", "terseLabel": "Programs added later" } } }, "localname": "ProgramsAddedAtLaterDate", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_RelatedPartyTransactionBoardAndScientificAdvisoryServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Board and scientific advisory services transactions with related parties.", "label": "Board and scientific advisory services" } } }, "localname": "RelatedPartyTransactionBoardAndScientificAdvisoryServicesMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vygr_RelatedPartyTransactionCollaborationArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration arrangement transactions with related parties.", "label": "Collaboration arrangement" } } }, "localname": "RelatedPartyTransactionCollaborationArrangementMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vygr_RelatedPartyTransactionConsultingAndManagementServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting and management services transactions with related parties.", "label": "Consulting and advisor services" } } }, "localname": "RelatedPartyTransactionConsultingAndManagementServicesMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "vygr_RemainingContractualLifeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Remaining Contractual Life Abstract", "verboseLabel": "Remaining Contractual Life" } } }, "localname": "RemainingContractualLifeAbstract", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "vygr_RevenuePerformanceObligationAllocationOfFixedTransactionPriceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue performance obligation allocation of fixed transaction price.", "label": "Revenue Performance Obligation Allocation of Fixed Transaction Price [Table Text Block]", "terseLabel": "Schedule of allocation of fixed consideration" } } }, "localname": "RevenuePerformanceObligationAllocationOfFixedTransactionPriceTableTextBlock", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "vygr_RevenuePerformanceObligationAllocationOfVariableTransactionPriceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue performance obligation allocation of variable transaction price.", "label": "Revenue Performance Obligation Allocation of Variable Transaction Price [Table Text Block]", "terseLabel": "Schedule of allocation of variable consideration" } } }, "localname": "RevenuePerformanceObligationAllocationOfVariableTransactionPriceTableTextBlock", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "vygr_RevenuePerformanceObligationsAllocationOfFixedTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of revenue performance obligation allocation of fixed transaction price.", "label": "Revenue, Performance Obligations, Allocation of Fixed Transaction Price", "terseLabel": "Allocation of fixed consideration" } } }, "localname": "RevenuePerformanceObligationsAllocationOfFixedTransactionPrice", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_RevenuePerformanceObligationsAllocationOfTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of revenue performance obligation allocation of transaction price.", "label": "Revenue Performance Obligations Allocation of Transaction Price", "terseLabel": "Allocation of transaction price" } } }, "localname": "RevenuePerformanceObligationsAllocationOfTransactionPrice", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_RevenuePerformanceObligationsAllocationOfVariableTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of revenue performance obligation allocation of variable transaction price.", "label": "Revenue Performance Obligations, Allocation Of Variable Transaction Price", "terseLabel": "Allocation of variable consideration" } } }, "localname": "RevenuePerformanceObligationsAllocationOfVariableTransactionPrice", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "vygr_RevenuePerformanceObligationsNumberOfMaterialRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of material rights..", "label": "Revenue Performance Obligations Number Of Material Rights", "terseLabel": "Number of material rights" } } }, "localname": "RevenuePerformanceObligationsNumberOfMaterialRights", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_RevenuePerformanceObligationsNumberOfPerformanceObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of performance obligations.", "label": "Revenue Performance Obligations, Number Of Performance Obligations", "terseLabel": "Number of performance obligations" } } }, "localname": "RevenuePerformanceObligationsNumberOfPerformanceObligations", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "integerItemType" }, "vygr_SalesMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales milestone achieved.", "label": "Sales milestone" } } }, "localname": "SalesMilestoneMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNovartisOptionAndLicenseAgreementDetails", "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and restricted cash.", "label": "Schedule of Cash Cash Equivalents And Restricted Cash [Table Text Block]", "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash" } } }, "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "vygr_SecondMaterialRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Second material right.", "label": "Second Material Right [Member]", "terseLabel": "Second Material Right" } } }, "localname": "SecondMaterialRightMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesPfizerOptionAndLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_Sidney75StreetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the lease at 75 Sidney Street.", "label": "75 Sidney Street" } } }, "localname": "Sidney75StreetMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails" ], "xbrltype": "domainItemType" }, "vygr_TouchlightIpLtdLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Touchlight IP Ltd License agreement.", "label": "Touchlight IP Ltd License Agreement [Member]", "terseLabel": "Touchlight IP Ltd License Agreement" } } }, "localname": "TouchlightIpLtdLicenseAgreementMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_TouchlightIpLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Touchlight IP Ltd.", "label": "Touchlight IP Ltd [Member]", "terseLabel": "Touchlight IP Ltd" } } }, "localname": "TouchlightIpLtdMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesTouchlightIpLtdLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "vygr_UnrealizedGainLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Unrealized Gain and Loss [Abstract]" } } }, "localname": "UnrealizedGainLossAbstract", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketableSecuritiesCashCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vygr_VestingOfRestrictedCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the value of vested restricted common stock.", "label": "Vesting Of Restricted Common Stock", "terseLabel": "Vesting of restricted stock units" } } }, "localname": "VestingOfRestrictedCommonStock", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "vygr_VestingOfRestrictedCommonStockInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of vested restricted common stock.", "label": "Vesting Of Restricted Common Stock In Shares", "terseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "VestingOfRestrictedCommonStockInShares", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "vygr_VyaadcProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This represents the information pertaining to Vayaadc Program.", "label": "VY-AADC" } } }, "localname": "VyaadcProgramMember", "nsuri": "http://www.voyagertherapeutics.com/20220930", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsAndContingenciesNeurocrineCollaborationAgreementDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r406": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r407": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r408": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r409": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r410": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r411": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r412": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r413": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r414": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r415": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r416": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r417": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r418": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" } }, "version": "2.1" } ZIP 67 0001558370-22-016733-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-016733-xbrl.zip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end